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Abstract 
 
There is an increasing demand for economic evidence on physical activity (PA) and sedentary 
behaviour (SB) interventions which can prevent noncommunicable disease (NCD). Trials assessing 
the impact of PA and SB interventions rarely collect and present economic data alongside their 
effectiveness results. The overarching aim of this PhD was to develop a multidisciplinary and 
pragmatic framework to support researchers carrying out trial-based economic evaluations of 
individual-level PA and SB interventions. The nature of this PhD project presented me with the 
opportunity to train in a new discipline, health economics, and draw on my existing discipline-
specific knowledge in anthropology and public health in order to make an interdisciplinary 
contribution to the field of public health economics applied to trials. In particular, my knowledge in 
anthropology, the study of human society and its complexity, supported my documentation of the 
complexity involved in developing and implementing a standardised pragmatic framework to the 
multidisciplinary field of economic evaluation in PA and SB. Complexity is reported throughout this 
thesis in the form of reflection boxes. The purpose of the reflections were to: (1) describe in detail 
the actions I took to develop a framework; and (2) explain why I believed these actions were fit for 
purpose. For the latter, I reflect on my prior knowledge in public health and anthropology, as well as 
on the complex detailed observations I made and informal multidisciplinary conversations I had 
during this PhD.  
In order to design an initial framework and to test the practicability of it, I carried out three key 
studies. Study one was a systematic review which aimed to identify how authors of existing 
economic evaluations of individual-level PA and SB interventions have addressed key 
methodological challenges associated with the conduct of economic evaluations in public health. In 
summary, the review showed that there are marked methodological differences in existing studies. 
Nevertheless, good quality methods were identified and drawn on in order to develop the initial 
framework. The initial framework comprised of 16 items along with guidance on how these items 
could be applied in the context of PA and SB. Study two involved applying the initial framework to a 
‘real world’ PA trial and reflecting on its practicability. Study three was carried out concurrently with 
study two and involved applying the initial framework to a ‘real world’ SB trial, also to see how the 
framework performed in practice. Narrative synthesis methods were used to bring together the key 
learnings and reflections from studies 1-3. The narrative synthesis shed light on how my 
interdisciplinary knowledge and experience could improve the procedures for identifying and 
measuring resource use within PA and SB trials. My revised systematic framework incorporates 
existing tools from the multiple research fields in which PA and SB cut across, namely public 
health, exercise science, behavioural science, anthropology and trial methodology. The final 
framework, presented in the form of a standard operating procedure (SOP), is recommended for 
use in trial units to support early career health economists to make and communicate decisions 
around the measurement of resource use in complex individual-level PA and SB trials. 
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1.1. Definitions for PA and SB 
Physical activity (PA) has been formally defined as “any bodily movement produced by skeletal 
muscles that results in energy expenditure” (Caspersen et al., 1985). This definition implies that PA 
is not necessarily planned, structured or repetitive. It indicates that PA can be performed as part of 
people’s daily life activities such as through workplace and household activities, as well as exercise 
and sport. In the PA literature, energy used up through PA is classified in units known as metabolic 
equivalent time (MET). METs have been defined as “the amount of oxygen consumed during PA” 
(Scholes, 2017). The Compendium for Physical Activities categorises PA into three levels based on 
the amount of METs used. These categories include light-intensity PA (1.6-2.9 METs), moderate-
intensity PA (2-5.9 METs) and vigorous-intensity PA (≥6 METs) (Ainsworth et al., 2011). More 
recently, the terminology for bodily movement has been extended to incorporate two low energy 
behaviours: sedentary behaviour (SB) and sleep. SB has been defined as “any waking behaviour 
characterized by an energy expenditure ≤1.5 METs while in a sitting or reclining posture” 
(Sedentary Behaviour Research Network, 2012). Sleep has been classified as using less than 1 
MET (Tremblay et al., 2017).  
1.2. Why intervention is needed for PA and SB 
1.2.1. Evidence on the benefits of PA and SB 
Since the industrial revolution, there has been a rapid increase in the development of new 
technology. In turn this increase in technology has led to a reduction in human energy expenditure 
since new technology has reduced the heavy labour and effort required to perform day-to-day 
activities (Hallal et al., 2012). One of the consequences of modern civilisation is an increased risk 
of noncommunicable disease (NCD). This is because key biological mechanisms in the human 
body are maladapted to a lifestyle that is less active (Booth et al., 2008). As a result, it has been 
claimed that there is overwhelming evidence to assert that physical inactivity is one the biggest 
public health challenges of the 21st Century (Blair, 2009). NCDs are important as they are the main 
cause for death and disability worldwide with incidence rates forecast to increase considerably 
(WHO, 2014). NCDs are often recognisable by their long-term nature and include conditions such 
as cardiovascular disease (CVD), type II diabetes (T2D), cancer, dementia and depression. 
Physical inactivity is one of the four main lifestyle risk factors, which has and continues to 
contribute to the global rise in NCDs and premature mortality (World Health Organisation, 2013). 
As a result, physical inactivity is the fourth leading cause of death globally (Kohl et al., 2012) and is 
attributable to one in six global deaths (Lee et al., 2012). Physical inactivity has been associated 
with a number of major NCDs including dementia, coronary heart disease (CHD), T2D, stroke, 
breast and colon cancer, and depression (Andersen et al., 2016, Department of Health, 2004, 
Trueman and Anokye, 2013).  
The most recent guidelines on PA from the UK emphases that: (1) any amount of PA can lead to 
health benefits; and (2) all age groups can benefit from PA (Gibson-Moore, 2019). Levels of PA 
below the current recommendations have even demonstrated important health benefits. A key 
review looking at the health effects of light-intensity PA for adults and older adults measured 
through objective measures, found that light-intensity PA was beneficially associated with obesity, 
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cardiometabolic markers and mortality (Füzéki et al., 2017). Furthermore, low doses of MVPA 
incorporated into an older persons daily life can reduce their risk of mortality by 22% (Hupin et al., 
2015). There is also evidence indicating that a single bout of resistance PA can have important 
health benefits for adults including a lowering effect on blood pressure which can last up to 24 
hours (Casonatto et al., 2016). In terms of mental health, a cross-sectional study from the USA with 
data from 1.2 million individuals found that individuals who reported exercising in the past month 
compared to those who did not, spent 1.49 days less per month in poor mental health. 
Furthermore, the authors found that all types of exercise were associated with a reduction in poor 
mental health (Chekroud et al., 2018). In terms of children and young people, epidemiological 
evidence indicate that children who develop a physically active lifestyle very early on in childhood 
are more likely to be active across the life course (Telama et al., 2014). There are also immediate 
benefits for children and young people, for instance, a large systematic review examining the 
evidence on objectively measure PA in 5-17 year olds from 162 studies, found that all forms of PA 
in terms of sporadic, bouts and continuous PA, are beneficial for children and young people’s 
health (Poitras et al., 2016). More specifically, the review reported an association between PA and 
physical, psychological, social and cognitive benefits. Overall, the benefits of PA are widespread 
for all age groups and they do not just include physical and mental health benefits. For instance, 
PA is associated with improvements in learning and attainment for children as well as 
improvements in workplace productivity for adults (Gibson-Moore, 2019).   
SB has also been identified as modifiable risk factor associated with NCD and premature mortality. 
Importantly, SB has been identified as having a negative impact on health, independent of 
moderate-to-vigorous intensity PA (Katzmarzyk et al., 2009, Hamilton et al., 2008, Buckley et al., 
2015). A key meta-analysis found that adults who were sedentary for prolonged periods were still 
at increased risk of mortality and morbidity, regardless of whether they were meeting the weekly 
guidelines for PA (Owen et al., 2010, Ekelund et al., 2016). The study found that in order to 
attenuate the risks associated with SB, adults would need to participate in 60 minutes of ‘moderate-
intensity’ PA per day. As over a third (35%) of females and a quarter (26%) of males in high-
income countries do not presently meet the recommended weekly guidelines of 150 minutes of PA 
per week (WHO, 2018b) then a daily target of 60 minutes, which equates to a weekly target of 420 
minutes, is unlikely to be attained. A more recent meta-analysis involving over one million 
participants showed that high levels of total sitting and especially TV viewing time, are associated 
with an increased risk of all-cause mortality, CVD mortality and incidence of T2D (Patterson et al., 
2018). Sitting for prolonged periods has also been associated with a decline in metabolic health. A 
large study from Australia found that for adults without a diagnosis of diabetes, who self-reported 
high-levels of TV viewing time, were also more likely to have undiagnosed abnormal glucose 
metabolism (Dunstan et al., 2004). Similarly, a large systematic review drawing on 235 studies 
from 71 countries, found an association between TV viewing for children and young people, and 
unfavourable cardiometabolic risk scores, body composition and behavioural conduct (Carson et 
al., 2016).  
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1.2.2. Recommended guidelines for PA and SB 
The terms ‘moderate’ and ‘vigorous’ are drawn on in the international guidelines for PA which aim 
to recommend how much PA adults should achieve per week in order to reduce their risk of NCD 
and pre-mature mortality (WHO, 2018b). Currently, the guidelines state that adults aged 18-64 
should aim to achieve at least 150 minutes of ‘moderate-intensity’ PA per week or 75 minutes of 
‘vigorous-intensity’ PA per week, or the equivalent weekly volume through a combination of 
moderate-to-vigorous PA. These guidelines were based on key systematic reviews from the US 
and Canada (Department of Health and Human Services, 2008, Warburton et al., 2010). Though 
the reviews were published over a decade ago, the evidence derived from them remains relevant 
today. For instance, the reviews found that 150 minutes of ‘moderate-intensity’ PA per week is 
associated with substantial health benefits across a diverse range of adult populations. 
Furthermore, they found that it is the overall volume of 150 minutes of ‘moderate-intensity’ PA per 
week, which is important, as opposed to the type of activity or frequency of PA sessions. Similar 
health benefits are accumulated when overall PA volume equates to 150 minutes per week, 
meaning it does not matter if this amount is achieved through short 10-minute bouts of PA or 
through long continuous PA sessions. That said, the guidelines do go on to recommend that in 
order to experience more acute benefits, it is better to spread the 150 minutes across the week. 
This is because acute effects of PA such as improved mood, insulin sensitivity and fat metabolism, 
only last up to 24-48 hours after a bout of PA (Department of Health and Social Care, 2011). 
Guidance has been provided by experts in order to improve our understanding further for the terms 
‘moderate’ and ‘vigorous’ activities. This is because METs is not a multidisciplinary measure, 
therefore the guidance states “moderate-intensity activities are those in which heart rate and 
breathing are raised, but it is possible to speak comfortably. Vigorous-intensity activities are those 
in which heart rate is higher, breathing is heavier, and conversation is harder” (O'Donovan et al., 
2010). On the contrary, to PA guidelines, due to the underdeveloped evidence base for SB, there 
are no international guidelines for SB and many countries have not quantified guidelines 
(Stamatakis et al., 2019). For example, the UK’s SB guidelines recommends that adults minimise 
the amount of time they are sedentary for extended periods but the guidelines do not quantify this 
(Department of Health and Social Care, 2011). 
1.2.3. Current global and national prevalence for PA and SB 
Globally, around one in four adults are not meeting the recommended guidelines for PA (WHO, 
2018b). Nationally, the latest Health Survey for England reported similar findings while also noting 
that a greater proportion of females (42%) are not meeting the guidelines compared to males 
(34%) (Scholes, 2017). In terms of SB, early evidence from the US indicated that Americans 
reportedly spend 55% of their leisure time in sedentary pursuits, including watching TV (Matthews 
et al., 2008). While in Europe, early evidence on SB suggested that European’s devote 40% of 
their leisure time to watching TV (Office for European Communities, 2003). In the context of the 
UK, the Health Survey for England (Scholes, 2017) also assessed SB levels and found that the 
same proportion (29%) of males and females are sedentary for six hours or more per day during 
their leisure time in the week. That said, at the weekend males were more likely to spend 6 or more 
hours of their leisure time per day being sedentary (40% vs 35% per day, respectively). The 
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difference between the findings from America and the UK may relate to the way SB was measured 
in the studies. The study by Matthew and colleagues uses objective measures, while the Health 
Survey for England draws on self-report measures. When objective and self-report measures have 
been compared in previous work, in the context of PA, the objective data has indicated that people 
may overestimate how active they are when they self-report their activity levels (Marteau, 2018, 
Scarborough et al., 2011). Overall, the current evidence base on PA and SB prevalence suggests 
that an important share of people’s waking hours is spent using very little energy. 
1.2.4. Costs associated with PA and SB 
The high prevalence and long duration of NCDs means their impact is widespread. Not only do 
they impact on the individual but also on numerous groups and sectors in society including the 
individual’s family, workplace, community and health sector. As a consequence, the global burden 
of NCD is substantial (WHO, 2018a). In the UK alone, NCDs are estimated to cost the economy 
£8.3 billion per annum (Gray et al. 2015; Department of Health, 2009). Inaction to invest in 
preventative interventions tackling detrimental levels of physical inactivity is expected to lead to 
greater levels of NCD, inequity, productivity losses and a continued overwhelming demand for 
costly curative healthcare services (Organisation for Economic Cooperation and Development, 
2015). Conservative estimates from 2013, report that the global economic burden of physical 
inactivity was around $58.3 billion per annum, of which more than half of this burden fell on the 
public sector (Ding et al., 2016). In the UK, Public Health England reported that physical inactivity 
costs the UK economy around £7.4 billion per annum (Public Health England, 2014). In other high 
income countries, physical inactivity is estimated to account for 1.5-3% of the total direct healthcare 
expenditure (Oldridge, 2008). In England, in 2009/10 the direct cost of physical inactivity to the 
National Health Service (NHS) was estimated to be around £900 million (Townsend et al., 2015).  
1.2.5. Determinants of PA and SB 
As well as reducing NCD and pre-mature mortality, an increase in PA and reduction in SB has the 
potential to contribute to making people more productive in the workplace and making the world 
more sustainable. For example, poor health has been associated with higher rates of workplace 
absenteeism and presenteeism (Scarborough et al., 2011, Buckley et al., 2015). Furthermore, it is 
expected that the promotion of PA through active transport can help reduce fossil fuel use, which in 
turn will lead to clearer air, less congested roads and ultimately a healthier environment (World 
Health Organisation, 2018). As well as PA and SB affecting productivity and the environment, work 
conditions and the environment can also affects people’s health. Key milestone publications have 
helped improved our understanding of this in terms of how fundamental economic, environmental 
and social conditions can determine health-behaviours such as PA and SB. In particular, there 
have been three key publications, which have raised awareness on the determinants of health, 
these include: the Ottawa Charter for health promotion (World Health Organisation, 1986); 
Dahlgren and Whitehead’s (1991) socioecological model; and the Marmot Review (Marmot et al., 
2010). Together, the reports illustrate that interventions need to be designed with an awareness of 
the prerequisites for health. In particular, the Marmot review draws on robust epidemiological 
evidence, which shows how that it is not just genetics, which determine our health and health 
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behaviour, but the type of environmental and societal structures in which we live also play a major 
role in determining our lifestyle behaviours and consequently our health status. 
1.3. Evidence on effectiveness of PA and SB interventions 
1.3.1. Complex interventions for PA and SB 
The determinants of PA and SB can change over time and are interrelated; this makes low PA and 
high SB levels complex public health challenges. This complexity has been explained through a 
recent framework produced as part of the Global Action Plan on PA (Rutter et al., 2018). The 
framework provides a visual depiction of the complex nature of PA, which can be used to help 
design effective PA and SB interventions. The framework builds on Dahlgren and Whitehead’s 
socioecological approach as it helps us understand how contextual factors such as political, social, 
cultural and economic factors, influence people’s response to PA interventions. More specifically, 
the framework disaggregates the influencing factors in order to demonstrate how there are multiple 
sectors and stakeholders involved in tackling the global problem of inactivity. The authors argue 
that the framework demonstrates that it is inappropriate to try and increase PA through a single 
response; rather they state that an effective response involves multiple sectors and multiple 
components. The Medical Research Council in the UK has provided guidance in order to help 
researchers deal with the complex nature of behaviour change interventions when developing and 
evaluating their interventions (Craig et al., 2008). The guidance is highly cited and due to be 
updated in order to incorporate recent methodological developments which includes complex 
systems thinking and natural experiments (Skivington et al., 2018). As the most recent version of 
the guidance is not yet published, key messages and concepts from 2008’s guidance explain why 
many PA and SB interventions conducted over the last decade are multi-component, target 
different levels of the socioecological model, are evaluated through experimental designs, and 
assess multiple outcomes. 
1.3.2. Effectiveness data for PA and SB interventions 
International experts in PA have identified seven types of strategies for increasing PA, which they 
claim have worldwide applicability and are supported by good evidence (International Society for 
Physical Activity and Health, 2012). In summary, the seven strategies include: 
1) Implementing whole school approaches to PA; 
2) Creating transport systems which enable ‘active transport’; 
3) Designing a built environment which provides opportunities for recreational PA and thus 
reduces people’s chance of sitting for prolonged periods; 
4) Encouraging primary and secondary healthcare professionals to prescribe PA as a form of 
‘medicine’ for NCD prevention; 
5) Raising awareness of PA benefits to the public through mass media campaigns; 
6) Using key settings such as local governments, schools and workplaces to integrate PA 
promotion approaches across the whole community; 
7) Encouraging participation in sport across the life span.  
These seven strategies support the argument that an active lifestyle should be promoted at all 
stages of the life course. For example, although PA promotion has the greatest potential in the 
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early years, it also has an important role in supporting healthy workplaces and ageing (World 
Health Organisation, 2013). Traditionally, experts in PA have classified PA approaches into three 
broader strategies: community-wide mass media campaigns and informational approaches; 
individual-level behavioural and social support approaches; and community-wide environmental 
and policy approaches (Heath et al., 2012). Much of the existing evidence on the effectiveness of 
PA and SB interventions comes from the evaluation of individual-level behavioural and social 
support interventions; this is due to the challenge of measuring PA outcomes at the population-
level. That said, the strength of these types of multicomponent individual-level interventions is that 
they can be developed and piloted in various settings before being scaled up to a community-wide 
and policy level (Craig et al., 2008).  
In particular, there has much interest in individual-level behavioural and social support 
interventions, which aim to help individuals to incorporate PA into their daily routine. One reason for 
this is because early evidence has suggested that interventions which focus on lifestyle PA through 
the production of tailored activity plans are better value for money than supervised structured 
exercise programmes (Sevick et al., 2000). More recently, the evidence from a key meta-analysis, 
which reviewed the evidence on behaviour change techniques for PA, supported the evidence for 
tailored PA lifestyle interventions. More specifically, the meta-analysis found that goal setting, self-
monitoring and person-centre methods (e.g. motivational interviewing and social determination 
theory) are effective techniques (Samdal et al., 2017). Compared to the PA literature, evidence on 
the effectiveness of SB interventions is less advanced. Overall, much of the evidence is limited to 
small non-powered and low quality studies (Shrestha et al., 2016). As office workers are one of the 
most sedentary populations (Clemes et al., 2014) SB interventions have typically been set in the 
workplace. A recent systematic review of the evidence on workplace SB interventions found that 
the existing evidence indicates that multicomponent behaviour change and environmental 
approaches are most effective for reducing workplace SB (Chu et al., 2016). That said, there 
remains a lack of evidence on the effectiveness of SB interventions that derives from RCTs 
(Gardner et al., 2016). Furthermore, there is a recognised need for more UK-based evidence on 
the effectiveness on workplace SB interventions (O’Connell et al., 2015) as well as evidence from a 
variety of workplaces (Mackenzie et al., 2015).   
1.4. Economic evaluations in public health  
1.4.1. Existing evidence on value for money 
Epidemiological evidence on the benefits of PA from a range of low-income, middle-income and 
high-income countries, have led to PA being identified as a low cost global strategy for reducing 
mortality and CVD amongst adults aged 30-70 years (Lear et al., 2017). That said, evidence on 
which PA and SB interventions offer the best value for money is lacking. Not enough is known 
about the economic viability of PA and SB interventions and their potential for reducing future costs 
to health and social care. It is crucial that evaluations in this field consider economic and public 
health outcomes and costs to the individual (Anokye et al., 2014). One reason for the lack in 
evidence is because economic evaluations are rarely embedded in trials which evaluate the 
effectiveness of PA and SB interventions. Reviews from the UK, which have assessed the value for 
money of public health interventions, inclusive of a range of PA interventions, concluded that the 
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existing evidence on public health interventions indicates that they represent good value for money 
(Owen et al., 2012, Owen et al., 2017, Wanless, 2004). Wanless (2004) argues that the 
assessment of the cost-effectiveness of public health interventions alongside effectiveness 
evaluations should be routine practice. Nonetheless, a more recent review has concluded that not 
all preventative interventions are cost-effective and furthermore some cost-effectiveness results are 
sensitive to the methodological approaches used, as well as the choice in comparator groups, 
costs and assumptions (Owen and Fischer, 2019).  
1.4.2. Fundamental economic concepts  
The discipline of economics is underpinned by the concept of scarcity. More specifically, 
economists are interested in a concept known as opportunity cost. Opportunity cost relates to the 
idea that resources (e.g. materials and people’s time) are limited and in most 
circumstances can only be used for one course of action at one point in time. Opportunity 
cost represents the consequence of allocating resources to one particular course of action instead 
of the next best alternative. That is to say, opportunity cost is the value of the benefits that could 
have been gained by choosing the next best alternative course of action instead (Morris et al., 
2012). Edwards and McIntosh (2019) summarise three additional concepts which underpin the 
study of health economics, these include: allocative efficiency, technical efficiency and equity. 
Edwards and McIntosh (2019) explain these concepts in the context of public health decision-
making within a public sector/ government economy:  
• Allocative efficiency aims to consider how society can maximise society’s welfare and 
asks: what public health goods, services and environments should be produced by 
society?   
• Technical efficiency aims to consider how levels of input relate to levels of output and asks: 
how should public health goods, services and environments be produced?   
• Equity aims to consider who to produce something for and asks: how should public health 
goods, services and environments be distributed across society?  
1.4.3. Overview of economic evaluation approaches 
Health economics is the study of how society allocates scarce healthcare resources. Economic 
evaluation is a key part of health economics as it compares the costs and effects of alternative 
courses of action (Drummond et al., 2015a). The principles and practice of health economics and 
economic evaluation can be applied to public health through the study of how society uses scarce 
resources to prevent ill health, promote healthy lifestyles and reduce inequalities (Edwards and 
McIntosh, 2019). There are four established approaches to economic evaluation, these include: 
cost effectiveness analysis (CEA), cost-utility analysis (CUA), cost-benefit analysis (CBA) and cost-
consequence analysis (CCA). The main difference between the techniques is the way in which they 
incorporate and value outcomes. For instance, the main difference between conducting CEA or 
CBA in practice, relates to: (1) the number of outcomes included in the analysis; and (2) whether 
outcomes are monetised or reported in natural units.  
In terms of CEA, this technique only compares aggregate costs to a single outcome measure. 
Furthermore, the chosen outcome measure is usually reported in natural units and not assigned a 
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monetary value. CUA is a variant of CEA as it also compares a single outcome measure to 
aggregate costs. However, CUA is unique as it uses preference-based outcome measures, which 
have preference weights attached to the various possible states of the outcome which means it is 
possible to rank and meaningfully compare outcomes. By contrast, CBA incorporate several 
outcome measures and CBA is not restricted to reporting outcome measures in their natural units 
or as a preference weight. CBA involves assigning monetary values to the different outcome 
measures. CBA presents a summary ratio statistic called the cost-benefit ratio which is the 
aggregate monetary value of all costs compared to the aggregate monetary value of all outcomes. 
Lastly, the main feature of CCA is that it involves listing all cost categories and outcome measures 
in a disaggregate format. A key difference between CCA and CBA is that although CCA reports 
costs and outcomes, it does not compare costs to outcomes.  
Economic evaluations in healthcare typically focuses on maximising health, while public health 
interventions aim to prevent ill health, promote healthy behaviour and reduce inequalities. More 
specifically, public health interventions aim not only to improve health but also to improve a 
person’s social circumstances (e.g. education, housing, pollution) (Marmot and Allen, 2014). Public 
health’s focus on the social determinants of health means there may be several outcome measures 
which can be reported. This implies CBA or CCA may be the most appropriate approaches for 
analysing public health interventions. Nevertheless, there is a lack of consensus on how analysts 
should address the methodological challenges associated with CBA, such as how to assign 
monetary values to social outcomes and how to account for the unfair distribution of income in 
society (Donaldson et al., 2002). Similarly, for CCA there is a lack of consensus on how a decision-
makers can implement the wide range results of CCA provides without the decision-maker’s bias 
influencing which results they choose to focus on.  
To date, there is no consensus in the literature for which economic evaluation methods should be 
used for public health economics. It is argued that due to the complex nature of public health 
interventions in terms of the multiple sectors, outcomes and components, there is no ‘one size that 
fits all’ (Edwards and McIntosh, 2019: 342). Some analysts choose evaluative frameworks that 
stem from the finance and accounting literature, including return on investment (ROI) and social 
return on investment (SROI). The appeal of ROI and SROI is that unlike CBA they provide a 
practical framework that is relatively straightforward for analysts with limited training in health 
economics to apply in practice. The limitations of ROI and SROI is that they lack the theoretical 
underpinning of welfare economics and ignore the methodological challenges which health 
economists have debated for over forty years (Fujiwara, 2015).  
1.5. Welfarism and extra-welfarism 
1.5.1. Welfare economics  
Boadway and Bruce (1984) refer to welfare economics as the systematic study of methods (e.g. 
frameworks) used to order and rank society’s preferences for any set of arrangements. A set of 
arrangements can include different states of the world and alternative courses of action (e.g. 
allocation of resources). The social ordering and ranking characteristic of welfare economics 
means the methods that underpin it are normative. This implies individual’s value judgements are 
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needed to order and rank preferences for alternative courses of actions. This allows alternative 
courses of action to be meaningfully compared against each other. Furthermore, this meaningful 
comparison enables the analyst to make statements about whether one course of action is better, 
worse or equally as good as the alternative courses of actions (Boadway and Bruce, 1984).   
1.5.2. Welfarism and extra-welfarism   
The most dominant framework for comparing and ranking different states of the world (alternative 
courses of action) as better, worse or equal is called welfarist economics. Welfarist economics is 
underpinned by utility-related principles, where utility is synonymous for ‘happiness’ or ‘satisfaction’ 
(Morris et al., 2012). More specifically, welfarism is underpinned by the following principles: (1) the 
individual makes rationale decisions in order to maximise their welfare; (2) the individual is the best 
person to decide on how to improve their own utility (happiness), not others (e.g. government); (3) 
utility comes from the outcome of a choice made to maximise welfare as opposed to the process of 
making the decision itself; and (4) judging the value of something can only be judged using utility-
based outcomes meaning all non-utility outcomes are irrelevant (Culyer et al., 2012). As welfarist 
methods are underpinned by individualism and the idea that only the individual can state what 
maximises their utility, welfarist economics is difficult to apply to health care and public health. This 
is because in many countries, it is the health professional who makes rational choices and 
decisions on behalf of the individual (Morris et al. 2012) as health and public health are highly 
specialised areas of study. Furthermore, in many countries, health and public health services 
(goods) are publicly funded which means decision-makers need to make comparisons between 
individuals in order to allocate resources across the public.  
Consequently, welfarism has been described as a restrictive evaluative framework compared to 
other frameworks such as extra-welfarism (Culyer et al., 2012). For example, extra-welfarism 
permits comparisons to be made between individuals as well as permitting utility to be judged and 
specified by others and not only the individual who is experiencing the outcome. Furthermore, 
extra-welfarism permits the analysis of not just utility, but also a broader range of non-utility 
outcomes including characteristics such as health status, capabilities, and other issues of concern 
that go beyond an individual’s utility (Culyer et al., 2012). For these reasons, extra-welfarism is 
described as a pragmatic framework since in practice it can be applied to a range of public policy 
challenges (Brouwer and Koopmanschap, 2000).  
1.5.3. Cost-utility analysis 
The pragmatic approach of extra-welfarism explains why it has been most commonly drawn on to 
address resource allocation problems within the field of health economics. In health economics, the 
most dominant extra-welfarist framework used is a species of cost-effectiveness analysis (CEA), 
called cost-utility analysis (CUA). It is important to note that in CUA, utility represents a measure of 
health characteristic. CUA measures health-related quality of life (HRQoL) not overall quality of life. 
The definition of utility in CUA therefore differs to the welfarist’s definition of utility which refers to 
an individual’s satisfaction. Analysts point out that use of the term utility in CUA is unhelpful as it is 
misleading (Culyer et al., 2012).  A key reason for the widespread adoption of the CUA in health 
economics, may relate to the way measuring health characteristics (utility) enables comparisons 
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between individuals to be made. Comparisons are important for health professionals and public 
policymakers since in most health economies, health professionals and policymakers make 
decisions on behalf of others due to the high level of knowledge and expertise required to make 
healthcare decisions.  
Health characteristics in CUA are measured using a multi-dimensional preference-based outcome 
measure. These measures captured include generic HRQoL measurements (e.g. EQ-5D) and 
disease specific quality of life measures (e.g. EORTC-8D). The EQ-5D which measures generic 
HRQoL, is the most commonly used instrument for measuring health characteristics (Rabin et al., 
2011). The preference-based element of the measure relates to the way in which the different 
characteristics of health can be assigned utility (preference) weights. These weights are cardinal 
numbers and represent the relative importance of each dimension from the quality of life tool. 
Specifying a set of utility weights is a normative process as it requires subjective value judgements 
to be made by a general or disease-specific population (Dolan, 1997). Application of the set of 
utility weights to an individual’s EQ-5D score is advantageous compared to non-preference based 
health measures, as the utility weights enables the analyst to infer whether a person’s health has 
improved or deteriorated and by how much (Dolan, 1997). On the contrary, the disadvantage of 
CUA is that the term utility within the CUA framework does not fully reflect the individual’s 
preferences and does not include all dimensions of health only those incorporated within the simple 
measurement tool. CUA is therefore seen as a pragmatic approach as it is practical (Brouwer and 
Koopmanschap, 2000). Nonetheless, CUA does not address all theoretical considerations.  
1.5.4. Cost-benefit analysis  
Although CUA uses a generic outcome measure which enables comparisons to be made across all 
disease areas, CUA has been criticised for not capturing the broader non-health outcomes which 
are important to individuals, families, communities and society (Edwards et al., 2013a). A 
framework is therefore required to specify what health and non-health outcomes are important, and 
how they should be measured and valued relative to each other. This is the role CBA seeks to play. 
The CBA framework assigns a monetary value to all outcomes so as outcomes can be aggregated 
into a single monetary value and compared with all aggregated costs. If the monetary value of the 
benefits are greater than the costs, then this can be interpreted as an efficient allocation of 
resources in society. CBA is often used by Governments in Impact Assessments for new policies.  
Although CBA is deemed theoretically superior than CUA, the approach is challenging to apply in 
health economic practice (Drummond et al., 2015a). In traditional economics, the market makes it 
possible to use a CBA framework to evaluate services. The market can be analysed to reveal the 
value individuals place on consumed goods. In health economies, the consumption of health 
(where health can be seen as a good) is distorted since individuals who consume health (e.g. 
patients) do not typically purchase health directly through the market. This means market prices do 
not exist for health and social outcomes (Drummond et al., 2015a). As an alternative to market 
prices, the CBA framework can use alternative approaches to generate monetary estimates, such 
as willingness to pay (WTP) methods. WTP methods use hypothetical scenarios to capture what 
prices people claim they would be willing to pay for a particular health outcome. The challenge of 
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applying a CBA approach within public policy is that the hypothetical compensation tests are 
determined by an individual’s pre-existing income and health, which is distributed unevenly across 
society (Donaldson et al., 2002). As a result, some argue that extra-welfarism approaches such as 
CUA may be more fair than welfarist approaches such as CBA (Brouwer and Koopmanschap, 
2000). This is because CUA provides a way to explicitly assign equity weights (utilities) to health 
states so as decisions can be based on need rather than an individual’s WTP. In the absence of 
consensus on what framework should be used for the evaluation public health trials, it is agreed 
that although CUA has limitations, QALYs are useful at illustrating that public health interventions 
are very cost-effective under NICE’s willingness-to-pay per QALY threshold compared to most 
curative interventions (Owen et al., 2012). 
1.6. Need for guidance on conducting economic evaluations 
1.6.1. Insufficient methodological guidance for PA and SB 
The methods used in economic evaluations of PA interventions vary substantially which contributes 
to the mixed results on whether specific PA interventions are good value for money (Vijay et al., 
2016, Williams et al., 2012). Reasons for the variation in the approaches to economic evaluations 
include the fact that researchers come from different countries which support different 
methodological principles and practices (Torbica et al., 2017). Furthermore, the normative and 
pragmatic nature of economic evaluations, as well as the relative infancy of the methods, means 
researchers are required to make a number of methodological choices and assumptions which are 
normative and specific to the intervention, setting and population being evaluated. Examples of 
these choices and assumptions include: what effects and costs should be included in the analysis, 
how inflation should be accounted for (Crowley et al, 2014), how future costs and benefits should 
be discounted, and how uncertainty should be characterised (Weatherly et al. 2009).  
In addition, four additional methodological challenges have been identified as being unique to the 
conduct of economic evaluations of public health interventions, which includes the conduct of PA 
and SB economic evaluations (Weatherly et al., 2009, Alayli-Goebbels et al., 2014). These four 
challenges are explored further in Chapter 2. Addressing these challenges requires adequate 
economic expertise and resources, which may explain why some researchers do not presently 
include a cost-effectiveness analysis in their evaluations. This may also explain why most clinical 
practice guidelines are primarily informed by the evidence from effectiveness evaluations since 
there is a lack of economic data being generated (van Mastrigt et al., 2016). Existing tools are 
available for assessing cost-effectiveness of PA interventions at the policy level, these include the 
MOVE (2.0) tool (Sport England, 2016) and HEAT tool (World Health Organisation, 2014). 
Nevertheless, the tools are restricted to the assessment of just two types of costs (immediate 
intervention operating costs and long-term disease costs). Furthermore, the tools require the user 
to have an aggregate unit cost for the intervention. The tools do not provide guidance on how to 
calculate the aggregate unit cost. Performing a microcosting exercise of new and complex 
interventions can be challenging as human resources (staff’s time) make up a large proportion of 
the costs (Glick et al., 2014, Mogyorosy and Smith, 2005).  
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1.6.2. Multidisciplinary understanding of economic evaluation in PA and SB 
There is widespread interest in economic data with the number of trials collecting economic data 
increasing (Ramsey et al., 2015). In the public sector, year on year the demand for cost data 
continues to grow (Curtis & Burns, 2018). Reasons for this include the fact that in a number of 
countries’ public sector budgets are tighter and healthcare demand is increasing (Weatherly, 
Cookson, & Drummond, 2014). In the UK, it is reported that Public Health Directors are ‘hungry’ for 
economic evidence on the short-term economic impact of the preventative interventions they 
commission (Willmott, Womack, Hollingworth, & Campbell, 2016). Similarly, health and social care 
bodies such as the National Institute for Health and Care Excellence (NICE) in the UK request 
economic evidence to support their decision-making (NICE, 2014a). Furthermore, the MRC 
guidelines for the conduct of evaluations of complex health and public health interventions name 
assessment of cost-effectiveness as a key stage in the evaluation process (Craig et al., 2008). 
Despite calls for economic evaluation to be routine practice in the evaluation of public health 
(Wanless, 2004), the evidence is scarce compared to the evidence on clinical effectiveness. In 
part, this may be due to the international shortage of health economic expertise. That is to say, 
there is a need for health economic training in order to meet the demands of current public health 
challenges (Frew et al., 2018). One reason for the lack of economic evaluations in the field of PA 
and SB may be due to the lack of multidisciplinary working across research centres (Davis et al., 
2014). Multidisciplinary working is important, as economic evaluations of PA and SB intervention 
cover a range of disciplines including: public health, exercise science, economics, policy and 
behaviour change (Davis et al., 2014).  
1.6.3. PA and SB as a priority area 
As public resources are scarce, evidence on the cost-effectiveness of PA and SB interventions is 
required to prevent politicians from disinvesting in highly cost-effective interventions. For example, 
in 2015, UK politicians disinvested £200 million in local public health budgets, which is forecast to 
cost the health sector £1 billion in the long-run (Allen, 2015). If economic evidence is not provided 
to demonstrate how PA and SB interventions can lead to large health gains and cost savings in the 
future, then politicians cannot be held accountable for disinvesting in PA and SB.  
PA and SB interventions are a priority area to gather economic evidence on since the latest UK 
guidelines of PA highlight that there is no minimum amount of PA required to achieve some health 
benefits (Gibson-Moore, 2019). If a range of PA/SB interventions are increasing PA by even just a 
small amount, then there is a need for economic evaluations to help decision-makers understand 
whether the increased amount of PA can be regarded as good value for money compared to the 
amount of PA achieved through alternative interventions.  
Economic evaluations of PA and SB interventions targeted at individuals who are highly sedentary 
is a particularly important area of study compared to other public health challenges. This is 
because these interventions have the potential to be highly cost-effective due to the curvilinear 
relationship between PA and health benefits (Warburton and Bredin, 2016). The curvilinear 
relationship shows that the less active an individual is prior to a PA intervention, the greater the 
health gains are for this individual. Furthermore, PA and SB intervention targeting individual’s who 
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are the least active in society align with the principle of proportional universality, the belief that 
greater efforts and resources should be allocated towards those who are in most need and who 
face barriers to participating in PA (World Health Organisation, 2018).  
1.6.4. The uniqueness of economic evaluation in PA and SB 
PA and SB are particularly challenging field of study in economic evaluation as PA and SB 
interventions are typically delivered in non-healthcare settings. More specifically, the four domains 
where PA and SB interventions are delivered, include: at work (e.g. walking meetings), at home 
(e.g. housework), through transportation (e.g. walking to work) and through leisure (e.g. dance 
classes at a leisure centre) (Strath Scott et al., 2013). This requires the researcher conducting the 
economic evaluation to have an understanding on the setting and organisation in which the 
intervention is implemented (e.g. workplace). Furthermore, PA and SB are both multi-dimension 
behaviours. For instance a PA/SB intervention may attempt to modify an individual’s frequency, 
intensity, time and/or type of PA (Barisic et al., 2011). Modifying these dimensions is likely to 
modify the amount of resources (e.g. time, materials, payments) required to deliver an intervention 
which may impact on the overall cost of the intervention.  
Overall, the multiple domains and dimensions of PA and SB requires that researchers carrying out 
economic evaluations in this area are aware of existing practical tools which can help them capture 
and understand the complex nature of the PA and SB intervention. Furthermore, studying the 
complex nature of PA and SB interventions requires a framework which encourages a 
multidisciplinary approach, since PA and SB cut across multiple disciplines and research fields, 
including: public health, health economics, anthropology, physiology, trial methodology, behaviour 
change. Importantly, a framework needs to describe an approach which can be applied in practice 
and explain why the approach is appropriate. Transparent reporting on what and why a method is 
recommended needs to be a key feature of a framework for PA and SB, so as those using the 
framework can critically appraise the approach outlined. This PhD project aims to develop a 
framework to support the conduct of economic evaluations for individual-level PA and SB 
interventions.  
As well as a framework which draws on knowledge and methods from multiple disciplines, the 
practicability of the framework will be assessed by piloting an initial framework to two case studies. 
These two case studies are: (1) an individual-level PA intervention delivered in a leisure centre (the 
leisure domain) which targets inactive individuals who have pre-existing health conditions; and (2) 
an individual-level SB intervention delivered in a contact centre (workplace domain) which targets 
SB amongst office workers. Targeting individuals with pre-existing health conditions is important as 
they are twice as likely to not be active enough to benefit their health than the general population 
(Public Health England, 2019). Similarly, office workers are also an important population to target 
as research shows that office workers reportedly spend upto 70-85% of their working day sitting 
(Healy et al., 2013, Clemes et al., 2014, Morris et al., 2019). As discussed, due to the curvilinear 
relationship between PA and health benefits, individuals who are less active prior to a PA 
intervention are more likely to achieve the greatest health benefits from an PA or SB intervention 
(Warburton and Bredin, 2016). As these two case studies target two different population groups 
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and are set in two different settings (domains), this provides an important opportunity to generate 
empirical evidence on the applicability of my framework.  
1.7. Epistemological background  
1.7.1. Overview of existing skills and knowledge   
Throughout this PhD project I acknowledge that my understanding on how knowledge can be 
generated and interpreted has been influenced by my previous training and research experience. 
Prior to starting this PhD I had discipline-specific knowledge in anthropology and public health, 
having studied these two subjects for my undergraduate and postgraduate master degrees, 
respectively. Furthermore, prior to undertaking this PhD project, I was employed for almost three 
years as a Research Assistant in Public Health at Liverpool John Moores University. Through this 
employment, I gained a substantial amount of practical experience in the conduct and analysis of 
structured qualitative methods (e.g. focus groups and interviews) and the application of social 
return on investment (SROI) methodology. 
This present PhD project in health economics presented me with the opportunity to train in a new 
field. It also presented me with the opportunity for me to build on my existing anthropology and 
public health skills and knowledge and develop as a true multidisciplinary researcher. Particular 
skills and knowledge I possessed before starting this PhD included: (1) an awareness of our need 
to understand the complexity associated with changing an individual’s lifestyle and cultural norms, 
through my study of anthropology; (2) the burden of noncommunicable disease and inequity on 
society, through my study of and employment in public health; and (3) the importance of capturing 
the wider social, economic and environmental benefits of services and involving stakeholders in the 
data capture process through my SROI work. These existing skills and knowledge have been 
particularly complementary to this PhD as the project focuses on complex individual-level PA and 
SB interventions. In the subsequence sections, I provide an introduction to the methods and 
paradigms that underpin the disciplines of anthropology and public health with the intention 
providing insight into the methods and beliefs I had when I began my PhD journey.   
1.7.2. Studying complexity  
Anthropology is the study of society and culture. Society refers to the way humans organise 
themselves in a meaningful way, such as their patterns of interactions and power relationships. 
Culture refers to the behaviour, beliefs and values adopted by members of society. Societies and 
culture are complex (Hylland-Eriksen, 2001). A key aim of anthropology is to describe how complex 
the real world is, rather than trying to simplify it (Hylland-Eriksen, 2001).  More specifically, 
anthropology aims to document the complex details of everyday life in which interventions, trials 
and policies are implemented, in order to help us understand what is appropriate and why certain 
results have been realised (Lambert and McKevitt, 2002). That is to stay, my anthropological 
background led me to believe it would be valuable to document the complexity of the everyday 
context in which my PhD framework is developed, through the use of anthropological methods 
which are typically informal and less structured approaches.   
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1.7.3. Naturalism and normative statements  
A key contribution of the discipline of anthropology, is the ethnographic methods which derive from 
the discipline, namely participant observation. In participant observation the researcher participates 
in the research activities so as they can document what actually happens. Participant observation 
helps distinguish between normative statements (i.e. what interviewees and focus group members 
say should be done) and actual practice (what was actually done) through the use of informal and 
less structured research methods such as observations, informal conversations and notes made in 
the field (Lambert et al. 2002). Lambert and McKevitt (2002) argue for greater use of informal data 
collection rather than relying solely on formal and structured qualitative methods. They explain that 
structured qualitative data, such as an interviewee’s normative statement, cannot be taken at face 
value. Furthermore, they claim that methods such as one-off interviews do not typically provide the 
broader context for an interviewee’s answer. The authors argue that there may be a difference 
between what the interviewee says and what actually happened, and that we can only know this by 
observing the action for ourselves. This is where methods such as participant observation have a 
key role in helping us understand this knowledge gap between what people say they do or plan to 
do, and what people actually do. That is to say, anthropology believes it is important to observe 
actions and events in their natural context through ethnographic methods (Hylland-Eriksen, 2001). 
Some refer to this belief as the ‘naturalism’ paradigm. The naturalism paradigm suggests that 
people’s actions, behaviour and values documented in their natural context without intervention 
(e.g. an RCT) is a valid source of knowledge. Some even argue that all phenomena should be 
studied in its natural state rather than in an artificial state (Atkinson and Hammersley, 2007). 
1.7.4. Positivism and evidence-based medicine   
The positivist research paradigm involves the testing of theories in artificial settings through 
experimental trials or through statistical control. This paradigm contradicts the belief of the 
naturalism paradigm which suggests actions should be observed in their natural settings. RCT 
methods traditionally belong to the postitivist paradigm, which is the belief that the best way to 
generate knowledge is through the use of standardised quantitative methods which can be 
replicated. In the 20th century, quantitative statistical methods developed rapidly which increased 
the popularity of positivist methods (Atkinson and Hammersley, 2007). In the second half of the 20th 
century, positivist methods continued to grow in popularity. There was a call in the discipline of 
medicine, for all evidence to be derived from positivist methods such as RCTs and systematic 
reviews which involve the testing of hypotheses through physical control, and standardised and 
replicable methods (Cochrane, 1972). Advocates of this new belief in what constituted ‘reliable 
knowledge’ claimed a new paradigm in medical practice was emerging and called this paradigm 
‘evidenced-based medicine’ (Guyatt et al., 1992). Prior to conducting this PhD I had not been 
involved in any clinical trials. That is to say, the Co-PARs and SLaMM trials provided me with the 
opportunity to gain practical experience in how experiments are set up and delivered in practice. 
Through my employment as a Research Assistant, I had been involved in a number of systematic 
reviews in the field of public health. I therefore understood the value of generating evidence from 
more positivist research methods such as systematic reviews which gather data from a large 
sample of studies through a structured and replicable process.  
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1.7.5. Multidisciplinary working and pragmatism  
My masters degree and employment in public health, introduced me to the idea that 
multidisciplinary and pragmatic research methods can improve our understanding of public health 
and health inequity. A recurring piece of literature discussed throughout my masters degree was 
the Marmot Review (2010). This review furthered my interest in inequity and made me aware of the 
relationship between the four major lifestyle diseases in the UK (one of which included physical 
inactivity) and socioeconomic status. In relation to my existing multidisciplinary experience, for 
masters degree I studied a broad range of disciplines including modules in statistics, epidemiology, 
public policy, health economics, sociology and psychology. This made me aware of how the data 
which is generated to improve our understanding of a public health challenge such as physical 
inactivity, can depend on the type of disciplines and research methods used to evaluate the public 
health problem. For example, through my masters I learnt that epidemiological methods 
traditionally study trends across time, places and people, and that psychology methods traditionally 
test hypotheses in artificial settings. This helped me recognise that these two different approaches 
will lead to different types of knowledge being generated. Moreover, through my public health 
employment I learnt more about mixed methods research and how it has an important role in 
addressing public health challenges. More specifically, I gained practical experience of triangulating 
qualitative and quantitative data and seeing how the two different methods can be complementary. 
As I was aware of the strengths of a multidisciplinary approach to addressing public health 
challenges, this PhD project aligns with the pragmatic paradigm. This means that the research 
methods I select to use throughout this thesis are be those which I believed are most appropriate 
for the research question and the context in which they are being applied (Johnson and 
Onwuegbuzie, 2004).   
 
1.7.6. Reporting the development of the framework   
John and Smith (2017) argue that one of the key contributions of anthropology is its generation of 
descriptive ethnographic data which documents and provide explanations on how and why actions 
occur. Throughout this thesis I have reported ethnographic data in the form of reflection boxes. The 
reflection boxes provide insight into how and why I have developed my systematic framework in a 
particular way. Reflective content has been be based on the notes I make in the ‘field’ during my 
PhD project. The ‘field’ in this context will refers to the everyday observations and interactions I 
had. These interactions include the informal meetings I had with stakeholders associated with my 
PhD, namely the researcher team linked to my PhD project (e.g. my supervisory team and the 
other postgraduate researchers), the health economists from Deakin University’s Health 
Economics group (Australia), and the staff from the local authority, leisure centres and workplace 
company in which my two trials were set.  
1.8. Aim of PhD 
The overarching aim of the PhD was to develop a multidisciplinary and pragmatic framework to 
support researchers from multiple disciplines to conduct economic evaluations of individual-level 
PA and SB interventions. These multiple disciplines include those involved in addressing the 
challenge of physical inactivity, namely: physiologists, psychologists, public health professionals 
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and trialists. Whilst the framework will be intended for researchers with limited or no specialist 
training in health economics, the framework may also be of use to health economists seeking a 
standardised approach to economic evaluation of individual-level PA and SB interventions. The 
three key objectives in order to achieve this aim were to: 
1) Conduct a systematic review of existing economic evaluations of individual-level PA and 
SB interventions in order to explore how analysts have addressed four key methodological 
challenges, which are regarded as being unique to the conduct of economic evaluations of 
public health interventions (Study 1, Chapter 2). 
2) Develop an initial framework which draws on good-quality methods identified from the 
systematic review (Chapter 3) 
3) Pilot the initial framework concurrently in two individual-level trials, with the aim of: 
i. Reflecting on the applicability of the framework to a PA trial (Study 2, Chapter 4) 
and SB trial (Study 3, Chapter 5) 
ii. Providing evidence on the cost-effectiveness of a PA on referral scheme 
intervention (Study 2, Chapter 4) and a workplace SB intervention (Study 3, 
Chapter 5) 
Chapter 6 synthesises the empirical findings from the studies 1-3 in order to recommend a refined 
version of the framework, make recommendations for future research, and consider implications for 
policy and practice. Figure 1 shows how each objective feeds into the subsequent studies and 
chapters. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of PhD
 
 
Chapter 2: Systematic review of the methods used in 
economic evaluations of individual-level PA and SB 
interventions 
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2.1. Introduction 
Despite recommendations for economic evaluations to become routine within public health 
interventions (Kelly et al., 2005) cost-effectiveness information on PA and SB interventions remains 
scarce (Abu-Omar et al., 2017). One reason for this lack of analysis may be due to the lack of 
guidance and multidisciplinary efforts to inform analysts on how to conduct economic evaluations in 
the field of public health (Davis et al., 2014). Economic evaluations of public health interventions 
are subject to four key methodological challenges identified and described in former reviews (Hill et 
al., 2017, Alayli-Goebbels et al., 2014, Weatherly et al., 2009) as: attribution of effects; measuring 
and valuing outcomes; identifying intersectoral costs and consequences; and incorporating equity.  
The first review to explore the economics of public health was conducted by Weatherly et al. 
(2009). These authors were the first to specify and name the four key methodological challenges 
for public health economic evaluations. The authors identified the four challenges after reviewing 
five reviews which discussed the economics of public health. The inclusion criteria for the review by 
Weatherly et al. (2009) was broad as it included economic evaluations from 11 public health areas. 
That said, the authors only reviewed studies published between 2000-2005. In total, 154 NHS 
Economic Evaluation Database (NHS EED) abstracts were examined, of which 53 related to the 
field of obesity and PA. The study identified four studies (3%) which claimed to be CBA, but the 
review authors reported that after further examination these were not CBAs but three CCAs and 
one CUA. Overall, the review authors claimed they gained little insight on how to address the four 
methodological challenges for public health studies. 
The review by Alauli-Goebbels et al. (2014) refers to methodological challenges identified by 
Weatherly et al (2009) and also assesses methodological quality of the studies. Furthermore, the 
review focuses on six key behaviour change areas: smoking, PA, dietary behaviour, drug use, 
alcohol use and sexual behaviour. The authors carried out their searches in 2009 and identified 
142 eligible studies which had been published between 1981-2009. Seventeen of these studies 
assessed PA. The authors reported that an overarching finding from their review was that that the 
studies do not always report sufficient details around the methods and study design they used. 
They explain that this made it difficult to see how studies had handled the methodological 
challenges. In relation to PA, the authors reported identifying studies which commented on 
psychological wellbeing being a broader outcome of PA interventions, however they reported that 
analysts did not incorporate this outcome into their economic evaluations.  
The study by Hill et al. (2017) reviewed 27 economic evaluations and priority-setting studies in the 
field of alcohol prevention, published between 2006-2016. The reviewers concluded that studies in 
the field of alcohol prevention are not addressing the methodological challenges unique to public 
health challenges. They found that most studies did not consider: long-term outcomes, wider 
perspectives or equity. They also reported a lack of CBA, CCA and priority setting studies. That 
said the reviewers did identify one CBA study, although they report that the authors of the CBA do 
not explain how they monetised the health benefits included in the analysis.  
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Overall, all three reviews explore the empirical evidence to see how the methodological challenges 
associated with public health are being addressed in practice. A key observation, is that all three 
reviews discuss how the studies do not provide sufficient detail on the methods they carried out. 
Although the study by Hill et al. (2017) looks at these challenges more recently, they focus on 
alcohol prevention. That is to say, there has been no review published on the methods used in PA 
economic evaluations since Alauli-Goebbels et al. (2014) conducted their searches in 2009. Since 
2009 there has been several reporting guidelines published in the fields of trial methodology 
(Schulz et al., 2010), intervention design (Hoffmann et al., 2014), economic evaluation (Husereau 
et al., 2013) and equity (Welch et al., 2017). That is to say, if authors are now required to report 
more detail on the methods they have used, this data has the potential to improve our 
understanding on the four methodological challenges can be addressed in PA-related studies. The 
four methodological challenges are described in greater detail in the subsequence sections. 
2.1.1. Challenge 1: Attribution of effects 
Randomised controlled trials (RCTs) are the gold standard for evaluating the effectiveness of an 
intervention. RCTs alone are however insufficient to inform long-term investment decisions in 
health systems aiming to be sustainable. This is because conducting experimental studies such as 
RCTs over many years or decades is likely to be resource intensive from both the research funder 
and participant’s perspective. Attrition from the trial and insufficient funding is inevitable. Yet, the 
greatest health outcomes and cost savings attributable to PA and SB interventions do not typically 
manifest until decades after an intervention has taken place.  Due to this long pay-back time 
(Wanless, 2004), it is recommended economic evaluations link up trial-derived intermediate or 
surrogate outcomes with additional sources of evidence (e.g. observational studies) (Ramsey et al., 
2015). 
2.1.2. Challenge 2: Measuring and valuing outcomes  
Previous PA studies have used different outcomes, or have classified the same type of outcomes 
in different ways, which makes it challenging to meaningfully use cost-effectiveness results and 
compare interventions (Abu-Omar et al., 2017). This is likely to be because PA and SB 
interventions are associated with a broad range of outcomes, many of which are not captured in 
evaluations that conduct just one type of valuation analysis. Furthermore, many broader important 
and relevant outcomes such as improved wellbeing or someone’s ability to return to work are 
difficult to assign a monetary value, as they do not have a market price (Weatherly et al., 2014).  
2.1.3. Challenge 3: Identifying intersectoral costs and consequences 
Many PA and SB interventions take place outside of the healthcare setting, necessitating a time 
and equipment commitment from intervention participants and providers (which has an opportunity 
cost). Moreover, PA and SB interventions are complex, impacting on multiple sectors 
simultaneously (Dahlgren and Whitehead, 1991). Therefore, it is important to consider the impact 
of these interventions on other stakeholders including public sector agencies beyond the health 
sector, private individuals and the voluntary sector (Weatherly et al., 2014, Weatherly et al., 2009). 
Yet, as there is no universal definition for each perspective type, the costs and consequences 
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deemed relevant for inclusion in the analysis is primarily analyst-dependent (Husereau et al., 
2013). 
2.1.4. Challenge 4: Incorporating equity  
A key objective in public health is to reduce inequity, meaning inequalities that are avoidable, but 
have not yet been avoided and are therefore unfair (Marmot and Allen, 2014). By contrast, a key 
objective in economic evaluation is to maximise efficiency across the whole population (Weatherly 
et al., 2014). If authors fail to acknowledge equity by not adapting their existing economic analysis 
approach, it is not transparent which socio-economic group have gained or lost out due to a 
resource allocation decision. Until the recent publication by Cookson et al. (Cookson et al., 2017) 
recommendations on how to incorporate equity have been limited within international and national 
guidelines for economic evaluation (Sanders et al., 2016, Ramsey et al., 2015, NICE, 2014a, 
Husereau et al., 2013). Approaches for incorporating equity into the analysis described by Cookson 
et al. (2017) include: equity impact analysis, equity constraint analysis and equity weighting 
analysis. 
2.1.5. Aim 
In an attempt to learn how the four challenges outlined above have been addressed in practice, this 
systematic review aims to provide an overview of the methods used in economic evaluations of PA 
and SB interventions since 2009. Alayli-Goebbels et al. (2014) and Weatherly et al. (2009) 
reviewed the methods reported in economic evaluations of a range of public health areas including 
17 and 26 PA economic evaluations published up to 2005 and 2009, respectively, but the reviews 
found little insight from the empirical evidence. Economic evaluation is a rapidly developing field 
especially with the growth of decision-analytic modelling and the economic evaluation reporting 
standards (Drummond et al., 2015b, Ramsey et al., 2015). Accordingly, there is a strong rationale 
to provide an update on methods carried out since 2009. 
2.2. Methods 
2.2.1. Information sources and search strategy 
A comprehensive search took place across six electronic databases that host reports from the 
medical and economic field (Medline via Ovid; SPORTSDiscus, EconLit and PsycINFO via 
EBSCOHost; NHS EED and HTA via the Cochrane Library). The database NHS EED stores 
records up to April 2015, thus searches in this database went up to 2015 only. Additional, 
supplementary searching was performed: key websites were searched for studies that included 
specific free text terms: ‘PA’, ‘SB’, ‘economic’ and ‘cost’; reference lists of two relevant systematic 
reviews (Gc et al., 2016, Wu et al., 2011) were hand searched; and protocols that met the majority 
of the eligibility criteria were used to search for completed studies via online searching and 
contacting the authors. An example of the full electronic search strategy for Medline is provided in 
Appendix A.1. This search was replicated for all databases, with amendments made as appropriate 
to align terms with individual database index terms.  
2.2.2. Study selection 
The protocol for this review can be retrieved from the PROSPERO database for registered 
systematic reviews (registration number CRD42017074382). Full economic evaluations of 
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interventions targeting individuals aged 16 years or over, who are defined as being physically 
inactive or sedentary, were eligible for inclusion in the review. Population level interventions were 
excluded as well as protocols. Eligible studies needed to capture PA and SB at two or more time 
points to observe if a change in behaviour has occurred. Comparators could be any alternative 
intervention including no intervention. Interventions and comparators targeting multiple behaviours 
such as PA and diet were excluded unless the multiple behaviours were PA and SB. Both trial and 
model based economic evaluations were eligible. Letters to editors and conference briefings were 
excluded. Both published and unpublished ‘grey’ literature were included. Abstracts where the full 
text could not be retrieved were excluded. Only English language studies were included due to the 
restricted language skills of the reviewers available. Eligibility criteria was applied during both 
screening phases. The present systematic review identifies and discusses studies published from 
January 2009 to March 2017. In addition, a rapid systematic scoping search was performed in 
Medline to understand whether new studies had been published in this area from March 2017 to 
January 2019. Details on methods of the scoping search are not discussed below, rather they are 
presented in Appendix A.2. 
2.2.3. Screening 
During the title and abstract screening phase two reviewers (first author, seventh author) screened 
10% (n=612/ 6,123) of the studies and there was a disagreement rate of 2.94% (n=18). Reviewers 
discussed the disagreements and resolved them without the need to seek the expertise of a third 
reviewer. Reviewer one (first author) went on to screen the rest of the studies, informed by the 
disagreement discussions. Similarly, during the full text screening phase reviewer two (seventh 
author) screened 10% (n=15/ 153) of the studies. There was disagreement for 33.33% (n=5) of the 
studies. The reviewers discussed the disagreements and again a consensus was met without the 
need for a third reviewer. Figure 2 shows an overview of the study selection process. 
2.2.4. Data extraction 
A data extraction form was developed based on the items featured on the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) checklist (Husereau et al., 2013). The form 
was piloted independently by two reviewers (first author, seventh author) on two (10%) randomly 
selected studies. Following discussions the form was shortened, and items relevant to the four 
methodological challenges, and key study characteristics were retained. Following the piloting 
stage, the first reviewer extracted data for the remaining studies. A template of the final data 
extraction form is provided in Appendix A.3. It was not necessary to request additional information 
from the study authors.  
2.2.5. Quality assessment 
Drummond’s 10-item checklist was selected as it is one of the most widely used quality 
assessment tools (Drummond et al., 2015b). A component approach was used when applying the 
checklist in Appendix A.4. This approach is advocated in the PRISMA statement and entails 
assessing each item individually rather than generating a summary score (Liberati et al., 2009). 
Two reviewers (first author, seventh author) independently conducted the quality assessment for 
10% (n=2/ 15) of the included studies. Disagreement was limited to item 6 (Item 6: Were costs and 
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consequences valued credibly?) on the checklist, examples in Drummond et al. (2015b) were 
consulted to overcome these disagreements. Practical application of item 10 (Item 10: Did the 
presentation and discussion of study results include all issues of concern to the users?) was 
challenging due to the limited guidance, thus findings from this question are less informative. Alayli-
Goebbels et al. (2014) also experienced this barrier in an earlier version of the checklist.  
2.2.6. Method of analysis 
The published narrative synthesis framework by Popay et al. (2006) guided the analysis to ensure 
a transparent and systematic approach was performed. The narrative synthesis in this review goes 
beyond describing how authors have addressed each of the four challenges by attempting to 
explain why specific approaches have been chosen. The analysis was an iterative process. A priori 
analysis involved tabulating the data and producing bar charts on key study characteristics: study 
design, time horizon, valuation technique, study perspective and explicit/ implicit equity analysis. 
The same study characteristics were focused on in the two former methodological reviews 
(Weatherly et al., 2009, Alayli-Goebbels et al., 2014). The wider literature also indicated that the 
following contextual factors were important to review when understanding an analyst’s approach: 
intervention setting, country and year of publication. Additional ad hoc analyses were performed 
where trends became apparent. Lastly, the strength of the narrative synthesis and the conclusions 
derived from it were considered by reflecting on the quantity of studies and results of the quality 
assessment.  
2.3. Results 
A total of 15 economic evaluations (17 publications) were included in the review (Figure 2). 
Searching across Medline, SPORTSDiscus, EconLit, PsychINFO, NHS EED and HTA databases 
retrieved 7,063 records. Supplementary searching retrieved six additional records including: two 
records from hand searching on key websites, two from the reference list of a systematic review 
(Gc et al., 2016), and a further two from searching for the completed studies of two protocols (Kolt 
et al., 2009, de Vries et al., 2013) in Appendix A.5. After removing duplicates 6,129 records 
remained of which a further 5,907 records were removed as title and abstracts did not meet the 
eligibility criteria. During the full text screening, 159 citations were examined in further detail, of 
which 142 studies were excluded. Reasons are outlined in Figure 2.  
 
 
45 
 
 
Figure 2. PRISMA flow diagram representing study selection process 
2.3.1. Study characteristics 
Of the 15 studies, ten were single trial-based economic evaluations and five were model-based; no 
studies were single trials that had extrapolated or modelled their results. Table 1 provides an 
overview of study characteristics for the trial- and model-based studies respectively. Studies are 
arranged by country followed by year of publication. Interventions were set in primary care, 
community and the home, and setting did not appear to be related to intervention type or country. 
As shown in Table 1, no studies targeted SB as an independent risk factor from PA. The range of 
interventions was limited to the following types: PA programme/ on prescription in primary care 
(n=9); brief advice in primary care (n=2); home-based informational advice (n=1); PA in a physical 
therapy setting (n=1); and fall prevention programme in both primary care and the home (n=1). The 
remaining study compared strategies for recruiting to PA interventions in primary care. The overall 
range of adult-based interventions matches the narrow range identified in a recent review of 
reviews focussing on the economic results of PA interventions (Abu-Omar et al., 2017). Studies 
came from four high-income countries. More than half (n=8) of the 15 studies came from the UK, 
with the remaining coming from New Zealand (n=3), the USA (n=2), and the Netherlands (n=2) 
(Table 1).  
2.3.2. Quality assessment 
Overall, studies performed well against Drummond’s 10-item quality assessment checklist 
(Drummond et al., 2015b) in Appendix A.4. Nevertheless, six studies scored ‘No’ on at least one 
item: two studies did not state their perspective (item 1); three studies did not include all costs and 
consequences relevant to their stated perspective (item 4); one study did not discount its costs and 
consequences (item 7); and one study did not report their price source (item 6). Interpretation on 
whether item 4 was met by any of the ten trial-based economic evaluations who captured costs and 
outcomes at two years or less is up for debate. It could be argued that not all important and 
relevant costs and consequences can be identified for studies, which do not take a systems 
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approach (e.g. if they do not consider the impact on the wider system in which an intervention is 
being implemented nor capture the long-term impact) (Rutter et al., 2017, Squires et al., 2016). In 
order to align with other reviews which have used Drummond’s checklist, the quality assessment 
results for item 4 were based on the checklist’s accompanying guidance (Drummond et al., 2015b). 
Costs and consequences identified, measured and valued are discussed in greater depth in the 
subsequent sections. 
 
 
Table 1. Overview of economic evaluations. 
Trial-based economic evaluations 
Study &  
Year of 
publication 
Stated 
perspect
ive  
Country Population targeted Sampl
e size 
Intervention  Comparator Setting Valuation 
technique 
Iliffe et al. 
2014 
Health 
sector 
UK Inactive ≥65 years old 
who had fallen less 
than times in the 
previous 12 months 
100 Falls Management 
Exercise Programme 
(Weekly group 
exercise class & 2 
home-based exercise 
sessions) 
Usual care (no 
intervention);  
Otago Exercise 
Programme  
Primary 
care & 
community 
(as Home-
based) 
CEA 
Edwards et al. 
2013;  
Murphy et al. 
2012 
Multi-
agency 
public 
sector  
UK Sedentary, and over 
16 years, with risk 
factors for coronary 
heart disease, or mild 
to moderate anxiety, 
depression or stress. 
798 ERS (primary care) Information leaflet 
only 
Primary 
care 
CUA 
Boehler et al. 
2011 
Health 
sector 
UK Inactive adults, 16 to 
74 years old 
46 Opportunistic 
recruitment strategy 
for PA interventions  
Disease register 
strategy; Hypothetical 
no intervention 
strategy 
Primary 
care 
CEA 
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Shaw et al. 
2011 
Not 
reported 
UK Inactive, adults (age 
not defined) 
79 Individualised walking 
programme: a 
pedometer and a 30-
min consultation  
Individualised walking 
programme: a 
pedometer, but and 5 
min brief advice 
Primary 
care 
CEA 
Larsen et al. 
2015 
Payer USA Inactive Latina women, 
18-65 years old 
266 Home print-based 
mail-delivered MVPA 
intervention 
linguistically and 
culturally adapted for 
Latinas 
Wellness contact 
(information on health 
topics excluding 
MVPA) 
Home-
based 
CEA 
Young et al. 
2012 
Societal  USA Women, following 
coronary artery bypass 
surgery  
40 Symptom 
management 
intervention delivered 
by telehealth device 
to improve the PA 
level  
Usual care, 2 week 
follow up call by the 
primary providers and 
cardiac specialists 
Community CEA 
de Vries et al. 
2016 
Societal  
 
Netherlands Sedentary adults (or at 
risk of losing active 
lifestyle in near future) 
with mobility problems, 
≥70 years old 
130 Patient-centred 
physical therapy  
Usual care for 
physical therapy, less 
patient-centred 
Physical 
therapy 
setting 
CUA 
 
 
49 
 
Maddison et 
al. 2015 
Not 
reported 
New Zealand  ≥18 years old with 
diagnosis of IHD within 
previous 3- 24 months.  
171 Exercise prescription 
and behavioural 
support by mobile 
phone text messages 
and internet  
Usual care 
(participation in usual 
Cardiac 
Rehabilitation e.g. 
education session 
and psychological 
support) 
Home-
based 
CEA; CUA 
Leung et al. 
2012 
Public 
health 
system 
and 
participa
nt  
New Zealand Inactive adults, ≥65 
years old 
330 Pedometer-based 
prescription, focus 
was on step-related 
goals  
Green prescription, 
focus was on PA 
time-related goals 
Community CEA; CUA 
Elley et al. 
2011 
Societal  New Zealand Inactive, 40- 74 years 
old 
974 Enhanced green 
prescription, 10 min of 
brief advice and a 
written exercise 
prescription with 
telephone support at 
9 months and 30min 
face-to-face support 
at 6 months. 
Usual care from GP 
(not standard green 
prescription, usual 
care from GP not 
defined) 
Primary 
care 
CEA 
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Model-based economic evaluations 
Study &  
Year of 
publication 
Stated 
perspect
ive  
Country Population 
targeted 
Model type & 
size of 
simulation 
cohort 
Intervention  Comparator Setting Valuation 
technique  
Campbell et 
al. 2015 
Health 
Sector 
UK Sedentary 
adults, ≥50 
years old 
Markov model 
(100,000 
simulation 
cohort) 
ERS (primary care) Usual care (refers to 
Pavey et al. 2011’s 
definition) 
Primary care CUA  
Anokye et al. 
2012; Anokye 
et al. 2014  
Health 
sector; 
Health 
sector 
and 
participa
nt for 
CCA 
UK Inactive, 
≥33 years 
old 
Markov model 
(100,000 
simulation 
cohort) 
Brief Advice (primary 
care) 
Usual care (no  
intervention) 
Primary care CUA (and 
CCA) 
Anokye et al., 
2011 
Health 
sector  
UK Sedentary 
adults, 40-
60 years old 
Decision tree 
model (1,000 
simulation 
cohort) 
ERS (primary care) Usual care (refers to 
Pavey et al. 2011’s 
definition) 
Primary care CUA 
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Pavey et al. 
2011 
Health 
sector 
CUA; 
Partial-
societal 
for CCA 
UK Sedentary 
adults, 40-
60 years old 
Decision tree 
model (1,000 
simulation 
cohort) 
ERS (leisure centre) Usual care (no 
active ingredient- 
PA advice or 
leaflets) 
Leisure-
centre  
CUA (and 
CCA) 
Over et al. 
2012 
Health 
sector 
Netherlands Inactive, 20- 
65 year olds 
Markov model 
(100,000 
simulation 
cohort) 
GP pedometer 
prescription, 
counselling combined 
with pedometer use 
Usual care (no 
intervention) 
Primary care CUA 
 ERS: Exercise Referral Scheme; GP: General Practitioner; MVPA: Moderate-to-vigorous PA; CEA: cost-effectiveness analysis; CUA: Cost-utility analysis 
 
 
2.3.3. Challenge 1: Attribution of effects 
Two thirds (n=10) of the studies in this review, all trial-based, did not compare the costs and 
consequences of the comparator groups beyond the trial follow up period (Table 2). More 
specifically, one study compared costs and consequences over a two-year period (Elley et al., 
2011), the remaining nine had a time horizon of 12-months or less. For six of these studies, authors 
referred to their short time horizon as a limitation of their study (de Vries et al., 2016, Leung et al., 
2012, Boehler et al., 2011, Larsen et al., 2015, Edwards et al., 2013b, Shaw et al., 2011). For 
instance, it precluded the incorporation of any potential long-term healthcare savings (Larsen et al., 
2015). Just one study suggested future modelling exercises could be used to address this 
challenge (Edwards et al., 2013b). Yet, for Shaw et al. (Shaw et al., 2011) a short-time horizon was 
justified as they reported there was insufficient data to extrapolate their results over the 
participants’ lifetime.  
By contrast, all five model-based studies extrapolated a pooled trial-derived effectiveness estimate 
over the rest of the participants’ lifetime; bridging the gap between the short- and long-term 
evidence (Table 2). Nevertheless, the assumptions underpinning the model-based studies varied 
considerably. Two studies (Anokye et al., 2011, Pavey et al., 2011b) made large assumptions 
unsupported by evidence about the duration of the effect, assuming that any short-term change in 
PA observed in the trials 6-12 months after the intervention, would be long-lasting. Over et al. 
(2012) employed a different approach by extrapolating an effect estimate, observed at 18 weeks, 
over a 40-year time horizon (the life expectancy of the participants). The authors assumed that only 
25% of the effect recorded at 18 weeks would remain over the 40-year time horizon; they too 
reported that their assumptions were unsupported by evidence. These findings demonstrate how 
studies will vary according to the assumptions made. It is therefore important that end-users of 
cost-effectiveness results check they agree with the assumptions that underpin the economic 
evaluation. 
Assumptions underlying the two other model-based studies (Campbell et al., 2015a, Anokye et al., 
2012) were supported by three robust cohort studies. Campbell et al. (2015a) replicated Anokye et 
al.’s (2012) approach. More specifically, they linked the short-term change in PA level observed in 
trial data, with Hu et al.’s (2007, 2003, 2005) cohort studies that followed a group of active and 
inactive individuals for a duration of at least 10 years to predict how their activity levels and risk of 
disease changed over time. Anokye et al. (2012) explain how their identification and use of the 
cohort studies has strengthened previous modelling attempts in the field of PA. Campbell et 
al.(2015a) reported this approach has enabled more conservative assumptions to be made around 
changing PA levels and disease development over time. 
 
 
 
Table 2. Time horizon and types of outcomes compared to costs 
Trial-based economic evaluations 
Study &  
Year of publication 
Time 
Horizon (trial 
follow up) 
Types of outcomes compared to costs per valuation technique 
Larsen et al. 2015 Trial 
duration (12 
months) 
CEA: Cost per minute of increase in PA 
Iliffe et al. 2014 Trial 
duration (12 
months) 
 
CEA: Cost per participant reaching or exceeding 150 minutes of moderate-to-vigorous PA per week  
Young et al. 2012 Trial 
duration  (3 
months) 
CEA: Cost per incremental change in daily estimated energy expenditure;  
 
CEA: Cost per the incremental change in minutes spent on moderate-to-vigorous activity 
Elley et al. 2011 Trial 
duration (24 
months;   12 
months) 
CEA: Cost per participant achieving 150 minutes of moderate intensity activity per week 
Boehler et al. 
2011 
Trial 
duration    (3 
months) 
CEA: Cost per participant achieving 150 minutes of moderate intensity activity per week 
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Shaw et al. 2011 Trial 
duration (12 
months) 
CEA: Cost per additional person achieving the target of a weekly increase of ≥ 15,000 steps. 
Maddison et al. 
2015 
Trial 
duration (24 
weeks /      
[6 months]) 
CEA: Cost per MET-hour of walking and leisure activity;  
CUA: Cost per short-term QALY gain 
Leung et al. 2012 Trial 
duration (12 
months) 
CEA: Cost per 30 minutes of weekly leisure walking;  
CUA: Cost per short-term QALY gain 
 
de Vries et al. 
2016 
Trial 
duration   
(6 months) 
CUA: Cost per short-term QALY gain 
 
Edwards et al. 
2013;  
Murphy et al. 2012 
Trial 
duration (12 
months) 
CUA: Cost per short-term QALY gain 
 
 
 
 
 
 
 
 
55 
 
Model-based economic evaluations 
Study &  
Year of publication 
Time 
Horizon (trial 
follow up) 
Types of outcomes compared to costs per valuation technique 
Campbell et al. 
2015 
Lifetime CUA: Cost per short-term QALY gain (mental health gain); Cost per QALYs associated with coronary heart 
disease, stroke, type 2 diabetes due to reduced risk for developing these health states 
Anokye et al. 
2012; Anokye et 
al. 2014  
Lifetime CUA: Cost per short-term QALY gain (mental health gain); Cost per QALYs associated with coronary heart 
disease, stroke, type 2 diabetes due to reduced risk for developing these health states 
CCA: Same outcomes outlined below for Pavey et al.’s (2011) CCA 
Anokye et al., 
2011 
Lifetime CUA: QALYs associated with coronary heart disease, stroke, type 2 diabetes due to reduced risk for developing 
these health states 
Pavey et al. 2011 Lifetime CUA: Cost per short-term QALY gain (mental health gain); Cost per QALYs associated with coronary heart 
disease, stroke, type 2 diabetes due to reduced risk for developing these health states 
CCA: Mental health (anxiety), Mental health (depression), Metabolic diabetes, Colon cancer, Breast cancer , 
Lung cancer, Hypertension (cardiovascular), Coronary Heart Disease, Stroke, Musculoskeletal (Osteroporosis), 
Musculoskeletal (Osteroarthritis), Lower back pain, Rhumatoid arthritis, Falls prevention, Absenteeism at work, 
Injury (disbenefit), Disability 
Over et al. 2012 Lifetime CUA: QALYs associated with myocardial infarction, stroke, diabetes, colorectal cancer, breast cancer due to 
reduced risk for developing these health states 
RCT: randomised controlled trial; cRCT: cluster randomised controlled trial; CEA: Cost-effectiveness analysis; CUA: Cost-utility analysis; CCA: cost-consequence analysis; 
MET: Metabolic Equivalent of Task 
 
 
2.3.4. Challenge 2: Measuring and valuing outcomes 
No studies in this present review conducted a cost-benefit analysis (CBA), despite health 
economists (Drummond et al., 2015b) stating this approach is superior to cost-utility analysis (CUA) 
(Drummond et al., 2015b). Recent UK and US guidelines recommended that studies report a broad 
range of outcomes alongside their economic analyses, through the use of approaches such as 
CBA, cost-consequence analysis (CCA) or an impact inventory (Sanders et al., 2016, NICE, 
2014a). Two studies (Anokye et al., 2012, Pavey et al., 2011b) included a CCA conducted 
alongside a CUA. A broad range of health outcomes were included in their CCA (Table 2) yet the 
only non-health outcome reported was absenteeism. 
Two thirds (n=11) of the studies presented just one type of valuation technique, either a CUA (n=5) 
or cost-effectiveness analysis (CEA) (n=6) (Table 2). Table 2 demonstrates further how despite 
having the same aim to increase PA levels and same valuation technique, the way results are 
presented to the end-user are inconsistent. Young et al. (Young et al., 2012) performed two CEAs 
reporting on the ‘cost per incremental change in daily estimated energy expenditure’ and ‘cost per 
incremental change in minutes spent on moderate-to-vigorous activity’. Three other studies (Iliffe et 
al., 2014b, Elley et al., 2011, Boehler et al., 2011) performed a different type of CEA reporting on 
‘cost per participant achieving 150 minutes of moderate PA per week’. The most common way to 
present the result of the valuation analysis was as ‘cost per short-term quality-adjusted life year 
(QALY) gain’. Nevertheless, this was reported for just under half (n=7) of the economic evaluations: 
four trial-based (Maddison et al., 2015, Leung et al., 2012, Edwards et al., 2013b, de Vries et al., 
2016) and three model-based (Campbell et al., 2015a, Anokye et al., 2012, Pavey et al., 2011b) 
studies. All model-based studies conceptualised the long-term gain in QALY in the same way, in 
terms of the QALYs gained due to not developing coronary heart disease, stroke or type 2 
diabetes, or experiencing premature mortality. Over et al.’s (2012) analysis differed slightly, as they 
also included colorectal and breast cancer. 
Rationale for the inclusion and exclusion of trial-derived QALYs varied considerably. Shaw et al. 
(Shaw et al., 2011) argued against the inclusion of trial-derived QALYs in their analysis, explaining 
it would be unnecessarily restrictive since evidence already shows that PA is associated with a 
reduction in NCD and premature mortality, which in turn is associated with a much greater gain in 
QALYs than trial-derived QALYs. Three model-based studies (Campbell et al., 2015a, Pavey et al., 
2011b, Anokye et al., 2012) deemed it appropriate to incorporate both short-and long-term gain in 
QALYs. They conceptualised the short-term QALY gain as being a one-off gain in mental health, 
which they assumed would be achieved as a result of becoming physically active for at least 90 
minutes per week. They assumed the one-off mental health benefit would last for just one year, 
which they claimed was a conservative assumption. Campbell et al. (2015a) reported that their 
cost-effectiveness result was highly sensitive to the inclusion and exclusion of the one-off gain in 
mental health.  
 
2.3.5. Challenge 3: Identifying intersectoral costs and consequences 
The most commonly reported perspective was the health sector perspective (n=7) (Table 1). Six of 
the eight studies from the UK were from this perspective. In 2014, the UK reference case was 
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updated to recommend the public sector perspective when conducting economic evaluations of 
public health interventions (NICE, 2014a). The multi-agency public sector perspective adopted by 
Edwards et al. (2013b) reflects the start of this paradigm shift. Two more recent UK studies 
(Campbell et al., 2015a, Iliffe et al., 2014b) did not adopt a public sector perspective. Despite 
studies being conducted from the same perspective, the type of costs identified as relevant varied 
within and across countries and intervention type. This weakness was identified through the quality 
assessment (Item 4 on Appendix A.4), as five studies (Young et al., 2012, de Vries et al., 2016, 
Boehler et al., 2011, Maddison et al., 2015, Shaw et al., 2011) did not relate their costs to a study 
perspective. More specifically, two studies did not report their perspective (Shaw et al., 2011, 
Maddison et al., 2015) and three included a narrower range of costs and consequences than would 
be expected for their stated perspective (Boehler et al., 2011, Young et al., 2012, de Vries et al., 
2016). For example, two studies stated their study was from the societal perspective yet assessed 
only direct intervention costs and short-term healthcare savings (de Vries et al., 2016, Young et al., 
2012), which were the same costs as studies which stated taking a health sector perspective 
(Table 1) Weatherly et al. (2009) also found that many studies included only a narrow range of 
costs within their stated study perspectives.  
 
Figure 3. Cost categories identified across all 15 studies 
Figure 3 shows that seven cost categories were identified across all 15 included studies. Like the 
findings in this review, Alayli-Goebbels et al. (2014) found the most common type of cost reported 
was the intervention costs, followed by healthcare costs. Participant out-of-pocket expenses and 
productivity losses appeared in only a small proportion of studies in this review and Alayli-Goebbels 
et al.’s (2014) review. Although most studies looked at both the direct and indirect costs of the 
interventions, only Edwards et al. (2013b) looked at the unintended productivity costs to the 
provider. More specifically, they examined whether the provider where the intervention was set (the 
leisure centre) experienced a loss in revenue, as a result of providing the intervention.  
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2.3.6. Challenge 4: Incorporating equity 
The two former reviews found that authors did not routinely consider equity in their analysis (Alayli-
Goebbels et al., 2014, Weatherly et al., 2009). Table 3 shows that all but one study (Shaw et al., 
2011) included in the present review did consider equity. All but one study (Edwards et al., 2013b) 
did this implicitly, conducting subgroup analyses of the cost-effectiveness result (n=6) or targeting 
the intervention at a population deemed in need of intervention (n=8). Edwards et al. (2013b) were 
the only authors to explicitly discuss equity and to consider socio-economic status in their equity 
analysis. They did this by asking participants from areas of different levels of deprivation about how 
much they would be willing to pay to participate in the intervention of interest; thus informing the 
reader about participants’ economic preferences. Notably this was an exploratory analysis and so 
the results were not incorporated in the CUA.  
Table 3. Types of equity considered 
Subgroup analyses of 
cost-effectiveness result 
Campbell et al. 2015 Pre-existing condition 
Pavey et al. 2011 Pre-existing condition 
Anokye et al. 2011 Pre-existing condition 
Edwards et al. 2013;  
Murphy et al. 2012 
Medical diagnosis 
Referral reason 
Adherence to scheme 
Gender 
Inequalities 
Age group 
Over et al. 2012 Age group 
Anokye et al.2012 ; 
Anokye et al. 2014 
Age group 
Intervention targeted at 
equity group 
de Vries et al.2016 Frail older adults with mobility 
problems 
Leung et al.2012 Older adults  
Iliffe et al. 2014 Older adults  
Boehler et al. 2011 Older adults  
Maddison et al. 2015 People with ischaemic heart 
disease 
Elley et al. 2011 Females 
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Young et al. 2012 Females 
Larsen et al. 2015 Latinas 
Willing to pay question Edwards et al. 2013;  
Murphy et al. 2012 
Socio-economic status (level of 
deprivation) 
 
Table 3 details the eight studies which targeted their intervention at a specific population group as 
well as the six studies that performed subgroup analyses of their cost-effectiveness result. Older 
adults was the most common equity subgroup targeted for intervention (de Vries et al., 2016, Iliffe 
et al., 2014b, Leung et al., 2012, Boehler et al., 2011), followed by females (Young et al., 2012, 
Elley et al., 2011). The most common subgroup analyses were on pre-existing condition/ medical 
diagnosis (Pavey et al., 2011b, Anokye et al., 2011, Edwards et al., 2013b, Campbell et al., 2015a) 
and age group (Edwards et al., 2013b, Over et al., 2012, Anokye et al., 2012). Edwards et 
al.(2013b) carried out seven types of equity analyses, all other authors conducted just one type. 
Furthermore, no studies attempted alternative equity analyses, such as an equity constraint or 
equity weighing analysis (Cookson et al., 2017).  
2.3.7. New studies  
The results of the rapid systematic scoping search are presented in Appendix A.2. In brief, four 
additional studies were identified as meeting the inclusion criteria of this review. Notably, one study 
(Gao et al., 2018) was an intervention targeting SB as an independent risk factor from PA. 
Furthermore, two studies (Gao et al., 2018; Harris et al., 2018) were both trial-and model-based 
economic evaluations, as the analysts had extrapolated their within-trial results a lifetime horizon. 
2.4. Discussion 
This review identified 15 economic evaluations of interventions that targeted physically inactive 
adults, and no economic evaluations of interventions that targeted sedentary adults (where SB was 
addressed an independent risk factor from PA). Like Abu-Omar et al’s (2017) review of reviews 
which focuses on the results of economic evaluations, this present review identified economic 
evaluations on a limited range of PA interventions (Abu-Omar et al., 2017). Studies came from just 
four high-income countries, with over half (n=8) coming from the UK. This points to an important 
evidence gap in countries where economic evaluations are deemed appropriate. Examining a 
country’s traditional beliefs around personal responsibility, efficiency and equity can explain why 
countries such as France and Germany are low users of economic evaluations and can in part 
explain why no studies in this review originated from these countries (Torbica et al., 2018). 
Regardless of cultural and institutional differences, globally health economists agree economic 
evaluations of preventative interventions are expected to have an important impact on future 
healthcare decision-making (ISPOR, 2018). In order to answer upcoming complex public health 
challenges, researchers need to go beyond clinical effectiveness methods and use a 
multidisciplinary suite of methods (Rutter et al., 2017) which includes economic evaluation. A 
prerequisite for this is an understanding on how key methodological challenges can be addressed.  
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2.4.1. Challenge 1: Attribution of effects 
2.4.1.1. Modelling exercises 
All ten trial-based economic evaluations in this review had a short time horizon; meaning they did 
not attempt to extrapolate or model the long-term impact of the intervention which could be used to 
informer longer term investment decision making. Any future reduction in incidence of NCD and 
premature mortality, attributable to PA and SB interventions, is unlikely to manifest until decades 
after the intervention has taken place. Yet, evaluating these interventions over the wrong timeframe 
means these interventions may appear ineffective or markedly less effective; they are at risk of not 
being appropriately prioritised by policymakers (Rutter et al., 2017). Curative interventions that 
rescue people from very poor health to better health will continue to be favoured, even if they are 
less cost-effective overall. Alayli-Goebbels et al. (2014) had previously suggested modelling as a 
way to extend the time horizon of trial-based studies, yet none of the ten trial-based studies in this 
review performed any modelling exercises. The challenges which can preclude extrapolation 
include the availability of data, and time and skills of the analyst (Squires et al., 2016). 
2.4.1.2. Cohort studies 
Campbell et al. (2015a) and Anokye et al. (2012) were the only two studies in this review to identify 
additional evidence to link up their short- and long-term effect estimate. The three other model-
based studies claimed there was insufficient evidence to verify the accuracy of their assumptions 
(Pavey et al., 2011b, Anokye et al., 2011, Over et al., 2012). Notably, the cohort studies which 
Campbell et al.(2015a) and Anokye et al.(2012) draw on were published several years prior to the 
publication of the three other model-based studies. This suggests that the methodological 
challenge of ‘attribution of effect’ may be more dependent upon the analysts’ time and skills as 
opposed to the availability of data.  
2.4.2. Challenge 2: Measuring and valuing outcomes 
2.4.2.1. Cost-effectiveness and cost-utility analyses 
This review found large inconsistencies in the types of outcomes measured and valued. There is 
no agreed classification system for PA outcomes (Abu-Omar et al., 2017) since the analysis of raw 
objective accelerometer data measuring objective PA levels is still in its infancy. Presenting a 
limited range of results can reduce the applicability of the study’s findings to other policymakers. 
Authors’ views also differed firstly on whether short-term QALYs should be included in the 
economic analysis, secondly on whether a short-term QALY gain represented a one-off gain in 
mental health or general functional health. Presently, within the economic literature the 
responsiveness of the EQ-5D-3L to detect important differences in the severity of health is being 
challenged, and had led to the development of the EQ-5D-5L, which measures health on five levels 
as opposed to just three (Glick et al., 2014). This review has shown that outcomes used in PA 
studies are diverse; therefore, there is a need for analysts to agree on a consistent outcome that 
best captures the objectives of a PA intervention.  
2.4.2.2. Cost-benefit and cost-consequence analyses 
No studies in this review performed a CBA and just two presented a CCA alongside their full 
economic evaluation. There is a lack of CBAs in other public health areas. Hill et al. (2017) and 
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Alayli-Goebbels et al. (2014) identified a small proportion of studies (n=1 and n=8 respectively) who 
reported conducting a CBA, but due to insufficient reporting gained limited insight into how these 
were performed such as how outcomes had been monetised (Hill et al., 2017, Alayli-Goebbels et 
al., 2014). Likewise, four studies claimed to be CBAs in the review by Weatherly et al.(2009), but 
after further assessment were re-classified as CCAs (n=3) and a CEA (n=1). Although classified as 
a partial-economic evaluation, CCA is a useful alternative to CBA since all relevant costs and 
consequences can be presented to the reader in the form of an inventory, rather than simplified 
into a single outcome measure or index as is the case in CEA and CUA, respectively. If an 
outcome is deemed relevant to the reader, they can reanalyse the data quantified in the CCA. 
However, CCA puts more onus on decision makers than CBA or CUA, as it does not roll outcomes 
into a summary measure that can be compared to a decision rule. An example of a decision rule in 
the UK is: invest where the incremental cost-effectiveness ratio is less than £30,000 per QALY 
(NICE, 2014a).  
2.4.3. Challenge 3: Identifying intersectoral costs and consequences 
2.4.3.1. Inconsistent perspectives 
The three most common perspectives stated were the health system, payer and societal 
perspectives. These match the three most commonly reported perspectives in the broader field of 
economic evaluation (Husereau et al., 2013). Only Edwards et al. (2013b) conducted their analysis 
from the public sector perspective, a perspective recently recommended in the UK reference case 
(NICE, 2014a). That said, Edwards et al. (2013b) did not incorporate participant costs in their CUA, 
only through an exploratory analysis. Only three studies considered the cost to the participant, 
which is not surprising since the health sector perspective was the most commonly stated 
perspective. Participant and voluntary sector costs are deemed important, but previously have not 
been routinely captured (Weatherly et al., 2009).  
It was found that even economic evaluations stated the same perspective did not always include 
the same costs and consequences. This is likely to be because there is a lack of standard 
definitions for the various perspective types (Husereau et al., 2013). Even where there are 
examples of standard definitions, such as those proposed by the Second US Panel on Cost-
Effectiveness in Health and Medicine (Sanders et al., 2016), not all economists agree with their 
definitions, and furthermore the definitions may not be applicable to other countries since there are 
distinct features of each health system (Torbica et al., 2018). For instance, deciding what costs and 
consequences to capture within a societal perspective is a normative question, requiring the 
analyst to make social value judgements (Drummond et al., 2015b). This is an important issue, 
since the exclusion of relevant consequences can lead to an underestimation of cost-effectiveness 
whilst the exclusion of relevant costs can lead to an overestimation of cost-effectiveness (Hill et al., 
2017). 
2.4.3.2. Cost categories identified 
The cost categories identified in this review match the five cost categories (healthcare services, 
intervention costs, patient and family costs, lost productivity costs, future costs) identified as most 
relevant for inclusion in economic evaluations, by health economists who recently took part in a 
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cross-Europe Delphi study (van Lier et al., 2017). This suggests analysts’ choice in costs in this 
review align with analysts in the more general field of economic evaluation. It should be noted 
however that there was a difference in one of the categories, as family costs were not identified as 
a relevant cost category in the studies from this present review. Just two trial-based studies 
included absenteeism in their study; similarly only two of the model-based studies included it in 
their CCA. It continues to be debated in the literature as to whether absenteeism is an outcome of 
cost-offset, and thus whether it should be included in the numerator or denominator part of the 
incremental cost-effectiveness fraction (Drummond et al., 2015b).  
2.4.4. Challenge 4: Incorporating equity considerations 
2.4.4.1. Presenting results by subgroups 
Equity impact analysis can be as straightforward as presenting cost-effectiveness results by equity 
subgroups (Hill et al., 2017, Alayli-Goebbels et al., 2014, Weatherly et al., 2009). Six studies in this 
review presented an equity impact analysis (Campbell et al., 2015a, Pavey et al., 2011b, Anokye et 
al., 2011, Anokye et al., 2012, Over et al., 2012, Edwards et al., 2013b). The most common 
subgroup analysed was individuals with pre-existing medical conditions, nevertheless this analysis 
was performed in just four studies (Campbell et al., 2015a, Pavey et al., 2011b, Anokye et al., 
2011, Edwards et al., 2013b). Furthermore, only one study (Edwards et al., 2013b) conducted more 
than one type of equity subgroup analysis. These findings suggest analysts are not performing 
equity analyses in a comprehensive nor consistent manner. Weatherly et al. (2009) outlined socio-
economic status as an important under-researched equity issue in economic evaluations, however 
only one study in this review researched socio-economic status by asking participants about their 
willingness to pay for an intervention component (Edwards et al., 2013b). Incorporating equity into 
decisions on PA and SB interventions is especially important, since it is amongst the lower 
socioeconomic groups where physical inactivity is greatest (Organisation for Economic 
Cooperation and Development, 2015).  
2.4.5. New studies 
Overall, the four studies published since March 2017 did not change the narrative of this review 
since there remains a dearth of economic evaluations in the field of PA and SB. What the studies 
have demonstrated is that firstly, there is an indication that health economic methods have begun 
to be applied to targeted SB interventions (Gao et al., 2018). Secondly, that it is feasible and 
informative to extrapolate beyond the trial (Gao et al., 2018, Harris et al., 2018). 
2.4.6. Strengths and limitations 
This is the first systematic review conducted since 2009 to review the methods used in economic 
evaluations of interventions targeted at physically inactive individuals, and the first systematic 
review to search for economic evaluations targeting SB as an independent risk factor from PA. This 
review included comprehensive literature searching and a rigorous methodology in line with the 
PRISMA guidelines (Moher et al., 2009). Economic evaluations aim to inform resource allocation 
decisions (Drummond et al., 2015b). Previous reviews have demonstrated that key methodological 
challenges preclude economic evaluations in the field of public health from achieving this aim 
(Weatherly et al., 2009, Alayli-Goebbels et al., 2014). By focusing on PA and SB, this review has 
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been able to not just provide an overview on whether or not the four key methodological challenges 
have been addressed in the last decade, but crucially explain in greater depth the methods 
performed in those few studies where progress has been made.  
More specifically, progress has been observed in the 14 studies which have considered equity in 
their analysis (Table 3) and the small proportion of studies where: the long-term model presented 
has been informed by robust epidemiological evidence (Anokye et al., 2012, Campbell et al., 
2015a); all important and relevant costs and consequences have been outlined to the reader in the 
form of a CCA (Pavey et al., 2011b, Anokye et al., 2012); and/or a multi-sector perspective has 
been selected (Edwards et al., 2013b). An output from the narrative synthesis of this review is a 
number of recommendations (as outlined in Table 2.4) explaining how analysts can continue to 
make progress towards addressing the four methodological challenges. Although, the 
comprehensive search strategy only goes up to March 2017, a rapid systematic scoping search is 
presented which highlights four new empirical studies. Two of these studies (Harris et al., 2018, 
Gao et al., 2018) support the recommendations emerging from this review in terms of linking up the 
intermediate evidence with longer term policy relevant outcomes. 
It was not within the scope of this research to review the methods used in population-level 
interventions such as national policies or media campaigns. It would therefore be useful for future 
reviews to explore how economic evaluations are being carried out within this area. In addition, this 
review focuses on the methods conducted in full economic evaluations and so there is scope to 
review the methods used in partial evaluations. Nevertheless, full economic evaluations are 
deemed more informative than partial evaluations, and so it would have been expected that 
analysts would conduct for instance, a CCA alongside their full economic evaluation, as was done 
in two studies (Pavey et al., 2011b, Anokye et al., 2014) in this review.  
2.4.7. Recommendations  
Table  4  presents  a list of recommendations for researchers and users of economic evaluations 
from a variety of disciplines (health economics, public health, PA etc)  to refer to when designing, 
analysing and appraising economic evaluations of targeted PA and SB interventions.  
 
 
 
Table 4. Key recommendations for future economic evaluations 
Challenge 
 
Recommendation Explanation 
Challenge 1. Attribution 
of Effects 
Modelling It is necessary for public health researchers to invest time in reviewing the existing evidence base 
and develop novel modelling skills. Best practice guidelines state well established published models 
are preferred to those developed specifically for a trial (Ramsey et al., 2015). If skill and time permits, 
analysts can draw on the structure of the published models (Campbell et al., 2015a, Anokye et al., 
2012) identified in this review and adapt them according to the local decision-making context.  
Challenge 2. Measuring 
and valuing outcomes 
Cost-consequence 
analysis 
 
There is a need for further methodological developments in the monetisation of effects in CBAs 
(Drummond et al., 2015b, Sanders et al., 2016). In the meantime, it is deemed more appropriate to 
conduct a good quality CUA which may be of a narrower perspective, than a poor quality CBA which 
captures a broader perspective (Hill et al., 2017, Weatherly et al., 2009). In order to report on multiple 
outcomes which extend beyond health, a CCA or impact inventory conducted alongside a full 
economic evaluation is recommended (NICE, 2014a, Sanders et al., 2016). If the word limit in 
journals precludes authors from presenting a CCA in the main manuscript, they should present this 
information in the online supplementary material. 
Challenge 3. Identifying 
intersectoral costs and 
consequences 
 
Multi-agency public 
sector perspective 
+ participants 
perspective  
 
Three studies in this review omitted costs, which would typically be deemed relevant to their stated 
perspective, and two studies did not report their perspective. It is imperative for analysts to describe 
and justify the costs and consequences, which they have deemed relevant for their chosen 
perspectives (Husereau et al., 2013). Inevitably different assumptions on what costs and 
consequences are included in the analysis leads to different results (Sanders et al., 2016). 
Furthermore, future studies should aim to present at least two types of perspectives and conduct a 
CCA or impact inventory alongside their CUA or CEA in order to present the various relevant costs 
and consequences to the various relevant sectors (Weatherly et al., 2009, Sanders et al., 2016, 
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Alayli-Goebbels et al., 2014). A multi-agency public sector perspective where costs and 
consequences are presented in their disaggregated form (i.e. in a CCA) for each sector is preferred 
over stating a societal perspective (Drummond et al., 2015b, Hill et al., 2017). It is also recommended 
that future studies, specifically trial-based studies, capture economic information on time, travel and 
out-of-pocket expenses incurred by the participant. The participant’s perspective is important as the 
amount of time and expenses they invest may have an impact on the participant’s uptake, adherence 
and overall acceptability of the intervention. 
Challenge 4. 
Incorporating equity 
 
Equity impact 
analysis 
 
Analysts should present costs and consequences explicitly in their disaggregated form for various 
equity groups, so policymakers can start to build a better picture on which population groups gain and 
lose from a specific decision (Hill et al., 2017). From here, analysts can conduct an equity impact 
analysis. This type of analysis is deemed easier than conducting equity constraint or equity weighting 
analysis (Hill et al., 2017). The equity effectiveness loop framework (Welch et al., 2008) and 
PROGRESS-Plus framework (O'Neill et al., 2014) are recommended to help analysts consider, in a 
structured way, which equity factors may be relevant to their study (Alayli-Goebbels et al., 2014, 
Welch et al., 2017).   
 
 
 
2.5. Conclusions 
A focus on the key methodological challenges in economic evaluations is important, as they can 
impact on the derived cost-effectiveness result, which ultimately can impact on a policymaker’s 
resource allocation decision. As economic evaluation is a rapidly developing field (Drummond et 
al., 2015b) this systematic review has provided an important update on the most recent methods 
used in targeted PA interventions. The review has also highlighted there is a scarcity of economic 
evaluations for targeted SB interventions. Importantly, this review makes it explicit to policymakers 
and researchers from the varied disciplines in which PA and SB falls under, that there are still key 
methodological challenges that need further attention. This review has highlighted that 
methodological choices vary widely not just between countries but also within them. Ultimately, 
these analyst-based choices affect the results presented and subsequent resource allocation 
decisions made. A recent consensus statement has called for collaboration across the disciplines 
to develop guidance specific to the context of economic evaluations of PA interventions (Davis et 
al., 2014). To date, no guidelines have been developed to address this need. The examples of 
methodological development identified from the studies in this review and the resulting review 
recommendations can be used to inform future guidelines and their supplementary materials. In 
particular, they will be used to develop an initial outline of the framework, which will be presented in 
Chapter 3. 
  
 
 
67 
 
 
Chapter 3: Development of an initial systematic 
framework for economic evaluations of individual-level 
PA and SB interventions 
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3.1. Chapter aim 
The systematic review presented in Chapter 2 demonstrated how economic evaluations are being 
performed inconsistently across interventions of the same nature including those from the same 
country. Accordingly, a framework is needed to support multidisciplinary researchers conducting 
trial-and model-based economic evaluations (Davis et al., 2014). The aim of this chapter was to 
develop an initial multidisciplinary framework which can be used by researchers including those 
who have limited or no specialist training in health economics and would like to conduct economic 
evaluations of individual-level PA and SB interventions. The framework may also be of use as a 
guiding framework for health economists seeking a standardised approach to economic evaluation 
of individual-level PA and SB trials. More specifically, the framework will be a guidance tool 
highlighting ideal practice to the user based on the literature and standard practice from the fields 
of: health economics, public health, behavioural science, PA, SB and trial methodology. In order to 
assess the practicality of the guidance framework, it has been piloted in two trials: (1) a pragmatic 
quasi experimental trial of a co-developed PA on Referral Scheme (Co-PARS) (Chapter 4); (2) a 
randomised controlled trial aiming to help mainly desk-based workers to Sit Less and Move More at 
work (SLaMM trial) (Chapter 5).  
3.2. Framework development  
3.2.1. Procedure  
Four key steps were taken to develop the framework, these included:  
1) Structuring the framework by drawing on the 10 generic methodological steps from the 
economic evaluation quality assessment checklist applied in Chapter 2.  
2) Drawing on the results from Chapter 2 to recommend how the four key methodological 
challenges could be addressed. 
3) Identifying data collection tools used in existing economic evaluations.  
4) Multidisciplinary team meetings 
 
3.2.2. Structuring the framework  
The structure of the framework draw on Drummond’s quality assessment framework (Drummond et 
al., 2015b) which had been applied in Chapter 2. This framework was selected as it names the key 
methodological steps for the conduct of generic economic evaluations. The framework was 
adapted so as costs and outcomes were itemised separately. This was because Chapter 2 had 
illustrated that the recommended approaches for identifying, measuring and valuing costs and 
outcomes would differ in a number of ways. Consequently, this led to three additional items being 
included in the framework. A further three items were also added based on key recommendations 
identified in the wider methodological literature. These additional methodological items considered, 
the need to: (1) adjust for baseline imbalances in costs and health-related quality of life values 
(Manca et al., 2005, Franklin et al., 2019); (2) consider equity (Weatherly et al., 2009); and (3) 
adhere to the consolidated health economic evaluation reporting guidelines (Husereau et al., 
2013). Overall, the structure of the framework comprised of 16 items. 
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3.2.3. Addressing the four key methodological challenges 
Chapter 2’s findings offered insight into how four key methodological challenges could be 
addressed in the context of individual-level PA and SB trials. Methodological approaches that were 
frequently reported and/or were reported in good quality studies, were deemed most important. In 
summary, based on Chapter 2’s findings the following types of recommendations were made: time 
horizon for the analyses, cost categories to assess, valuation techniques for measuring and valuing 
the outcomes, and lastly an approach for incorporating equity into the assessment.     
3.2.4. Identifying data collection tools 
To produce a framework that can be applied by researchers wishing to explore cost-effectiveness, 
it was necessary to provide specific guidance on what cost items would be captured for each cost 
category and what measurement tools would be used to capture these items. The initial intention 
was to revisit studies from the review in Chapter 2 and perform a more granular analysis of the 
data collection methods used in studies that met items 1, 4, 5 and 6 from the quality assessment 
checklist (Appendix A.4). These four quality assessment items were deemed most relevant to the 
purpose of the synthesis, as they consider the perspective stated, and how costs and effects were 
identified, measured and valued (Drummond et al., 2015b). Five trials and one modelling study met 
the four specified inclusion items (these studies are listed in Appendix B.1). It should be noted that 
two modelling studies (Campbell et al., 2015b, Anokye et al., 2011) also met the inclusion items for 
nine of the items, but not item 5, as it was not possible to know whether appropriate physical units 
had been measured accurately. Nonetheless, the two studies referenced the same microcosting 
study (Isaacs et al., 2007) and so the cost items used in that study were reviewed (Appendix B.1). 
By large, it was found that the data collection methods in the studies from Chapter 2, were poorly 
reported and so it was not possible to draw useful information from these studies. Accordingly, the 
database of instruments for resource use measurement (DIRUM) (Ridyard and Hughes, 2012) was 
drawn on to identify appropriate measurement tools to recommend in the framework. Just one tool 
was identified from the database to measure participant costs which was a generic tool for any 
disease area. No tools were identified for measuring productivity or intervention costs for any of the 
disease areas listed in the database. 
3.2.5. Multidisciplinary team meetings  
Several iterations of the framework were drafted and reviewed through my supervisory team that 
comprised of senior researchers in PA and SB (n=2), public health (n=1) and public health 
economics (n=1). I had monthly meetings with my supervisors at the development phase of my 
framework. At these meetings, I shared: (1) key observations I had made regarding the methods 
used in the studies included in my systematic review; and (2) key reflections I had made regarding 
the relevance of additional methodological papers I had come across in the health economic and 
public health literature. The aim of these meetings was to informally discuss and reflect on the 
relevance, importance and practicality of the approach I was developing for the framework.  
During the development stage of the framework, I was successful in gaining an international 
mobility award which enabled me to draw on additional health economic expertise at Deakin 
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University. I undertook a three-week study placement that included two one-hour face-to-face 
meetings with three senior health economists who had recently been involved in conducting an 
economic evaluation of an individual-level SB trial. I asked these experts to share their experience 
on conducting an economic evaluation in the field of public health. For instance, I asked them how 
they typically identified intervention activities and how they incorporated productivity into their 
studies. In addition, I presented the findings and recommendations from my systematic review to 
the whole health economic group at Deakin University. I invited the group to ask me questions in 
order to yield insight into what they thought about my recommendations. The main discussion was 
around equity. There was consensus amongst the group that equity was important to include in 
public health economic evaluations, but most felt it was not yet standard practice. I reflect further 
on these key discussions in the reflection boxes in the section 3.3.   
3.3. Initial outline of a framework 
An initial outline of a framework was developed, this is presented in Table 1 in the form of 
questions Section 3.3 provides recommendations on how the framework can be applied in practice. 
Alongside the recommended items are reflections which explain why specific items were included 
in order to ensure the design of the framework is transparent. sections. Box 1 below introduces the 
main types of economic evaluation. 
Box 1. Definitions: Economic Evaluation Techniques 
Full economic evaluation: There are three established techniques for “full” economic evaluations: 
cost-effectiveness analysis (CEA), cost-utility analysis (CUA) which is often called CEA or 
referred to as a special type of CEA, and cost-benefit analysis (CBA). The economic evaluation 
handbook by Drummond et al. (2015) includes further detail around these techniques, including 
their theoretical underpinning. In summary, the important difference to note is the way in which 
the techniques include and value outcomes in the analysis. The main difference between 
conducting a CEA or CBA in practice relates to how many outcomes you include in the analysis 
and how you choose to value your outcomes. CEAs incorporate just one outcome measure (as 
well as costs) which is reported in non-monetary units. By contrast, CBA can include several 
outcomes, which are converted into monetary values. Partial-economic evaluation: Cost-
consequence analysis (CCA) is a partial-economic evaluation as costs are not compared to 
effects. Instead, the technique involves listing all costs and effects in their natural units but does 
not attempt to aggregate the costs and effects into a summary statistic. 
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Table 1. Summary of items to consider when conducting an economic evaluation of an individual-
level PA and SB intervention 
Items* 
1 What components make up a well-defined study question? 
2 What does a comprehensive description of the comparators look like? 
3 What does an appropriate study design look like? 
4 What costs are important and relevant? 
5 What effects are important and relevant?  
6 How and when can costs be measured? 
7 How and when can effects be measured? 
8 How can costs be valued? 
9 How can effects be valued? 
10 How can costs and effects be discounted to a present day value? 
11 What summary statistics can be presented? 
12 What adjusted analyses can be performed? 
13 What equity subgroups can be considered? 
14 What uncertainty analyses can be performed? 
15 How can the results be interpreted?  
16 How can trial-based economic evaluations be reported? 
* Adapted from the methodological checklist outlined in the Drummond et al. (2015) quality assessment 
appraisal checklist for economic evaluations 
3.3.1. Item 1. What components make up a well-defined study question? 
The five pieces of information listed 1.1-1.5 below can help with defining your study question. The 
reflection boxes help explain why these five pieces of information are advised. 
3.3.1.1. Item 1.1. Comparison of both costs and effects for at least two groups 
It is advisable that you confirm that both costs and effects of at least two comparator groups are 
being evaluated. Often this might be an intervention vs. a ‘no intervention’ or ‘treatment as usual’ 
comparator.  
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Reflection on item 1.1 
This framework starts by recommending the analyst confirms that their study has two 
fundamental characteristics: (1) a comparison of at least two comparator groups (where 
the term comparator group is synonymous with the term intervention, service and 
strategy); and (2) a comparison of both costs and effects. It was through the process of 
developing the eligibility criteria for my systematic review that I discovered that the health 
economic literature define an economic evaluation as having these characteristics and as 
being one of the following techniques: CEA, CUA, CBA and CCA (Drummond et al., 
2015b). Initially I was surprised to learn that SROI, an economic technique I had used as 
a Public Health Assistant, was not reported as a main evaluative method. However, the 
definition helped me recognise that the SROI evaluations I had performed in my previous 
job were limited to one comparator group (they were typically ‘before and after’ 
evaluations) and therefore did not meet the study design criteria to be regarded as an 
economic evaluation. For this reason, I have not recommended SROI for my initial 
framework. In terms of clinical effectiveness trials, although they typically have two or 
more comparator groups but they typically only compare effects.   
 
3.3.1.2. Item 1.2. CEA as the primary analysis 
It is helpful to specify the primary analysis by reporting: (1) the type of economic evaluation you will 
conduct (see Box 1); and (2) the country and decision-maker (perspective) your results are 
intended for. Before specifying your primary analysis check whether your country has specific 
guidelines on what the preferred primary analysis is. If your country does not specify which analysis 
technique is preferred, it is advised that a CEA is conducted as opposed to a CBA. Secondly, it is 
advised that you conduct the analysis from a broad perspective including all stakeholders who 
have the potential to be affected by the intervention rather than just the perspective of healthcare 
organisation. One way to help you identify which additional organisations and individuals may be 
important, is to identify who is involved in paying, providing and/or setting up the intervention of 
interest. 
 
Reflection on item 1.2 
The type of economic evaluation recommended for the primary analysis is a CEA. All 
studies identified in my systematic review (Chapter 2) had conducted a CEA (or CUA) 
with no studies performing a CBA. In the discussion section of my systematic review, I 
indicate that this may be due to the practical challenge of conducting a CBA (e.g. the 
difficulty of assigning monetary values to non-health outcomes). I did not have any 
experience or practical examples from the literature on how to deliver a CBA in practice, 
therefore I do not recommend it in this initial framework.  
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In my review, I also suggest that the choice in methods is likely to be also due to the fact 
many countries have guidelines or a ‘reference case’ which states the country’s preferred 
analysis technique. Through my health economic reading, I learnt that the aim of a 
reference case is to improve comparability of studies reported from the same country 
(ISPOR, 2019). Prior to conducting the systematic review I had not come across the term 
‘reference case’ as this concept is not referred to within the clinical effectiveness 
evaluations. An example from the UK’s ‘reference case’ is that it recommends a specific 
type of CEA, a CUA, is performed for the primary analysis (NICE, 2014).  
 
3.3.1.3. Item 1.3. CCA as a secondary analysis 
CEA produce aggregate summary outcome statistics, therefore it is recommended that a cost 
consequence analysis (CCA), also known as an impact inventory, is conducted alongside the 
primary analysis (Sanders et al., 2016). This is so all relevant costs and outcomes assessed can 
be interpreted separately. As interventions can be delivered in public or non-public sector settings, 
the CCA may include costs and effects deemed important to both the public and private sector 
agencies who are involved in paying, providing and/or setting up in the intervention. In addition, it is 
recommended that the participant’s perspective (also known as the private individual’s perspective) 
is captured in the CCA.  
 
Reflection on item 1.3 
CCA is considered a partial-economic evaluation since costs and effects are not 
compared in order to produce a summary cost-effectiveness statistic (Drummond et al., 
2015a). In my systematic review (Chapter 2), I identified two studies that reported a CCA 
alongside their primary analysis (CEA or CUA). I saw how the disaggregated format of the 
costs and effects presented in these CCA made it clear to identify which costs and effects 
were relevant to which stakeholder. In addition, my review identified four economic 
evaluations, which had included participant costs in their analysis. Even though many 
country’s guidelines including the UK do not recommend the inclusion of participant costs 
(ISPOR, 2019, NICE, 2014a) I felt the participant’s perspective was important to include in 
the CCA. This is because the behavioural science literature argues that the participant’s 
acceptability of (perspective on) an intervention can provide influence the success of an 
intervention (Michie, Atkins, & West, 2014). 
 
3.3.1.4. Item 1.4. Time horizon 
It is recommended that the primary analysis is conducted over the trial follow up period (trial time 
horizon). If there is sufficient data, time and expertise, a decision model could also be conducted. 
The model could assess the costs and effects over the rest of the participant’s life (lifetime 
horizon). 
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Reflection on item 1.4  
When resource use is collected from a single trial, best practice guidelines state that a 
trial-based economic evaluation is always conducted before any modelling and therefore 
the first analysis should be based on a short time horizon which will be the trial follow up 
period (Glick et al., 2014). My systematic review (Chapter 2) indicated that trial-based 
economic evaluations that do not extrapolate beyond the trial follow up period are more 
commonly performed than economic evaluations that do extrapolate. Nonetheless the 
epidemiological literature indicates that the greatest potential benefits of increasing your 
weekly PA levels are unlikely to accrue until decades after the intervention has taken 
place. My systematic review identified a small number of studies which estimated the 
long-term cost-effectiveness of the PA interventions by linking up short-term surrogate 
outcomes with published epidemiological evidence. This made me aware that there are 
epidemiological data available within the literature in order to build evidence-based 
decision model for PA interventions.   
 
3.3.1.5. Item 1.5. Target population and subgroups 
It is helpful to confirm the target population for the economic evaluation. The target population for 
the trial-based economic evaluation could be the participants recruited for the clinical effectiveness 
trial. The modelling analysis could include a broader population if there is sufficient evidence from 
other studies published.  In addition, confirm which equity subgroups will be considered, at a 
minimum consider: age, sex, socioeconomic status and medical condition. 
 
Reflection on item 1.5  
Socioeconomic status, sex, age and pre-existing medical condition were the most 
common types of equity subgroups identified in my systematic review (Chapter 2). The 
public health research I was involved with before I undertook this PhD had made me 
believe that socioeconomic status is likely to be an important equity subgroup for public 
health trials.   
 
3.3.2. Item 2. What does a comprehensive description of the comparator groups look like? 
Key information required to describe the intervention groups is likely to be provided in the trial’s 
protocol and the CONSORT flow diagram if available. If you feel the protocol and CONSORT flow 
diagram does not provide sufficient detail, it is helpful to heck your interpretation of the comparator 
groups with those leading the clinical effectiveness trial. After the intervention has been delivered, it 
is also advised that you check with the staff who delivered the intervention whether any additional 
intervention operating and/ or set up costs were incurred. These could be costs that have not been 
accounted for in the trial protocol or CONSORT diagram. In addition to describing the intervention 
of interest, it is recommended that you describe what usual care is, as usual care may vary 
geographically and/or by organisation. The description of the comparator groups can be used as 
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the first step to populating a microcosting tool (Table 5). The tool can be populated by the research 
team and/or staff delivering the intervention. 
Reflection on item 2 
I was interested in how the studies I included in my review had calculated the intervention 
costs, since the descriptions of the interventions in the articles were brief and the authors 
did not comment on the methods used to identify the resource quantities. During my study 
placement with Deakin University’s Health Economics group, I had the opportunity to 
explore the costing of complex public health interventions with three senior academic 
health economists. They discussed that they typically use the CONSORT diagram and 
study protocol to identify the multiple intervention activities and the resources required to 
deliver them. The idea to check whether any additional unexpected intervention costs had 
been incurred after the delivery of the intervention came from one of the studies in my 
review (Edwards et al., 2013b). This study conducted telephone interviews with the 
intervention providers after the intervention had been delivered.    
 
3.3.3. Item 3. What does an appropriate study design for trial-based economic evaluations 
look like? 
In order for the results of your economic evaluation to be applicable to ‘real world’ decision maker 
who need to make inevitable decisions around resource allocation, it is recommended that the 
economic data you use in your analysis is derived from a pragmatic trial. If possible, a randomised 
controlled trial (RCT) is recommended for the trial design. Furthermore, it is recommended that the 
Intention-to-treat (ITT) principle is followed for the primary analysis of the trial data, whereby 
participants are analysed according to the same group they were assigned to, even if they do not 
adhere to their allocated intervention. If there is a more than 10% of data missing, then a complete 
case analysis is recommended. 
Reflection on item 3 
Pragmatic trial 
It was through my reading of one of the health economic handbooks that I became aware 
that there was consensus amongst the health economic community that economic 
evaluations should be delivered alongside pragmatic trials (Drummond et al., 2015a). I 
think my anthropology background also helped me recognise why pragmatic trials were 
required for economic evaluations of behaviour change trials (e.g. changing PA and SB 
levels). Anthropology is the study of complexity. I therefore had experiencing of studying 
complexity which is important for complex interventions. There is increasing recognition in 
the trial literature that there is a need to document and understand complexity of 
interventions, in order to understand why some interventions fail to be implemented into 
the ‘real world’ (Moore et al., 2015).  
 
Intention-to-treat principle 
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A key feature of pragmatic trials is that it necessitates that study participants are analysed 
in accordance to the comparator group they are assigned to at baseline, even if the 
participant does not adhere to the protocol or changes groups during the trial. This trial 
design feature is known as the intention to treat (ITT) principle. I verified that the ITT 
principle applied to trial-based economic evaluations by consulting good practice 
guidelines provided by the International of Society for Pharmoeconomics and Outcomes 
Research (ISPOR) (Ramsey et al., 2015).  
 
Complete case analysis 
Complete case analysis is reportedly the most common way to analyse incomplete 
datasets in trial-based economic evaluations (Noble et al., 2012). I tried to understand 
why multiple imputation was not used more commonly for economic evaluations. I came 
across a methodological study which suggested that this may be due to the lack of 
guidance for addressing missing data in the context of economic evaluation (Leurent et 
al., 2018). I used the literature to inform my recommendation on what the cut-off point 
would be for missing data. I identified a study which stated that for multi-item 
measurement tools where only a small proportion of the data is missing (less than 10%) it 
is deemed acceptable to impute the mean of each group for participants missing an item 
(Eekhout et al., 2014).  
 
3.3.4. Item 4. What costs are important and relevant? 
Important and relevant costs categories are likely to be influenced by the country and/or audience 
of your economic evaluation (as discussed in item 1). The description of the comparator groups as 
described in item 2 will help you judge what costs are relevant. At a minimum, if conducting your 
analysis from a multi-agency public sector perspective (as recommended in item 1) it is helpful to 
consider including the following perspectives and associated cost categories: 
1. Payer’s perspective: intervention costs, which could include the setting up (organising) and 
operating (delivery) costs.  
2. Provider’s perspective: any additional intervention operating and setting up costs, not 
accounted for before the trial is conducted 
3. Health and social care perspective:  
o Short-term primary healthcare activity including: consultations with the GP, 
practice nurse and allied health professionals, and medications prescribed in 
primary care 
o Short-term secondary healthcare activity including: emergency, outpatient and 
inpatient visits 
o Long-term healthcare activity: secondary data can be used to estimate potential 
future treatment costs in a decision model. For PA it is recommended that future 
treatment costs for the following diseases are considered: Type 2 diabetes (T2D), 
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stroke and Coronary Heart Disease (CHD). For SB interventions, at a minimum 
treatment costs for T2D.  
4. Participant’s perspective: out of pocket expenses such as clothing and travel costs, and 
time costs such as loss in leisure time to attend intervention activities. In addition, an 
exploratory analysis is recommended whereby participants are asked about their 
willingness-to-pay for a PA or SB intervention. 
5. Employer’s perspective: losses and gains in productivity. This will be particularly relevant if 
the intervention is set in the workplace and/or requires the participant to lose time from 
work in order to participate in the intervention.   
 
Reflection on item 4 
Identification of cost categories 
A key finding from my systematic review (Chapter 2) was that studies conducted from the 
same perspective (e.g. societal perspective) included different cost categories in their 
analysis. This even applied to studies conducted in the same country. The health 
economic literature reports that, internationally, the process for identifying cost categories 
and items for each perspective type (e.g. healthcare, societal, payer) is in part analyst-
dependent as international standardised definitions do not exist (Husereau et al., 2013). 
The studies in my review did not state why they had included or excluded specific cost 
categories. As a result, I found it difficult to recommend a systematic approach for 
identifying all important cost categories. The approach I therefore recommend is a 
comprehensive approach as it lists all the cost categories which could be included in a 
study. This list was identified from seven studies from my review which met items on my 
quality assessment checklist relating to the reporting of study perspective and costs 
(Table 1 in Appendix B.1 lists the seven studies and their cost categories used). The cost 
categories I identified through the seven studies included: intervention operating costs, 
intervention setup costs, immediate healthcare utilisation, future healthcare utilisation, 
participant costs and productivity costs included in this framework. At the time of 
conducting this assessment of cost categories, a Delphi study was published with similar 
findings to my own (van Lier et al., 2017). The Delphi study identified five key cost 
categories: intervention costs, healthcare costs, patient and family costs, lost productivity 
costs and future costs.  
Long-term (future) healthcare costs 
In addition, I conducted a content analysis of the discussion sections of the 10 studies 
included in my systematic review which had not included future (long-term) costs in their 
analysis. I wanted to explore whether the authors saw this as a limitation of their study. I 
found that eight of the 10 studies reported that the exclusion of long-term costs was a 
limitation of their analysis. The two studies which did extrapolate their single trial-based 
results in order to consider the future costs conducted modelling and drew on pre-existing 
models (Gao et al., 2018, Anokye et al., 2018). It also saw that one author recommended 
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that existing models are drawn on to develop new decision models (Edwards et al., 
2013b).  
 
3.3.5. Item 5. What effects are important and relevant? 
As discussed in item 1.2, many countries have guidelines (or a ‘reference case’) which specifies 
what the preferred outcome measure is for the primary analysis. It is therefore recommended that 
you consult your country’s guidance. Guidelines can be retrieved from the ISPOR webpage on 
pharmacoeconomic guidelines from around the world: https://tools.ispor.org/peguidelines/ (ISPOR, 
2019). If no guidelines are available for your country of interest, it is recommended that it is 
recommended that a single generic measure of health is used as the primary outcome measure 
(e.g. the QALY). Additional wider effects of interest may have also been identified by the trial team 
working on the clinical effectiveness evaluation. All effects for which it is not possible to assign a 
monetary value, can be presented alongside the cost data in the secondary analysis, the CCA. 
Reflection for item 5 (reflections in item 1.2 also relevant to this item) 
The most common primary outcome measure included in my systematic review (Chapter 
2) was the QALY. QALYs are the most commonly used outcome measure in the literature 
and have fewer measurement problems compared to other outcomes such as DALYs. 
Although some studies in my review reported a measure of PA as the primary outcome, 
the outcome was reported in different units (e.g. one minute of PA, one person achieving 
150mins of PA per week).  
 
3.3.6. Item 6. How and when can costs be measured? 
3.3.6.1. Item 6.1. Intervention operating and setting up costs 
Prospective data collection is preferred as it is expected to be more accurate since it does not rely 
on participant/ staff/ researcher recall. Intervention operating and setting up costs can therefore be 
recorded by the research team during the trial using the microcosting tool (Table 5). The tool 
provides examples of the types of costs typical of individual-level PA and SB interventions such as 
staff type and time, equipment and capital equipment. The tool can be applied in Excel or similar 
software. The comprehensive descriptions of the new and existing interventions reported in item 2 
can be used to support the microcosting exercise. It is helpful to engage the trial protocol, 
CONSORT flow diagram and wider research team in this process.  
 
Reflection on item 6.1. 
Three studies in my systematic review (Chapter 2) reported generating their intervention 
resource use estimates through study records (Iliffe et al., 2014a, Elley et al., 2011, 
Isaacs et al., 2007). Nevertheless, the authors did not provide examples on the tools or 
templates used to document these records. Another study from my review reported using 
a budget breakdown to estimate costs, which they retrieved from the organisation who 
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was paying for the intervention (Edwards et al., 2013b). It was not clear what tool or 
template was used by the local authority to document the intervention costs.  
 
I had come across the DIRUM database through my reading of one of the health 
economic handbooks (Drummond et al., 2015a). As discussed in my systematic review, 
DIRUM is a repository of papers about resource use and cost measurement (Ridyard and 
Hughes, 2012). I searched the DIRUM repository to see if I could find a tool or template to 
help me document intervention costs in a systematic and comprehensive way- I could not 
identify any. It is possible that this is because tools used by health economists to evaluate 
complex lifestyle interventions may not have been validated and shared yet as DIRUM is 
a relatively new initiative and microcosting methods are underdeveloped (Frick, 2009). 
Nevertheless, there is recognition that microcosting is becoming increasingly important for 
newly developed complex multi-component interventions (e.g. individual-level PA and SB 
interventions) since it is likely these interventions have not been assigned an aggregate 
cost that is available in the published literature (Glick et al., 2014). In the absence of a 
validated microcosting tool, I developed my own novel microcosting tool in order to 
document interventions costs for the Co-PARS and SLaMM trial (Table 5). The structure 
of my tool in terms of the variables which have been included, were informed by the NHS 
reference cost structure (NHS Improvement, 2018). The content of the tool for the types 
and descriptions of the cost items (e.g. staff type, printing, room hire) was based on my 
content analysis of the cost items reported in the studies in my systematic review. More 
specifically, I analysed the method and result sections of seven studies which had 
adequately reported what cost items they measured for each cost category (see Table 1 
in Appendix B.1).  
 
Table 5. Microcosting tool to record operating and setup costs 
Payer's perspective 
  
Intervention 
operating/ 
setup costs 
Name and 
description of cost 
item 
Average 
quantity of 
cost item 
Average 
quantity 
of time, if 
applicable  
Total 
Quantity  
 Unit 
Cost 
Total 
Cost 
Staff's time Staff type (including 
details on: 
qualification level 
and/or grade) and 
time for the following 
activities: training, 
travel, preparation, 
delivery and clear-up 
          
Equipment  Printing           
Physical materials           
Promotional 
materials/ 
advertisements 
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Refreshments           
Study specific 
software 
          
Staff clothing           
Home working 
facilities 
          
Postage            
Stationary            
Phone costs      
Fixed  Private room           
Non-study specific IT 
equipment 
     
Non-study specific 
software 
     
Staff overheads      
Room hire      
 
 
3.3.6.2. Item 6.2. Additional intervention operating and setup costs 
These costs can be captured at the end of the trial by interviewing staff from the settings where the 
interventions are being delivered. The interview schedule provided in Appendix B.1. is 
recommended. 
Reflection on item 6.2.  
The recommended schedule for interviewing relevant staff/ stakeholders is presented in 
Appendix B.1. I identified just one study in my systematic review (Chapter 2) which 
captured additional operating and set up costs, and they had done this using telephone 
interviews with staff (Edwards et al., 2013b). Nonetheless, the study did not include an 
example of the interview schedule they used to capture this cost type. I therefore 
searched the DIRUM database to see if I could identify a template for an interview 
schedule that had been used to capture similar costs. I could not identify any appropriate 
tools. I therefore, draw on the wording used in a questionnaire (Thompson and 
Wordsworth, 2001) that was available on the DIRUM repository which asked participants 
about their out of pocket expenditure. I felt the wording of the questions was appropriate 
as they asked whether any additional costs were incurred and if so, what the purpose of 
the cost was as well as the estimated amount spent.    
 
3.3.6.3. Item 6.3. Health and social care costs 
These can be captured at baseline and at the same follow up time points as the effectiveness 
evaluation. An adapted version of the Client Service Receipt Inventory (CSRI) (Beecham and 
Knapp, 1999) is presented in Appendix B.1. If data on long-term treatment costs for NCD is 
available in the literature, this can be included. This data should be taken from published studies.  
Reflection on item 6.3 
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Authors from the studies included in my systematic review (Chapter 2) reported various 
methods for assessing the short-term (immediate) health and social care costs, these 
included: participant diaries, self-report questionnaires or GP medical records (see Table 
1 in Appendix B.1). In order to help me decide which method would be best I consulted 
the wider health economic literature. I identified a Delphi study which had asked health 
economists about their preferred methods for capturing healthcare utilisation (van Lier et 
al., 2017). The authors found there is disagreement amongst health economists on 
whether patient-based reporting (e.g. diaries or questionnaires) or the use of secondary-
level (e.g. routine medical records) data is preferred. The paper discussed the pros and 
cons of both methods. For instance, self-reported data is subjective and relies on the 
participant’s accuracy and ability to recall their healthcare use, however it might be easier 
and cheaper to collect this data. On the contrary electronic medicals records can 
sometimes be incomplete, costly and typically data management systems vary across 
agencies making it difficult to compare similar data variables (Hughes et al., 2016).  
 
One study (Edwards et al., 2013b) from my systematic review referenced the self-report 
questionnaire they had used to capture healthcare utilisation. I searched for the 
questionnaire on the DIRUM repository to learn more about it. The questionnaire was 
called the client service receipt inventory (CSRI) and was a widely validated tool that has 
been applied to various intervention and setting types (Beecham and Knapp, 2001, 
Ridyard and Hughes, 2012). The original questionnaire content relates to psychiatric 
services, therefore the wording and cost items included in the questionnaire were not 
relevant to an evaluation of a PA and SB intervention. I searched the DIRUM database 
and found a modified version of the CSRI by Mayer and Beecham (2005) which I draw on 
for the wording and structure. The specific examples I gave of health professionals were 
those which I had identified by analysing the content of the cost items (e.g. health 
professional types) included in seven good quality studies from my systematic review (see 
Table 1 in Appendix B.1).  
 
3.3.6.4. Item 6.4. Participant costs 
These can be captured at the same follow up data collection time points as the effectiveness 
evaluation. The participant cost questionnaire presented in Appendix B.1. can be used, this is an 
adapted version of a self-report questionnaire (Wordsworth and Thompson, 2001) retrieved from 
the DIRUM database. The aim of this questionnaire is to ask participants to report on their time 
spent taking part and travelling to the interventions of interest, the travel costs and any out-of-
pocket expenses.  
Reflection on item 6.4.  
Out of pocket costs for PA and SB 
Through the methods reported in the studies in my systematic review (Chapter 2), I found 
that there appears to be two main approaches to measuring participant out-of-pocket 
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costs and time costs: participant recall diaries or self-reported questionnaire. No studies in 
my review reported the measurement tool they had used to capture patient costs. I 
searched the DIRUM repository and identified the annotated patient costs questionnaire 
(Thompson and Wordsworth, 2001). The questionnaire wording and structure seemed 
appropriate. In order to tailor the questionnaire so as it referred to cost expenses 
associated with PA and SB interventions, I analysed the content of the costing methods 
used in the studies from my review (see Table 1 in Appendix B.1). There was a range of 
participant cost items measured, these included: clothes and shoes, memberships and 
classes fees, childcare, travel purchases (petrol based on distance travelled, public 
transport fee) and sports/ exercise equipment.  
 
Recall period  
In order to decide how often participants should be asked to recall their participant costs, I 
looked at recall periods reported in the studies in the systematic review. Overall, there 
was no trend in the recall period for both the diaries and questionnaire methods, with the 
recall period varying from 1 to 12 months. The literature on trial-based economic 
evaluations recommends that the recall period should align with the data collection points 
of the clinical effectiveness protocol (Glick et al., 2014). This option made sense since 
there are no existing guidelines on how frequently this data should be collected; and this 
option reduces participant and research burden.  
 
Participant’s acceptability 
In addition to asking the participant to record their out-of-pocket costs, I felt it was 
important to ask participants about their preferences and their willingness to pay for a PA 
and SB intervention. This type of additional exploratory analysis was done by one of the 
studies I identified in my review and seemed to illustrate how preferences and 
acceptability may differ by equity subgroups (e.g. socioeconomic status) (Edwards et al., 
2013b) which is an important consideration in the field of public health (Marmot et al., 
2010). Furthermore, I was aware that understanding participants preferences is an 
important field of study within the behavioural science literature, as the acceptability of an 
intervention to the participants can impact on the success of the intervention (Michie et al., 
2014).  
 
Time costs and loss in earnings from the participant’s perspective 
I had identified two studies (Iliffe et al., 2014a, Isaacs et al., 2007) in my review, which 
had looked at participant costs in terms of the time the participants gave up to participate 
in the intervention. More specifically, they had asked participants to clarify whether they 
had participated during their work or non-work time, and whether the participant 
experienced a loss in earnings as a result. Similarly, a third study (Elley et al., 2011) from 
my review also asked about work, but with the intention of capturing whether the 
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intervention had reduced or increased sickness- and accident-related absenteeism. I 
therefore felt it was important to measure productivity and so incorporated key questions 
about this (see participants cost questionnaire in Appendix B.1).   
 
3.3.6.5. Item 6.5. Productivity loss from the employer’s perspective 
If the intervention of interest is delivered in the workplace, it is recommended that absenteeism and 
presenteeism can also be measured using validated self-report questionnaires. The workplace 
limitations questionnaire (WLQ) (Lerner et al. 2001) is recommended since it one of the three main 
validated tools used to capture presenteeism (Kigozi et al., 2017). In addition, if the intervention is 
delivered in a workplace setting, the time taken away from productive work to take part in the 
intervention can be recorded by the staff delivering the intervention. 
Reflection on item 6.5  
Although no studies in my review included presenteeism in their economic evaluation, I 
felt this productivity measure was important to capture. This is because the economic 
literature argues that presenteeism is a greater contributor to employer-related 
productivity losses than absenteeism (Schultz et al., 2009) and that national guidelines 
should emphasise the importance of including presenteeism in analyses conducted from a 
broader perspective (Kigozi et al., 2017). The reason for the lack of studies capturing 
presenteeism in economic evaluations may be due to national guidelines often stating that 
absenteeism is preferred over presenteeism (Knies et al., 2010). 
 
3.3.7. Item 7. How and when can effects be measured? 
It is recommended that you consult your country’s guidelines (see item 5) to see if there is a 
preferred approach to measuring the primary outcome. If you choose to measure QALYs there are 
a number of steps involved in the calculation of QALYs. QALYs encapsulates both quantity and 
health-related quality of life (HRQoL) in a single value. The number of years lived, known as life 
years (LYs) is calculated based on whether a participant is alive or dead. These years are adjusted 
according to the HRQoL reported. There are a number of HRQoL measurement tools, however the 
EuroQol EQ-5D is the most common tool used in economic evaluations and is freely available for 
research purposes (Rabin et al., 2011). The latest version of the tool asks participants to rank each 
of the 5 health dimensions using 5 levels of severity as opposed to 3 levels. You may prefer to use 
this tool as it is more sensitive at detecting differences in HRQoL. It is recommended that HRQoL is 
measured at the same time points as the clinical effectiveness evaluation (Glick et al., 2014). 
EuroQol’s user guide for the EQ-5D can provide further guidance on employing the EQ-5D 
questionnaire (Rabin, Oemar, Oppe, Janssen, & Herdman, 2011). The long-term effects of PA and 
SB interventions on QALYs can be done by identifying pre-existing models, which relate a 
reduction in NCD (e.g. T2D, CHD and stroke) with a gain in QALYs.   
 
Reflection on item 7 
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Short-term effects 
Prior to commencing this PhD, I had come across the terms QALYs and EQ-5D in the 
literature but had not realised that there were a number of steps involved in the calculation 
of a QALY that go beyond the measure of HRQoL using the EQ-5D measurement tool. I 
was surprised to learn that the EQ-5D was a generic measure for health since the tool 
seemed quite limited. I recommend the use of the EQ-5D as it was the most commonly 
used tool reported in the studies in my review.  
Long-term effects 
In my review I identified two models which draw on epidemiological evidence to relate 
levels of PA with a reduction in TD2, CHD and stroke events, and as a consequence a 
gain in QALYs (Anokye et al., 2012, Campbell et al., 2015b).   
 
3.3.8. Item 8. How can costs be valued? 
Unit costs for the economic evaluation should primarily come from national published sources. For 
participant costs, the actual price incurred by the participant was deemed appropriate. If published 
sources or participant reported prices are not available for a specific resource item or category (e.g. 
presenteeism) then the resource can be reported in its natural units rather than be assigned a 
monetary value.  
3.3.8.1. Intervention costs 
Typically, aggregate unit costs do not exist for new interventions or even for existing individual-level 
PA and SB interventions. Therefore, resource items recorded in the microcosting tool can be 
assigned an individual unit cost before being aggregated together. Published unit costs can be 
used to value the individual resource items. If no unit cost is available unit costs from a similar 
resource can be used. All sources of unit costs can be recorded along with the date the source was 
accessed.   
3.3.8.2. Health and social care costs 
For health and social care costs national standard unit costs can be used. If no unit cost is 
available then the unit cost of a similar resource can be used. All sources of the unit cost and date 
the source was accessed can be recorded.  
3.3.8.3. Participant out of pocket costs 
Unit costs for participant’s out of pocket costs (e.g. clothing, equipment, gym membership) will be 
the actual prices self-reported by the participants as in the participant cost questionnaire. Time and 
distance travelled will be reported in their natural units.  
3.3.8.4. Employer costs 
For employer costs a national average earnings can be applied where participants lose time at 
work due to participating in the intervention. 
 
Reflection on item 8 
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Internationally the health economic literature suggests the preferred approach for valuing 
healthcare utilisation is by assigning national published unit costs to resource quantities 
(van Lier et al., 2017). The studies in my review had drawn on published unit costs in 
order to value healthcare use. The studies from the UK helped me identify the unit cost 
series for health and social care which is published annually (Curtis and Burns, 2018). I 
was surprised that I had not come across this unit cost series during my training in SROI 
when I was a Research Assistant in Public Health. Another observation I made was that 
the authors in my review did not report the sources they used in order to assign unit costs 
to the intervention resources. This may be due to most studies having reported using the 
budget breakdown from the funding application of the trial, rather a conduct a 
microcosting exercise.   
 
3.3.9. Item 9. How can effects be valued? 
Effects only need to be valued if a CUA has been performed. In addition, it is recommended that 
you consult your country’s guidelines to identify when there is a preferred valuation approach 
(ISPOR, 2019). If the EQ-5D tool has been used as recommended in item 7, then EuroQol’s user 
guide can be referred to in order to create a EQ-5D HRQoL profile for each of your participants 
(Rabin et al., 2011). All EQ-5D profiles already have a utility weight (also known as a preference 
score) assigned to them by a sample of your country’s population. Assign your country’s published 
stated utility weights to each of your participant’s EQ-5D profiles. This utility weight is calculated 
from country-specific catalogues before being combined with data on length of life data to estimate 
the number of QALYs experienced over the specified time horizon. You can combine these utility 
weights with the time lived by the participants (during the trial) in order to estimate the number of 
QALYs gained or lost during the trial. Ideally, HRQoL should be collected on a schedule and you 
can interpolate between points to calculate the QALYs as the area under the curve. To determine 
cost effectiveness, many countries have guidelines to see what the maximum amount of money 
your country is willing-to-pay per gain in QALY. For modelling studies the unit cost/ price from the 
initial treatment of a stroke or CHD event, and the ongoing annual treatment for treating stroke, 
T2D or CHD can be taken from the existing literature. For the CCA, all disaggregated effects can 
be reported in their natural units. 
participants HRQoL at baseline and all other data collection time points, you can assign a utility 
weight to each participant’s score.  
Reflection on item 9 
I was surprised to learn that the key difference between the different types of economic 
evaluations is the methods they used to value the effects (outcomes) of interest. It also 
made me realise that unless a CBA was conducted then the result of a single CEA was 
limited to just one outcome measure. There is consensus amongst health economists that 
CBA is deemed theoretically superior to CEA and CUA as it can incorporate and monetise 
multiple outcomes (Drummond et al., 2015b). Yet in practice CBA is challenging to 
execute as demonstrated through the finding in my review and former reviews which 
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found no studies had performed a CBA or explain how they had monetised the outcomes 
(Weatherly et al., 2009, Alayli-Goebbels et al., 2014, Hill et al., 2017). During my time as a 
Public Health Research Assistant, I became increasingly aware that SROI was similar to 
CBA as it included and monetised non-health outcomes. In the SROI evaluations I had 
conducted, it was standard practice to assign a ‘shadow’ market price to outcomes which 
did not have a national published unit cost. I explored why the SROI methodology had not 
been adopted by the health economic community. Some economic analysts claimed that 
the SROI methodology had several theoretical problems which would need addressing 
before further adoption of the methodology (Fujiwara, 2015). In order to explore this 
further, in 2016 at the start of my PhD, I emailed a senior academic health economist from 
one of the health economic groups in the UK, to seek their opinion on the role of SROI 
and CBA in public health evaluations. The health economist informed me that they were 
unfamiliar with the SROI methodology. In terms of CBA, they explained that they felt CBA 
had the potential to generate useful information if done in accordance with the principles 
of the Washington State Institute of Public Policy and UK’s Treasury Green Book. 
Nonetheless, they claimed that in general they believe CBA is often not conducted well in 
practice and does not address distributional issues (e.g. the UK’s income distribution). 
This pre-PhD discussion had reassured me that the difficulty in producing a well-
conducted CBA in practice was likely to explain why I had come across any CBA studies 
in my systematic review (Chapter 2). That is to say, until further methodological 
development is made in the field of CBA, I recommend in my initial framework that CEA 
and CUA are carried out as the preferred valuation technique.  
 
3.3.10. Item 10. How can costs and effects be discounted to a present day value? 
For trial-based economic evaluations that do not extend beyond 12 months, no discounting is 
necessary. For those that go beyond 12 months it is advised that you check your country’s 
guidelines (see link in item 5) to see which discount rate is recommended for costs and effects. In 
the absence of country-specific discount rates, 3% can be used, as employed by the World Health 
Organisation (WHO) (World Health Organisation, 2017).   
Reflection on item 10 
Through my reading in the health economic literature, I became aware that different 
countries specify different discount rates. For example the WHO (2003) recommends 3% 
as the annual discount rate for costs and effects when there is no country-specific 
guidelines available. In the UK, NICE state that costs and effects should be discounted at 
a rate of 3.5% per annum (NICE, 2014a). In my previous public health SROI evaluations, I 
had come across the term discounting, however I had not considered how it was 
calculated. I found it interesting to read about discounting in the health economic 
literature, where some claim that discounting is important because a phenomenon has 
been observed which indicates that people typically prefer to gain benefits now and incur 
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the costs later (this phenomenon is known as positive time preference). This makes sense 
when recognising that the benefits gained in the immediate future are more certain than 
those gained in the distant future (Drummond et al., 2015b).   
 
3.3.11. Item 11. What summary statistics can be presented? 
For the initial summary statistics for costs and effects, means and standard deviations are 
recommended for continuous variables. For categorical variables, proportions are recommended 
along with the numerator and denominator. Where one comparator group is more expensive and 
less effective than the other(s), then it be evident which group is the best option to invest in. 
However, if your results indicate that some group is more effective but also more expensive, an 
incremental cost-effectiveness ratio (ICER) statistic is recommened. The calculation for the ICER is 
presented in Figure 4. An ICER summarises the additional cost per additional unit of effect gained. 
More specifically, the summary statistic allows a pre-specified decision rule to be applied in order to 
interpret whether the gain in effect falls within a threshold in which we are happy to pay for one 
additional unit of effect. The ratio can be interpreted by comparing the ratio to a willingness to pay 
(WTP) threshold if your country has one or an incremental health opportunity cost (Woods et al. 
2016). An example of a willingness-to-pay threshold is £20,000- £30,000 per QALY gained, as 
applied in England (NICE, 2014).  
 
Figure 4. Incremental cost-effectiveness ratio calculation 
 
Reflection on item 11 
Mean and standard deviation 
Despite cost data typically being skewed to the right with a long tail, and HRQoL data 
being typically right censored (as many HRQoL measurement tools have ceiling effects), 
the health economic literature argues that evidence on the mean is more relevant and 
useful to decision makers than the median. I was surprised when I first read about this in 
the economic literature since in clinical effectiveness literature it is standard practice to 
report the median instead of the mean, if data is not normally distributed. By contrast, the 
economic evaluation literature it is helpful to present the mean in economic evaluations, 
as the median runs the risk of underestimating the amount of resources that need to be 
budgeted for (Gray et al., 2012). Transforming skewed data is also not recommended for 
economic evaluations since it is the arithmetic mean that is required rather than the 
geometric mean (Glick et al. 2014). 
 
 
 
88 
 
 
Incremental cost-effectiveness ratio 
I had not calculated an ICER before, however the studies in my review indicated to me 
that this was the most common way to report the results of an economic evaluation. I was 
surprised to learn that the calculation for the ICER seemed straightforward. I think it was 
the different terminology used which had made me expect the calculation would be more 
complex. In the health economic literature, the term incremental cost and effects is 
commonly used. Incremental analysis is more commonly known in the clinical 
effectiveness literature as the between-group difference in effects. A further key difference 
I observed between the clinical effectiveness literature and economic literature was that 
there is consensus in the economic evaluation literature that a meaningful difference is 
typically conceptualised as being the decision-makers willingness-to-pay per unit of effect. 
In the clinical effectiveness literature, a meaningful difference is typically conceptualised 
as the minimum clinical important difference based on previous evidence and does 
therefore not incorporate the decision-makers willingness-to-pay into account. 
 
3.3.12. Item 12. What adjusted analyses can be performed? 
It is recommended that costs and effects are adjusted for baseline imbalances in costs and 
HRQoL. Multiple regression is recommended to control for the baseline covariates. Adjustment is 
recommended as it will improve the precision of the cost and effect estimate by reducing some of 
the unexplained variance in the cost and effect estimates. Both unadjusted and adjusted means 
and standard deviations for costs and effects can be reported (Franklin, Lomas, Walker, & Young, 
2019). 
Reflection on item 12 
Previous research stresses that when comparing QALYs of at least two intervention 
groups, adjustments should be made to the mean costs and effects to account for 
imbalances in the participants’ baseline costs and HRQoL utility (Manca et al. 2005; Glick 
et al. 2014). I draw on the economic evaluation literature in order to advise on how 
baseline imbalances could be controlled for. I found a study in one of the main health 
economic journals (Health Economics) which claimed that parametric tests such as 
multiple regression which can control for some variables, have been shown to be robust 
to skewed economic datasets and can generate similar results to nonparametric methods 
e.g. the nonparametric bootstrap method (Nixon et al., 2010).  
 
3.3.13. Item 13. What equity subgroups can be considered? 
Equity is an important objective for public health interventions, not just effectiveness. It is advised 
that at a minimum, the following four equity subgroups are included or discussed in your study: 
socioeconomic status, age, sex and medical condition. Furthermore, it is recommended that all 
equity-related data is collected at baseline from the participants via a self-report questionnaire. 
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Reflection on item 13  
Equity was a key topic I learnt about through my Masters in Public Health and my 
Research Assistant job in Public Health. I was therefore interested to learn that one of the 
main challenges in public health economic evaluations, is the incorporation of equity into 
the analysis (Weatherly et al., 2014). The four most relevant equity subgroups for PA 
identified from my review, include: age, sex, socio-economic status and pre-existing 
medical condition. In particular, one of authors from one of the studies in my review 
reported that their cost-effectiveness result was particularly sensitive to age and pre-
existing condition demonstrating that heterogeneity and subgroup analyses are important 
to consider (Campbell et al., 2015b). Literature from the UK also indicates that sex and 
socio-economic status are important subgroups to consider for PA evaluations (Scholes, 
2017).  
 
3.3.14. Item 14. What uncertainty analyses can be performed for trial-based economic 
evaluations? 
It is recommended that the nonparametric bootstrapping technique is used to explore stochastic 
uncertainty in the sample and hence any uncertainty in the ICER point estimate. The 
nonparametric bootstrapping simulation randomly draw cost and effect pairs from the original 
dataset, in order to produce 1,000 empirical-based bootstrapped ICERs (Gray et al. 2012). This 
technique can produce uncertainty intervals (e.g. 95% confidence intervals) around the central 
estimate of cost effectiveness and can produce a cost effectiveness acceptability curve (CEAC) 
which assesses the probability of the intervention of interest being cost-effective at various WTP 
thresholds (e.g at £1,000 per QALY, £10,000 per QALY; £100,000 etc). The CEAC is 
recommended as it will enable you to assess the probability that an intervention would be cost-
effective at different levels of willingness to pay. In addition to stochastic uncertainty, it is 
recommended that you assess the uncertainty associated with the methodological choices made 
by the analysis. This can be done using an approach called one-way scenario analysis. One-way 
scenario analysis involves making plausible changes to the parameters input into the ICER 
calculation one by one, in order to assess how a change in one parameter can impact on the ICER 
result. 
Reflection on item 14 
Stochastic uncertainty 
The studies in my review did not provide guidance on how to address stochastic 
uncertainty in the cost-effectiveness result. Furthermore, I read in the health economic 
literature that characterising uncertainty is a key methodological challenge that is 
experienced across the whole field of health economics. In order to learn what standard 
practice was for addressing stochastic uncertainty in economic evaluations, I attended a 
3-day training course in applied cost-effectiveness analysis at the University of Oxford. 
The first fundamental thing I learnt on the course was that it is not possible to calculate a 
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standard error statistic for a ratio statistic. The course tutors with expertises in the health 
economics, recommended that stochastic uncertainty in the ICER statistic could be 
assessed through a nonparametric bootstrapping simulation.  
 
Methodological uncertainty 
One-way scenario analysis was the most common way studies in my review addressed 
uncertainty in the methodological choices made by the analyst. I felt confident in doing 
this type of uncertainty analysis since I had performed a similar uncertainty analysis in the 
SROI evaluations I had conducted when I was a Research Assistant in Public health.  
 
3.3.15. Item 15. How can the results be interpreted?   
It is recommended that methodological choices are reflected on in the discussion section of the 
economic evaluation in order to help the read interpret the results. Key methodological choices 
which can be reflected on include: the perspective, the trial design, the sample size, the 
comparators, the costs and effects included/ excluded, the measurement tools, and the equity 
subgroup included. n addition, heterogeneity, generalisability and transferability are concepts which 
may also be help you interpret your results. Heterogeneity in terms of the comparator groups 
including different subgroups is also an important issue to consider in economic evaluations, since 
heterogeneity can drive the cost-effectiveness results. Generalisability can be reflected on in terms 
of whether results are relevant beyond the sample and location where the interventions are set. 
Transferability can be reflected on in terms of whether the results are relevant beyond the country 
the study has been carried out in. 
Reflection on item 15 
A key finding from my review was that the analyst’s methodological choices and 
assumptions make it difficult to compare cost-effectiveness results from different studies, 
even if they are from the same country and perspective. This finding highlighted to me 
that it is important to reflect on our analyst-based choices and help the end user of the 
results interpret our study findings. This is especially important, since I am aware that 
there is a shortage of health economic expertise internationally, which means it is likely 
that decision-makers who may be using the results may not be familiar with how the 
summary decision indices (e.g. the ICER point estimate) are constructed and what the 
result means. Furthermore, guidance for the quality assessment checklist by Drummond 
et al. (2015) reports that heterogeneity and generalisability are important factors to 
consider when interpreting results.   
 
3.3.16. Item 16. How can trial-based economic evaluations be reported?  
As economic evaluations involve numerous methodological steps, it may be helpful to consult the 
main economic evaluation reporting guidelines called the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS). More specifically, the CHEERS checklist’s explanation 
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and elaboration document provides examples on how different sections of the economic evaluation 
can be written up and presented. Although these are generic guidelines, the items included will 
ensure you report all the necessary features of your study in order to help the reader interpret your 
methods, analysis and results, and consider whether they apply to their own context. Lastly, if a 
CCA is conducted for the secondary analysis, it might be necessary to report this in the 
supplementary material since the CCA constitutes a full impact inventory of costs and effects, 
which is likely to be lengthy.   
Reflection on item 16 
For my systematic review (Chapter 2) I had drawn on the reporting guidelines called 
PRISMA. I had been using the Equator-network to access these guidelines. I searched 
this to see what economic guidelines were available and discovered that in 2013, the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS), a set of 
international reporting guidelines for economic evaluations, had been published 
(Husereau et al., 2013). After observing heterogeneity in the methods reported across the 
studies in my review, I felt the use of reporting guidelines would be one way make the 
study reporting more systematic and improve the comparability of methods and results 
across studies.  
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Chapter 4: Application of the initial framework to the 
evaluation of a co-developed PA on Referral Scheme 
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4.1. Introduction 
4.1.1. Background and rationale 
Despite the abundance of evidence on the benefits of PA, evidence on the cost-effectiveness of PA 
programmes is less certain, specifically for exercise referral schemes (ERSs) (Owen et al., 2017). 
ERSs are a common intervention strategy, with there being reportedly over 600 different types of 
schemes across the UK (Pavey et al., 2011a). Despite early calls for schemes to focus on helping 
people to incorporate PA into their lifestyles, the majority of ERSs are 12-16 week programmes 
which focus on encouraging structured exercise (Dugdill et al., 2005). A key systematic review 
found that those who participate in ERSs are more likely to improve their PA levels compared to 
those receiving PA advice only (Campbell et al., 2015b). That said, the review authors concluded 
that the specific components of ERSs, which support long-term behaviour change of PA, are 
unknown. Evidence from a high quality RCT on the short-term effects of ERSs found that benefits 
include increased PA levels of PA for those with CHD as a pre-existing medical condition, as well 
as lower levels of anxiety and depression amongst those with mental health or mental health and 
CHD as pre-existing condition (Murphy et al., 2012).  
Historically, ERSs have not been underpinned by evidence-based behaviour change techniques. 
Recognising this, NICE in England and Wales, now recommends that all future trials on ERS 
clearly justify the behaviour change techniques they have incorporated into their intervention 
(NICE, 2014b). In the same guidance, NICE also acknowledge the lack in economic evidence on 
ERS, and recommend that trials measure cost-effectiveness and health-related quality of life 
(HRQoL) alongside their effectiveness evaluation. The present study aligns to these 
recommendations by assessing the cost-effectiveness of a co-developed PA on referral scheme 
that is underpinned by the current evidence on behaviour change (Buckley et al., 2018, Buckley et 
al., 2019).  
4.1.2. Aims 
The overarching aim of this study was to apply the initial version of the framework (Chapter 3) in 
order to:  
1. reflect on the relevance and applicability of the framework to a real-world PA trial. 
2. assess the cost-effectiveness of a co-developed PA referral scheme (Co-PARS) compared 
to (a) an existing exercise referral scheme (usual care) and (b) a no treatment control 
group.   
The development of the framework was an iterative process. In my reflection boxes throughout this 
chapter I will revisit the framework items and consider how well they have been implemented in 
practice. The aim will be to describe any complexity involved in the conduct of the economic 
evaluation with the intention of generating theory about what is likely to be a helpful approach to 
address this complexity.  
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4.2. Methods for Aim 1: Reflections  
Reflections on the planned and actual application of the initial version of the framework are 
documented throughout the methods and results sections. The reflections aim to provide valuable 
insight into of the actions I took in order to develop and apply the framework in practice. 
Importantly, the reflections aim to provide explanations for why I believed these actions were 
appropriate. That is to say, the reflections are based on my experience of applying the initial 
version of the framework to the Co-PARS trial. The reflections offer insight into how the framework 
may be modified in a future refined version.  
For the costing approach I performed, I documented all of my decisions in an Excel spreadsheet so 
as my assumptions were transparent and I kept a record of the complexity in which was involved in 
my costing decisions (an example of the Excel spreadsheets is provided in Appendix C.2). In 
addition, I also reflect on relevant literature from the different disciplines. A key method I used in 
order to help me interpret the applicability of the framework was informal conversations and 
meetings with the Co-PARs trial team, my supervisory team, researchers from the Health 
Economic group at Deakin University (where I did a three week study placement) and the 
intervention staff. Meeting with this range of researchers and stakeholders ensured I was capturing 
a multidisciplinary perspective (e.g. public health, health economics, behavioural science).  
In particular, a key meeting I arranged was to discuss items 4-9 from my framework (identification, 
measurement and valuation of costs and effects). I wanted to understand how these six items were 
perceived from the multidisciplinary perspectives of the experts who I was working with. I arranged 
a one-hour consultation with my supervisory team and key members from the Co-PARs trial team. 
Key members from the trial team included the PhD student (BB) and the trial manager (PW) who 
was also one of my supervisors. Both were selected to be involved in the meeting as they had 
been involved in the design of the Co-PARs intervention content and the setting up of the 
intervention in the leisure centres. In addition, they both had expertise in physiology, public health 
and behavioural science. As discussed earlier in this PhD, my supervisory team also included a 
range of expertise (e.g. physiology, behavioural science and public health, health economics). I 
therefore deemed my supervisory team’s involvement in the one-hour meeting as being valuable. 
In total six researchers (my four supervisors and two PhD students, which included myself) took 
part in the consultation. Prior to the meeting I circulated an agenda to inform everyone that we 
would focus our discussion around items 4-9 from my framework. These items all related to the 
data collection plan. More specifically they related to the identification, measurement and valuation 
of the cost and HRQoL data. The key objectives of my consultation meeting were to: (1) identify all 
perspectives (stakeholders) who could experience a change in cost or effects due to the Co-PARs 
trial; (2) discuss the feasibility of incorporating the resource use and EQ-5D-5L questionnaires in 
the patient questionnaire booklet as well as discuss the feasibility of capturing intervention costs 
through budget breakdowns and telephone interviews; (3) explain the different approaches to 
valuation I planned to use; and (4) clarify roles and responsibilities for the data collection process at 
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the key follow up time points. Overall, the meeting was a good example of multidisciplinary 
working.  
4.3. Methods for Aim 2: Economic Evaluation  
4.3.1. Trial design  
The present economic evaluation was part of a larger trial (Buckley et al., under review) which took 
place between 2018- 2019. The trial was a quasi-experimental design comparing three groups: (1) 
a co-produced PA referral scheme (Co-PARS); (2) a usual care ERS; and (3) a no treatment 
control group. The primary outcome measure for the trial was cardiorespiratory fitness (measured 
as change in VO2 max score). The primary outcome measure for the present economic evaluation 
was quality-adjusted life years (QALYs).  
Reflection on item 1.1- What components make up a well-defined study question? (costs and 
effects of two or more groups) 
In item 1.1. of the initial version of the framework, I explained that at least two comparator 
groups are required for an economic study to be identified as a “full” economic evaluation by the 
health economic community. The Co-PARS clinical effectiveness evaluation was being set up to 
compare the effects of three comparator groups. “Piggy-backing” the economic evaluation on the 
back of the effectiveness trial would necessitate additional data to be collected to capture 
resource use and HRQoL. I discussed this with the trail team and we came to the conclusion that 
the additional collection of economic data would not involve changing the fundamental design of 
the trial and would also be inexpensive to do.  
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Reflection on item 3- What is an appropriate study design for a trial-based economic evaluation? 
In item 3 of the initial framework, I recommend that a PA trial is delivered in a setting which 
reflect the ‘real world’. By this I mean a setting where the intervention could be rolled out in 
practice on a larger scale. Both the Co-PARs and usual care interventions were set within a local 
authority leisure centre and delivered by a qualified exercise referral practitioner (ERP) which 
reflected what is likely to happen under ‘real world’ conditions. Prior to starting this PhD I had not 
been involved in the design or delivery of a clinical trial before. It was through the regular 
monthly meetings I had with the Co-PARs trial team that I became aware of the numerous trial 
design decisions that had been made during and immediately following the feasibility trial in 
order to inform the definitive trial design. I tried to understand whether these various trial design 
decisions were appropriate from a health economic perspective by consulting the Drummond 
Handbook for Economic Evaluation for Health Care Programmes.  
 
In the Handbook I came across a tool called the pragmatic-explanatory continuum indicator 
summary (PRECIS) which described several domains for trial design (Thorpe et al., 2009). In 
turn, this reference led me to a more refined version of the PRECIS tool, called the PRECIS-2 
tool which discusses 9 domains of trial design (Loudon et al., 2015). The PRECIS-2 tools is 
designed to help researchers understand how trial design impacts on the degree to which the 
trial’s results can be used to inform ‘real world’ decision making. I recognised this was an 
important factor to consider. During my Masters in Public Health I had learnt about a concept 
called the ‘implementation gap’. The ‘implementation gap’ refers to the problem where the 
results of health research are valid in the context of a ‘ideal conditions’ but are not fit to inform 
‘real world’ decisions. As the purpose of economic evaluations are to inform ‘real world’ resource 
allocation decisions, then there is consensus that economic evaluations should be conducted 
alongside more pragmatic orientated trials as opposed to explanatory trials. I therefore felt it is 
important that I recommend that the framework encourages health economic researchers to 
reflect on the PRECIS-2 tool from the trial outset.   
 
4.3.2. Participants and recruitment  
The target population for the trial was adults (≥18 years old) who had a health-related risk factor 
(e.g. hypertension, non-diabetic hyperglycaemia, obesity) and/or a health condition (e.g. diabetes, 
cardiovascular disease, depression) that may be improved through PA. Participants with 
uncontrolled health-conditions and severe psychological or neurological conditions were excluded. 
Participants from the Co-PARS and usual care were invited to take part in the trial by the 
receptionists at the leisure centres. This took place when patients visited the leisure centre to book 
their induction (after being referred to the leisure centre by a health professional). After participants 
consented to having their contact details shared, one of two PhD researchers (Ben Buckley) sent 
the participant an information sheet before full consent was obtained. Participants in the no-
treatment control were recruited via posters, electronic invitations, email communications and 
ClinicalTrials.gov. Ethical approval was obtained from the North West - Preston Research Ethics 
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Committee (NHS Health Research Authority): 18/NW/0039. Both PhD researchers (Madeleine 
Cochrane and Ben Buckley) attended the ethics committee interview. 
4.3.3. Comparator groups 
All comparator groups received a lifestyles advice booklet, which contained information on England 
and Wale’s national guidance for PA, diet, smoking and alcohol.  
4.3.3.1. Usual Care exercise referral scheme (ERS) 
Usual care followed a standard ERS model, which comprised of one 1-hour induction to the leisure 
centre by an exercise referral practitioner (ERP). This was followed by 12 weeks free access to the 
swimming pool and subsidised access (£1 per visit) to the gym and group classes during off-peak 
hours. During the one-hour induction, the ERP devised a 12-week exercise plan appropriate for the 
health condition of the participant. 
4.3.3.2. Co-developed PA of referral scheme (Co-PARS) 
Co-PARS included the same 12 weeks free and subsidised access to the leisure centre and one 1-
hour induction. In addition, Co-PARS included four 30-minute consultations with the ERP, which 
took place at week 4, 8, 12 and 16. The aim of the Co-PARS intervention was to achieve sustained 
improvement in PA by encouraging people to incorporate PA into their daily activities. Furthermore, 
the Co-PARS intervention draw on evidence-based behaviour change techniques such as goal-
setting and self-monitoring, that were underpinned by self-determination theory (SDT) (Buckley et 
al., 2018).  
4.3.3.3. Control 
The control group received no treatment except for the lifestyles advice booklet. 
Reflections on item 2-  What does a comprehensive description of the comparator groups look 
like?  
As recommended in the initial framework, the trial protocol and CONSORT flow diagram were 
consulted in order to describe the three comparator groups: (1) 18-week co-developed PA on 
referral scheme (Co-PARS); (2) 12-week usual care (defined as existing exercise referral 
scheme); and (3) no treatment control. The descriptions in the protocol and CONSORT flow 
diagram provided an initial overview of the intervention groups, however I felt that analysing the 
pathway in this way did not provide enough detail about the context in which the interventions 
were delivered and the resource quantities involved. I noted that item 6 in my framework offered 
a more comprehensive approach to describing the comparator groups. This repetition of items 2 
and 6 indicated to me that item 2 would not be required as a separate item, but could be 
incorporated into item 6.  
 
4.3.4. Type of economic evaluation 
This economic evaluation compares the costs and outcomes for the three intervention arms over a 
6-month time horizon (the 6 month time horizon meant discounting was not required). The primary 
 
 
98 
 
 
economic analysis was to conduct a trial-based cost-utility analysis (CUA) from a multi-agency UK 
public sector perspective (agencies are discussed in the subsequent section). The secondary 
economic analysis was to conduct a cost-consequence analysis (CCA). The methodological 
approach was informed by the recommended framework in Chapter 3. Full details on how the initial 
version of the framework has been applied to this trial is documented alongside the study 
reflections findings in section 5.3.4.  
Reflections for item 1.2- What components make up a well-defined study question? (Primary 
Analysis) 
In item 1.2 of the initial version of the framework, I advise that it is helpful for analysts to check 
their country’s guidelines (referred to as the ‘reference case’ by the health economics 
community) to see if there is a preferred analysis type for that country. The UK’s reference case 
recommends a CUA is performed for the primary base case analysis. This explains why I 
decided to conduct a CUA for the primary analysis. I felt it was important that my analysis 
technique was consistent with other UK-based economic evaluations. The UK’s reference case 
specifies CEA (where outcomes are reported in their natural units), CBA and CCA are 
appropriate for additional analyses. In my systematic review (Chapter 2), I concluded that a CCA 
conducted alongside a CUA or CEA would be helpful for the multi-sector audience of the PA and 
SB interventions to see a breakdown of the costs and outcomes which relate to them. I had not 
identified any examples of CBA applied to PA through my review, so I did not feel confident in 
carrying out a CBA without accessing additional training. At the time I was planning my analysis, 
I did not come across any practical training opportunities in the UK.   
 
4.3.4.1. Perspective 
The CUA was conducted from the multi-agency public sector perspective, which included: primary 
and secondary healthcare agencies, local government (payer), the leisure centre (provider and set 
up costs) and the research institute (set-up costs), as recommended for interventions outside the 
healthcare setting (NICE, 2014a). The CCA included the public sector agencies outlined for the 
CUA, as well as the participants’ perspective. Cost categories for each perspective and economic 
evaluation type are outlined in Table 6.  
Table 6. Perspective, costs categories and economic analysis 
Sector Perspective Cost category Economic 
evaluation type 
Public  Payer intervention 
costs 
Intervention operating 
costs 
CUA; CCA 
CCA 
Leisure Centre 
(Provider) 
Intervention additional 
operating costs 
CUA; CCA 
Healthcare sector Primary healthcare CUA; CCA 
Secondary healthcare CUA; CCA 
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Prescriptions CCA 
Research Institute Intervention set up 
costs 
CCA 
Private Participant (Private 
individual) 
Time costs CCA 
Travel costs CCA 
Out-of-pocket costs CCA 
CUA – cost utility analysis, CCA – cost consequence analysis 
 
4.3.4.2. Data collection procedure 
The trial had three key data collection points. Baseline data was collected 1-3 weeks prior the 
intervention start date. The two follow up time points took place 12 weeks and 6 months after the 
intervention start date. Baseline and 12-week data collection took place in the university 
laboratories. Participants had various physiological measures taken which are described in the 
main trial (Buckley et al. under review). The demographic and economic were measures using self-
reported questionnaires. Six-month data collection was collected via post; the PhD researcher 
(Madeleine Cochrane) was responsible for coordinating this data collection. In addition Madeleine 
Cochrane was responsible for the data handling and analysis of all economic data from the three 
time points. Additional intervention cost data was sought by Madeleine Cochrane through a face-to-
Reflection for item 1.2-  What components make up a well-defined study question? 
(Perspective) 
In item 1.2 of the initial version of the framework, I advise that the primary analysis is 
conducted from the public sector perspective. In my previous role as a Research Assistant, I 
had frequently been involved in identifying the stakeholders involved in the service 
evaluations I was performing. I believe this experience of identifying stakeholders helped 
me recognise that the health economic term ‘perspective’ is similar to the public health term 
‘stakeholder’. Furthermore, I was able to recognise that the payer’s point of view in the Co-
PARS evaluation is the local government and that the provider was the local authority 
leisure centre.  
Prior to conducting the systematic review, I had not considered set-up costs as being 
different to the delivery costs. In my systematic review (Chapter 2), the study by Edwards et 
al. (2013) had identified set-up costs as a key cost category. That said, during my research 
placement at Deakin University, the health economists informed me that they do not usually 
include set-up costs in their economic evaluations. They explained that their country’s 
guidelines preferred them to evaluate interventions as though they are operating as a 
‘steady state’. The UK’s economic guidelines do not specify whether public health 
evaluations should include set-up costs, I therefore chose to take a more comprehensive 
approach and included it. 
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face consultation with the gym manager and ERP at each leisure centre. The researcher Ben 
Buckley, who was also responsible for all clinical data, collected data at baseline and 12 weeks. 
 
4.3.5. Cost measures 
Costing necessitated the collection of two types of data: (1) quantities; and (2) unit costs. For the 
present study, primary data collection methods were used to estimate resource use quantities, 
while unit costs came from secondary sources except for participant costs, which used actual 
prices reported by the participants. Measurement tools used to capture resource use quantities are 
outlined below and described in Appendices B.1 and C.3. Research costs were not included in the 
study. Costs categories included are detailed in the subsequent sections. 
Reflections on item 4- What costs are important and relevant? 
In item 4 of the framework I provide examples of five perspectives that may be relevant to the 
analysis of a PA intervention: the payer, the provider, health care, the participant and the 
employer. In order to help me identify the organisations and individuals which related to these 
five categories for the Co-PARS trial I arranged a one-hour consultation with my supervisory 
team and key members from the Co-PARs trial (see section 4.2 for further details on the 
consultation). At the meeting, the trial team confirmed that the payer of the intervention was the 
local authority and that the leisure centre was the provider. In terms of including healthcare 
costs, although no-one at the meeting had experience of collecting these costs in a trial-based 
evaluation, there was recognition that from a public health perspective the Co-PARs intervention 
could have the potential to reduce the demand for primary care visits and prescribed 
medications. Similarly, no-one at the meeting had experience of including participant out-of-
pocket costs in their trial-based questionnaire booklets, however there was consensus from a 
behavioural science perspective as well as an equity (public health) perspective that the financial 
and time costs incurred by the participant were important as they might reveal hidden barriers 
which had not been considered e.g. the type and amount of time given up to travel to and 
participant in the Co-PARs intervention. I feel the health economic perspective of time being 
given up by the participant was an interesting discussion which many of us at the meeting had 
not previous incorporated into our data collection questionnaires. The meeting also helped me 
recognise the benefits of meeting with the trial team to capture a multidisciplinary perspective.   
 
4.3.5.1. Intervention costs: quantities 
It was initially intended that a budget breakdown of the intervention costs would be acquired from 
the local government who allocate funding to the ERS programmes across the Liverpool region. 
This budget breakdown was not available since funding was based on a payment transfer system. 
Instead, a microcosting exercise was conducted. The CONSORT flow diagram from the larger trial 
(Appendix C.1) was firstly used to identify key intervention activities for each site. Further detail on 
the activities (e.g. how they were delivered and/or modified in practice) were captured 
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retrospectively through a one-hour consultation with the ERP and leisure centre manager at each 
intervention site. The TIDieR framework checklist was used to guide the discussion. This data was 
recorded in a modified version of the microcosting tool (Appendix C.1 provides an example on how 
the microcosting tool was applied).  
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Reflections on item 6.1- How can costs be measured? 
Intervention operating and set up costs (planned and additional costs) 
It was not possible to access a budget breakdown for the ERS from the local authority since the 
payment system for the ERS programme was a block contract. As a result all intervention 
resource data were collected retrospectively through face-to-face meetings with the leisure 
centre managers (n=2), ERPs (n=2) and the trial manager (n=1). Research costs were not 
included in the analysis, however the trial manager was consulted as they were able to recall the 
number of meetings that were needed between the ERP, leisure centre managers and local 
authority staff in order to set up and provide information about the new Co-PARS intervention. I 
had not been involved in the development and set-up of the Co-PARS intervention at the leisure 
centres since this preliminary work began at the beginning of 2016, before I had begun my PhD 
project. Therefore I was not able to ask the trial team to document these set up costs. I feel that 
a key learning point for me was that it would be helpful to have a health economic perspective 
involved from the inception of the project. In addition, another key learning point for me was 
about the benefits of being flexible with the intervention staff. I had originally planned to arrange 
telephone interviews with the intervention staff to collect intervention resource use data. 
Nonetheless, the leisure centre staff requested if they could meet face-to-face and so I changed 
my approach in order to ensure this resource use data was collected. 
 
I also changed my microcosting approach. I had originally recommended that the CONSORT 
flow diagram and trial protocol could be used to identify resource use quantities. However, I 
found that this approach did not comprehensively identify all intervention resources. Prior to 
collecting data on the intervention costs, I had become aware through informal conversations 
with the trial team that the intervention was more complex than I thought and involved multiple 
components. I therefore became aware that the brief telephone interview schedule (Appendix 
B.1) and the simple microcosting tool (Table 5 in Chapter 3) I had proposed in the original 
framework in Chapter 3 were unlikely to be able to capture the complexity of the Co-PARs and 
usual care intervention. I sought advice around capturing the complexity of the intervention from 
one of the senior health economists from Deakin University who I had met during my study 
placement and who had experience of costing public health interventions. They informed me 
about an approach called ‘pathway analysis’ which was used in the ACE-Prevention project (Vos 
et al., 2007). ACE-Prevention was a national project in Australia involving Deakin University, 
which assessed the cost-effectiveness of preventative interventions. I was informed that pathway 
analysis can be helpful for conceptualising a complex intervention as it asks: “who does what, to 
whom, when, where, and how often?” (Vos et al. 2007: 11). I recognised that this analysis 
framework was very similar to item 2 of the critical appraisal checklist by Drummond et al. (2015) 
which I had used in my systematic review (Chapter 2). The critical appraisal checklist explains 
that identification of intervention costs requires information about: “who does what to whom, 
where, and how often?” (Drummond et al. 2015: 45). This indicated to me that there was some 
evidence of consensus across the health economic literature, on how interventions can be 
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conceptualised. I made a similar observation with the template for intervention description and 
replication (TIDieR) framework which is published in the public health and behavioural science 
literature. Similar to the ACE-prevention and Drummond’s checklist, the information deemed 
important for understanding an intervention using the TIDieR checklist is: “why, what, who 
provided, how, where, when and how much, tailoring, modifications and how well?”. The TIDieR 
checklist includes additional factors such as ‘how’, ‘tailoring’, ‘modifications’ and ‘how well’. The 
latter two concepts (modifications and how well) refer to the difference between the planned 
intervention and the intervention that was actually delivered in practice. I recognised that these 
two items had the potential to capture data which distinguished between the planned costs and 
actual costs (e.g. any additional costs) which I had identified in one of the studies in my 
systematic review (Edwards et al., 2013b).  
 
From the perspective of the behavioural science and public health literature, the authors of the 
TIDieR checklist explain that a comprehensive description is important for replicating the 
intervention and using the results as historically interventions have been poorly described in 
clinical effectiveness literature (Hoffmann et al., 2014). Poor reporting is thought to be due to 
journal authors and editors not having provided guidance on what to report (Schroter, Glasziou, 
& Heneghan, 2012). From a health economic perspective, a comprehensive description of the 
intervention is important as the resources used to deliver the interventions may drive the cost 
and explain the cost-effectiveness result (Anderson, 2010). From the perspective of the 
behavioural science literature, the description is important and may explain some of the 
mechanisms of behaviour change which can help with the design of a more effective and 
efficient intervention (Michie et al., 2013). Overall, these observations helped me identify an area 
for where multidisciplinary working had the potential to succeed.   
 
4.3.5.2. Intervention costs: unit costs   
Published unit costs were used as recommended in the framework (Chapter 3). This included costs 
for staff time to deliver and set up the intervention (e.g. time of the ERP, Receptionist and 
Researcher). The salary unit costs used included overhead costs in their calculations, therefore the 
cost of the capital equipment used to deliver the intervention (e.g. the private room, IT system and 
telephone in the leisure centre and research institute) was not included in the analysis, but these 
items are still quantified in their natural units. Printing costs derived from published unit costs, while 
a proxy cost was assigned to the subsidised membership since no unit cost was available for this 
item. All unit cost calculations for the microcosting exercise are provided in Appendix C.2. 
4.3.5.3. Healthcare resource use: quantities 
An adapted version of a widely used healthcare utilisation questionnaire called the client service 
receipt inventory (CSRI) (Mayer and Beecham, 2005, Beecham and Knapp, 2001) was completed 
by participants. The questionnaire asked participants to recall their healthcare use over the 
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previous 6 months, therefore participants were only asked to complete the questionnaire at 
baseline and the 6-month data collection point.  
4.3.5.4. Healthcare resource use: unit costs 
Healthcare unit costs were sourced from the England’s annual Health and Social Care unit cost 
publication (Curtis and Burns, 2018). Participants were not asked to distinguish between their 
hospital outpatient and day case visits, consequently an average of the unit cost for outpatient and 
day case visits was assigned from England’s database for secondary care reference costs (NHS 
Improvement, 2018). Medication costs were reported in their natural units. Cost calculations and 
unit cost sources are provided in Appendix C.2.  
4.3.5.5. Participant resource use and opportunity cost of time 
An adapted version of the annotated patient costs questionnaire (Thompson and Wordsworth, 
2001) was completed by the participants at 12-weeks and 6 months (Appendix C.3). In brief, the 
questionnaire captured participants’ out-of-pocket costs and any time they spent participating in the 
intervention including whether this was time lost in work. In the CSRI healthcare questionnaire 
(described in the previous section), participants were asked to tick whether they paid privately for 
any healthcare costs. As the study was from the public sector perspective, these costs were 
reported in the CCA but excluded from the CUA. 
4.3.5.6. Participant costs: unit costs 
Time was reported in natural units (hours/ minutes). Out-of-pocket costs for equipment and leisure 
centre memberships were reported and valued using the actual prices reported by the participants. 
Private healthcare utilisation was reported using unit costs from the UK’s annual Health and Social 
Care unit cost publication (Curtis and Burns, 2018).  
4.3.5.7. Currency, price year and conversion for all costs 
Dates of all prices are reported in Appendix C.2. Nearly all unit costs came from secondary sources 
for the current price year (2018/19). Where the price year differed, a price-year adjusted cost 
estimate was calculated by adjusting unit costs to the target year (2018/19) and by applying the 
UK’s GDP deflator index (HM Treasury, 2019). All unit costs came from UK sources meaning it was 
not necessary to convert currencies. 
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Reflection on item 1.4- What components make up a well-defined study question? (Time 
Horizon) 
In item 1.4 of the framework presented in Chapter 3, I advise that if there are sufficient data, time 
and expertise, then a decision model can be conducted after the trial-based economic 
evaluation. There were two main barriers which precluded a decision-model being built for my 
analysis of the Co-PARS trial. These related to the time it would take to build a decision model 
from scratch and secondly my lack of my involvement in the early stages of the trial.  
 
Firstly, through discussions with other health economists during my study placement with Deakin 
Health Economics group we concluded that building a decision model from scratch for the Co-
PARs economic evaluation would be a time-consuming process and would be beyond the scope 
of the aims of my PhD project. Therefore, rather than building a model from scratch we 
concluded it would be sensible to contact the authors of the pre-existing models I identified in my 
systematic review (Chapter 2) to see if they were able to share the data they had used to build 
their model. I contacted the two key corresponding authors of the PA models from my systematic 
review twice, however I received no reply from either author.  
 
Secondly, another barrier related to the fact that I had conducted my systematic review at the 
same time in which the feasibility study for the Co-PARS trial was being carried out. I therefore 
conducted my review before the study design for the definitive trial of Co-PARS had been 
finalised. I was aware that PA levels was being measured as the primary outcome for the 
feasibility study. For this reason, I limited the eligibility criteria of the studies in my review to the 
assessment of PA levels only. Findings from the feasibility study, led the trial team to decide that 
there was not be enough time or resource to assess PA levels as the primary outcome for the 
definitive clinical effectiveness trial (since a large sample size would be required), therefore the 
trial was designed to be powered to collect VO2 max scores as the primary outcome. I had not 
identified any decision models in my systematic review where short-term VO2 max or EQ-5D 
scores had been used to link these short-term effects with long term impact (e.g. increase in 
QALYs and reduction in treatment costs).  
 
Both these barriers highlighted to me the need for sufficient time and appropriate data in order to 
build a decision model. This first-hand experience helped me understand why most analysts in 
my review had not gone on to produce a decision model after conducting a trial-based economic 
evaluation. This experience also highlighted to me the importance of the health economic 
analyst becoming involved in the feasibility stage of the trial rather than the definitive stage. I feel 
I would have benefit from getting involved earlier so as I could consider how the data 
completeness results might impact on the economic analysis plan for the definitive trial.  
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Reflections on item 10- How can costs and effects be discounted to a present day value? 
As I did not include future costs and effects in the analysis I was not required to apply a discount 
rate. The trial-based economic evaluation assessed costs and effects over a 6-month time 
horizon only.  
 
4.3.6. Economic outcome measures 
4.3.6.1. Quality-adjusted life years 
EuroQol’s validated and widely used generic measurement tool called the EQ-5D-5L (EuroQol 5 
dimension, 5 level) measured HRQoL (Rabin et al., 2011). Pre-existing preference weights 
(HRQoL index scores) for the UK population were matched to each health state to calculate each 
participant’s HRQoL utility score. This is the preferred method for the main economic analysis 
conducted from the UK’s public sector perspective (NICE, 2014a). The final step to deriving the 
EQ-5D scores involved mapping the EQ-5D-5L index scores to the EQ-5D-3L using a 
recommended mapping function (van Hout et al., 2012). Mapping is recommended in NICE’s 
recent position statement for the valuation of the EQ-5D-5L measurement tool (NICE, 2018). The 
EQ-5D-5L was completed at baseline, 12 weeks and 6 months. In order to calculate QALYs for 
each participant, an average of each participant’s three EQ-5D scores was used and then 
combined (through multiplication) with length of life, which at 6 months was 0.5 life years.  
Reflections on item 5- What effects are important and relevant?  
As recommended in item 5 of the framework, I used a single generic measure of health benefit 
for the primary outcome. Overall, item 5 was straightforward to apply. I feel this was because 
there is clear consensus on what the preferred methodological approach is for studies conducted 
from the UK. For instance, the UK reference case clearly stated that the Quality-Adjusted Life 
Year (QALY) is the preferred measure for the primary outcome of public health economic 
evaluations evaluation adult-based interventions (NICE, 2014a). More specifically, the EQ-5D 
measurement tool is recommended to measure the HRQoL part of the QALY calculation. In 
order to provide a breakdown of the QALY calculation I presented this in the CCA which was 
straightforward to do.  
 
4.3.6.2. Willingness-to-pay preferences 
At 6 months, participants across all three groups were asked about their willingness-to-pay (WTP) 
for a hypothetical PA on referral scheme that involved one-to-one consultations with an ERP and 
access to leisure centre services. WTP questions are outlined in Appendix C.3. 
4.3.7. Analysis 
4.3.7.1. Complete case analysis  
The CUA was a complete case analysis, which aligned to the intention-to-treat (ITT) principle. For 
multi-item measurement tools where only a small proportion of the data was missing (less than 
10%) it was deemed acceptable to impute the mean of each group for participants missing an item 
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(Eekhout et al., 2014). In the CCA medication data, participant costs and WTP questions were 
reported based on the number of available-cases. Heterogeneity between the groups was 
assessed through descriptive statistics by comparing the groups’ baseline characteristics.    
4.3.7.2. Summary statistics 
A patient-level analysis was performed, where costs and QALYs for each participant were 
presented. Total mean costs were calculated using the absolute intervention and healthcare costs 
incurred between baseline and the 6-month follow up period. Area under the care data for the 
period between baseline, 12 weeks and 6 months estimated the change in QALYs. From here, 
measures of central tendency for the QALYs and costs were calculated for each group. Co-PARS 
mean costs and QALYs were compared to the mean values for: (1) usual care; and (2) no-
treatment control. The incremental cost-effectiveness ratio (ICER) was estimated. Measures of 
sampling variability are presented alongside the point estimates (e.g. standard deviations and 95% 
confidence intervals). Results of both unadjusted and adjusted analyses are presented. For the 
adjusted analyses, multiple regression was performed to adjust for baseline differences in HRQoL 
utility values and healthcare costs. 
Reflections on item 12- What adjusted analyses can be performed? 
The six month costs and QALYs were adjusted for baseline imbalances in healthcare costs and 
HRQoL scores using multiple regression. Adjusting for baseline imbalances using multiple 
regression is a widely used statistical approach within the clinical effectiveness literature. I 
therefore identified several practical examples on how to conduct this analysis in practice. I 
therefore felt confident my approach and results (Table 8). 
 
4.3.7.3. Uncertainty analysis 
Since it is not possible to estimate standard error for a ratio statistic (Gray et al., 2012) stochastic 
uncertainty was assessed through a bootstrapping simulation of 1,000 bootstrapped replicates. 
From here, cost-effectiveness planes and cost-effectiveness acceptability curves were produced to 
help show the uncertainty in the summary statistics. In addition, a one-way scenario analysis was 
performed to consider the variation and uncertainty in the total cost estimate when a different unit 
cost was used for outpatient and day case patient.  
4.3.7.4. Equity considerations 
At baseline participants self-reported equity-relevant demographic data: socio-economic status 
(postcode area), age, sex, medical condition referred for, number of medical conditions, ethnicity 
and occupation status. Epidemiological evidence from the UK highlights that the following 
subgroups were more likely to be physically inactive: females, aged 55 or over, obese, living in the 
most deprived quintile (Scholes, 2017). The equity impact analysis was exploratory as it was 
performed for participants within the Co-PARS group only. This was because only the Co-PARS 
group had a large enough sample, to have subsamples of 10 or more observations. 
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4.3. Results of the Economic evaluation 
4.3.1. Baseline characteristics 
A total of 68 participants were enrolled onto the trial between March- August 2018, 55 of whom 
provided measures at all three time-points (Figure 5). The largest group across all three time points 
was the Co-PARS group. Participant characteristics for each comparator group are presented in 
Table 7. The table shows that the proportion of individuals in each group was similar for ethnicity, 
sex, age, referral reason and co-morbidity status (having more than one health condition). In 
general, across all groups the majority of participants were white British, had a co-morbidity and 
were aged 50 years or over. Almost half (48%, n=12/ 25) of the Co-PARS group lived in an area 
classed as England’s most deprived quintile compared to just over a quarter (28.5%, n=4/14) of the 
control group, and a fifth (18.8%, n=3/ 16) of the usual care group. Control group participants were 
more likely to be in full or part time employment than both Co-PARS and usual care participants. 
Furthermore, the Co-PARS and usual care groups included participants who were absent from 
work due to long-term sickness/ disability or retirement, while the control group included no 
participants with these characteristics. 
 
 
 
Figure 5. Flow diagram of participants enrolled on Co-PARS trial 
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Table 7. Baseline Characteristics 
Characteristic Comparator groups 
Co-PARS (n=25) 
 
Usual Care (n=16) Control (n=14) 
EQ-5D score 0.640 (0.039) 0.724 (0.049) 0.872 (0.053) 
Live in top 20% most 
deprived area 
nationally 
48.0% (n=12) 18.8% (n=3) 28.5% (n=4) 
Ethnicity: White 
British 
84.0% (n=21) 93.8% (n=15) 78.6% (n=11) 
Occupation: Full-
time employment 
20.0% (n=5) 25.0% (n=4) 71.4% (n=10) 
Occupation: Part-
time employment 
4.0% (n=1) 25.0% (n=4) 21.4% (n=3) 
Occupation: Retired 24.0% (n=6) 25.0% (n=4) 0.0% (n=0) 
Occupation: Long-
term sickness or 
disability 
28.0% (n=7) 12.5% (n=2) 0.0% (n=) 
Sex: Female 60% (n=15) 56.3% (n=9)  57.1% (n=) 
Main referral reason: 
Cardiometabolic 
60.0% (n=15) 43.8% (n=7) 64.3% (n=) 
Main referral reason: 
Mental Health 
24.0% (n=6) 18.8% (n=3) 21.4% (n=) 
Main referral reason: 
Musculoskeletal 
issues 
12.0% (n=3) 31.3% (n=5) 7.1% (n=1) 
Co-morbidity  88.0% (n=22) 100% (n= 16) 78.6% (n=11) 
Mean age (years) 55.9(±13.7) 55.3(±16.3) 49.6(±17.3) 
Aged 55 and over 56.0% (n=14) 56.3% (n=9) 50.0% (n=7) 
 
4.3.2. Cost-utility analysis 
4.3.2.1. Summary statistics 
Table 8 reports the CUA results adjusted for baseline differences. At 6 months follow-up mean 
incremental QALYs were higher in the Co-PARS group compared to usual care (+0.021, 95% CI: -
0.008 to 0.05) and the control group (+0.003, 95% CI: -0.03 to 0.036) (Table 8). At 6 months mean 
incremental costs were higher in the Co-PARS group compared to usual care (+£322.34, 95% CI: 
£-476.53 to £1,121.20) and the control group (+£471.27, 95% CI: £-363.95 to £1,306.48). In 
summary, the Co-PARS group costed more but gained more QALYs at 6 months follow up. 
Nevertheless, the 95% CIs indicate that there is uncertainty in whether the true difference is 
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negative or positive. In terms of cost-effectiveness, the point estimate of the ICER for Co-PARS 
compared to usual care was £15,349 per QALY. Employing NICE’s WTP threshold suggests Co-
PARS is cost-effective compared to usual care. By contrast, the ICER for Co-PARS vs. control 
group was £157,088 per QALY. Using NICE’s WTP threshold suggests Co-PARS is not cost-
effective compared to the control group. Results of the CUA based on the original unadjusted data 
are presented in Appendix C.4. See Table 9 in the CCA for breakdown in the results.   
Table 8. Results for CUA at 6 months 
Variable Co-PARS Usual Care ERS Control 
Mean at 6 months 
(SE) per participant 
Mean at 6 months 
(SE) per participant 
Mean at 6 months 
(SE) per participant 
QALYs & Costs at 6 months* 
QALYs 0.385 (SE:0.008; 95% 
CI: 0.37 to 0.40) 
 
0.364 (SE: 0.009; 
95% CI: 0.35 to 0.38) 
0.382 (SE: 0.010; 
95% CI: 0.36 to 0.40) 
Total costs  £852.82 (SE: 
£201.70; 95% CI: 
£447.90 to £1257.75) 
£530.49 (SE:£252.05; 
95% CI: £24.27 to 
£1,036.51) 
£381.56 (SE: £270.01; 
95% CI: £-160.51 to 
£923.63) 
Incremental QALYs & Costs * 
Incremental 
QALYs: Co-PARS 
vs Usual Care 
 
0.021 (SE:0.012; 95% CI: -0.008 to 0.05); p-value=0.230 
Incremental 
QALYs: Co-PARS 
vs Control 
 
0.003 (SE:0.013; 95% CI: -0.03 to 0.036); p-value=1.000 
Incremental Costs: 
Co-PARS vs Usual 
Care 
 
£322.34 (SE:£322.71; 95% CI: £-476.53 to £1,121.20); p-value=0.968 
Incremental Costs: 
Co-PARS vs 
Control 
£471.27 (SE:£337.39; 95% CI: £-363.95 to £1,306.48); p-value=0.506 
ICER statistic at 6 months* 
Variables Co-PARS vs Usual Care  Co-PARS vs Control 
ICER point 
estimate 
 
 
£15,349 per QALY £157,089 per QALY 
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ICER 95% CIs at 6 months** 
Variables Co-PARS vs Usual Care Co-PARS vs Control 
95% CI for ICER 
based on 1,000 
bootstrapped 
simulations 
-£188,650 to £229,599  -£16,035 to £374  
 *Adjusted for baseline imbalances in EQ-5D score and healthcare costs; ** original unadjusted data 
Reflections on item 1.2- CUA as the primary analysis 
The initial framework advised the following analysis items which relate to the analysis approach: 
conduct a CEA (or CUA) as the primary analysis (item 1); present an incremental analysis (item 
11); adjust for baseline imbalances (items 12); and assess uncertainty in the results (item 14). I 
conducted a CUA in line with the UK’s reference case. The first part of the CUA calculation was 
similar to the methods I had come across for public health clinical effectiveness evaluations. I 
observed a small difference in terminology between the effectiveness and economic evaluation 
literatures. In effectiveness evaluations the analysis is typically referred to as ‘the between group 
difference in effects’. In economic evaluations, the same analysis is referred to as ‘the 
incremental effects’ and includes an assessment of the ‘the incremental costs’ (Table 8). 
Economic evaluations also have an additional second part to the ‘between group difference’/ 
‘incremental analysis’ which does not feature in effectiveness evaluations. The between group 
difference in costs is typically compared to the between group difference in effects so as the 
‘cost per effect’ (e.g. cost per QALY) can be presented. I felt confident in how to calculate the 
incremental cost-effectiveness ratio, as I found a plethora of examples in the health economic 
literature. Nevertheless, the confidence intervals for the cost data in Table 8 indicate there is a 
large amount of sampling variation and thus a considerable amount of uncertainty in the results. 
This indicated to me that it may have been inappropriate to perform a CUA on the sample from 
this trial as the small sample size and non-randomised nature of the trial is likely to have 
influenced the results for the within and between group analyses.   
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Reflections on item 11- What summary statistics can be presented? 
An important observation I noted was that when I informed the non-health economic researchers 
from the Research Institute I was studying at, that the Co-PARS vs usual care result was 
“£15,349 per QALY” they initially interpreted this result to mean that the Co-PARS intervention 
was decisively cost-effective. This made me aware of the consequence of reporting the ICER 
result by itself. I felt ICER statistic by itself did not inform people about the uncertainty that 
underpins my data and thus the ICER result. Similarly, through the informal conversations I had 
with non-health economic researchers at a PA conference in London in 2018 (the International 
Society for PA and Health congress), I became aware that many of the non-health economic 
researchers I spoke to had heard of the cost-effective result term the ‘ICER’, but they had not 
heard of the uncertainty analyses that health economists typically present alongside ICER 
results e.g. cost-effectiveness plane and cost-effectiveness acceptability curve (CEAC). I 
therefore feel that item 11 (presentation of the ICER) could be combined with item 14 
(presentation of the uncertainty analyses) in order to encourage these results and analyses to be 
reported and interpreted in tandem.   
 
4.3.2.2. Uncertainty analyses 
The ICERs’ 95% confidence intervals generated through the non-parametric bootstrapping 
simulation confirm the findings of the adjusted incremental analyses whereby there is substantial 
uncertainty in whether Co-PARS is associated with lower or higher QALYs and costs, and thus 
whether Co-PARS is likely to be cost-effective (Table 8). 
Cost-effectiveness planes 
The scatter plot of the bootstrapped incremental costs and QALYs comparing Co-PARS to usual 
care (Figure 6) shows that there is substantial uncertainty in whether Co-PARS generates a 
change in QALYs and costs compared to usual care. This is evident since the bootstrapped ICERs 
fall across all four quadrants of the cost-effectiveness plane. By contrast, the scatter plot of the 
bootstrapped incremental costs and QALYs comparing Co-PARS to the control group (Figure 7) 
shows that it is likely the Co-PAR group generates higher costs and less QALYs than the control 
group. This is evident since the majority of bootstrapped ICERs fall on the north-west quadrant of 
the cost-effectiveness plane.  
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Figure 6. Cost-effectiveness plane for Co-PARS vs usual care at 6 months 
 
 
Figure 7. Cost-effectiveness plane for Co-PARS vs control at 6 months 
Cost-effectiveness acceptability curves 
Cost-effectiveness acceptability curves (CEAC) have been presented to help show how the 
decision on whether the probabilistic findings are deemed cost-effective depends on NICE’s 
maximum willingness to pay threshold (£20,000-£30,000 per QALY). As shown in Figure 8, at a 
threshold of £30,000 per QALY, there is a 26.8% probability that Co-PARS will be cost-effective 
compared to usual care. This probability increases slightly when the threshold increases, indicating 
that the results are influenced by the difference in costs, rather than QALYs. Figure 9 shows that 
even at a threshold of £50,000 per QALY, Co-PARS had zero chance of being cost-effective 
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compared to the control group. This implies that the results are being driven by the difference in 
QALYs.  
 
Figure 8.Cost-effectiveness acceptability curve showing the probability of short-term (at 6 months) cost-
effectiveness for the Co-PARS group vs usual care group at different willingness to pay per quality adjusted 
life year (QALY) thresholds 
 
 
Figure 9. Cost-effectiveness acceptability curve showing the probability of short-term (at 6 months) cost-
effectiveness for the Co-PARS group vs control group at different willingness to pay per quality adjusted life 
year (QALY) thresholds 
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Reflection for item 14- What uncertainty analyses can be performed for trial-based economic 
evaluations? 
Prior to conducting this PhD project, in the public health evaluations I had conducted, I had 
primarily characterised the uncertainty in my results by using hypothesis testing. This was 
because the purpose of the public health research I had been involved in was about making 
inferences about a particular phenomenon. Through this PhD project and my reading of the 
health economic literature, I became aware that the primary purpose of economic evaluations is 
not to test hypotheses and make inferences about phenomenon, but to inform unavoidable 
decisions about resource allocation. There is consensus amongst leading health economists in 
the UK that estimation is more appropriate than hypothesis testing when assessing uncertainty 
in the results of economic evaluations (Drummond et al., 2015a).     
 
The first type of uncertainty measures I presented using an estimation approach were the 95% 
confidence intervals (CIs) for the incremental QALYs and costs (Table 8). These 95% CIs are 
the uncertainty measures that are commonly reported alongside the results of effectiveness 
evaluations and so although I had tended to report only p-values as a Research Assistant in 
Public Health, I was familiar with the concept of 95% CIs. The second type of estimation 
approach I used for characterising uncertainty in my cost-effectiveness result (the ICER) was the 
non-parametric bootstrapping method. This method enabled me to build an empirical estimate of 
the sampling distribution of the ICER. This method is standard practice in applied economic 
evaluations (Gray et al., 2012). The estimated sampling distribution enabled me to visually 
present the stochastic uncertainty associated with the ICER result through the presentation of 
cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs).  
 
Cost-effectiveness planes and CEACs are unique to the field of health economics. Prior to this 
PhD, I had not come across these types of graphs in the public health effectiveness literature. 
Understanding how to generate an empirical sampling distribution for the ICER and go on to 
present cost-effectiveness planes and CEACs involved specialist knowledge. I was unable to 
find step-by-step practical guidance on how to this and so it was only through a specialist three-
day Applied Methods in Cost-Effectiveness Analysis course at the University of Oxford that I 
gained this practical knowledge. This made me realise that it would be challenging to incorporate 
this knowledge in my framework as it require specialised knowledge with practical examples. 
 
4.3.2.3. Equity considerations 
The equity impact analysis was only performed for the Co-PARS group. The exploratory analysis 
indicated that Co-PARs was more effective and less expensive for participants: (1) living in the 
most deprived quintile; and (2) referred for cardiometabolic reasons (e.g. Diabetes, High Blood 
Pressure and/or Obesity) (Appendix C.4). In terms of age, Co-PARS was more effective but more 
expensive in older participants (those aged 55 years and over), under NICE’s threshold the older 
cohort were more cost-effective (£2,033 per QALY).   
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Reflections on item 1.5-  What components make up a well-defined study question? (Target 
population and subgroups) 
As recommended in my framework the target population for the economic evaluation were the 
same participants who were recruited for the effectiveness evaluation. I felt that this was an 
efficient approach as it meant only one recruitment protocol was required for the trial team. In the 
initial framework.  
 
Reflections on item 13- What equity subgroups can be considered? 
I worked with the PhD student (BB) and trail manager (PW) of the Co-PARs trial to specify in the 
protocol what baseline data would need to be collected in order to permit these subgroup 
analyses. The team was not planning to collect baseline data on socioeconomic status, I 
therefore explained why I felt this was an important piece of data to collect having studied the 
Marmot Review (Marmot et al., 2010) during my Masters in Public Health in 2012. I suggested to 
the team that we could collect socioeconomic status data by asking participants to report the first 
part of their postcode as then I could map the postcode to England’s Index of Multiple Derivation 
(IMD) (Department for Communities and Local Government, 2015). I had come across the IMD 
while working as a Research Assistant in Public Health. The results of the exploratory subgroup 
analysis for the Co-PARS sample indicated that future trials might benefit from explore the 
impact of PA interventions on the those living in the most deprived areas and those who are 
referred for cardiometabolic conditions.  
 
As specific challenge I came across when carrying out the subgroup analyses, was that due to 
the trial’s small sample size I had to be pragmatic when defining my subgroups. Clearly specified 
definitions for the subgroups was not something I had considered when drafting the initial 
framework. Due to the small sample, I decided to categorised the equity subgroups into binary 
variables. The PA literature was reviewed in order to establish how the equity variables could be 
categorised into a binary variable. Key UK literature informed the following binary variables: 
females vs males, aged 55 or over vs under 55; cardiometabolic condition vs other condition, 
most deprived quintile vs the four least deprived (Scholes, 2017). For socioeconomic status I 
used deprivation quintiles. The way I categorised this variable into a binary variable was in part 
influenced by the sample sizes of the groups. For instance, there were a very small number of 
observations in each of the four least deprived quintiles. I therefore aggregated participants from 
the four least deprived quintiles to form one equity group and compared this with participants 
from the most deprived quintile.  
 
4.3.3. Cost consequence analysis 
The CCA balance sheet is presented in Table 9 and provides a breakdown of the mean costs and 
consequences at 6 months (unless stated otherwise) from the difference perspectives: research 
institute, primary and secondary healthcare, employer, employee. Appendix C.4 provides a more 
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detailed breakdown of the various costs and consequences.  This balance sheet as well as the 
results in Appendix C.4 can be considered in conjunction with the primary outcome of the 
effectiveness evaluation, which has been reported elsewhere (Buckley et al., under review). 
 
 
Table 9. Cost consequence balance sheet 
Costs 
Public sector perspective 
Variable Co-PARS  
Mean (SE) at 6 
months 
Usual Care 
Mean (SE) at 6 
months 
Control 
Mean (SE) at 6 
months 
Incremental difference at 
6 months (per participant): 
Co-PARS vs Usual Care 
Incremental difference at 
6 months (per participant): 
Co-PARS vs Control 
Leisure Centre operating 
costs per participant* 
 
£130.53 £76.55 £0 +£53.98 +£130.53 
Leisure Centre set up 
costs (one-off cost, all 
participants) 
£464.10 
(All participants) 
£0 £0 +£464.10 
 
(All participants) 
+£464.10 
 
(All participants) 
Research Institute set up 
costs (one-off upfront 
costs) 
£1,271.16 
(All participants) 
 
£0 £0 +£1,271.16 
(All participants) 
+£1,271.16 
(All participants) 
Primary healthcare per 
participant* 
£191.65 (£34.52) £96.17 (£43.01) £94.66 (£46.53) +£95.48 (95% CIs:-
£40.82 to £231.78; p-
value=0.267) 
 
+£96.99 (95% CIs:-
£47.37 to £241.35; p-
value=0.307) 
Secondary healthcare per 
participant* 
£1,326.03 
(£387.63) 
£1,370.21 
(£483.15) 
£1,129.88 
(£517.71) 
-£44.18 (95% CIs:-
£1,579.60 to £1,491.25; 
p-value=1.000) 
+£196.15 (95% CIs:-
£1,40.65 to £1,801.96; p-
value=1.000) 
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Private perspective 
Variable Co-PARS  
Mean (SE) at 6 
months 
Usual Care 
Mean (SE) at 6 
months 
Control 
Mean (SE) at 6 
months 
Incremental difference at 
6 months (per participant): 
Co-PARS vs Usual Care 
Incremental difference at 
6 months (per participant): 
Co-PARS vs Control 
Total employer’s loss 
productivity (numerator/ 
denominator)# 
 
£36.28# (total for 2 
participants out of 
15) 
£14.51#(total for 1 
participant out of 
9) 
n/a Insufficient data for 
comparative analysis 
Insufficient data for 
comparative analysis 
Total participants loss of 
earnings (numerator/ 
denominator); type 
 
£14.51**(Not mean 
as only n=1/15) 
£0 (n=0/9) n/a Insufficient data for 
comparative analysis 
Insufficient data for 
comparative analysis 
Total participant private 
healthcare (numerator/ 
denominator); type 
£262.40 (n=4/25) 
Acupuncturist; 
Chiropractor; 
Podiatrist 
£0 (16/16) £270.00 (n=1/14) 
Sports Massage 
 
Insufficient data for 
comparative analysis 
Insufficient data for 
comparative analysis 
Total participant private 
healthcare (numerator/ 
denominator); type 
£541.20 (n=3/25); 
Acupuncturist; 
Counsellor; 
Podiatrist 
£447.99 (2/16); 
GP consultations; 
Podiatrist 
£655.5 (n=2/14); 
Physiotherapist; 
Chiropractor; 
Sports Massage 
 
 
Insufficient data for 
comparative analysis 
Insufficient data for 
comparative analysis 
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Willingness to pay per 
induction with ERP for 
hypothetical PA 
intervention  
 
£8.22 (£1.52) £9.25 (£1.90) £19.64 (£15.58) -£1.02 (95% CIs:-£7.03 to 
£4.98; p-value=1.000) 
-£11.42 (95% CIs:-£17.70 
to -£5.15; p-value=0.000) 
Willingness to pay per 
face to face consultation 
with ERP for hypothetical 
PA intervention  
 
-£4.64 (£1.62) £6.51 (£2.02) £13.23 (£2.16) -£1.88 (95% CIs:-£8.27 to 
£4.52; p-value=1.000) 
-£8.60 (95% CIs:-£15.26 
to -£1.97; p-value=0.007) 
Willingness to pay per 
telephone consultation 
with ERP for hypothetical 
PA intervention  
 
 
 
 
 
 
 
 
 
£0.64 (£0.88) £1.91 (£1.10) £6.50 (£1.17) -£1.27 (95% CIs:-£4.80 to 
£2.21; p-value=1.000) 
-£5.86 (95% CIs:-£9.49 to 
£2.24; p-value=0.001) 
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Consequences 
Public sector perspective 
Variable Co-PARS  
Mean (SE) 
Usual Care 
Mean (SE) 
Control 
Mean (SE) 
Incremental difference at 
6 months (per participant): 
Co-PARS vs Usual Care 
Incremental difference at 
6 months (per participant): 
Co-PARS vs Control 
HRQoL mean 6 Month 
score* 
0.783 (0.029) 0.708 (0.035) 0.767 (0.040) +0.075 (95% CIs:-0.036 
to 0.187; p-value=0.305)* 
+0.016 (95% CIs:-0.111 
to 0.144; p-value=1.000)* 
Change in prescribed any 
medication 
Improvement, 2 
less from n=14/16 
at baseline  
No change from 
n=12/13 at 
baseline 
No change from 
n=9/10 at 
baseline 
Insufficient data for 
comparative analysis 
Insufficient data for 
comparative analysis 
Change in High 
Cholesterol prescriptions 
Improvement, 1 
less from n=4/16 at 
baseline  
No change from 
n=4/13 at 
baseline 
No change from 
n=2/10 at 
baseline 
Insufficient data for 
comparative analysis 
Insufficient data for 
comparative analysis 
Change in 
Antidepressants 
prescriptions 
Improvement, 1 
less from n=3/16 at 
baseline  
No change from 
n=3/13 at 
baseline 
Worse, from 
n=1/10 at 
baseline to 2/10 
at 6 Months 
Insufficient data for 
comparative analysis 
Insufficient data for 
comparative analysis 
Change in Moderate to 
strong painkillers 
prescriptions 
Improvement, 1 
less from n=1/16 at 
baseline  
No change from 
n=12/13 at 
baseline 
Worse, from 
n=1/10 at 
baseline to 2/10 
at 6 Months 
 
Insufficient data for 
comparative analysis 
Insufficient data for 
comparative analysis 
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Private perspective 
Variable Co-PARS  
Mean (SD) 
Usual Care 
Mean (SD) 
Control 
Mean (SD) 
Incremental difference at 
6 months (per participant): 
Co-PARS vs Usual Care 
Incremental difference at 
6 months (per participant): 
Co-PARS vs Control 
Participant incurred an 
out of pocket for anything 
PA-related, excluding 
induction fee (numerator/ 
denominator) 
68.00% (n=17/25) 80.00% (n=12/15) 57.14% (n=8/14) Insufficient data for 
comparative analysis 
Insufficient data for 
comparative analysis 
*adjusted for baseline value of that same variable; base on UK’s average earnings and hours (unit cost calculation in Appendix C.2). Participant only reported 
missing 1 hour in work; #Calculations based on consultation frequency and duration of consultations reported.
 
 
Reflection on item 1.3- What components make up a well-defined study question? 
(Secondary Analysis) 
 I feel the results of the cost-consequence analysis (CCA) (Table 9) make it easier for 
different stakeholders to identify how the different cost categories are impacted. I became 
aware of the value of the CCA in January 2019, when I attended a meeting with staff from 
the local authority. The staff who attended the meeting were involved in the 
commissioning of the ERS across Liverpool’s local authority leisure centres. At the 
meeting I presented and discussed some of the preliminary results of my Co-PARS 
analysis. It was through this meeting that I became aware that the staff from the local 
authority were interested in the results which related to them. More specifically, rather 
than the total overall cost, they were interested in the breakdown of the results by cost 
category. In particular, they asked me about how the Co-PARS intervention had impacted 
on medication use and GP visits during the trial period. The most senior staff member at 
the meeting informed me that prescription costs was an important topic for local 
authorities. I also presented a slide about the potential long-term costs which could be 
made to the NHS if the Co-PARS intervention reduced the number stroke and coronary 
heart disease events, and incidents of type 2 diabetes. Although, the local authority staff 
acknowledge this was important, there was less discussion about this slide compared to 
the cost savings which could be made over the short-term (i.e. during six month trial 
period). The literature suggests local authority public health teams in the UK are under 
pressure to contain costs due to the nature of the short-term budget cycles they operate 
within (Bryan and Williams, 2014). This made me aware of the importance of presenting: 
(1) the short-term costs and effects; and (2) costs by perspective type rather than a single 
total cost which value incorporates the costs from all organisations. 
 
4.3.3.1. Intervention costs 
From the leisure centre’s perspective (in this case, a public sector agency) the operating 
costs for Co-PARS were £53.98 and £130.53 more per person compared the usual care and 
control group respectively (Table 9). Total set up costs were calculated for the Co-PARS 
intervention only. There were estimated to be a total of £464.10 and £1,271.16 from the 
Leisure Centre and Research Institute’s perspectives, respectively. Appendix C.1 provides a 
more granular breakdown of the intervention costs incurred by the leisure centre (operation 
and set up costs), research institute (set up costs) and participant (out of pocket costs). This 
breakdown makes it clear that the largest portion of total costs is attributable to human 
resource time to deliver the consultations. 
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Reflections on item 8.1- How can costs be valued? (Intervention costs) 
All unit costs for the intervention resources were calculated using published sources. 
However, not all resource use items have a published unit cost, or a unit cost, which is 
easy to assign. Each unit cost for the intervention resources therefore required several 
calculations. These calculations and the assumptions associated with the calculations 
were recorded in an Excel spreadsheet (Table 2 in Appendix C.2). As a budget 
breakdown was not available from the local authority, I draw on the Agenda for Change 
salaries for a range of staff salaries. For example, I used the Agenda for Change Band 4 
Fitness Instructor salary as a shadow price for the salary of the Exercise Referral 
Practitioner at the local authority leisure centre.  
 
Originally, I had considered asking the intervention staff if they were happy to confirm their 
salaries. Nonetheless, the more I discussed and read in the literature about costing 
approaches I decided this was not the most appropriate method. More specifically, I 
discussed costing methods with a group of Health Economists during my study placement 
at Deakin University. We came to the consensus that it would be inappropriate to ask staff 
their salaries as some people might feel uncomfortable sharing such information. In 
addition, an individual’s salary may not be representative of the salary observed in 
standard practice and staff are unlikely to include overhead, superannuation and training 
costs in their calculations. 
 
Even though I used published unit costs from the NHS (Agenda for Change) it was a time-
consuming task which involved a number of analyst-based assumptions. For example, I 
had to decide whether to assign a cost to the room and IT system that was used for the 
one-to-one consultations for the Co-PARS and usual care interventions. The consultation 
room and IT system were existing capital equipment at the leisure centre and so I asked 
the Leisure Centre Manager to confirm whether the PA intervention meant the room and 
IT system represented an opportunity cost (i.e. could it have been used for another 
activity which would have been more beneficial). The Managers at both leisure centre did 
not believe the use of these resources were displacing other valuable activities and so it 
was assumed the opportunity cost was small. As a result, I did not assign a unit cost to 
the room nor IT system. In the initial framework in Chapter 3 I had not considered this. 
However, this economic concept, known as ‘opportunity cost’ is an important factor to 
consider and requires gathering additional contextual information from the intervention 
providers (hosts).  
 
Overall, I found there was very little published guidance on how to assign costs to the 
intervention resources without having a budget breakdown available. I also felt the costing 
approaches I had used in SROI methodology as a Research Assistant in Public Health 
had not adequately addressed this methodological challenges associated with costing. I 
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think this is because SROI methodology draws on costing methods from the accounting 
literature. Some economists feel accounting practices ignore important issues related to 
costing (Fujiwara, 2015). A key health economic study which I used to support many of 
my costing decisions was a study from the UK which had been recently published in a 
high-quality journal, the BMJ (Anokye et al., 2018). I identified this study when I updated 
my literature search in my systematic review (Chapter 2). The supplementary material for 
this study provided a detailed breakdown of the calculations performed to calculate the 
unit costs for the resources to set-up and deliver the intervention, as well as the costs for 
primary and secondary healthcare utilisation.   
 
4.3.3.2. Healthcare utilisation 
At 6 months follow up the Co-PARS participants had incurred around twice as much primary 
care costs than usual care and the control group. Secondary care costs were greatest in the 
usual care group (Table 9). Nonetheless, as the wide 95% confidence intervals suggest, 
there is a lot of uncertainty in these results and the mean differences between the groups 
were not statistically significant (Table 9). Out of all healthcare activity, the most commonly 
used service was the GP. Though less common, consultations with a Practice Nurse, 
Physiotherapist and Counsellor were the next cost drivers (most common and/or greatest 
unit cost) in primary care. Inpatient admissions had the greatest unit cost across all 
healthcare activity despite only being accessed by a minority of individuals (see Appendix 
C.4).  
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Reflections on item 6.2- How can costs be measured? (Health and social care costs) 
Participants were asked to recall their healthcare utilisation over the last 6 months as this 
aligned with the clinical evaluation data collection time points. Nonetheless, it should be 
made explicit why healthcare utilisation was not collected at the 12 week data collection 
point. The one-hour consultation meeting with the team had identified that the 
questionnaire booklet might be too much of a burden if all questionnaires are asked at all 
three time points (baseline, and 12-week and 6-month follow up). In addition, studies 
identified from the systematic review had indicated that it was standard practice to ask 
participants to recall healthcare use over a 6-month recall period. That said, a 
consequence of having just two data collection points meant it was not possible to know 
whether more recent improvements were being overshadowed by high healthcare use in 
earlier months. In general, completeness of the healthcare utilisation questionnaire was 
good for most items except for the medication question. For example, a third of the 
sample failed to report their medication use at follow up. This meant the sample size for 
complete data was small and so I felt it was inappropriate to present a comparative 
analysis for the CUA and CCA. 
 
Initial and annual ongoing treatment cost data on CHD, stroke and T2D were expected to 
come from existing models identified in the systematic review (Campbell et al. 2015; 
Anokye et al. 2012). When it came to performing the modelling, this was deemed 
inappropriate for several reasons. These reasons are discussed in the reflection box for 
item 1.4. 
 
 
127 
 
Reflections on item 8.2- How can costs be valued? (Health and social care costs) 
Assigning unit costs to the healthcare professionals included in my healthcare utilisation 
questionnaire involved a number of calculations and assumptions. These were recorded 
in an Excel spreadsheet for transparency (Table 1 in Appendix C.2). By large I draw on 
the published unit costs available from the UK’s unit cost series for health and social care 
(Curtis and Burns, 2018). Some published definitions for unit costs in this series differed 
to the way unit costs were defined in the healthcare utilisation questionnaire and so I had 
to make some assumptions about what the best shadow price would be.  
 
An additional challenge was that there is no guidance on how to correctly select and 
assign unit costs for prescribed medications. I referred to the British National Formulary to 
access specific medication prices, however I observed that assigning a cost involved 
knowing the dose, quantity and frequency of the medication. Medication data was poorly 
reported, around a third of participants had not reported medication use despite this 
information being requested in the questionnaire. 
 
Assigning unit costs for secondary care activity was also challenging. In the UK, there are 
2,812 healthcare resource groups (HRG), representing a wide of treatments available in 
secondary care (NHS Improvement, 2018). It was not possible to know which HRG unit 
cost was appropriate to assign out of the hundreds of HRGs. This would have required 
working with secondary care experts to understand what HRG would be most appropriate. 
My PhD project did not have enough funding to pay a secondary care health professional 
to work with me to assign HRGs. I therefore addressed this costing issue by using the 
aggregate average unit costs for outpatient, inpatient, day cases and emergency care 
visits (NHS Improvement 2018). This is a less accurate approach to costing however it 
was a quicker and more pragmatic approach, and I ensured I applied the same method to 
all three comparator groups. 
 
A further issue was that my healthcare utilisation questionnaire only asked participants to 
name the type of secondary care department they visited and I did ask them to specify 
whether their hospital visit was an outpatient and day case visits. As a result, I used a 
mean unit cost (£433) for outpatient and day case visits (NHS Improvement 2018). This 
was a less accurate but more pragmatic approach. 
 
4.3.3.3. Prescribed medication use 
Just over two thirds (n=39/55, 70.91%) of participants reported their medication use across 
the three groups. The most common prescription type which related to a condition that can 
be alleviated by PA was for high cholesterol medication. Overall, changes in medication over 
the 6 month time horizon were small. Table 9, does show a slight trend whereby at 6 months 
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fewer Co-PARS patients are being prescribed specific medication for a condition which can 
be alleviated by PA.  
4.3.3.4. Participant time and out-of-pocket costs 
Loss in productivity was small with just one participant in the Co-PARS group reporting they 
had a loss in earnings due to taking 1 hour off work to attend the consultation (Table 9). A 
small number of participants incurred costs for seeking private healthcare across all three 
groups. Out-of-pocket expenses for PA-related activities and equipment were reported 
incurred by more than half in each group at both 12 weeks and 6 months. The difference in 
unit used to report these costs precluded any mean cost calculations (Appendix C.4).  
Reflections on item 6.3- How can costs be measured? (Participant costs) 
It is unknown whether participants reported the same resource items at 12 weeks and 6 
months. In addition, it was not possible to know how often an out of pocket cost was 
incurred by the participant. My original questionnaire did not ask participants to specify 
these units (e.g. per event, per month, per 6 months). Around a third of participants did 
not complete the questions around participant costs meaning it was inappropriate to 
present a comparative analysis in the CCA. An additional observation was that nearly all 
participants left the questionnaire’s comments boxes blank which suggested that they did 
not think it was necessary to provide context about the costs they had incurred. 
Nonetheless, as the analyst, I found it was difficult to interpret this data without any 
additional units or context.  
 
Reflections on item 8.3- How can costs be valued? (Participant costs) 
Prices reported by the participants at 12 weeks and 6 months were used to estimate the 
costs incurred by the participants. There was a lot of uncertainty in the participant costs 
which I attribute to the design of the questionnaire I used. In the questionnaire, I had not 
asked participants to report the frequency of the prices they reported. Therefore, I was 
unable to tell whether the price reported was a one off payment or a reoccurring cost. This 
made me recognise the importance of piloting the health economic questionnaires during 
the feasibility stage of the trial development rather than in the definitive trial.  
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Reflections on item 6.4- How can costs be measured? (Productivity costs) 
Only 25/55 participants correctly answered the question about whether they had lost time 
in paid work due to participating in the intervention. The chief reason for incorrectly 
answering the productivity question was due to participants selecting two or more 
activities (instead of one activity) for explaining how they typically spent their time when 
they were not taking part in the intervention. Of the 25 participants who correctly 
completed the intervention, just 20% (n=5) lost time in work in order to take part, with just 
one participant reporting a loss in earning due to taking part. This suggests that this issue 
is worth exploring further with a larger sample size to understand how common it is for 
participants to experience a loss in earnings or give up their leisure time and to 
understand whether this relates to the outcomes achieved by these participants.   
 
Reflections on item 8.4- How can costs be valued? (Productivity costs) 
I had intended to use the UK’s average earning from the ONS (2018) to assign a cost for 
the amount of time participants miss in employment due to taking part in the interventions. 
Nonetheless, less than half of the participants (45.45%, n=25/55) correctly answered this 
question and so I reported time lost in work in minutes as opposed to in monetary terms. I 
felt the sample size was too small and a single cost would be misleading.  
 
4.3.3.5. Change in EQ-5D score 
Table 10 reports each groups EQ-5D score for the three time points as well as the mean 
difference between groups at each time point. This data has also been presented visually in 
figure 10. The data shows that at baseline the Co-PARS group has a mean EQ-5D score 
that was lower than the usual care and control group. At baseline this difference was 
statistically significant (p=0.003) between Co-PARS and the control group, but not 
statistically significant (p=0.563) between Co-PARS and usual care (Table 10). Figure 10 
also shows the three time points, the Co-PARS group had the largest and most sustained 
improvement in mean EQ-5D score. For usual care and the control group, their mean EQ-5D 
score fluctuated over time but by a small magnitude.  
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Reflections on item 7- How can effects be measured? 
The EQ-5D-5L questionnaire was straightforward to use. In the Co-PARs study HRQoL 
was collected at baseline, 12 weeks and 6 months. The area under the curve approach 
was used to calculate each participants HRQoL utility score over the 6 month period. This 
score was be combined with life years (the trial follow up period, 0.5 years) to estimate 
each participants’ QALY score. After conducting the trial-based economic evaluation, I 
had intended to draw on the cohort studies (Hu et al. 2003; 2005; 2007) used in the 
economic models by Anokye et al. (2012) and Campbell et al. (2015) in order to build a 
decision-analytical model. Future long-term outcomes were not included due to 
insufficient data, time and expertise (see reflections in item 1.4) 
 
Reflections on item 9- How can effects be valued? 
During the time of the trial, NICE released a position statement where they recommended 
that the UK’s value set for the EQ-5D-5L should not be used to calculate QALYs. NICE 
recommended that if a study has used this tool (which was the situation I found myself in 
with the Co-PARS trial) then HRQoL data should be mapped to a published mapping 
function (NICE 2018). HRQoL scores were valued by mapping EQ-5D-5L scores to the 
UK’s EQ-5D-3L value set through a published mapping function (van Hout, Janssen et al. 
2012). This observation highlighted to me the importance of consulting the latest national 
guidelines for the preferred valuation methods. For the CCA, as recommended all 
disaggregated effects were reported in their natural units. Reporting the HRQoL scores in 
their natural units was straightforward. 
 
Table 10. Mean difference in EQ-5D score at 3 time points 
Time point for 
EQ-5D score 
Co-PARS  
Mean 
(SE) 
Usual Care 
Mean (SE) 
Control 
Mean (SE) 
Mean difference 
(per participant): 
Co-PARS vs Usual 
Care 
Mean difference 
(per participant): 
Co-PARS vs 
Control 
Baseline 0.640 
(0.039) 
0.724 
(0.049) 
0.872 
(0.053) 
-0.084 (95% CIs -
0.563 to 0.072; p-
value= 0.563) 
-0.233 (95% CIs 
-0.395 to -0.070; 
p-value= 0.003) 
12 weeks score* 0.804 
(0.026) 
0.754 
(0.031) 
0.798 
(0.035) 
+0.051 (95% CIs:-
0.050 to 0.151; p-
value=0.663)* 
+0.006 (95% 
CIs:-0.107 to 
0.120; p-
value=1.000)* 
6 Months score* 0.783 
(0.029) 
0.708 
(0.035) 
0.767 
(0.040) 
+0.075 (95% CIs:-
0.036 to 0.187; p-
value=0.305)* 
+0.016 (95% 
CIs:-0.111 to 
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0.144; p-
value=1.000)* 
*adjusted for baseline value of that same variable 
 
 
 
Figure 10. Mean EQ-5D score per comparator group at three time points 
4.3.3.6. Willingness-to-pay analysis 
At 6 months, participants in the control group were willingness-to-pay more for key 
components of the hypothetical PA intervention. For example they were willing to pay twice 
as much as the Co-PARS and usual care groups for an induction and face-to-face 
consultation. These differences in willing-to-pay was found to be statistically significant when 
comparing Co-PARS and the control groups prices (Table 9).   
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Reflections on item 15- How can the results be interpreted? 
Methodological choices and any heterogeneity identified are reflected in the strengths and 
limitations section of the discussion in order to consider how they may have influenced the 
results and to consider the external validity of the findings. The PRECIS-2 tool was used 
to support my interpretation of the results (see reflections on item 1.4 for a more detailed 
explanation of the role of the PRECIS-2 tool in study design and results). In brief, the 
PRECIS-2 tool goes beyond reflecting on the setting. I found the tool was useful for 
considering how applicable my results were to standard practice. For instance, I highlight 
in the discussion section that a strength of this trial was the number of pragmatic 
featuressuch as: the intervention was delivered by staff who were already employed in the 
leisure centres, eligibility for the Co-PARs intervention was done by the health 
professional rather than the researchers, the non-randomised nature reflects standard 
practice (as participants go to the leisure centre nearest their house) and there was a lack 
of intensive monitoring of patients to ensure they adhered to the intervention. All of these 
features are what is likely to happen if the intervention was rolled out standard practice. 
This means the resource use required if the study was rolled out is likely to be similar to 
the resource use reported in this study.   
 
Nevertheless, there were features of the trial which did not reflect what would happen in 
the intervention was rolled out on a larger scale. For instance, the research team 
coordinated and arranged the set-up meetings. This was initially a hidden resource cost 
that I had not considered until I came across the inclusion of set-up costs in one of the 
studies in my review (Chapter 2). The co-ordinating role by the research team was 
important to support the implementation of the intervention. There is the risk that if these 
hidden costs are not documented as intervention costs, then the intervention may not 
successfully be implemented rolled out in the ‘real world’. I reflect on this issue of the 
‘implementation gap’ in greater detail in my reflection box for item 3.  
 
 
Reflections on item 16- How can trial-based economic evaluations be reported? 
The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist 
was used to write up the methods and results for this study. I found the reporting 
guidelines particularly useful since I had never conducted nor written up the results of an 
economic evaluation before. It was therefore a useful checklist for me to refer to as it 
reassured me that I had reported all the key methods and results of an economic 
evaluation. Nonetheless, I felt that the explanatory and elaboration notes accompanying 
the CHEERS checklist would not be appropriate for researchers without training in health 
economics as the authors use terminology (e.g. cost-effectiveness planes, perspective, 
discounting) which are not used in the clinical effectiveness literature and so a list of 
definitions would be required if this checklist is to be used by non-health economic 
researchers.  
 
4.4. Discussion 
The overarching aim of this study was to apply the initial framework from Chapter 3 to the 
Co-PARS trial. More specifically, the study had two concurrent aims: (1) to reflect on the 
applicability of the framework to a real world PA trial; and (2) to present an economic 
evaluations of the Co-PARS trial. The discussion therefore starts with discussion on the 
reflections on the application of the framework, before going on to discuss the results of the 
economic evaluation. 
4.4.1. Principle findings: Application of the framework 
As discussed in the reflection boxes nearly all items in the initial version of the framework 
require some form of modification. By large, items were not easy to implement in practice as 
they required further additional calculations and analyst-based judgements to be made, 
especially in relation to collecting and valuing the resource use data, and interpreting the 
ICER and uncertainty results. Discussion on how the framework could be improved future 
application is provided below. These recommendations have been based on the reflection 
boxes. Reflection boxes in which the recommendations relate to are signposted in 
parentheses.  
4.4.1.1. Primary economic analysis  
Additional guidance is required to support analysts conducting economic evaluations 
alongside trials, notably smaller scale trials and pilot trials where the intervention and/or trial 
methods are still being refined. The refined framework can recommend that in these 
circumstances, the primary economic analysis could be to present costs and consequences 
in a disaggregated format. This should prevent end-users misinterpreting or misusing the 
point estimates (ICERs) without looking at the results of the uncertainty analysis (see 
reflections in items 1.2 and 1.3). Similarly, in these circumstances, the refined framework 
should also explain how modelling may not always be required if there is insufficient robust 
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data and/or it is anticipated that the benefits of building a model will not outweigh the 
additional research efforts (costs) (see reflections in items 1.4 and 7.2). Instead, the focus of 
the economic study should be on generating good quality disaggregated economic data. 
Systematic reviews can use this disaggregated data to build theory around: (1) how different 
combinations and levels of resources lead to different levels of outcomes; (2) and how 
different contexts and patient groups affect this (Anderson, 2010) (see reflections in item 
1.4).  
A structural modification for the refined framework relates to the recommendation that the 
summary statistics item (item 11) and uncertainty analysis item (item 14) should be 
amalgamated into the same item. This is because this study found that the uncertainty 
analysis was important for interpreting the robustness and generalisability of the results (see 
reflections in items 1.4, 11 and 14).Overall, the point estimates of the summary statistics 
presented in this study may be misleading if interpreted alone. As highlighted in the initial 
version of the framework explanatory notes, if users of the summary decision indices (e.g. 
ICERs) are not familiar with how these estimates are constructed, then they are less likely to 
check the results of the uncertainty analyses and demographic data in order to consider the 
robustness and generalisability of the results, respectively.  
Presenting the total mean unit cost for the intervention costs alongside healthcare costs as 
was done in the CCA, makes it explicit to the decision-maker, how the cost of preventative 
interventions compare to curative healthcare activity. For example, total cost for the Co-
PARS and usual care interventions were £130.53 per person and £76.55 per person, 
respectively. These costs are negligible compared to the cost of secondary healthcare 
services, which were the main cost drivers in this study. Average secondary healthcare unit 
costs for 2018 in the UK were: £3,894 per hospital admission for inpatient care; £742 per 
day case visit; £160 per A&E visits and £125 per outpatient appointment (NHS 
Improvement, 2018). To put this in perspective, delivering the Co-PARS interventions to the 
25 participants in this study costed £3,263, which costs less than one inpatient admission.   
4.4.1.2. Trial design  
Economic evaluations are best suited to pragmatic trials (Drummond et al., 2015b). That is 
to say, the analyst responsible for the economic evaluation should be involved in the trial 
design from the outset. For instance, during the design stage the health economic analyst 
should reflect on the nine characteristics of a pragmatic trial, as specified in the PRECIS-2 
tool (Loudon et al., 2015) (see reflections in item 3). A key recommendation for the 
framework is that not only should the analysts consider the PRECIS-2 tool (Loudon et al., 
2015) during the design stage (as recommended in the trial design section), but the 
PRECIS-2 tool can also help in understanding the generalisability of the results after the trial 
has been conducted (see reflections in item 15). Lastly, as there are ongoing developments 
in the field of economic evaluation the framework should stress that analysts keep updated 
on the latest version of their country’s guidelines (see reflections in item 9.1) 
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4.4.1.3. Data collection 
The refined framework can suggest that if the trial is constrained by time and resources, the 
data collection efforts can be prioritised to focus on the most frequently used and/or most 
costly resource items. Based on this study’s findings, the priority resources would be: staff 
time for delivering and setting up the intervention; GP, practice nurse, physiotherapist and 
counsellor visits; inpatient, outpatient, day case and emergency visits (see reflections in item 
4.3). In particular, for intervention costs, this study found that the TIDieR checklist was a 
useful tool for carrying out the intervention microcosting exercise (Hoffmann et al., 2014). 
The framework should also emphasise the importance of understanding how the intervention 
was delivered in practice from the providers perspective (e.g. the ERPs and leisure centre 
managers perspectives). This necessitates the researcher to be flexible in their collection 
approach, in terms of whether this is data is captured prospectively or retrospectively, and 
via telephone, email or face-to-face (see reflections in item 6.1). 
The refined framework can recommend that it is acceptable to ask participants to recall their 
healthcare utilisation for the previous 6 months (as opposed to more frequently, 12 weeks). 
In terms of other participant-reported data, since participants’ out of pocket costs, time and 
medication use were reported poorly in this study, there is a need to provide additional 
guidance around these data collection methods. For participant out of pocket expenses and 
time costs, the refined framework can recommend that the wording in the questionnaire is 
improved, so as participants are requested to report the frequency in which they incur a 
specific out of pocket cost (see reflections in item 8.3). In the present study, comment boxes 
had been provided so as participants could detail such context alongside their responses, 
nevertheless these were infrequently used. This means that the framework could also 
recommend that a subsample of participants could be asked questions about their out of 
pocket and time costs in interviews/ focus groups to provide clarification, context and an 
understanding of the acceptability of these out of pocket costs and time costs (see 
reflections in items 6.3, 6.4 and 8.4). Lastly, as reported in the recent literature, the 
framework will recommend that it is acceptable to report medication data descriptively, since 
the data collection methods for medication use is presently underdeveloped, yet public 
health agencies are interested in data on medication use (Thorn et al., 2018)(see reflections 
in item 6.2). 
4.4.1.4. Assigning unit costs  
The refined framework could request analysts to consider whether the capital equipment 
required for the intervention represents an opportunity cost. This can be done by reflecting 
on the likelihood that the capital equipment would have been used for an alternative purpose 
(i.e. is it likely that the private room used for the Co-PARS and usual care inductions would 
have been used for an alternative purpose, and thus there was a missed opportunity). 
Questioning whether a resource could have been used for an alternative purpose, which 
may have generated more benefits, is known as the opportunity cost. This is one of the 
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fundamental concepts in health economics. If it is unlikely that the capital equipment (private 
room, IT system, telephone) would have been used for an alternative purpose at the point in 
time it was used for the Co-PARs and usual care schemes, a unit cost does not need to be 
assigned to these resource items. Instead, staff overhead costs can be assumed to account 
for all capital equipment. Nonetheless, all capital equipment should still be reported and 
quantified in the natural units, so as e.g. leisure centres which do not have private rooms are 
aware that this resource is required (see reflections in item 8.1). Reporting capital costs in 
natural units is a strength that will increase the study’s applicability to other researchers and 
decision-makers.  
For the present study, matching unit costs to the collected resource use data was a resource 
intensive task. This was due to the questionnaire requesting participants report their 
resource use in units of measurement that different to the units in the available published 
unit costs. The refined framework can therefore recommend that during the questionnaire 
design stage, the analyst familiarises themselves with the units used in published unit costs. 
It was also challenging to assign an appropriate cost to the secondary care activity. This is 
because firstly, participants only reported the departments they visited and secondly in the 
UK, there are 2,812 unit costs available for the various healthcare resource groups (HRGs). 
The refined framework can recommend that if analysts are unfamiliar with the HRGs in their 
country and do not have detail on the exact treatment received by the participants, then a 
less precise estimate can be used. These can be the average unit costs for inpatient, 
outpatient, day case and emergency visits. Moreover, the framework can recommend that 
future healthcare utilisation questionnaire items distinguish between outpatient and day case 
visits. Overall, judging what were the most appropriate unit costs to use for some resource 
items was challenging since a number of assumptions are required, especially as 
organisations provide unit costs that draw on difference accounting methods. This challenge 
was reported in a recent study, which relied on the assumptions and judgement of the 
analyst when assigning a HRG unit cost (Anokye et al., 2018). Early research efforts to 
produce a standard costing methodology for assigning unit costs to self-reported healthcare 
utilisation have not been successful (Busse et al., 2008). 
4.4.1.5. Equity considerations 
This study demonstrates wider variations in cost-effectiveness between the subgroups within 
the Co-PARS sample. Although, the results of the equity impact analyses are limited to the 
Co-PARS group only and by the small sample sizes, they indicate that all four types of 
equity groups (age, sex, socioeconomic status and medical condition) which were 
recommended in the initial version of the framework, should continue to be considered in 
larger future trials. That said, additional guidance is required for analysts wanting to consider 
equity in small-scale studies. For example, the framework can recommended that additional 
literature is sought in order define the equity subgroups into binary variables (see reflections 
in item 13). 
 
 
137 
 
4.4.2. Principle findings: Economic evaluation 
The primary economic analysis of this study was to evaluate the cost-effectiveness of Co-
PARS using cost-utility analysis. The CUA comparing Co-PARS to usual care generated a 
cost-effectiveness ratio of £15,349 per QALY, which is lower than NICE’s maximum 
willingness to pay threshold of £20,000-£30,000 per QALY. By itself, this point estimate 
suggests Co-PARS is cost-effective compared to usual care. Nonetheless, this cost-
effectiveness result needs to be interpreted with caution, since the results are not robust to 
the 95% confidence intervals (-£188,650 to £229,599) and uncertainty analyses.  There is 
uncertainty in where the true population ICER falls on the cost-effectiveness plane and the 
CEAC indicated that there is only a 26.8% probability that Co-PARS will be cost-effective 
compared to usual care. The shape of the curve suggests these results are being driven by 
the between group difference in costs, since cost-effectiveness increased as the threshold 
increased. The CUA comparing Co-PARS to the control group generated a cost-
effectiveness ratio of £157,089 per QALY which is much greater than NICE’s threshold. This 
point estimate needs to be interpreted carefully since the 95% confidence intervals (-
£16,035 to £374) and uncertainty analyses indicated that these results are not robust. For 
example, the CEAC suggested that Co-PARS has no chance of being cost-effective 
compared to the control group. The shape of the curve suggests this may be due to the 
between group difference in QALYs rather than costs. This is because, as the threshold 
increased, cost-effectiveness did not increase. 
4.4.3. Comparison with other studies 
Four of the ten trials identified in the systematic review of Chapter 2 assessed the cost-
effectiveness of PA/ exercise on prescription interventions. Just two of these studies 
conducted a CUA (Leung et al., 2012, Edwards et al., 2013b), with the study by Edwards et 
al. (2013) being the only UK-based trial assessing this intervention type. The study had just 
two comparator groups, the intervention and one control group (who received an information 
leaflet only). The authors reported an ICER of £12,111 per QALY over a time horizon of 12 
months, which they reported as being robust with an 89% probability of the ERS being cost-
effective at £30,000. These findings differ substantially to the ICER of £157,089 per QALY 
reported in the present study when Co-PARS is compared to control group who received no 
intervention. Likely reasons for this relate to the difference in sample size, Edwards et al. 
(2013) had a much larger sample size of 798 individuals. Previous modelling studies from 
the UK looking at the cost-effectiveness of ERS over a lifetime horizon reported that their 
results were not robust. They found their results to be highly sensitive to small changes in 
the assumptions made around the cost and effect parameters (Campbell et al., 2015b, 
Anokye et al., 2011).  
In particular, Co-PARS and the control group differed in terms of socio-economic status, 
which meant heterogeneity may have been directly impacting on the cost-effectiveness 
result. Future studies should aim to recruit more participants from the most deprived 
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quintiles, particularly in the no treatment control group. This is an important issue since 
equity is a key objective of public health interventions in the UK, yet still equity is not 
routinely or systematically addressed in economic evaluations (Chapter 2). Without 
considering this equity factor, the conclusions on point estimates risk implicitly saying that it 
is more cost-effective to do nothing in less deprived groups than to do something in more 
deprived groups. This would mean decision-makers would be unknowingly choosing to 
disinvest in the Co-PARS population, who are more likely to be deprived individuals. This 
opposes the increasing recognition of the need to invest in more inequitable groups (Claxton 
et al., 2015). Claxton suggests that deprived groups are given additional weighing in cost-
effectiveness analyses, where decision-makers agree to pay a greater amount of money per 
QALY for disadvantaged groups. Future trials could aim to stratify their recruitment strategy 
in order to recruit a greater proportion of participants from the most deprived quintile so as 
the comparator groups are better balanced.  
This study found the Co-PARS intervention costed £131 per person. This is much lower than 
the very small intervention costs reported in literature. The systematic review in Chapter 2 
found that three of the UK-based models draw on the intervention cost (£186 per person) 
estimate from a study conducted in 2007 (Isaacs et al., 2007). Reasons for why this estimate 
may be greater than the intervention cost in this study may be due to the type of activities 
costed. The EXERT trial which Isaacs et al.’s study assesses, evaluates the costs of a 
leisure based exercise class intervention. The activities they perform their microcosting 
study for is based on the cost per exercise class, which is estimated to have a unit cost of 
£8.02 per PA session attended. The unit cost per 30-minute PA consultation for the Co-
PARS intervention was £12.90, which is similar. However, Co-PARS participants could only 
attend a maximum of four follow up consultations, whereas mean attendance at the exercise 
classes EXERT trail was reportedly 22.08 sessions. Though both conducted in a leisure 
centre, the activities involved in the EXERT intervention differed to Co-PARS. This highlights 
the importance of clearly describing the activities of the interventions being costed 
(Hoffmann et al., 2014). The ERS intervention assessed by Edwards et al. (2013) is £385 
per person. Reasons for why this cost is greater than Co-PARS estimate, also relate to the 
type of activities costed, for instance, national operating and set up costs are included, as 
well as local authority and capital costs (e.g. room hire, IT equipment). These costs are 
appropriate due to the study being conducted at a national level as opposed to two leisure 
centres. The present study excludes set up costs from the £131 estimate for the Co-PARS 
intervention, it is deemed appropriate to exclude one-off training from the primary analysis 
(van Lier et al., 2017) and estimate the intervention as operating in a ‘steady state’ (Gao et 
al., 2018, Vos et al., 2007).  
In terms of mean EQ-5D scores reported in other studies, the study by Edwards et al. (2013) 
reported an EQ-5D score of 0.64 in the intervention group at 12 months. Interestingly, 0.64 
was the baseline EQ-5D score for the Co-PARS participants. However, at 6 months this 
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score had increased to 0.78. Previous work has found that physically activity people are 
associated with having 0.072 higher EQ-5D score than inactive people (Pavey et al., 2011a). 
Furthermore, some health economists claim that an improvement of 0.08 represents a 
minimal clinically important difference (MCID) (Luo et al., 2010). However, caution should be 
taken when interpreting these results, as there is substantial disagreement amongst health 
economists around whether a MCID is appropriate when interpreting cost-effectiveness 
results (ISPOR, 2017). Some argue that even a minor improvement in quality of life can be 
regarded as being cost-effective if someone is willing to pay for that improvement (Glick et 
al., 2014). The observed improvement in HRQoL in the Co-PARS group therefore is an 
important and relevant finding which relates to recent debates in the literature around the 
short-term gains in HRQoL and should therefore be researched further (Campbell et al., 
2015b).  
4.4.4. Strengths and limitations 
The 95% confidence intervals for the incremental analyses, along with the results of the 
uncertainty analyses indicated that the results in this study were not robust which may be 
due to a number of reasons. Firstly, it is possible that the study was not sufficiently powered 
to detect a difference. Secondly, the study was non-randomised which will have increased 
the risk of there being random variation between the groups which has not been possible to 
control for through randomisation. Randomisation was deemed unethical in this study, as it 
was important that participants could select a leisure centre that was most convenient for 
them. This was a pragmatic feature of the study which reflected standard practice. Since 
randomisation is not appropriate, future trials should aim to achieve a larger sample size and 
more leisure centres. Thirdly, the small sample size in the usual care group (n=16) and 
control group (n=14) meant it would have been inappropriate to adjust for additional baseline 
variables. This means there may have been heterogeneity driving the cost-effectiveness 
results which were not controlled for. For example, the baseline HRQoL results 
demonstrated that there was a statistically significant difference between the Co-PARs and 
control group. At baseline the control group had a mean baseline EQ-5D score of 0.87, while 
Co-PARS mean score was 0.64 group. The control groups score aligned more closely to the 
reported average for the UK general population which in 1999 was recorded as being 0.86 
(Kind et al., 1999). Furthermore, the demographics illustrated that there were slightly larger 
proportion of deprived and economically inactive participants in the Co-PARS group 
compared to the other two groups, which may have also been driving the results. Finally, a 
key limitation of the present economic evaluation was that almost a fifth (19.18%, n=13/68) 
of participants from the original trial were excluded from the analysis, as they were lost to 
follow up at the 6 month follow up point. Future studies with a larger sample should compare 
the characteristics of those participants with missing data to those remaining in the study to 
assess whether there are key participant characteristics, which may explain why participants 
were loss to follow up. This is important since the existing literature suggests loss to follow 
up is more likely to be in the least active, thus those who could benefit from the intervention 
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the most (Iliffe et al., 2014b). A pragmatic feature of the study was that the trial was set in 
two leisure centres, the Co-PARS intervention was only ran in one centre, which means at 
present it is uncertain whether the findings such as the observed improvements in mean EQ-
5D score, apply to the Co-PARS leisure centre only, or can be applied to other centres 
across Liverpool.   
The Co-PARS intervention made use of the existing leisure centre staff such as the ERP 
and receptionist, which was a highly pragmatic strategy. In addition, the usual care 
intervention was a pre-existing ERS meaning it represented what already happened in 
standard practice. A further strength of this study is that the participants were not recruited to 
the trial until they had already been referred to an ERS by a health professional. A strength 
of the analysis for this study was that an intention-to-treat analysis was conducted which is 
the preferred approach for economic evaluations, as it means the participants were not 
intensively monitored to ensure they stuck or adhered to the intervention and therefore 
reflects what would happen in the ‘real world’ (Hughes et al., 2016).  
 
4.5. Conclusion 
The first aim of the study was to reflect on the application of the initial version of the 
framework to this Co-PARS trial. The framework was not straightforward implement as 
around two thirds (n=10/16) of the items needed additional methodological judgements to be 
made by the analyst. In order to fulfil the aim of providing a multidisciplinary framework that 
ensures a standardised approach to conducting economic evaluations, methodological 
improvements are required to collect, value and present cost data in a clear and 
comprehensive way. The cost-consequence balance sheet addressed some of these 
challenges. The second aim of the study was to present the results of the CUA. The ICER 
statistic indicated that at 6 months the Co-PARS intervention was cost-effective compared to 
usual care, but not compared to the control group. Nevertheless, results from the uncertainty 
analyses indicate that there is uncertainty in whether the true mean ICER value takes a 
negative or positive value. The improved EQ-5D score in the Co-PARS participants warrants 
a larger trial with greater power. 
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Chapter 5: Application of the initial framework to the 
evaluation of a multi-component intervention aiming 
to reduce occupational sitting 
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5.1. Introduction 
5.1.1. Background and rationale 
Though the literature on SB has only emerged in the last decade, a high quality meta-
analysis published in 2012 has shown that SB is associated with elevated risk of 18 types of 
chronic disease (Wilmot et al., 2012). In particular, the authors of the meta-analysis 
identified a strong association between SB and diabetes. This is an important finding, since 
epidemiological and economic data from 184 countries has demonstrated that the global 
economic burden for diabetes in adults is substantial with the global cost estimated to be 
$1.31 trillion dollars in 2015 (Bommer et al., 2017). Authors of a more recent meta-analysis 
focusing on depression argue that reducing SB is not just important for diabetes, but should 
also be advocated as a strategy for preventing depression (Zhai et al., 2015). In England, 
self-report data for SB has also illustrated that high levels of SB are associated with poor 
mental health (Hamer et al., 2014).  
Populations most at risk of high levels of SB include office workers. Evidence suggests office 
workers spend 70-85% of their working day sitting (Healy et al., 2013, Clemes et al., 2014, 
Morris et al., 2019). There is consensus amongst experts in SB that during a typical working 
day, workers should aim to accumulate 2-4 hours of standing or light intensity PA per day at 
work (Buckley et al., 2015). Consequently, interventions aiming to reduce SB in the 
workplace have become increasingly important. One strategy for which the preliminary 
evidence has shown positive findings for is the provision of height-adjustable desks in the 
workplace (Shrestha et al., 2016). These desks enable workers to break up their sitting time 
by standing up while they continue to work. As demonstrated in Chapter 2’s systematic 
review, the health economic evidence for height-adjustable desk interventions is scant which 
provides a clear rationale for the present study (Chapter 2).  
5.1.2. Aim 
It was not possible to draw on the reflections and recommendations from the Co-PARS trial 
since this study took place during the same period. Therefore, the overarching aim of this 
study was to apply the initial version of the framework (see Chapter 3) to a SB trial. More 
specifically, the study had two specific aims:  
(1) to reflect on the relevance and applicability of the framework to a real-world SB trial.   
(2) to assess the cost-effectiveness of two multi-component workplace interventions, 
which aim to reduce occupational sitting amongst highly sedentary office workers 
(contact centre workers). 
 
5.2. Methods for Aim 1: Reflections 
Reflections on the planned and actual application of the initial version of the framework are 
documented throughout the methods and results sections. The reflections aim to provide 
valuable insight into of the actions I took in order to develop and apply the framework in 
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practice. Importantly, the reflections aim to provide explanations for why I believed these 
actions were appropriate. That is to say, the reflections are based on my experience of 
applying the initial version of the framework to the SLaMM trial. The process I followed for 
the reflections was similar to the process outlined for the Co-PARs trial. This is because the 
trials were carried out concurrently and so it was not possible to modify the methods based 
on the findings of the Co-PARs study. More specific details related to the process can 
therefore be found in section 4.3. In summary, the reflections describe the actions I took to 
implement the framework and try to explain why these actions were deemed appropriate. A 
key action I took which was time-consuming was documenting my costing calculations an 
Excel spreadsheet so as I had a record of the complexity decisions and assumptions that 
are involved in assigning unit costs to resource use items (see Appendix D.3). In addition, 
my reflections refer to the informal conversations and meetings I had with the different 
researchers and workplace stakeholders involved in my project. In particular, I arranged a 
one-hour consultation with my supervisory team and key members from the SLaMM trial 
team. Key members include the PhD student (AM) and MPhil student (DG) working on the 
trial and the trial manager (LG) who was also one of my supervisors. All three were selected 
to be involved in the meeting as they had been involved in the design of the SLaMM 
intervention content and the setting up of the intervention. In addition, they had expertise in 
physiology, public health and behavioural science. The key objectives of my consultation 
meeting were to discuss the identification, measurement and valuation procedures. More 
specifically, this involved: (1) identifying all perspectives (stakeholders) who could 
experience a change in cost or effects due to the SLaMM trial; (2) discussing the feasibility 
of incorporating the resource use and EQ-5D-5L questionnaires in the patient questionnaire 
booklet and the feasibility of capturing intervention costs; (3) explaining the different 
approaches to valuation I planned to use; and (4) clarifying roles and responsibilities for the 
data collection process at the key follow up time points. The meeting was a good example of 
multidisciplinary working.  
5.3. Methods for Aim 2: Economic Evaluation 
5.3.1. Trial design  
This economic evaluation is part of a larger pilot trial (Morris et al. in preparation) which the 
researcher (Madeleine Cochrane) contributed to all stages of the trial including trial and 
intervention design, recruitment, set up, data collection and analysis. The pilot randomised 
controlled trial (RCT) compared two groups: (1) the Sit Less and Move More (SLaMM) 
group; and (2) the SLaMM Plus (SLaMM+) group (described in section 5.2.3). The 
intervention start date was the first working day the SLaMM+ agents received their height-
adjustable desks (in July 2018). The primary outcome measure for the trial was occupational 
sitting time. The primary outcome measure for the present economic evaluation is the ICER 
which will be presented as cost per quality-adjusted life year (QALY).  
 
 
144 
 
Reflection on item 1.1- What components make up a well-defined study question? (costs 
and effects of two or more groups) 
Similar to the process for the Co-PARs trial, I was able to explain to the SLaMM trial team 
that the economic evaluation would have little impact on the trial design that had already 
been planned for the clinical effectiveness evaluation. There was consensus with the 
team that the trial provided an important and efficient opportunity to collect additional data 
for the economic evaluation.    
 
Reflections on item 3. What is an appropriate study design for a trial-based economic 
evaluation? 
My initial framework recommended that the economic evaluation is conducted alongside a 
pragmatic trial. My understanding of what made a trial pragmatic was primarily based on 
the trial setting and the intention-to-treat principle. Both the SLaMM and SLaMM+ 
interventions were set in a ‘real world’ setting as they were delivered in the workplace. I 
discuss the design of the SLaMM trial in further detail in the reflection box for item 15.  
 
5.3.2. Participants and recruitment  
The target population for the trial was adults (≥18 years old) who worked ≥22.5 hours per 
week as a contact centre agents who will be referred to as agents from here on. In the UK, 
agents are defined as workers in a contact centre who respond to customer enquiries via the 
telephone, email or online chat (National Careers Service, 2019). Agents who had a health 
condition which would prevent them from standing for bouts of 10 minutes or longer, or were 
pregnant, were not eligible to take part in the trial (see Appendix D.1 for full eligibility 
screening form). Recruitment posters and emails were disseminated informing agents about 
the study during May and June of 2018. During the same time period, agents were 
scheduled to attend a 15-minute group agent briefs (presentations) to learn more about the 
study. If agents expressed an interest to take part in the trial at the agent briefs, they were 
requested to provide their personal phone number and/or email so they could be contacted 
via the research team, to be assessed for their eligibility to take part. All eligible agents were 
scheduled to complete a 60-minute baseline data collection session during their working 
hours. At baseline data collection, agents received a participant information sheet and full 
written consent was obtained. Following baseline data collection, a random number 
generator was used to randomly allocate trial participants to the two comparator groups 
(SLaMM and SLaMM+). Ethical approval was obtained from Liverpool John Moores 
research ethics committee (16/SPS/033).   
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Reflections on items 1.5 and 13-  What components make up a well-defined study 
question and what equity subgroups can be considered? (Target population and equity 
subgroups) 
The target population was highly sedentary contact centre workers which aligned with the 
population group targeted for the effectiveness evaluation. The protocol for the 
effectiveness evaluation included collecting baseline data on age and sex. Nonetheless, 
there were an insufficient proportion of males and older adults to conduct an equity impact 
analyses on these subgroups. Due to human error, baseline data on socioeconomic 
status and pre-existing medical conditions was not included in the baseline 
questionnaires. I felt socioeconomic status data was particularly important to collect so I 
made an additional effort to collect this data at the 12-week follow up time point. I 
requested participants to report the start of their postcode which I could then map to the 
Index of Multiple Deprivation map (Department for Communities and Local Government, 
2015). I had learnt this technique during my experience as a Research Assistant in Public 
Health. Overall, I feel my belief around the importance of collecting data on 
socioeconomic status came from my Masters in Public Health training where I learnt 
about the Marmot Report, a review of health inequality in England (Marmot et al., 2010). 
 
Only around a third (37.5%) of agents provided their postcode data at the 12-week follow 
up period, this highlighted the importance of requesting this data at baseline alongside the 
other demographic variables. Due to the limited amount of data on socioeconomic status, 
it was not possible to do a subgroup analysis according to area of deprivation. As an 
alternative, I conducted a post-hoc exploratory analysis for socioeconomic status where I 
used education level as an indicator for socioeconomic status. I made the assumption 
education was an appropriate indicator as evidence from the UK shows that those with 
university degrees have better health and live longer than those without (Marmot, 2010).  
 
5.3.3. Comparator groups 
5.3.3.1. Sit Less and Move More (SLaMM) intervention 
The SLaMM intervention was a 12-week intervention comprising of the following key 
components, which included: three 30-minute education and training sessions about the 
benefits of, and ways to, reduce SB in the workplace; 12 weekly infographic emails 
promoting increased movement in the workplace; and a timer and daily goal-setting log 
book. Examples of the weekly emails and daily logbook which the researcher (Madeleine 
Cochrane) contributed to are provided in Appendix D.1.  
5.3.3.2. Sit Less and Move More Plus (SLaMM+) 
The SLaMM+ intervention was a 12-week intervention comprising of the same key 
components as the SLaMM intervention, but with the addition of a height-adjustable desk. All 
SLaMM+ agents were provided with their own personal height-adjustable desk. These desks 
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are intended to allow participants to carry out their work in a seated or standing position with 
the flexibility to alternate between the two options during the working day.    
5.3.4. Type of economic evaluation 
This economic evaluation compares the costs and consequences for the two intervention 
groups over a 12-week time horizon. The primary analysis of this study was to conduct a 
trial-based CUA from a multi-agency UK public sector perspective. The secondary analysis 
was to present a CCA. A key methodological feature of this study is the piloting of the initial 
framework. Table 18 (section 5.3.4) illustrates how the framework was intended to be 
applied to the present study along with the reflections on how it was actually applied. 
5.3.4.1. Perspective 
As the trial was set in the workplace, a CUA was conducted from a multi-agency public 
sector perspective, as recommended in the UK’s guidelines for the assessment of 
interventions delivered in non-healthcare settings (NICE, 2014a). The multi-agency public 
sector perspective included the research institute (payer), and primary and secondary 
healthcare agencies. The CCA included the same public sector agencies listed for the CUA, 
as well as the perspective of the private agencies/ agents which included the employer and 
employee (participant). Cost categories deemed relevant for each perspective and economic 
evaluation type are outlined in Table 12. Rationale for the choice in cost categories is 
provided in Chapter 3. 
Table 11. Perspective, cost categories and economic analysis 
Sector Perspective Cost category Economic 
evaluation type 
Public  Research Institute (Payer) Intervention operating costs CUA; CCA 
Intervention set up costs CCA 
Healthcare sector  Primary healthcare CUA; CCA 
Secondary healthcare CUA; CCA 
Prescribed medications CCA 
Private Employer (Host) Intervention operating costs CCA 
Intervention set up costs CCA 
Absenteeism CCA 
Presenteeism CCA 
Agents (Participants) Time costs CCA 
Travel costs CCA 
Out-of-pocket costs CCA 
CUA – cost utility analysis, CCA – cost consequence analysis 
5.3.4.2. Data collection procedure 
The trial had two key data collection points. Baseline data collection took place 2-4 weeks 
prior to the start of the intervention. The follow-up data collection point took place 12 weeks 
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after the start date. All data collection took place at the contact centre during the agents 
working hours. Demographic measures reported in this study were collected at baseline. 
Economic measures were collected at both baseline and 12 weeks. The primary economic 
researcher (Madeleine Cochrane) supported the wider collection of data and in particular, 
was responsible for coordinating and handling the collection and analysis of all economic 
data. This included the data from the intervention microcosting exercise, which were 
collected during the trial period. Additional outcome measures such as occupational sitting 
time and a range of physiological measures were collected as part of the clinical 
effectiveness trail, but are reported elsewhere (Morris et al., in preparation).  
5.3.6. Cost measures 
Two types of data were required: (1) quantities; (2) unit costs. For the present study, primary 
data collection methods were used to estimate resource use quantities, while unit costs 
came from secondary sources. Measurement tools used to capture resource use quantities 
are outlined below and described in Appendix B.1. Research costs were not included in the 
study. Costs categories included are detailed in the subsequent sections. 
Reflections on item 6.2- How can costs be measured? (Health and social care costs) 
At baseline and 12-weeks follow up, the self-report healthcare utilisation tool presented in 
Appendix B.1. was be used. Participants were asked to recall their healthcare utilisation 
over the last 12 weeks to align with the clinical evaluation data collection time points. 
Just under a fifth (17.5%; n=7/40) did not complete the medication question. Participants 
left this question blank which made it difficult for me know whether it was blank because it 
did not apply to them or because they could not recall the medication they were being 
prescribed. As discussed in the reflection box for item 1.4, I did not have the time or 
expertise to build a model to estimate the long-term effects of the SLaMM+ and SLaMM 
intervention. Future healthcare treatment costs were not therefore included.   
 
Reflections on item 6.3- How can costs be measured? (Participant costs) 
Participant out of pocket costs were requested in the 12-week follow up questionnaire 
(see Appendix B.1). In future studies in similar workplaces, if questions need to be 
removed from the questionnaire booklet in order to reduced participant burden then this 
would be a question that could potentially be removed. I recommend this because no 
participants from the SLaMM trial reported experiencing out of pocket costs due to taking 
part in the intervention. I expect this is likely to be due to the nature of the SB trial which 
involved encouraging low intensity PA in the workplace (e.g. increasing standing and 
walking during working hours). 
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Reflections on item 6.4- How can costs be measured? (Productivity costs) 
I obtained objective absenteeism and presenteeism data (company-specific job 
performance metrics) from the employer for the 12 weeks prior and 12 weeks after 
baseline. The objective job performance data (presenteeism) provided by the employer 
was incomplete and was difficult to make a meaningful comparison from. Therefore this 
data was not presented in the CCA. The data was complex to interpret because different 
agents had been assigned different performance targets depending upon which specific 
job contract (job role) they were employed on that week. In total participants were working 
across three types of job contracts. In addition, some agents changed contracts multiple 
times over the 24 week period (12 week before and after baseline) making it difficult to 
identify a trend and change in their productivity levels. I was surprised by this finding since 
staff at the company had mentioned on several occasions about the importance of the 
productivity metrics. I discussed this with the Centre Contracts and they explained that 
because there was a high turnover of staff at the company, with around a third of agents 
leaving within the first three months, for some agents the team managers monitored the 
individual’s immediate day-to-day metrics, rather than the longer term metrics (e.g. 12 
weeks). Overall, understanding the employer’s productivity data, linking up multiple 
datasets which comprised of the productivity data and deciding how informative the data 
would be was a time-consuming exercise. This experience made me consider if this was 
the reason why I did not identify any studies through my systematic review (Chapter 2) 
which had included objective measures for presenteeism. By contrast, the self-reported 
presenteeism questionnaire by Lerner et al. (2001) had a 100% (n=40/40) completion rate 
and provided a standardised way to measure presenteeism. In terms of objective 
company absenteeism data, this data was incomplete for 25% (n=10/40) of agents 
despite my additional efforts being to retrieve this data from the company. Overall, this 
experience made me recognise the complexity and challenge associated with accessing 
robust cost data from data sources which are not set up for research studies.   
 
5.3.6.1. Intervention costs: quantities 
The trial protocol and CONSORT flow diagram were firstly drawn on to identify key 
intervention activities for each comparator group (Appendix D.2). In addition, more precise 
prospective microcosting methods were employed during the 12-week intervention period. 
The researcher (Madeleine Cochrane) and the Resource Planner from the Contact Centre 
recorded the type and price of the equipment, and amount of time that was spent on 
delivering and setting up the intervention using weekly electronic logs. Structure of the 
weekly electronic log was informed by the diaries used a previous public health microcosting 
study (Charles et al., 2013). Retrospective microcosting methods were also performed, this 
included a one-hour consultation with two centre contacts at the company where the 
intervention was hosted. The centre contacts were key to the set up and delivery of the 
intervention. More specifically, they were two members of staff employed by the workplace 
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who were selected by the workplace’s senior management team to be the point of contact 
for the researchers. The centre contacts liaised with the researchers in order to support the 
implementation of the interventions. Therefore, they were requested to recall and estimate 
the amount of time and/or equipment they had invested in delivering and setting up the 12-
week intervention. The consultation drew on the template for the weekly electronic log as 
well as the items for intervention description in TIDieR framework (Hoffmann et al., 2014). All 
data was recorded in a single microcosting spreadsheet (see Appendix D.2 for an example 
on how the microcosting tool was populated).   
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Reflection on item 4- What costs are important and relevant?  
In item 4 of the initial framework I provide examples of five perspectives that may be 
relevant to the analysis of a SB intervention: the payer, the provider, health care, the 
participant and the employer. As I was involved in the implementation and delivery of the 
SLaMM trial, I was able to identify who the payer and provider was through my own 
observations. That said, I had expected the employer organisation (call centre) to 
predominantly represent the payer, provider and employer perspective. To my surprise 
the costs associated with the employer organisation in the SLaMM trial was much more 
complex. I documented this complexity through my daily observations. I feel the CCA 
provides a summary of this complexity as it shows which stakeholder incurs which costs. 
For example, the breakdown in the resource costs in the CCA reveals that the average 
SLaMM+ operating costs incurred by the employer were similar to the average SLaMM+ 
operating costs incurred by the Research Institute (excluding trial-related research costs). 
The Research Institute paid for a large proportion of the operating costs of the intervention 
since the PhD students delivered three the education and training sessions over the 12-
week period (week 1, 3 and 10). This is an interesting observation to reflect on in terms of 
considering who would deliver the education and training components if the intervention 
was rolled out across multiple organisations. The people delivering the education and 
training component would require expertise in SB in order to provide this component. 
Training key staff members from the workplace to be able to deliver this component of the 
intervention could be one way to achieve this and would incur a one-off training cost.  
 
Another interesting observation through the CCA in relation to relevant costs, is that the 
average SLaMM+ set up costs incurred by the employer are greater than the average 
SLaMM+ set up costs incurred by the Research Institute. I had expected that the 
Research Institute would have a greater role in the set-up that the employer organisation. 
Through informal data collection methods (face-to-face one-hour discussion and weekly 
logs) I became aware of the amount of the time Centre Contacts and Resource Planner 
have input into the set up stage of the SLaMM+ intervention, these included additional 
meetings and planning time: Installation of height-adjustable desks, a one-hour 
consultation with senior management at the centre contact, 30 minutes consultation with 
Resource Planning team, organisation of Team Manager briefs, organisation of call agent 
briefs (by scheduling offline time for the agents). The Resource Planner explained that 
scheduling offline time for the agents (study participants) was a time-consuming and 
complex process, as it required them to schedule enough agents to work ‘offline’ (i.e.not 
available to answer phonecalls to customers) at the same time so as the meetings did not 
need to be repeated. Nonetheless, the staff reported that they needed enough agents to 
be working ‘online’ (i.e. answering phonecalls from customers) in order to avoid the 
SLaMM trial impacting on the company’s business metrics. This highlighted to me the 
relevance of capturing the employer’s perspective in economic evaluations assessing 
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workplace interventions. It also helped me realise that the problems the company were 
facing related to resource use (in terms of time). It made me realise the it could be helpful 
to incorporate a greater economic perspective into the design of interventions in order to 
ensure they are pragmatic and acceptable from a resource (and employer’s) perspective.  
 
I had expected loss in earnings to be incurred by the employer only however through the 
analysis of the demographic and absenteeism data I became aware that the participants 
also experienced a loss in earnings if they were off work sick due to ill health. More 
specifically, through the demographic data I learnt that the majority of agents (85%, 
n=34/40) who took part in the SLaMM trial were agency staff. The Centre Contracts 
explained that agency staff do not receive pay when they take uncertified sickness. The 
absenteeism data I analysed revealed that participants were more likely to take uncertified 
sickness than certified sickness (Appendix D.4). Productivity loss (in terms of loss of 
earnings) was therefore was an important cost category from the participant’s perspective. 
This highlighted to me the importance in understanding how a company is organised.  
 
Analysis of the healthcare utilisation data revealed which healthcare activities were the 
cost drivers and could therefore be prioritised in future studies. I refer to cost drivers as 
the healthcare activities which were more frequently used by participants and/or had a 
greater unit cost relative to the other activities. For example, GP, Practice Nurse and 
Counsellor visits were the most commonly used healthcare professionals in primary care. 
In addition, although secondary care healthcare use was reported less frequently than 
primary care activities, secondary care activity typically had a much greater unit cost than 
primary care activity. 
 
5.3.6.2. Intervention costs: unit costs   
Published standardised unit costs were used as recommended in the framework. This 
included published unit costs for all staff’s time, travel and printing costs. Salary oncosts 
(national insurance and superannuation at 14%) were included for all staff except for the 
agents since these were by large non-permanent staff. Overhead costs for the interventions 
were minimal, it was therefore appropriate to exclude these costs (Edwards et al. 2019; 
Drummond et al. 2015). Consequently, all capital equipment (e.g. the private room, IT 
system, telephone) are not included in the total intervention set up and operating costs. 
Nevertheless, they were still quantified in their natural units and are reported in the CCA. All 
unit cost calculations and secondary unit cost sources are detailed in Appendix D.3.   
5.3.6.3. Healthcare costs: quantities 
At baseline and 12 weeks, participants self-reported their healthcare use over the previous 
12 weeks using an adapted version of the widely used healthcare utilisation questionnaire 
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called the client service receipt inventory (CSRI) (Mayer and Beecham, 2005, Beecham and 
Knapp, 2001).   
5.3.6.4. Healthcare costs: unit costs 
As recommended in Chapter 3, national published unit costs were sourced. More 
specifically, primary healthcare unit costs came from the UK’s annual Health and Social 
Care unit cost publication (Curtis and Burns, 2018) and secondary healthcare costs came 
from the UK’s reference costs database (NHS Improvement, 2018). Calculations and unit 
cost sources are provided in Appendix D.3. Medication costs were not assigned a unit cost 
due constraints in the patient-level data, and the researcher’s time and expertise. That is to 
say, prescription medication costs are not included in the total healthcare utilisation costs. 
Nonetheless, medication quantities are reported in their natural units in the CCA. 
5.3.6.5. Employer costs: quantities 
Participant’s productivity in terms of presenteeism was captured via self-report at both 
baseline and 12 weeks using the Workplace Limitations Questionnaire (WLQ). Absenteeism 
from the employer’s perspective was quantified objectively using certified sickness data 
provided by the employer. The company provided data on absenteeism for the 12 weeks 
before and during the intervention.   
5.3.6.6. Employer costs: unit costs 
Certified absenteeism was interpreted as being part of the numerator (cost) part of the 
analysis. By contrast, as the methods for incorporating presenteeism into economic 
evaluations are underdeveloped, presenteeism was reported in the CCA in its natural units.  
5.3.6.7. Participant costs: quantities  
An adapted version of the annotated patient costs questionnaire (Thompson and 
Wordsworth, 2001) was completed by the participants at baseline and 12 weeks (see 
Chapter 3). This questionnaire asked participants whether they had incurred any out-of-
pocket costs due to participating in the intervention. The CSRI healthcare questionnaire 
(section 5.2.6.4) asked participants to report if they paid privately for any healthcare they 
accessed. These costs were reported in the CCA but excluded from the CUA, as the CUA 
was from a public sector only perspective. Absenteeism from the participant’s perspective 
was quantities objectively using uncertified sickness data provided by the employer. The 
company provided data on uncertified absenteeism for the 12 weeks before and during the 
intervention.  
5.3.6.8. Participant costs: unit costs 
Time was reported in natural units (hours/ minutes). Out-of-pocket costs for equipment and 
leisure centre memberships were reported and valued using the actual prices reported by 
the participants. Private healthcare utilisation was reported using unit costs from the UK’s 
annual Health and Social Care unit cost publication (Curtis and Burns, 2018). Uncertified 
sickness, which for most participants was taken for less than 4 days in a row, was 
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interpreted as being a loss in earnings from the employees perspective. The company 
provided this contextual information regarding the nature of the agent’s non-permanent 
contracts. Consequently, uncertified absenteeism was costed using the human capital 
approach, whereby time lost in work (in minutes) due to uncertified sickness was a loss in 
earnings for the participant. 
Reflections on item 8.3- How can costs be valued? (Participant costs) 
Participant’s costs also included the loss in earnings due to uncertified sickness. A human 
capital approach was used whereby the mean time missed due to uncertified sickness 
was matched to average wages. No participants reported any out of pocket costs. 
Productivity loss was identified as an important participant cost as the majority (85%, 
n=34/40) of participants were agency staff. The Centre Contacts and Resource Planner 
explained that non-permanent staff did not receive earnings when they were off sick, 
unless this was certified sickness or the agent had been sick for 4 or more days in a role. 
Human capital approach was appropriate as it is a commonly used method which takes 
the perspective of the sick employee (van den Hout, 2010). Only a minority of agents had 
uncertified sickness for either: (1) 4 or more working days in a row; or (2) at least 2 
working days in a row, which in addition took place the day before or after a non-working 
day (the weekend). These definitions were based upon the UK’s eligibility items for 
statutory sick pay. There was uncertainty in whether these agents claim statutory sick 
pay. That is to say, I employed a standardised approach was used, whereby I assumed 
that all participants with uncertified sickness experienced a loss in earnings for their 
uncertified sickness hours. This assumption may mean loss in earnings from the 
participant’s perspective are overestimated. For certified sickness for the agency-based 
staff I used the UK’s weekly Statutory Sick Pay (SSP) for 2018/19 (HM Treasury, 2019) to 
represent the cost provided by the government when a participant took certified sick leave 
for specific time period. Overall, the costing approach I have outlined here demonstrates 
the many calculations and assumptions required by the analyst. 
 
5.3.6.9. Currency, price year and conversion 
Dates of all prices are reported in Appendix D.3. Nearly all unit costs came from secondary 
sources for the current price year (2018/19). Adjustments were made to all unit costs before 
they were multiplied by the resource quantity data. Where the price year diffed, a price-year 
adjusted cost estimate was calculated. This was done by adjusting unit costs to the target 
year (2018/19) and by applying the UK’s GDP deflator index (HM Treasury, 2019). All unit 
costs came from UK sources so currency conversions were not necessary. As this is a trial-
based economic evaluation conducted over a 12-week time horizon, no discounting was 
required.  
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Reflection on item 1.4- What components make up a well-defined study question? (Time 
Horizon) 
In item 1.4 of the framework presented in Chapter 3, I advise that if there are sufficient 
data, time and expertise, then a decision model can be conducted after the trial-based 
economic evaluation. There was one main barrier which precluded a decision-model 
being built for my analysis of the SLaMM. This related to the time it would take to build a 
decision model from scratch. Through discussions with other health economists during my 
study placement with Deakin Health Economics group we concluded that building a SB 
decision model from scratch for the SLaMM economic evaluation would be a time-
consuming process and would be beyond the scope of my PhD project. Therefore, rather 
than building a model from scratch we concluded it would be sensible to discuss the 
potential long-term impact in a descriptive way.  
 
Reflections on item 10- How can costs and effects be discounted to a present day value? 
As I did not include future costs and effects in the analysis I was not required to apply a 
discount rate. The trial-based economic evaluation assessed costs and effects over a 12-
week time horizon only.   
 
5.3.7. Economic outcome measures 
5.3.7.1. Quality-adjusted life years (QALYs) 
The primary outcome measure for the CUA was quality adjusted life years (QALYs) as 
recommended in the UK’s reference case (NICE, 2014a). EuroQol’s validated and widely 
used generic measurement tool called the EQ-5D-5L (EuroQol 5 dimension, 5 level) was 
used to measure HRQoL (Rabin et al., 2011). Pre-existing preference weights (HRQoL 
index scores) for the UK population were matched up to each health state to calculate each 
participant’s HRQoL utility score. This is the preferred method for studies from the public 
sector perspective in the UK (NICE, 2014a). The final step to deriving the HRQoL scores 
involved mapping the EQ-5D-5L index scores to the EQ-5D-3L using a recommended 
mapping function (van Hout et al., 2012). Mapping is recommended in NICE’s recent 
position statement for the valuation of the EQ-5D-5L measurement tool (NICE, 2018). The 
EQ-5D-5L was included in the questionnaire booklet at baseline and 12 weeks. In order to 
calculate QALYs for each participant, an average of each participants two HRQoL utility 
scores was calculated and then combined (through multiplication) with length of life which at 
12 weeks was (0.23 years). A breakdown of HRQoL over time was reported in the CCA 
table.  
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Reflections on items 5, 7 and 9: What effects are important and relevant and how can 
they be measured and valued?  
As recommended in item 5 of the framework, I used a single generic measure of health 
benefit for the primary outcome (the QALY). Overall, items 5 and 7 were straightforward to 
apply. Nonetheless, calculating the length of life part of the calculation required some 
additional consideration as I needed to calculate what the equivalent of 12 weeks was 
using the 1 life year metric. In terms of calculating the quality of life side of the QALY 
calculation, I feel this was straightforward as there is clear consensus on what the 
preferred methodological approach is for studies conducted from the UK. More 
specifically, the EQ-5D measurement tool is recommended to measure the HRQoL part of 
the QALY calculation (NICE, 2014a). Valuing the EQ-5D utility scores was straightforward 
as I followed the UK-specific guidelines. The reflections I reported in the reflection box for 
item 9 in Chapter 4 (the Co-PARs study) apply to my experience in the SLaMM trial as 
both trials were carried out in tandem.  
 
5.3.8. Equity considerations 
Demographic equity-relevant data was collected at baseline through the self-report 
questionnaire booklet. The main demographic information collected aligned with the equity 
characteristics recommended in Chapter 3: socio-economic status (postcode), age and sex. 
As there was insufficient postcode data available, tertiary education was used as an 
indicator for socio-economic status.   
5.3.9. Analysis 
5.3.9.1. Complete case analysis 
The CUA was a complete case analysis and followed the per-protocol principle, whereby 
participants were excluded from the analysis is they did not adhere to the intervention. For 
multi-item measurement tools where only a small proportion of the data was missing (less 
than 10%) it was deemed acceptable to impute the mean of each group for participants 
missing an item (Eekhout et al., 2014). In the CCA, medication, absenteeism and 
presenteeism data were reported based on the number of available-cases. Heterogeneity 
between the groups was assessed through descriptive statistics by comparing the groups’ 
baseline characteristics.    
5.3.9.2. Summary statistics 
A participant-level analysis was performed, where costs and QALYs for each participant 
were presented. Total mean costs were calculated using the absolute intervention and 
healthcare costs incurred between baseline and the 12 week follow up period. Area under 
the curve between baseline and 12 weeks was used to estimate the change in QALYs. 
SLaMM+ mean costs and QALYs were compared to the mean values for the SLaMM group. 
The incremental cost-effectiveness ratio (ICER) was estimated. Measures of sampling 
variability are presented alongside the point estimates (standard deviations and 95% 
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confidence intervals). Precision in the mean estimates was improved by adjusting for 
baseline differences in the dependent variable using multiple regression. Results based on 
unadjusted estimates are presented in Appendix D.4. 
5.2.9.3. Stochastic uncertainty analysis 
Stochastic uncertainty was assessed through a bootstrapping simulation of 1,000 
bootstrapped replicates. From here, cost-effectiveness planes and cost-effectiveness 
acceptability curves were produced to help show the uncertainty in the summary statistics. In 
addition, a one-way scenario analysis was performed to consider the variation and 
uncertainty in the total cost estimate when the employer’s intervention and certified 
absenteeism costs were included in the CUA.  
5.4. Results 
5.4.1. Baseline characteristics 
Figure 11 shows the number of agents invited, eligible and enrolled to take part in the trial 
between May-July 2018. In total, 60 agents were enrolled onto the trial, half (n=30) were 
randomised allocated (through a computer randomisation system) to the SLaMM+ 
intervention and provided with a height-adjustable desk. Forty participants completed the 12-
week follow up assessment and were included in the complete case analysis. As highlighted 
in Figure 11, the most common reason (70.58%, n=12/17) for discontinuing with trial, was 
due to the agent leaving the company. 
 
 
 
Figure 11. Flow diagram for participants enrolled on the trial
 
 
 
Table 12 details participant characteristics for the economic sample. In general, the 
characteristics of the two intervention groups were similar. As noted in the table, the 
SLaMM+ group had a slightly greater proportion of white British participants, males, 
smokers, non-binge drinkers and agency contracted employees. As socioeconomic status 
was excluded from the baseline and 12-week follow up questionnaire, this data was 
requested retrospectively. Just over a third (37.5%, n=15/40) provided this information.  
Table 12. Baseline characteristics 
Variable SLaMM+ (n=19) SLaMM (n=21) 
Tertiary educated 52.9% (n=9/17) 47.6% (n=10/21) 
Ethnicity: White British 100% (n=18/18) 85.7% (n=18/21) 
Smoker 55.6% (n=10/18) 28.6% (n=6/21) 
Average number of fruit and 
vegetables eaten per day 
2.4(±0.55) (n=15/18) 1.8(±1.49) (n=18/21) 
Binge drink 0.0% (n=0/12) 16.7% (n=3/18) 
Employment status: non-
permanent agency contract 
100% (n=18/18) 76.2% (n=16/21) 
Sex: Female 68.4% (n=13/19) 81.0% (n=17/21) 
≤1 year at the company 88.9% (n=16/18) 81.0% (n=17/21) 
Mean age (years) 27.7(±9.5) (n=18/18) 31.3(±11.1) (n=21/21) 
Aged 55 or over 0.0% (n=0/18) 4.8% (n=1/21) 
Work full-time (37.5 hours 
per week) 
88.9% (n=16/18) 81.0% (n=17/21) 
Live in 20% most deprived 
area nationally 
100% (n=7/7) 75% (n=6/8) 
 
 
 
5.4.2. Cost-utility analysis 
5.4.2.1. Summary statistics 
Cost and QALYs based on the adjusted analysis are presented in Table 14. At 12 weeks 
mean incremental QALYs were higher in the SLaMM+ group (+0.006; 95% CI:0.190 to 
0.206) compared to the SLaMM group. Mean incremental costs were also higher in the 
SLaMM+ group (+£228.55; £-978.65 to £521.55). In summary, the SLaMM+ group costed 
more, but also experienced more QALYs. In terms of cost-effectiveness, the ICER was 
£38,091 per QALY, which under NICE’s WTP thresholds suggests SLaMM+ is not cost-
effective compared to SLaMM. In all incremental analyses, the 95% confidence intervals 
crossed zero indicating the results were not statistically significant (Table 14). The results of 
the CUA based on all unadjusted patient-level data are presented in Appendix D.4.   
Table 13. Results of CUA 
Variable SLaMM+ SLaMM 
Mean at 12 weeks (SD) per 
participant 
Mean at 12 weeks (SD) per 
participant 
QALYs* 0.198 (SE:0.004; 95% CI: 
0.190 to 0.206) 
 
0.192 (SE: 0.004; 95% CI: 0.185 
to 0.199) 
Total costs*  £518.65 (SE: £265.78; 95% 
CI: -£19.88 to £1,057.17) 
£290.10 (SE:£252.56; 95% CI:  
-£221.64 to £1,057.17) 
Incremental QALYs & Costs * 
Incremental 
QALYs: SLaMM+ 
vs SLaMM 
0.006 (SE:0.005; 95% CI: -0.005 to 0.017; p-value=0.266) 
 
 
Incremental Costs: 
SLaMM+ vs 
SLaMM 
£228.55 (SE:£370.20; 95% CI: £-978.65 to £521.55; p-
value=0.541) 
ICER statistic at 12-weeks* 
ICER point 
estimate 
£38,091 per QALY 
  
ICER 95% CIs at 12 weeks**: SLaMM+ vs SLaMM 
95% CI for ICER 
based on 1,000 
bootstrapped 
simulations 
-£254,156 to £173,247  
 *Adjusted for baseline imbalances in HRQoL score and healthcare costs; ** original 
unadjusted data 
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Reflections for items 1.2 and 11- What components make up a well-defined study 
question (primary analysis)? And what summary statistics can be presented? 
The primary analysis of this study was to conduct a CUA. This aligned with the 
recommendations I made in my framework in Chapter 3. My reflections on whether the 
CUA was most appropriate for the primary analysis are similar to the reflections I have 
made for the Co-PARs trial (see the reflection box for items 1.2 and 11 in Chapter 4). As 
the Co-PARS and SLaMM trial ran concurrently my reflections on the Co-PARS analysis 
and results had not been systematically studied in time in order to inform the SLaMM 
analysis.  
 
Overall, I felt the ICER result by itself did not inform the team about the uncertainty in the 
data that underpins the ICER calculation. When I reported to the team who had been 
involved in designing the SLaMM trial that the ICER was above £20,000 per QALY (Table 
14) I found it difficult to explain the uncertainty associated with the ICER statistic, which 
was represented in the cost-effectiveness planes, and cost-effectiveness acceptability 
curves I produced. I showed the uncertainty analysis to my three supervisors who were 
non-health economic researchers. I was aware that these concepts were difficult to 
understand without training in health economics as they are not used in the clinical 
effectiveness literature. Prior to completing the Applied Methods of Cost-effectiveness 
Analysis course at the University of Oxford in 2018, I too had felt that I did not completely 
understand these concepts. It was only through doing practical exercises that I felt more 
confident in the meaning of the uncertainty results. This made me realise it would be 
difficult for my framework to include guidance to non-health economic researchers on how 
to carry out an uncertainty analysis for an economic evaluation. 
 
Nevertheless, I was able to explain to the team that the small sample size may have lead 
to the uncertainty observed in the summary statistics for the mean cost and QALY data, 
as shown through the 95% confidence intervals (Table 14). 95% confidence intervals are 
commonly discussed in the effectiveness literature and so this was easily understood by 
the team. The team understood that the large confidence intervals may be related to the 
small sample size and therefore the results need to be interpreted cautiously. It is not 
possible to calculate confidence intervals for ratio statistics such as the most commonly 
used cost-effectiveness summary statistics, the ICER statistic.   
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Reflections on item 12- What adjusted analyses can be performed? 
The12-week costs and QALYs were adjusted for baseline imbalances in healthcare costs 
and HRQoL scores using multiple regression. As discussed in Chapter 4 for the Co-PARs 
study, I felt confident in the adjusted analysis I performed (Table 14) as multiple 
regression is a widely used statistical approach within the effectiveness literature.  
 
5.4.2.2. Uncertainty analyses  
Cost-effectiveness plane 
The bootstrapped ICER was assessed visually on the cost-effectiveness plane (Figure 12). 
Figure 12 shows that a large proportion of the bootstapped ICERs fall within the north-west 
quadrant meaning SLaMM+ intervention is more likely to generate less QALYs (be less 
effective) and incur more costs than SLaMM. Notably, some cost and QALY replicates fall 
within the other three quadrants, which demonstrates that there is uncertainty around the 
direction of the incremental costs and QALYs. 
Reflection for item 14- What uncertainty analyses can be performed for trial-based 
economic evaluations? 
Through this PhD, I became aware that the health economic literature recommends that 
uncertainty in the cost-effectiveness result is best represented through estimation 
approaches rather than hypothesis testing. Prior to commencing the PhD, I was familiar 
with representing uncertainty in my effects through 95% confidence intervals, 
nonetheless, I did not have experience of representing uncertainty in a ratio statistic such 
as the ICER. This required specialist knowledge and training in order to estimate 
uncertainty in the sampling distribution of the SLaMM+ and SLaMM participants and to 
present uncertainty through visual graphs such as the cost-effectiveness plane and cost-
effectiveness acceptability curve (CEAC). I provide a more detailed reflection on this item 
in the reflection box for item 14 within the Co-PARs study (Chapter 4).  
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Figure 12. Cost-effectiveness plane for SLaMM+ vs SLaMM at 12 weeks 
Cost-effectiveness acceptability curve 
A cost-effectiveness acceptability curve (CEAC) was produced to help visualise uncertainty 
around the probability of being cost-effective. For example, Figures 13 show that the 
probability of SLaMM+ being cost-effective compared to SLaMM at a willingness-to-pay 
threshold varying from £0 to £50,000 per QALY. The curve shows that based on the 
participant-level data derived from this study and comparing with NICE’s WTP threshold of 
£20,000-30,000 per QALY, there is only a 15% probability that SLaMM+ will be cost-
effective compared to SLaMM.  
 
 
 
163 
 
Figure 13. Cost-effectiveness acceptability curve showing the probability of short-term (at 12 weeks) 
cost-effectiveness for the SLaMM+ group vs SLaMM group at different willingness to pay per quality 
adjusted life year (QALY) thresholds 
One-way scenario analysis 
The aim of the one-way scenario analysis was to assess how sensitive the cost-
effectiveness results were to the inclusion of the employer’s intervention operating costs 
(employer’s absenteeism costs were excluded due to this data being incomplete for 25% 
(n=10/40) of participants). This analysis may be of interest to public sector contact centres. 
The results show that the inclusion of employer’s costs almost doubled the per person costs. 
As shown in Table 15, the results were the same as the base case results (differing by just 
£0.50), where under NICE’s threshold, SLaMM+ was cost-ineffective compare to SLaMM. 
 
 
 
 
 
 
 
 
Table 14. One-way scenario analysis for intervention costs including employer’s costs 
Variable SLaMM+ per person SLaMM per person 
Base case: Public sector 
costs excluding employer’s 
costs 
 
£23.06  £8.83 
Sensitivity analysis: Public 
sector costs including 
employer’s costs 
£40.51 £26.28 
Base case ICER £38,091.17 per QALY 
ICER adjusted for baseline 
HRQoL and healthcare 
utilisation 
£38,091.67 per QALY 
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5.4.2.3. Equity considerations 
Equity subgroup analysis was not performed for the SLaMM+ group nor for the following 
subgroups for SLaMM: age, sex and deprivation as there would have been less than 10 
observations per subgroup making it difficult to interpret these results (Table 16). As an 
alternative, equity was considered in the context of education level for the SLaMM group. As 
shown in Table 16, the analysis suggests that those educated to tertiary level are more likely 
to cost more but also experienced more QALYs. Under NICE’s threshold of £20,000-30,000 
per QALY, the ICER was not cost-effective and the incremental analyses showed the 
differences to be non-significant (Table 16).  
Table 15. CUA for non-tertiary educated vs tertiary educated SLaMM participants 
Analysis Results  
Incremental costs Non-tertiary educated agents (n=11) cost £413.08 more per person, 
than tertiary educated agents (n=10)* (95% CIs: £-426.16 to 
£1,252.32; p-value=0.315) 
 
Incremental QALYs Non-tertiary educated agents (n=11) experienced 0.001 more 
QALYs per person, than tertiary educated agents (n=10)* (95% CIs: 
-0.010 to 0.012; p-value=0.860) 
 
ICER £413,080 per QALY 
 
 
5.4.3. Cost consequence analysis  
The CCA balance sheet (or impact inventory) is presented in Table 17 and provides a 
breakdown of the mean costs and consequences at 12 weeks (unless stated otherwise) 
from different perspectives: research institute, primary and secondary healthcare, employer, 
employee. Appendix D.4 provides a more detailed breakdown of the various costs and 
consequences.  This balance sheet can be considered in conjunction with the primary 
outcome of the effectiveness evaluation, which has been reported elsewhere (Morris et al., 
in preparation).  
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Reflection on item 1.3- What components make up a well-defined study question? 
(Secondary Analysis) 
The cost consequence analysis (CCA) lists the costs and effects relevant from the 
perspectives of the participants and the employer as the intervention takes place during 
employees’ working hours. I felt that the presentation of the results in tabular form made it 
easier to discuss with the team and workplace how the two interventions differed in terms 
of delivery, set up, productivity and health costs and consequences. I found that 
discussing the cost categories with the most relevant stakeholders was easier and more 
appropriate than discussing a total cost which incorporated all costs (as shown in Table 
14 of the CUA results). 
 
 
Table 16. Cost consequence balance sheet 
Costs 
Public sector perspective 
Variable SLaMM+ SLaMM Mean difference between groups (per 
participant) 
Research Institute operating costs 
per person 
£23.06  £8.83 +£14.23 
Research Institute set up costs per 
person 
£5.77 £3.36 +£2.41 
Primary healthcare at 12-weeks per 
person* 
£141.31 £50.76 +£90.56 (95% CIs:-£8.95 to £190.05; p-
value=0.073) 
Secondary healthcare at 12-weeks 
per person* 
£355.08 £229.79 +£125.29 (95% CIs:-£576.19 to £846.757; 
p-value=0.727) 
Private perspective 
Employer’s operating costs per 
person** 
£17.45 £17.45 £0 
Employer’s set up costs per person £15.77 £9.26 +£6.51 
Employer’s absenteeism at 
Baseline (numerator/ denominator) 
£24.74 (n=1/16) £0 (n=14/14) Insufficient data for comparative analysis 
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Employer’s absenteeism at 12-
weeks (numerator/ denominator) 
£7.07 (n=1/16) £14.81 (n=1/14) Insufficient data for comparative analysis 
Participant’s private healthcare 
(numerator/ denominator) 
£0 (n=19/19) £0 (n=19/19) £0 
Participant’s out of pocket 
(numerator/ denominator) 
£0 (n=18/18) £0 (n=19/19) £0 
Participant’s loss in earnings at 12-
weeks (uncertified sickness)*# 
£92.52 (n=11/16) £59.48 (n=10/14) +£33.04 (95% CIs:-£21.17 to £87.24; p-
value=0.222)* 
Consequences 
Public sector perspective 
Variable SLaMM+ SLaMM Mean difference between groups (per 
participant) 
HRQoL at Baseline 0.780 (0.212) 0.884 (0.154) -0.104 (95% CIs -0.222 to 0.136; p-value= 
0.081) 
HRQoL mean 12-week score* 0.882 0.830  
+0.052 (95% CIs:-0.041 to 0.146; p-
value=0.266)* 
HRQoL mean change score* 0.047 -0.005 
Change in prescribed any 
medication 
+20% (n=3/15) +5.55% (n=1/18) Insufficient data for comparative analysis 
Change in moderate-to-strong 
painkillers  
No change: 13.33% (n=2/15) -5.56% (n=1/18) Insufficient data for comparative analysis 
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Private perspective 
Variable SLaMM+  
% productivity loss 
SLaMM 
% productivity loss 
Mean difference between groups (per 
participant) 
Employer’s perspective: % 
productivity loss mean 12-week 
score* 
19.48% (n=19/19) 18.63% (n=21/21) +0.85% loss in productivity (95% CIs: -
1.80% to 3.51%; p-value: 0.518) 
Employee’s perspective: Days of 
Uncertified sickness 
1.18 (n=8/16) 0.64 (n=7/14) +0.49 (95% CIs: -0.36 to 1.33; p-value: 
0.249) 
*adjusted for baseline value of that same variable; **assuming a ‘steady state’ by excluding set up costs;# managerial staff at the company reported that 
agency staff did not receive pay for uncertified sickness unless they claimed statutory sick pay. 
 
 
5.4.3.1. Intervention costs 
Table 17 presents the intervention operating and setting up costs the perspectives of the research 
institute and employer. From the research institute’s perspective (a public sector agency) SLaMM+ 
costed £14.23 more per person than the SLaMM group. From the employer’s perspective, there 
was no difference in operating costs between the groups. Mean set up costs were also greater in 
the SLaMM+ intervention compared to SLaMM. Appendix D.4 provides a more detailed breakdown 
of the intervention costs incurred by the research institute (payer) and the employer (setting). This 
breakdown makes it clear that after the height-adjustable desks, the second largest cost is staff 
time to attend three 30-minute education and training sessions. 
Reflection on item 2 – What does a comprehensive description of the comparator groups 
look like? 
It was planned that the trial protocol and CONSORT flow diagram would be consulted to 
describe the two comparator groups (SLaMM+ and SLaMM). From an economic 
perspective, the protocol and CONSORT flow diagram did not provide sufficient detail of 
all the resource types and quantities that are involved in the intervention. I felt that the 
microcosting exercise I conducted as part of item 6 in the framework generated a more 
comprehensive description of the intervention. Therefore, in future iterations of the 
framework I feel item 2 is not required as a separate item but can be incorporated into 
item 6.   
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Reflections on items 2 and 6.1– What does a comprehensive description of the 
comparator groups look like and how can intervention costs be measured? 
 
I along with three Contact Centre staff provided data to populate the intervention 
microcosting database (Excel spreadsheets). The microcosting database comprised of 
data on the resource items and quantities required to set up and deliver the intervention. I 
was involved in the design, implementation and delivery of the SLaMM+ and SLaMM 
interventions and so I recorded this information on a weekly basis in an Excel 
spreadsheet. I also had informal conversations with the research team to verify that they 
agreed with the time costs I had allocated for certain intervention components. The 
aggregate data from the Excel spreadsheet are illustrated in Appendix D.2. 
 
As discussed, I was directly involved in the delivery of the SLaMM+ and SLaMM 
interventions. This meant I was able to observe the complexity involved in implementing a 
new intervention into a workplace setting. One of the most important observations I made 
was that there were additional activities and time commitments being carried out by the 
staff at the workplace, namely the Resource Planner and two Centre Contacts, which I felt 
had not been quantified or captured yet in the intervention description sections of the 
protocol and CONSORT flow diagram. A further observation I made was that the Centre 
Contract felt it was necessary to have two Centre Contracts rather than one in order to 
support the implementation and delivery of the interventions. I believe my Masters in 
Public Health training informed my decision to capture these modifications and 
understand the complexity involved in implementing an intervention. During my Masters I 
learnt about a key challenge faced by the health community called ‘the implementation 
gap’. This is the idea that a large proportion of findings from high-quality research studies 
fail to be implemented into the ‘real world’ due to the research studies not capturing the 
complexity involved in implementing evidence into practice (Haines et al., 2004).  
 
In order to capture the additional activities and time commitments of the two Centre 
Contracts and Resource Planner, I requested that these three staff complete a weekly 
electronic log over the 12 week intervention period. In my initial framework, I had not 
recommended this approach as I thought it would suffice to capture these additional costs 
retrospectively through telephone interventions. However, I was aware that the 
organisation we were working with has a high turnover of staff and so I felt it was best to 
collect this data prospectively. I therefore did some additional literature searching to see if 
I could find a template to use for the staff to log their activities and time commitment. I 
came across a public health study which had used weekly diaries with intervention staff 
for their microcosting exercise (Charles et al., 2013). I used the structure of these diaries 
to inform my own electronic logs. Nevertheless, completeness of the electronic logs was 
poor for the two Centre Contacts. I tried several strategies to support the two Centre 
Contracts to complete their logs including sending email and telephone reminders at the 
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start and end of each week for three consecutive weeks. Nonetheless, the Centre 
Contracts reported not having the time to do this on a weekly basis. The Centre Contracts 
agreed to estimate the time they spent implementing the intervention retrospectively 
through a one-hour face to face informal meeting with me at the 12-week follow up time 
point. As the two centre contacts preferred to meet face-to-face to discuss intervention 
resource use with me, this made me aware that the approach used to collect data for the 
microcosting exercise requires some degree of flexibility. By contrast, the Resource 
Planner reported no issues with completing electronic weekly logs.  
 
In the initial framework, I designed and presented a non-study specific interview schedule 
and microcosting tool which could be used to capture intervention resource quantities. 
Through my observations during the trial, I found my interview schedule and microcosting 
tool was too simple and would not capture all the complex resource use involved in the 
delivery of a complex workplace trial (SLaMM). I therefore added content to the weekly 
log and informal meeting schedule (see Appendix D.2). This content was informed by a 
tool from the public health and behavioural science literature, the TIDieR framework 
(Hoffmann et al., 2014). 
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Reflections on item 8.1- How can costs be valued? (Intervention costs) 
The reflections I describe in the reflections box for item 8.1 in Chapter 4 for the Co-PARs 
trial also apply here to the SLaMM trial. For example, costing the intervention involved 
numerous calculations and the assumptions. These calculations were recorded in an 
Excel spreadsheet (see Appendix D.2). A budget breakdown was not available for the 
intervention costs since the funding application for the SLaMM trial related to the funding 
of two PhD students’ and one MPhil student’s research programmes rather than an 
independently funded trial. I used national published costs for the salaries of the staff from 
the company receiving the SLaMM trial. Nevertheless, calculating the unit costs was a 
time-consuming task as it involved considering overhead costs, as well as the 
intervention-specific capital costs. For example, in order to assign a unit cost to the 
height-adjustable desk required for the SLaMM+ intervention I needed to make several 
adjustments to the price reported in the expense claim forms. This was because I had 
read in the health economic literature that assigning a unit cost to capital equipment, 
which would not have been purchased on the same scale without the intervention, 
requires consideration of the “life” of the equipment (Drummond et al., 2015a). I followed 
the guidance by Drummond et al. (2015) and assumed that the life of the desk would be 5 
years. From here, I calculated how much the height-adjustable desk cost for the 12-week 
time horizon of the trial. For other capital, such as the rooms used for the education and 
training sessions, I assumed the opportunity cost was small and so did not assign a unit 
cost to these resource items. I felt it was appropriate to assume the opportunity cost was 
small since the rooms and IT systems had pre-existed at the company prior to the SLaMM 
trial being introduced. The costing procedures described here, illustrate the complexity 
involved in costing and how I found it difficult to recommend a standardised approach that 
would not be influenced by the study’s context.   
 
5.4.3.2. Healthcare utilisation 
At 12 weeks the SLaMM+ group had incurred greater primary and secondary care costs compared 
to the SLaMM group (Table 17). Nonetheless, as the 95% confidence intervals suggest, there is a 
lot of uncertainty in these results and the mean difference was not statistically significant (Table 
17). Appendix D.4 provides a breakdown of the most commonly used and most costly primary and 
secondary care activities. Out of all healthcare activity, the most commonly used service was the 
GP, followed by the Practice Nurse and Counsellor. Although, secondary care activity had the 
greatest unit costs, at both time points secondary care was only utilised by a minority of 
participants.  
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Reflections on item 8.2- How can costs be valued? (Health and social care costs) 
Assigning unit costs to the healthcare activity reported in the questionnaires involved 
several calculations and assumptions. These were recorded in an Excel spreadsheet for 
transparency (see Appendix D.3). The reflections reported in the reflection box for item 
8.2 in Chapter 4 (the Co-PARs study) apply to the SLaMM trial, as the trials were 
conducted concurrently.  
 
5.4.3.3. Prescribed medication 
In both groups, medication use did not decrease over the 12-week period. The type of medications 
taken varied widely. Across both groups, moderate-to-strong painkillers were the most commonly 
prescribed medication (Table 17). A more detailed breakdown of the most common medications is 
provided in Appendix D.4. Importantly, 17.5% (n=7/40) participants did not report their medication 
use. 
5.4.3.4. Employer’s productivity loss 
Employer’s costs was only included for participants who were off sick but the sickness was certified 
(approved by a medical professional). For certified sickness, it was assumed Statutory Sick Pay 
(SSP) would be paid to the agent by the employer. In both comparator groups, just one participant 
was driving the certified sickness estimates at 12 weeks. Nonetheless, it should be noted that this 
data was only available for 75% (n=30/40) of participants. A minority of participants took uncertified 
sickness for four or more days in row (Appendix D.4).   
Reflections on item 8.4- How can costs be valued? (Productivity costs) 
As uncertified sickness was costed from the participant’s perspective (see reflection 
boxes for items 4 and 8.3), only certified sickness was costed from the employer’s 
perspective. A human capital approach was used which may have overestimated these 
costs (Hanly, 2012). Nevertheless, just one participant per comparator group at each time 
point reported a certified sickness day, making the likely impact on the results small. I had 
seen that an alternative approach to calculating absenteeism costs called the friction 
approach, was reported in the literature. However due to the short follow up period of this 
study, I felt it was more appropriate to carry out a human capital approach. In terms of 
assigning a unit cost to presenteeism, I could not find any practical guidance in the 
literature on how this could be done. I sought advice about this during my study 
placement at Deakin University. There was consensus between the health economics 
group that due to the subjective nature of presenteeism, it was difficult to assign a 
monetary value to presenteeism. As an alternative, I believed it was appropriate to report 
this data in its natural units. 
 
5.4.3.5. Participant costs including loss in earnings 
No participants reported incurring any out of pocket expenses as a result of participating in the 
intervention. Mean loss of earnings, based on the amount of time taken as uncertified sick leave, 
was a relevant cost that nearly all participants incurred during the 12 weeks (Table 17). The 
 
 
174 
 
difference in mean loss in earnings between the groups was uncertain based on the 95% CIs and 
p-value.   
5.4.3.6. Health-related quality of life (HRQoL) 
Health-related quality of life (HRQoL) as measured with the EQ-5D-5L was greater in the SLaMM 
group at baseline, but not significantly greater (Table 17). At 12 weeks the SLaMM+ group had a 
greater HRQoL score (+0.052), but the 95% CIs demonstrated this difference was not statistically 
significant. 
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Reflections on item 15- How can the results be interpreted? 
I reflected on my analyst-based decisions in relation to the design of the SLaMM trial in order to 
consider how these design decisions relate to the applicability of my results to similar workplaces 
who are interested in implementing a SB intervention. A tool for assessing applicability of trial-
based results is the PRECIS-2 tool. I discuss the PRECIS-2 tool in greater depth in reflection 
box for item 3 for the Co-PARs trial (Chapter 4). In brief, the tool lists nine trial design features 
which can be reflected on in order to consider whether the trial is more pragmatic or explanatory 
orientated. In the initial framework in Chapter 3, I recommended reflecting on the setting in which 
the trial is conducted but I had not previously considered other design features which can 
improve the applicability of trial results to the ‘real world’. These design features from the 
PRECIS-2 tool include: delivery of the intervention in a way that could be done if rolled out 
across multiple workplaces; encouraging participants to adhere to the intervention in a similar 
way that would be possible in the ‘real world’; following up patients to assess the benefits of the 
intervention to the similar intensity that would be done if the intervention was rolled out in 
practice; using an outcome measure that is important to the participants; enrolling participants 
onto the intervention in a similar manner that would be done if implemented without the research 
team as well as ensuring these participants are similar to those who would be eligible if rolled 
out; and conducting an intention-to-treat analysis. I believe my economic perspective helped me 
recognise that if an intervention is not delivered in the same way as it would be in the real world, 
then this means the resource use data I was presenting would not be useful for ‘real world’ 
decisions.   
 
Prior to conducting the SLaMM trial I had limited experience of designing a RCT in order to 
support decision-making. In part, my background in anthropology has led me to believe the 
PRECIS-2 tool is important. This is because anthropology is about describing complexity, which I 
feel the PRECIS-2 tool also aims to capture through the nine domains of trial applicability. In 
addition, my key hands-on role in the setting up and delivery of the SLaMM+ and SLaMM 
interventions also made me aware of the amount of resource (namely organisation time and 
travel time) that is involved in the implementation of interventions. I feel these time costs 
represent hidden costs which are not usually documented in published effectiveness evaluations 
but may contribute to the ‘implementation gap’ phenomenon (see the reflection box for item 3 in 
Chapter 4 for further discussion about the ‘implementation gap’).   
 
Another key aspect that attracted me to the PRECIS-2 tool is its focus on making it explicit what 
the intended purpose of the trial. A key feature of a good quality economic evaluation is about 
being explicit about what the intended purpose of the trial by reporting the study perspective 
(perspective is more commonly referred to as the ‘stakeholders’ in the public health literature). 
Clinical effectiveness trials do not typically report who their study is aimed at but the inclusion of 
this factor in the PRECIS-2 tool suggests that there might be a move towards requesting trialists 
to be more explicit about who their results intend to inform. 
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Reflections on item 16- how can trial-based economic evaluations be reported? 
I found the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
checklist useful for writing up the methods and results for this study. Nonetheless, during 
the first six months of this PhD project (late 2016-early 2017) when I was still relatively 
new to the discipline of health economics, I found the terminology in the CHEERS 
checklist challenging to understand as there are many concepts which are not used in the 
effectiveness evaluation literature. I feel therefore feel that the terminology used in 
CHEERS may therefore act as a barrier to researchers or decision-makers without health 
economic training. This is an issue if it prevents: (1) researchers from adequately 
reporting their methods; and (2) decision-makers from using the results from economic 
evaluations. 
 
5.5. Discussion 
The overarching aim of this study was to apply the initial framework from Chapter 3 to the SLaMM 
trial. More specifically, the study had two concurrent aims: (1) to present an economic evaluations 
of the SLaMM trial; (2) to reflect on the applicability of the framework to a real world SB trial. The 
discussion therefore starts by an interpretation of the results of the economic evaluation, before 
going on to discuss the reflections from the initial version of the framework and consider how the 
framework could be improved for future application.  
5.5.1. Principle findings: CUA 
The primary economic analysis of this study was to evaluate the cost-effectiveness of the SLaMM+ 
intervention using CUA. The comparative analysis of the SLaMM+ intervention to the SLaMM 
intervention generated a cost-effectiveness ratio of £38,091 per QALY. This ICER is higher than 
NICE’s maximum willingness to pay threshold of £20,000-£30,000 per QALY. This suggests that 
SLaMM+ is not cost-effective compared to SLaMM. That said, the results of this analysis should be 
treated with caution. The standard deviations, 95% confidence intervals, cost-effectiveness plane 
and cost-effectiveness acceptability curve indicate that there is a lot of uncertainty in these results. 
In particular, uncertainty can be seen in the shape of the CEAC, which shows that as a decision-
maker’s willingness to pay threshold increases, the probability of SLaMM+ being cost-effectiveness 
compared to SLaMM decreases. This suggests that the cost-effectiveness results may be driven by 
the between group difference in QALYs (EQ-5D score). Overall, the summary ICER result is not 
supported by the uncertainty results. In part, the difference may reflect the type of analysis 
techniques selected. For instance, the nonparametric bootstrapping simulation draws on original 
cost and QALY data. By contrast, the ICER statistic has been adjusted for imbalances in costs and 
QALYs using multiple regression, as recommended in the literature (Franklin et al., 2019, Manca et 
al., 2005).  
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5.5.2. Comparison with other studies  
A similar trial-based economic evaluation from Australia which assessed a SB workplace 
intervention called Stand Up Victoria (Gao et al., 2018) was identified in Chapter 2’s systematic 
review. It is challenging to compare the results of the present study with the study by Gao et al. 
(2018) since the authors do not report their results as ‘ICER per quality of life year’. Instead, the 
analysts present ‘ICER per reduction in sitting time’. In the UK, the ICER per QALY is the preferred 
way for summarising economic evaluations (NICE, 2014a). In terms of presenteeism, the present 
study found no significant difference in presenteeism at 12 weeks. A similar UK-based RCT called 
the Stand More at Work (SMArT) trial, also observed no differences in presenteeism at 3 months 
(Edwardson et al., 2018). On the contrary, presenteeism was not included nor commented on the 
Stand Up Victoria study (Gao et al., 2018). Instead, the authors restricted their analysis to 
absenteeism at 12 months, for which they identified a 2-day difference in sick days between the 
comparator groups. Alike the difference in uncertified sickness in this study, the results were not 
statistically significant. No significant difference in HRQoL was observed between the SLaMM+ and 
SLaMM agents at 12 weeks. Similarly, the trial by Gao et al. (2018) found no significant difference 
in quality of life in their trial-based analysis. These findings contradict the results of the SMArT trial 
by Edwardson et al. (2018) which did observe a significant increase in quality of life in the 
intervention group compared to the control group (usual practice) at both 6 and 12 months. A 
recent high quality meta-analysis of 18 original studies found lower levels of SB are associated with 
higher quality of life indicating this is an important outcome measure to assess (Boberska et al., 
2018).  
There are key methodological differences between the SLaMM, SMArT and Stand Up Victoria 
analyses, which may explain some of the inconsistencies in results. For example, all three trials 
used different quality of life measures as well as different intervention components. Furthermore, 
the control groups for the SMArT and Stand Up Victoria trials received no intervention components 
(only results of their health measures in the SMArT trial’s control participants) while the SLaMM 
comparator group received multiple intervention components except for a height-adjustable desk. 
Secondly, the SMArT and Stand Up Victoria were larger trials with longer time horizons, as 107 
and 167 participants provided 12-month follow up data respectively. Nevertheless, a key strength 
of the SLaMM trial is that out of the three, it was the only study which presented a comparative 
analysis of healthcare utilisation. This is surprising since the systematic review in Chapter 2 found 
that comparative analyses for primary and secondary healthcare use was performed in the majority 
of PA studies. Despite this study having low power, the evidence in this trial contributes to the 
literature since there is lack of evidence on the cost-effectiveness of individual-level SB 
interventions (Chapter 2).  
5.5.3. Principle findings: Application of the framework recommendations 
Table 18 shows that the majority (n=14/ 16) of the items in the initial version of the framework 
require some form of modification (structural or additional guidance). More specifically, 11 items 
were not easy to implement and required analyst-based decisions to be made. For these items it 
was felt additional guidance will be needed to ensure the framework facilitates a standardise 
approach. Recommendations on how the framework could be improved future application are 
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outlined below. These recommendations have been based on the reflections in Table 18. 
Framework items in which the recommendations relate to are signposted in parentheses.  
5.5.3.1. Primary economic analysis 
Similar to findings in Chapter 4, additional guidance is required to support analysts conducting 
economic evaluations alongside pilot trials. The refined framework should recommended that the 
provision of a breakdown of costs and consequences the primary analysis (see reflections in item 
1.2 and 1.3). Summary of the costs and consequences should be presented by sector in tabular 
form, as seen in Table 17 in this study. This disaggregated format has been used in existing high 
quality studies (Jacklin, 2003) and is recommended as the results are easier to understand. The 
research should also point out to the reader that this disaggregated cost and consequence data 
can be used to inform the design of future larger trials and interventions (see reflections in item 
1.3). In summary, CUA as well as decision-analytical modelling is not recommended as the primary 
analysis for the framework (see reflections in 1.4 and 7.2).  
5.5.3.2. Trial design 
Similar to findings in Chapter 4, the refined framework should recommend that the economic 
researcher is involved in the trial design from the outset to ensure the trial is fit for purpose (see 
reflections in item 3 and 15). External validity is important for economic evaluations as well as 
behaviour change interventions. Historically, within the general literature for health research there 
has been a lack of focus on the external validity of trials (Rothwell, 2005). The nine domains of a 
pragmatic trial described in the PRECIS-2 tool can be drawn upon (Loudon et al., 2015) as 
demonstrated in section 5.4.3.2.  
5.5.3.3. Incorporating productivity  
All 30 agents with complete absenteeism data in this study were agency workers. Reportedly, this 
meant they were not eligible for statutory/ company sick pay unless they were absent for 4 or more 
days in a row. As most agents in this study took less than 4 days sick days in a row, uncertified 
absenteeism data was costed from the participant’s perspective (see reflections in 6.4). The 
framework should therefore recommended that contextual factors related to the employees’ 
contract is captured. Importantly, in the UK, if the sick employee is sick for less than 4 days and is 
contracted via an agency, then they may be the one who experiences a loss in earnings, as 
opposed to the employer (HM Treasury, 2019). For this scenario, the framework should 
recommend using the human capital costing approach, which takes the perspective of the sick 
employee, when estimating productivity losses.  
5.5.3.4. Cost drivers for future data collection  
In the pilot study the economic data collected can be simplified to the focus on collecting data for 
the key cost drivers. In terms of intervention costs, this study found that staff time was a cost driver 
for the intervention set up and operating costs from the perspectives of the research institute and 
employer. For example, the Resource Planner’s time to schedule the Education and Training 
sessions, had not previous been reported as a key activity in the trial protocol and CONSORT 
diagram (see reflections in items 4.1 and 6.1). Similar to the recommendations in Chapter 4, the 
framework can recommend that the TIDieR checklist (Hoffmann et al., 2014) and mircocosting tool 
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by Charles et al. (Charles et al., 2013) can be used to structure data collection methods such as 
consultations and weekly electronic logs, respectively. Key cost drivers from the healthcare 
perspective that the framework can recommend as priority items for data collection include: all 
secondary care activities and primary care consultations with the GP, Practice Nurse and 
Counsellor (see reflections in item 4.2). No participants reported incurring any out of pocket costs 
due to participating in the intervention. This is likely to be due to the aim of the intervention only 
requiring agents to predominantly stand and walk more during work hours. The framework can 
recommend that this type of cost does not need to be prioritised for data collection in similar 
workplace studies, if research resources are restricted (see reflections in item 6.3).  
5.5.3.5. Assigning unit costs 
Similar to findings in Chapter 4, the framework should recommend that all capital equipment needs 
to be quantified and reported alongside the other intervention resources. However, it can be 
suggested that not all items may need to be assigned a unit cost. Overhead and capital equipment 
costs can be excluded, if the resource (e.g. private room/ lighting) would not have been used for an 
alternative purpose (opportunity cost) and the resource use is minimal. This approach has been 
applied within the public health economics literature (Edwards and McIntosh, 2019). Capital 
equipment required only for the intervention (e.g. the height-adjustable desk) should be assigned a 
unit cost and included in the total intervention cost calculation. If the life of the capital equipment 
being costed is unknown, 5 years can be used, as this is seen as a conservative estimate 
(Drummond et al., 2015a). Furthermore, the framework can advise that the unit cost estimate for 
key capital equipment is adjusted according to the number of weeks the equipment is required for. 
This approach was used by Anokye et al. (2018) in a recent PA trial (see reflection in 8.1). In 
relation to unit costs, the framework can recommend that until more standardised methods are 
developed for measuring and valuing medication use (Thorn et al., 2018), this data does not need 
to be prioritised for data collection in SB trials, or if deemed important for a specific study, it can be 
reported descriptively (see reflections in 8.2). Lastly, the framework can provide additional 
guidance on costing productivity. For example, it can be advised that if productivity is interpreted as 
loss of earnings from the employee’s perspective, the human capital approach is appropriate. 
Similarly, this approach is also deemed acceptable for small scale studies, since it is easier to 
apply and commonly used (Edwards and McIntosh, 2019). On the contrary, larger studies exploring 
productivity from the employer’s perspective should aim to use a friction approach since the human 
capital approach is expected to overestimate productivity loss in this context (van den Hout, 2010) 
(see reflections in 8.3 and 8.4).  
5.5.4. Strengths and limitations 
Strengths and limitations of the trial design have been reflected on firstly by considering the internal 
validity of the results drawing on concepts from the CONSORT framework for social and 
psychological interventions (Grant et al., 2018). Secondly, the PRECIS-2 tool (Loudon et al., 2015) 
has been used to assess the external validity (generalisability) of the study. PRECIS-2 is a well-
known tool developed by 25 international trialists and methodologists, with the aim of providing a 
tool which support researchers to reflect on the design of their trials in a systematic, transparent 
and comprehensive manner. The tool aims to prevent waste in health research.   
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5.5.4.1. Internal validity 
A strength of this trial has been the random allocation method used to assign participants to the 
two comparator groups. For example, the demographic data indicates that randomisation controlled 
for a number of demographic variables. Nevertheless, even when randomisation is used, the health 
economic literature recommends that baseline costs and HRQoL are controlled for when estimating 
total costs and QALYs, as was done in this study (Manca et al., 2005, Franklin et al., 2019). The 
multiple regression method used in this study has therefore enabled more precise estimates to be 
generated. That said, even though baseline imbalances were adjusted for, no statistically 
significant differences were observed between the groups for any of the costs or consequences 
measured. This may be due to there being insufficient power to detect a difference and/ or the time 
horizon of the study being too short. One way to conduct addressing the missing data could have 
been increased, would have been by performing multiple imputation methods rather than a 
complete case analysis. There is a lack of guidance on how to perform multiple imputation in trial-
based economic evaluations which has been highlighted in the literature (Leurent et al., 2018) 
meaning complete case is the most common approach used for handling missing data in economic 
evaluations (Faria et al. 2014). Similarly, low power has been outlined as being a common issue 
within this field of research. A review from 2016 found that most effectiveness evaluations which 
assessed workplace height-adjustable desk interventions had low power and high risk of bias 
(Shrestha et al., 2016). Due to the small sample size, the pre-specified equity impact analyses for 
age, sex and postcode were not performed. An additional limitation related to the data available, 
was that there was incomplete absenteeism and medication data, 25% (n=10/40) and 17.5% 
(n=7/40) of data were missing respectively. 
5.5.4.2. External validity  
The generalisability of the SLaMM and SLaMM+ interventions to other workplaces is unknown 
since the study was conducted in just one workplace. That said, the agents who took part in the 
trial are likely to be representative of the contact centre since the eligibility items was kept 
intentionally broad. A limitation of this study is that the per-protocol principle was whereby 
participants were excluded from the study if they did not adhere to the intervention they were 
assigned to. Per-protocol principle restricts the readers understanding on how resources are 
actually being used in practice (Ramsey et al., 2015). Some aspects of the interventions delivery 
are unlikely to reflect what would happen if the intervention was scaled up, this includes the 
education and training sessions being delivered by the research team. Measuring the healthcare 
utilisation, presenteeism and HRQoL variables through self-report questionnaires was cheap and 
easy. In this trial, these measures were collected face-to-face by the research team, however 
future studies could collect this data in practice with little resource impact from the employer’s 
perspective. This may be especially true if the questionnaire is disseminated and completed via a 
secure confidential link online. For example, the Centre Contact could disseminate the link via 
email, similar to how the weekly emails were disseminated, which reportedly took no more than 5 
minutes to do. A strength of using this method would be that the participants who had left the 
company and thus did not complete the 12-week follow up could be also sent this link if they 
consented to this approach at the start of the trial. Inevitably, self-report measures are subject to 
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bias, however subjective measures are the preferred approach for presenteeism and healthcare 
utilisation due to objective data being incomplete, difficult to obtain and having poor external validity 
(Franklin and Thorn, 2019, Kigozi et al., 2017). 
5.5.4.3. Economic studies alongside pilot RCTs 
One of the main limitations of this study was that the economic evaluation was carried out 
alongside a pilot RCT. This meant the sample size was small and the study did not need statistical 
power for the clinical outcome. Furthermore, the sample size reduced further due to the contact 
centre company experiencing a high-turnover in staff. As this study was a pilot RCT it was the first 
time the trial team had worked with this type of contact centre company. The team had therefore 
not anticipated that a fifth (20%, n=12/60) of participants would leave the company during the 12-
week trial period and therefore discontinue with the study. No data was collected for these 
participants at the 12 week period and so we do not know for certain whether they experienced 
different outcomes to those who remained in the study. Another consideration with a pilot RCT and 
small sample size, is that there is a greater risk of outliers having a dramatic impact on the cost 
data (Simpson et al., 2014). Nevertheless, some argue that cost data is typically skewed anyway 
and has typically has a variance than clinical outcomes (Briggs, 2000).  
The advantage of conducting an economic evaluation alongside a pilot RCT is that it provides the 
opportunity to collect some evidence on the costs and implications of the intervention which may be 
important if there is not the time or funding to conduct a full trial (Glick et al., 2014). Collecting data 
alongside small scale studies may be particularly relevant to public health decision-makers in the 
UK who operate on short-term annual budgets and therefore require evidence to be generated 
rapidly (Willmott et al., 2015). Another advantage of incorporating economic procedures in a pilot 
trial is that it allows the trial team to assess the feasibility and acceptability of the data collection 
methods (Blatch-Jones et al., 2018) and refine their methods for future trials, as is the case with my 
framework. Moreover, an additional argument for collecting economic evidence alongside a pilot 
RCT is that even within full RCTs the statistical power for the economic end point is rarely 
calculated. In part this is because of the complex nature of the outcome of interest in economic 
evaluations (cost-effectiveness result) which is the joint distribution of differences in costs and 
effects (Petrou and Gray, 2011). Furthermore, due to the large variability in cost data, it is expected 
that a very large sample size would be required which may be unethical and costly. For these 
reasons, some argue that the focus of economic evaluations should be on reporting the cost-
effectiveness result because the confidence intervals will reveal if a study has low power (Briggs, 
2000). The wide confidence intervals for the cost data presented in this present study (SLaMM trial) 
indicate this study was underpowered.  
5.6. Conclusion 
In order to fulfil the first aim of providing a multidisciplinary framework that ensures a standardised 
approach to conducting economic evaluations, there is a need to improve costing methodology in 
particular, the methods used for capturing productivity and assigning unit costs. Importantly, the 
key reflections based on piloting of the initial version of the framework to this empirical trial have 
highlighted how the framework can be improved in order to emphasise the importance of 
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disaggregating costs and consequences and by collecting contextual data in order to consider who 
the results may be relevant to. The second aim of the study was to present the results of the CUA. 
The ICER statistic indicated that at 12 weeks when SLaMM+ was compared to SLaMM, the 
SLaMM+ group had an ICER that was just over NICE’s willingness to pay per QALY threshold. The 
uncertainty analyses indicated that there is a low probability the SLaMM+ will be cost-effective 
compared to SLaMM. Though, this study was a pilot RCT and thus was underpowered to make 
more robust conclusions. The second aim of the study was to reflect on the application of the initial 
version of the framework to the SLaMM trial. The framework was not straightforward implement as 
around two thirds (n=11/16) of the items needed additional guidance. 
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Chapter 6: Synthesis of findings & presentation of a 
standard operating procedure 
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6.1. Introduction 
6.1.1. Revisiting the aim & objectives 
The overarching aim of the PhD was to develop a multidisciplinary and pragmatic framework to 
guide researchers in conducting economic evaluations of individual-level PA and SB interventions. 
In order to address this aim, the following three objectives were undertaken:  
1. To conduct a systematic review of the empirical literature in order to identify and critically 
appraise the methods applied in existing economic evaluations of individual-level PA and 
SB interventions (Chapter 2, Study 1).  
2. The development of an initial multidisciplinary and pragmatic framework, which draw on 
good quality methods identified from Study 1 (Chapter 3).  
3. To apply the initial version of the framework to one PA trial (Chapter 4, Study 2) and one 
SB trial (Chapter 5, Study 3) in order to report and reflect on the applicability of the 
framework as well as provide evidence on the cost-effectiveness of the interventions under 
study. 
 
Section 6.2 provides an overview of each chapter’s methods and contributions. In section 6.3 I 
discuss the narrative synthesis methods I used to merge the reflective content from the thesis.  
Section 6.4 presents an overview of key findings from the narrative synthesis which relate to: (1) 
the challenges I came across when implementing the framework; and (2) the actions I took to 
facilitate implementation of the framework. In sections 6.5 I provide a critical discussion of these 
challenges and facilitators by interpreting them in the context of the wider literature. In section 6.6 I 
outline the implications for research practice. Lastly, in section 6.7 I present a revised version of the 
framework in the form of a standard operating procedure (SOP). In research, a SOP is guidance 
document which outlines a clinical trial unit’s preferred methods for carrying out a specific 
procedure. In brief, SOPs play an important role in quality assurance, transparency and 
consistency (Dritsaki et al., 2018), similar to the role I believe my framework can play. In section 
6.6.4, I explain further why I have chosen to disseminate my framework in the form of a SOP. 
6.2. Overview of thesis chapters 
6.2.1. Chapter 2: Systematic review 
The aim of the systematic review was to understand how existing economic evaluations of 
individual-level PA and SB have addressed four key methodological challenges. Just 15 studies 
were identified from four countries. Furthermore, no interventions being evaluated in these 
economic evaluations had assessed SB as an independent risk from PA, before 2018. Just one 
study made assumptions around the long-term impact of the PA intervention which was supported 
by evidence. This demonstrated that progress is being made to address the challenge of linking up 
short-term and long-term evidence. Though many country’s provide guidelines on their preferred 
techniques for measuring and valuing outcomes in economic evaluations, there was 
inconsistencies within studies from the same country on how resources were measured and 
valued. Comparability of studies was therefore challenging. Furthermore, the literature had 
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suggested that outcomes may be valued using CBA technique, but the review identified no 
examples of this. The most frequent costs and consequences incorporated into the economic 
evaluations reviewed were intervention operating costs and healthcare utilisation costs. A minority 
of studies included a slightly broader range of costs including: participant’s out-of-pocket costs; 
participant’s productivity loss (time off work to participate in PA intervention); provider’s productivity 
costs (loss in revenue); and provider’s intervention set up costs. The systematic review found that 
all but one study incorporated equity into their study, demonstrating that this is common practice. 
That said, only one study looked at more than one equity subgroup, which suggested that equity 
was not being considered in an explicit nor systematic way.  
6.2.2. Chapter 3: Development of an initial framework 
Four key steps were taken to develop the initial version of the standardised framework. The first 
step involved specifying the structure for the framework. The structure included 16 items which 
were deemed important and were predominately informed by the 10 items in the methodological 
quality assessment checklist by Drummond et al. (2015). In addition, the structure aimed to be 
incorporated the learnings from my systematic review (Chapter 2) such as a greater emphasis on 
incorporating equity and outlining the identification, measurement and valuation procedures 
separately for costs and effects. The second step involved drawing on the findings from my 
systematic review in terms of what costs, outcomes and equity subgroups are appropriate to 
recommend in the framework and in order to address the methodological challenges associated 
with public health economics. The third step entailed identifying data collection tools to measure 
the costs and outcomes deemed relevant. This step was challenging, since by large the studies 
from my systematic review did not report or provide examples of the measurement tools they had 
used to collect healthcare utilisation, intervention resource use and productivity data. 
Consequently, the DIRUM database was used to identify tools from other disease areas, which 
could be modified. Lastly, the fourth step involved arranging regular informal meetings with my 
supervisory team, trial team and other experts in order to discuss and reflect on the relevance, 
importance and practicality of the approach I was specifying in the framework and to ensure the 
approach was multidisciplinary and pragmatic. A key learning in the development of the initial 
framework was that standardisation of some methodological steps was constricted due to the need 
to recommend that the reader consults national guidelines, costing databases and/or position 
statements for the country in which they are conducting the analysis from.   
6.2.3. Chapter 4: Application of the framework to the Co-PARS trial 
The overarching aim of this study was to pilot and test the initial framework in a ‘real world’ PA trial. 
The study had two aims which were to reflect on the application of the initial version of the 
framework, and to assess the relative cost-effectiveness of the Co-PARS intervention compared to 
usual care and the control group. An important finding from the reflections on applying the 
framework was that it was challenging to implement many items of the framework without practical 
and formal training in economic evaluation. Furthermore, my reflections on the ICER result, led me 
to believe that the ICER statistic generated from a CUA is too simple and hides the complexity and 
wider benefits and costs of delivering a PA intervention such as Co-PARs. By contrast, I found that 
my secondary analysis, the cost consequence balance sheet where costs were disaggregated 
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(Appendix C.4), provided a whole range of information relevant to a number of different 
stakeholders (perspectives) including the participants. It was felt that this data was more helpful 
than the ICER for a number of reasons: the disaggregated results helped in me understand what 
the key cost drivers are (e.g. secondary healthcare costs and GP visits). In addition, my reflections 
illuminated the practical challenges in costing methodology in terms of: (1) how to assign unit costs 
in a standardised way without the need to make additional analyst-based assumptions and 
calculations; and (2) how to simplify the measurement of participant’s out-of-pocket costs and 
prescribed medication costs. More specifically, the unit cost calculations presented in Appendix C.3 
demonstrate the various levels of precision, adjustments and secondary sources required for 
costing. Finally, it was not possible to produce a decision-analytic model due to there being 
insufficient time, expertise and robust data from the trial. In terms of cost-effectiveness, the ICER 
indicated that from NICE’s perspective, the Co-PARS intervention was cost-effective compared to 
usual care but not compared to the control group. Though these results should be treated with 
caution due to the small study size. A future study with larger power is recommended to better 
understand the probability of the Co-PARs intervention being cost-effective compared to usual 
care. The stochastic uncertainty analyses indicated there was a lot of uncertainty in the original Co-
PARs dataset. 
6.2.4. Chapter 5: Application of the framework to the SLaMM trial 
The overarching aim of this study was to pilot and test the initial framework in a ‘real world’ SB trial. 
The study had two aims, which were to reflect on the application of the initial version of the 
framework, and to assess the relative cost-effectiveness of the SLaMM+ (height-adjustable desk 
group) intervention compared to the same intervention without a height-adjustable desk. My 
reflections on applying the initial framework to the SLaMM trial build on the findings observed in the 
Co-PARS study, specifically in relation to the usefulness of the ICER summary statistic in the 
SLaMM trial. Nonetheless, there were some differences that predominately related to the setting in 
which the framework was implemented. The SLaMM trial was delivered in a workplace which 
provided an opportunity for me to explore the employer’s perspective and access objective 
absenteeism data. That said, the absenteeism data precluded a comparative analysis, since a 
large proportion of this data was incomplete. I believe, this highlights the need to understand the 
quality of the existing datasets that may be available, before the trial commences, so as solutions 
can be sought to improve the quality of the collection recorded prospectively. The SLaMM trial 
helped me realise the importance of checking my assumptions around how the company hosting 
the intervention is organised, in order to avoid assigning resource use and savings to a narrow or 
incorrect perspective. For instance, prior to informally discussing how the company was organised 
with the senior managers, I had assumed that all paid work productivity loss would be incurred by 
the employer. However, I discovered it was actually the employees who were also likely to have a 
loss in earnings if they were off sick due to the nature of their job contracts. An important finding 
from the SLaMM trial, which differed to the design of the Co-PARs trial was that the researchers 
(including myself) delivered a large proportion of the intervention. By participating in the 
intervention delivery, I was able to provide prospective data on the type and amount of resources 
used for the intervention set up and operating costs. Nevertheless, on some weeks, some 
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company staff reported inputting more time than expected into supporting the implementation of the 
intervention. I asked these staff to document their time by completing weekly logs. For two of the 
three company staff, they reported not having the time to complete the logs on a regular basis. This 
showed that flexibility is needed for some key informants, for instance, this data may need to be 
collected retrospectively if weekly logs or diaries are deemed to be too onerous. In terms of cost-
effectiveness, the ICER indicated that from NICE’s perspective, the SLaMM+ intervention was just 
over the cost-effectiveness threshold. The small sample size as well as the results of the 
uncertainty analysis make it challenging to make conclusions about the cost-effectiveness results.   
6.3. Methods of narrative synthesis 
The reflective content interwoven throughout this thesis was based on a variety of ethnographic 
data sources, primarily these included the observations, notes and informal conversations which 
surfaced during the development and application of my framework. As a result, the reflections 
provide valuable insight into of the actions I took in order to develop and apply the framework in 
practice. Importantly, the reflections also provide explanations for why I believed these actions 
were appropriate. In order to revise and improve the initial framework from chapter 3, I have used 
methods of narrative synthesis to merge and organise the reflective content from chapters 4 and 5. 
The narrative synthesis involved organising my reflections into the two broad themes which relate 
to the aim of my framework, multidisciplinary and pragmatism. Interpreting the multidisciplinary and 
pragmatic content of my framework helped me discover that my reflections relate to two more 
specific themes: (1) the practical challenges a researcher may face when conducting an economic 
evaluation of an individual-level PA and SB intervention; and (2) the actions a researcher could 
take in order to support the implementation of an economic evaluation of individual-level PA and 
SB interventions. I provide a critical discussion of the factors which relate to these themes by 
interpreting them in the context of literature from health economics, public health, behavioural 
science and trial methodology.  
6.4. Narrative synthesis of key themes 
6.4.1. Overview of key challenges to framework implementation 
6.4.1.1. Complexity 
The reflective content in this thesis highlighted the complexity in developing and applying a 
standardised and principle-based framework for the economic evaluation of individual-level PA and 
SB interventions. One reason for this complexity relates to my observation that economic 
evaluations of individual-level PA and SB interventions requires skills and knowledge that go 
beyond the traditional disciplines of evidence-based medicine and welfare economics which are 
theoretically underpinned by positivist and normative methods, respectively. More specifically, 
economic evaluations in the field of PA and SB, require skills and knowledge from a wide range of 
relatively new research fields which are underpinned by methods which aim to be practical 
(pragmatic). The pragmatic-orientated methods and topic areas which feature in the reflections in 
this thesis include: cost-utility analysis, cost-consequence analysis, trial methodology, estimation 
statistics, public health, behavioural science, PA and SB. 
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6.4.1.2. Assigning unit costs 
A major theme in this thesis was that some of the methodological approaches outlined in the initial 
framework were not straightforward to apply in practice. This was despite my initial framework 
being informed by the methods used in existing studies identified in my systematic review (Chapter 
2), searches carried out across the DIRUM database and the use of handbooks and best practice 
guidelines for the generic field of health economics. In particular, I found it challenging to 
standardise my costing methods within and across the Co-PARs and SLaMM trials. Different cost 
types required different sources of unit costs and additional calculations, and in many cases there 
was no standardised published data available so I was required to use shadow prices and make 
study-specific analyst-based assumptions.  
6.4.2. Comparison of effectiveness and economic evaluations 
6.4.2.1. Standardised and validated measurement tools 
A key observation I made when trying to measure intervention, participant and productivity costs 
was that there was a lack of standardised and validated tools for complex public health 
interventions such as the Co-PARs and SLaMM interventions. Through this PhD project, I became 
increasingly aware that compared to the methods for effectiveness evaluations, economic 
evaluations measurement and reporting tools are underdeveloped. For example, in the field of 
economic evaluation, there is a lack of validated and standardised tools to measure resource use 
items for specific areas of health. By contrast, in the field of effectiveness evaluation, there is an 
initiative which specifically supports the standardisation and validation of health condition specific 
outcome measures. This project is called the core outcomes measures in effectiveness trials 
(COMET) initiative and aims to develop an agreed core set of outcomes for specific areas of health 
(COMET, 2020).  
6.4.2.2. International vs country-specific guidelines 
Another difference I observed was that analysts leading the effectiveness evaluations for the Co-
PARs and SLaMM trial draw on international guidelines to inform the primary outcome measure 
and design of their evaluations. By contrast a number of key methodological steps I carried out for 
the economic evaluation of the Co-PARs and SLaMM trials were informed by country-specific 
guidelines (NICE, 2014a). In part, this is due to the different theoretical underpinnings of the two 
evaluation types. Prior to undertaking this PhD, I was unaware of these theoretical differences. For 
instance, clinical effectiveness evaluations appear to derive from the paradigm of evidence-based 
medicine which are traditionally underpinned by positivist methods. Meanwhile, economic 
evaluation stems from welfarism and extra-welfarism which are traditionally underpinned by the 
paradigms of normative methods, with extra-welfarism including pragmatic methods to determine 
how health states are measured and weighted. Nevertheless, the thesis highlights that economic 
evaluation studying complex lifestyle behaviours such as PA and SB incorporate draws of 
positivist, normative, pragmatic and naturalist methods, suggesting overall the field of study 
necessitates a pragmatic approach. Overall, my reflections on this topic helped me to recognise 
that it would be challenging for me to produce a practical framework that addressed all the steps 
involved in an economic evaluation and had international applicability. 
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6.4.2.3. Terminology 
Another observation I made was that there is stark differences between the terminology involved in 
the conduct of trial-based economic evaluations and trial-based effectiveness evaluations. Having 
never conducted a clinical trial or an economic evaluation prior to commencing this PhD, many of 
these differences only became apparent in the field when I was applying my framework to the Co-
PARs and SLaMM trials. For instance, the health economic literature includes terms such as 
perspective, opportunity costs, time horizon, discounting, cost-effectiveness planes, cost-
effectiveness acceptability curves, incremental analysis.  
6.4.2.4. Specialised training 
During the data analysis phase of Co-PARS and SLaMM trials, I was surprised to find there was a 
dearth of practical guidance and examples in the economic evaluation literature on how to apply 
the principles of economic evaluations to the analysis of data from trials of complex PA and SB 
interventions. As a result, I completed a 3-day training course called ‘Applied Methods of Cost-
effectiveness Analysis in Health Care’. The course gave me ‘hands on’ computer-based experience 
on how to perform the statistical and uncertainty analysis for a trial-based economic evaluation. 
The practical methods taught on the course were reported as being standard practice in the UK. As 
the Co-PARS and SLaMM studies were the first trial-based economic evaluations I had conducted 
and as there is no published critical appraisal tools for assessing the quality of statistical and 
uncertainty methods in economic evaluations, I replicated the approach I was taught on the course. 
Furthermore, my supervisor who had expertise in health economics also helped me carry out and 
interpret the uncertainty analysis. This means I did not attempt to improve or change the approach I 
was taught by the course or advised by my supervisor. Nonetheless, I did reflect on the cost-
effectiveness results including the uncertainty analyses such as the cost-effectiveness plane and 
cost-effectiveness acceptability curve. I recognised that interpretation of the results from these 
economic analyses differed to the interpretation of the results from clinical effectiveness 
evaluations. Overall, understanding the uncertainty in the results presented required specialist 
knowledge of health economic concepts which I feel would be challenging for non-health 
economists to understand without formal training or expert guidance.   
6.4.3. Overview of actions to facilitate framework implementation 
6.4.3.1. Documenting and reporting complexity 
Ethnographic research in the form of observations and informal discussions can help researchers 
discover what the research is really about (Atkinson and Hammersley, 2007). I feel that the 
ethnographic notes and reflections I made during this PhD project enabled me to discover what 
contribution to practice my framework could make. It was through my practical experience of trying 
to design, implement and refine a novel standardised framework which covers the many complex 
steps involved in the conduct of an economic evaluation, that I discovered that even within the 
generic field of economic evaluations, some methodological steps are underdeveloped. I reflected 
on the scope of my PhD and recognised that I would only have the time, expertise and practical 
knowledge to make a novel contribution to a number of key methodological steps. Many of my 
reflections refer to the identification and measurement of resource use, this revealed to me that this 
is where my prior knowledge in public health can make an important contribution to the design of a 
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framework for assessing PA and SB interventions. My reflections also show how anthropological 
methods such as ethnographic data can support the analyst to document and explicitly report what 
was done and why. This transparency in methods and rationale is important since it helps the user 
of the results understand the context of the results, intervention and overall economic evaluation. 
The reporting guidelines published over the last decade indicate there is a drive towards 
transparency in trial-based research.  
6.4.3.2. Describing, identifying and measuring resource use for complex PA and SB interventions 
In my reflections, I refer to existing guidelines from the public health literature (e.g. TIDieR and 
PRECIS-2 frameworks) which are designed to capture complexity. Through this PhD I demonstrate 
how existing public health frameworks can support the practical steps in an economic evaluation 
for PA or SB. For example, the TIDieR framework is designed to improve the reporting of 
intervention descriptions. In Chapter 4 and 5, I found the TIDieR framework helpful for identifying 
intervention costs in terms of the types and quantify of resource use items. I also found the TIDieR 
framework was a more comprehensive way to describe a complex individual PA and SB 
intervention, when compared to existing health economic approaches, such as the pathway 
analysis approach. Pathway analysis involves specification of the intervention by asking the 
following questions: “who does what, to whom, when, where, and how often?” (Vos et al., 2007). 
Content of the TIDieR framework and pathway analysis approach are similar which indicates that 
from both a public health and health economics perspective, capturing detail and complexity about 
how the intervention is delivered is important. I found the TIDieR framework captures more detail 
as it includes items which require the analyst to distinguish between planned and actual resource 
use. Furthermore, my prior knowledge in anthropology has helped me recognise that the ‘thick’ 
description approach used in ethnographic research is also similar to the TIDieR framework and 
pathway analysis approach as anthropology’s ‘thick’ description approach aims to ‘provides clues 
to decide when, where, with whom, how and on which issues to intervene’ (Krumeich et al. 2001: 
216).  
6.4.3.3. Applying health economic concepts to public health trials 
Through my PhD journey, I have identified existing practices and concepts from the health 
economic literature which I believe can improve the quality of PA and SB trials. These include 
explicitly stating who the results are for, a concept known in health economics as stating the study 
perspective and presenting this in a table (as I did for the cost-consequence balance sheet). 
Furthermore, defining the perspective (where perspective is synonymous for stakeholder) in terms 
of what resource use and effects are likely to fall under the definition of each perspective, 
acknowledging that some categories such as productivity may be relevant to more than one 
perspective. As well as stating the study perspectives, another health economic concept which I 
believe can improve public health research is the concept ‘opportunity cost’. In the Co-PARs and 
SLaMM trial, through informal discussions and meetings with the leisure centre and workplace 
staff, I became aware of which resources potentially represented an opportunity cost and were 
therefore a priority item to capture data on. For example, where the staff felt some or all of the time 
they allocated to deliver some of the intervention activities could have be used to deliver more 
important non-intervention related activity, then represent an opportunity cost from their 
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perspective. Furthermore, I believe my focus on the economic features of the trails helped me 
recognise that the planned interventions for the Co-PARs and SLaMM trials as reported in the 
protocols, had not captured all important resources (e.g. staff time, travel and private rooms) which 
were required to support the implementation of the intervention. I feel a health economic 
perspective may therefore help translate research findings into practice and address the 
‘implementation gap’.   
6.5. Critical discussion of key themes 
6.5.1. Standardising the first-step in the costing process 
For more than a decade there has been a call for more methodological research in order to 
standardise costing methods (Mogyorosy and Smith, 2005). While this issue is too substantial for 
this thesis to address through a single framework, the previous chapters in this thesis have 
illustrated where standardisation is achievable. Standardisation is possible if resource consumption 
is quantified and presented in its natural units as seen in the cost-consequence balance sheets in 
study 2 and 3. This is because costing is a two-step process, involving firstly the quantification of 
resource use and secondly the assignment of unit costs. The reflections on piloting the framework 
in study 2 and 3 have illustrated that the second stage (assigning unit costs) of costing is the most 
challenging. Practically this stage involves numerous calculations, assumptions and secondary 
sources of varying quality as demonstrated in Appendices C.2 and D.3. Furthermore, as the 
authors of the studies reviewed in Chapter 2 do not discuss the calculations and assumptions they 
have made when assigning their chosen unit costs, it is likely that this stage of costing is analyst-
dependent. Researchers and decision-makers unfamiliar with economic evaluation are unlikely to 
be aware of these challenges and thus without training in health economics, may not feel 
competent enough to critically appraise the costing methods performed. A consequence of this is a 
lack of transparency in how economic evaluations are performed which contradicts the 
standardised approach that the framework aims to achieve. Additionally, standardisation for the 
methods used to assign unit costs is complicated further by the fact that different countries and 
organisations have different healthcare systems and accounting practices (Cylus et al., 2016). 
Earlier efforts to standardise costing methodology for health research have not been successful 
(Busse et al., 2008).  
Critically, costing methodology has not received the same attention as outcome methodology. 
Health economists have pointed out that when resource use data is collected from RCTs, it is often 
done inconsistently on a case-by-case basis and as a result there are calls for a research agenda, 
which focuses on improving methods for resource use measurement (Thorn et al., 2013a). 
Initiatives aiming to improve methods for measuring resource use, such as the PECUNIA and 
ISRUM projects, have been launched within the timeframe of this PhD, highlighting the timeliness 
of the findings in this thesis (PECUNIA, 2019, Thorn et al., 2018). The results of my systematic 
review (Chapter 2) as well as the process in developing the initial framework (Chapter 3) illustrated 
that resource use is being measured inconsistently both within and between countries, in terms of 
what resource use categories and items are deemed relevant and important to measure for various 
perspectives (multiple stakeholders). It has been argued that although the number of trials 
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collecting economic data has increased over time, the credibility and usefulness of this data is 
restricted by the variation in cost-effectiveness methods and reporting (Ramsey et al., 2015).  
The revised version of my framework focusses on the methods for collecting and presenting 
resource (economic) data in its natural units alongside effectiveness data. By reporting 
disaggregated resource use and quality of life data, this may help make results more useful for 
other researchers, which will increase the visibility and impact of economic evidence. Systematic 
(and pragmatic) reviews can draw on this economic data, which can be used as input parameters 
for decision-analytic models (Sculpher, 2015, Briggs et al., 2006). Disaggregated data is typically 
input into decision-analytical models rather than meta-analyses of cost-effectiveness results. 
Anderson (2010) argues that the pooling of cost-effectiveness results is futile, due to the contextual 
differences between economic evaluations. Another advantage of presenting a breakdown of the 
resource use data is that reviewers can use this data to identify trends in terms of if, and how, 
outcomes vary by level of resource (Anderson, 2010). This information can also be used to inform 
the design of interventions in term of informing what type and quantity of resources optimise the 
outcomes of interest. Abu-Omar et al. (2017) suggests a similar analysis, as they argue that PA 
studies should assess whether the type of staff delivering an intervention can shape whether an 
intervention is cost-effective. Bryan and Williams (2014) propose this type of economic research as 
being knowledge-generating. They argue that a more positive (as opposed to normative) approach 
to the evaluation of economic data, could generate results that are meaningful to a broader range 
of decision-makers including researchers designing interventions. Others have recognised that 
there is scope for the discipline of economics to contribute to the design of interventions in order to 
bring about change at the macro- and micro-level (Frew et al., 2018). 
6.5.2. Presenting resource use data alongside effectiveness data 
Research has shown that when economic evaluations are simultaneously published with results 
from the effectiveness evaluation, this is likely to improve overall dissemination of the economic 
evidence (Thorn et al., 2013b). Although, publication bias is a known phenomenon for 
effectiveness results (Song et al., 2000), publication bias and delays in publication are even greater 
in the field of economic evaluations (Greenberg et al., 2004). The review by Thorn et al.(2013b) 
observed a two-year delay in publication when economic evaluations are not published alongside 
the effectiveness results. The reviewers claim this as concerning, arguing that a two-year window is 
enough time for effectiveness results to bring about change in practice and reimbursement 
decisions without consideration of the economic evidence. A recent study of a workplace SB trial 
published in a high impact journal provides a good example of how the economic-related variables 
quality of life, absenteeism and presenteeism can be quantified and presented in the same 
publication as the effectiveness results (Edwardson et al., 2018). More specifically, the study briefly 
describes the main results in the main manuscript and signposts the reader to the supplementary 
materials for a transparent breakdown for each comparator group. That said, the authors state the 
cost-effectiveness results will be reported in a future study, which may explain why the resources 
required to set up and deliver the intervention are not comprehensively quantified. If future 
systematic reviews therefore want to explore how levels of resource use relate to levels of 
outcome, the reviewers will be required to contact the authors, which may be challenging if this is 
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some time after the study. Alternatively, they would have to make assumptions about the levels of 
resource use, which will be less precise prospective study records. For almost two decades it has 
been argued that a range of costs and consequences should be presented in trials, including 
quality of life and intervention costs as these are relevant to decision-makers and practitioners 
(Tunis et al., 2003). The CCA makes it explicit what costs and consequences have been included 
and omitted, which overall means the results are more likely to influence real-world decision 
making as decision-makers can apply their own values to the results so as they align better to their 
local context (Coast, 2004). 
6.5.3. Applying existing public health methods to the field of economic evaluation  
One way to reduce the researcher burden from collecting resource use data could be to draw on 
tools that are already used when assessing PA and SB intervention. This thesis has shown, that 
the TIDieR framework is useful for collecting data on intervention staff type, materials and capital 
equipment needed to carry out an intervention and that the PRECIS-2 framework is useful for 
understanding and quantifying the resources associated with the contextual factors. At present, 
analysts are only required to report this qualitatively when they submit their journal papers. There is 
scope to quantify this data further by using the microcosting tool, which has been developed and 
refined during the evaluation of the Co-PARS and SLaMM trial. The refined version of the 
microcosting tool and examples of its application are provided in appendix E.1 and E.2. 
 
6.5.4. Complexity in assigning costs to resources 
 
‘Collecting cost data in a manner that is simultaneously concise, understandable for patients, valid, 
precise, consistent between trials, and generalizable is challenging.’  
(Thorn et al. 2017,p648) 
The quote by Thorn and colleagues refers to the present challenges even researchers trained in 
health economics face when collecting economic data alongside trials. Fundamentally, this 
challenge is likely to be due to the fact costing methodology is deeply underdeveloped. In the 
SLaMM and Co-PARS trials, participants were asked to self-report the secondary care 
departments they were admitted to and visited for their outpatient and day case appointments. 
Similarly, participants were asked to name the type and dose of the medication they were being 
prescribed. Data were collected as it was expected that it would be a straightforward exercise 
assigning unit costs to the secondary care and medication received. The UK has comprehensive 
and standardised databases, which list the unit costs for hundreds of different treatment and 
medication types offered within the NHS (NHS Improvement, 2018, NHS Digital, 2018). The 
selection of an appropriate unit cost was time-consuming and relied heavily on the researcher’s 
(Madeleine Cochrane) judgement. The idea that cost-effectiveness studies may not be cost-
effective themselves is discussed by Drummond et al. (2015b) who claim that costing is a skill 
which involves a trade-off between precision/accuracy, and research effort/ feasibility. That is to 
say, this may have been the case when conducting the Co-PARS and SLaMM trials, as the 
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calculation of individual unit costs was a time-consuming process. Furthermore, feasibility in 
relation to costing methods, has been described as being the ‘ability to observe’ the resource use 
as well as the cost of collecting it (Mogyorosy and Smith, 2005). Others have commented on this, 
claiming that precision can be compromised by the availability of data and time for the study 
(Kinsella, 2008). This can be understood by considering whether there is ‘enough precision for the 
decision’ (Lipus, 2018). It is argued that less accurate resource use estimates may suffice for a 
particular decision (Mogyorosy and Smith, 2005). Thorn et al. (2018) draw attention to this 
challenge faced by researchers: ‘there is a trade-off between gathering as much information as 
possible (with increased patient burden and possible poor response rates) and gathering less 
information (which may not allow an accurate analysis to be conducted)’(p641) (Thorn et al., 2018). 
6.5.5. Timely and relevant data for public health stakeholders 
As discussed in my systematic review (Chapter 2), one of the challenges decision-makers face 
when investing in preventative programmes is attributing long-term costs and consequences to the 
intervention under study. In general, there is a lack of longitudinal evidence identified to accurately 
estimate the long-term impacts of PA and SB interventions. However, the Co-PARS trial indicated 
that an increase in quality of life and reduction in GP consultations may be observable over a 
shorter timeframe, in this case the 6-month trial time horizon. The ability of the framework to 
consider the immediate resource impacts (costs) may increase the role of economic evidence in 
public health commissioning. A study exploring the perspectives of the Directors of Public Health 
across local authorities in the UK, found a need for more evidence on the short-term economic 
impact of the public health interventions they commission, in order to make the case for investing in 
preventative interventions to local government (Willmott et al., 2016).  NICE’s most recent 
methodological guidelines recommend that economic evidence on short-term evidence from trials 
should be included in economic evaluations (NICE, 2014a). Importantly, the short-term data is 
likely to be relevant to public sector decision makers who operate on a short-term budgetary cycle 
(PHE, 2018, Willmott et al., 2016). If more immediate resource use and quality of life evidence is 
generated in the short-term, there is a need to ensure this data is disseminated amongst those who 
can use it.  
6.5.6. Evidence fit for a non-health economic audience 
The summary cost-effectiveness and uncertainty results of the primary analysis (CUA) in the 
SLaMM and Co-PARS trials presented complex information that was not easy to understand 
without training in health economics. By contrast, the disaggregated results and cost consequence 
balance sheets are easier to interpret for each stakeholder (perspective). In addition, this approach 
promotes transparency. As seen in the Co-PARS and SLaMM trial, it was clear to see what costs 
and consequences each stakeholder experienced. This balance sheet complements the recent 
drive towards systems thinking within the public health (Rutter et al., 2017) whereby the 
perspective of multiple sectors are taken into account. Evidence that is easy to interpret is 
important to both the researcher and decision-maker if resource allocation and intervention design 
are to be informed by evidence. There is a need to ensure that the results generated by studies 
which use the refined framework are relevant and accessible to the reader. A consequence of not 
presenting evidence that is clear and easy to understand is that the decision-makers cannot be 
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fully accountable for their decisions (Bryan and Williams, 2014). Owen et al. (2017) argue that it is 
important that decision-makers understand why cost-effectiveness results vary across studies. 
Some decision-makers expect CUA and CEA studies to be performed as ‘add on’ exercises 
alongside effectiveness evaluations. This places an unrealistic expectation on researchers, since 
this thesis has shown that costing methodology is underdeveloped and consequently involves 
many analyst-based decisions.  
Evidence suggests that local level decision-makers firstly, do not always understand the health 
economic analyses they are presented with and secondly, find the recommendations from cost-
effectiveness studies are unrealistic for ‘real world’ decision-making (Bryan and Williams, 2014). 
For instance, some have difficulty in redirecting resource use, while others are under pressure to 
contain costs due to the nature of the short-term budget cycles they operate within (Bryan and 
Williams, 2014). A recent Delphi study aiming to capture public health decision-makers views on 
economic evaluation found that the decision-makers reported that cost-effectiveness ratios were 
not helpful, they preferred the results to be presented transparently in terms of costs and outcomes 
being presented by sector and population group (Frew and Breheny, 2019). A previous study also 
claimed QALYs are not well understood by decision-makers (Drummond, 2003). Cylus et al. (2017) 
describes cost-effectiveness results which are reported as “resource use per unit of health system 
output” as being “beguilingly simple” as it does not account for the complexity of the health system 
and is only looking at one independent variable in isolation.  
6.6. Implications for research practice 
6.6.1. Capturing complexity through informal conversations with stakeholders 
Recent discussions around the methodological challenges experienced in the wider economic 
evaluation literature indicate that the identification of costs and consequences from multiple 
sectors, as discussed as one of the four key challenges in my systematic review (Chapter 2), may 
no longer be regarded as being a challenge unique to public health trials (Ramsey et al., 2015, 
Drummond et al., 2015b). This suggests the discussions within this thesis may be informative to 
researchers and decision-makers in the wider field of economic evaluation. During the design stage 
of future economic evaluations, analysts could conduct multi-stakeholder and expert consultations 
to map out which costs and consequences (Squires et al., 2016) are relevant to the CCA. A 
systems thinking approach (Rutter et al., 2017, Squires et al., 2016) is recommended to ensure 
interventions’ indirect and unintended costs and consequences on multiple sectors are considered, 
not just those experienced by the health sector or payer. Two recently published frameworks can 
help analysts apply a systems approach (Cylus et al., 2016, Squires et al., 2016). 
6.6.2. Adopting existing tools from public health 
A surprising finding which emerged in my systematic review (Chapter 2), was that authors of 
existing PA and SB economic evaluations did not reference or provide templates in the 
supplementary materials for the type of measurement tool they were using to measure resource 
use. More specifically just one (Edwards et al., 2013b) of the 15 studies reviewed in Chapter 2 
provided a reference to the tool they used to measure healthcare utilisation. Together this evidence 
shows there is potential for researchers from multiple disciplines to develop and pilot resource use 
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measurement tools in their future PA and SB trials. This can be developed and shared free of 
charge via the DIRUM database. A key learning from this thesis, was that there are existing 
multidisciplinary standardised tools within the clinical effectiveness literature such as the TIDieR 
and PRECIS-2 tools which implicitly incorporate concepts that are relevant to economic 
evaluations. In particular, these tools may be helpful for capturing intervention costs and contextual 
factors respectively. In order to reduce the burden on trialists collecting resource use quantities 
throughout their trial in terms of healthcare utilisation, Chapter 4 and 5 identified resources that are 
more likely to be cost drivers. For primary healthcare the Co-PARS and SLaMM trials identified the 
same priority resource items, this included the GP, Practice Nurse and Counsellor. In addition, 
visits to the Physiotherapist were also identified as being relevant to the Co-PARS trial. That is to 
say in future studies, if time and resources are limited, researchers could prioritise data collection 
for these cost items.  
All five models in Chapter 2’s review presented a visual depiction of the disease pathway for PA. 
Researchers could draw on the disease pathways presented in the model-based studies in Chapter 
2 in order to help policymakers and those designing interventions populate a logic model with the 
long-term costs and consequences associated with PA and SB. The visual presentation of a logic 
model is recommended in public health effectiveness evaluations (Moore et al., 2015). More 
systematic evaluation of care pathways is advocated to find efficient ways to integrate behaviour 
change and treatment services, to prevent major chronic diseases such as T2D (ISPOR, 2018). A 
visual developed during the design stage of the trial can make it clear to the researchers and 
commissioners of the evaluation how immediate investments to PA interventions have the potential 
to make substantial savings in the future, through the aversion of costly treatment for CHD, T2D 
and stroke (Campbell et al., 2015b). To date, even when cost-effectiveness has been incorporated 
in a logic model of a high quality study, this has typically been limited to stating ‘intervention is cost-
effective’ rather than specifying what costs may be modified (Edwardson et al., 2018). 
6.6.3. Supporting practice for early career health economists  
It was originally anticipated that all researchers from the wide range of disciplines in which PA and 
SB interventions include, as well as health economists, would be able to use the framework for 
their upcoming PA and SB trials. However, as numerous examples across the thesis have brought 
to light, the methods and terminology involved in economic evaluations differ substantially to 
effectiveness evaluations. As a researcher who had no formal training in economic evaluation 
before commencing this PhD, I found there was a lack of detailed practical guidance in the 
literature to guide me through the practical steps in conducting an economic evaluation. This meant 
I was unable to implement all steps in my planned framework without receiving additional formal 
training in economic evaluation. I was access a 3-day practical course on economic evaluation 
principles applied in practice. It would have been inappropriate for me to repeat the content of the 
training course in my framework especially as my approach would not have been novel and 
furthermore I believe the most important aspects of the course were the practical computer-based 
exercises which went beyond the scope of my framework. Through the development and 
implementation of my framework I discovered my framework has the potential to make an 
important contribution to early career health economists who do not have prior knowledge in public 
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health, but are required to conduct economic evaluations of individual-level PA and SB 
interventions. More specifically, through my reflections I discovered that existing public health 
guidelines (e.g. PRECIS-2 tool, TIDieR checklist) and literature are helpful for the economic 
evaluation steps that involves the identification of relevant perspectives and resources. I have also 
discovered that anthropological methods such as observations and informal conversations with the 
various stakeholders involved in the commissioning, set up, delivery and hosting of the intervention 
are helpful when measuring the amount of resources used or saved. 
6.6.4. Standard Operating Procedure 
In order for an organisation to be registered as a clinical trials unit by the UK Clinical Research 
Collaboration (UKCRC), the organisation needs to demonstrate they have a number of key 
competencies. The UKCRC recommend the use of standard operating procedures (SOP) to 
demonstrate the key competency of quality assurance (UKCRC, 2019). SOPs are documents, 
which explicitly specify an organisation’s preferred approach to carrying out a specific trial 
procedure (e.g. randomisation, database, document control, data management, statistics). The aim 
of SOPs are to achieve consistency, efficiency and quality in a specific procedure across an 
organisation. The UKCRC lists 19 procedures for which they argue it is essential to have a SOP 
for. Trial units across the UK usually have their own SOPs for the various procedures. They also 
play a key role in supporting communication between multidisciplinary teams. At present, health 
economic SOPs are not essential, however some argue that health economic SOPs would support 
the integration of health economic procedures into clinical trials (Edwards et al. 2008). The 
intention of my framework presented in chapter 3 was to provide a multidisciplinary and pragmatic 
framework for economic evaluations in the field of PA and SB. Through my PhD journey I have 
become aware of the differences in methods and terminology of effectiveness and economic 
evaluations. I believe an interface which supports multidisciplinary working in public health 
economics, such as a SOP, is required to support the communication and implementation of my 
framework for identifying and measuring resource use. The SOP I present in the subsequent 
section draws on my reflections on developing the initial framework (Chapter 3) and applying the 
framework to the Co-PARs (Chapter 4) and SLaMM trial (Chapter 5).   
6.7. Presentation of the standard operating procedure 
 
Standard operating procedure for resource use measurement in the 
economic evaluation of individual-level PA and SB interventions 
 
1. Purpose 
The purpose of this standard operating procedure (SOP) is to describe a non-study specific 
approach to the planning, collecting and presenting of resource use data for individual-level PA and 
SB trials. The aim of this SOP is to standardise some of the routine steps in the conduct of an 
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economic evaluation of individual-level PA and SB interventions. The SOP describes a minimum 
set of perspectives, resource categories and equity subgroups for the field of PA/SB.  
2. Scope 
This SOP can be applied to funding applications, protocols, ethical approval processes, health 
economic analysis plans, interim and final reports, and journal publications. The SOP is intended 
to: (1) support early career health economists applying economic evaluation to the field of PA and 
SB; and (2) act as an interface between health economic analysts and a multidisciplinary trial team. 
The SOP is complementary to country-specific guidelines for economic evaluations. It does not 
replace country-specific guidelines since these are generic guidelines to the field of health. Instead 
the SOP provides guidance for analysts to carry out additional analyses which could be specific to 
the PA and SB community. 
3. Introduction 
Economic data in terms of resource use and generic quality of life data (final health outcomes) is 
important for ensuring society’s scarce resources are being allocated to interventions which 
achieve the greatest value for money. The complex design of individual-level PA and SB trials 
demands health economists have an understanding of at least the following culture and context 
specific factors: (1) the organisational structure of the setting in which the PA and/or SB 
intervention is set (this is likely to be a non-healthcare setting); (2) the expertise, materials or 
capital (e.g. private rooms) at the setting and whether these resources represent an opportunity 
cost; (3) the various perspectives (stakeholders) who may be affected intentionally and 
unintentionally by the PA and SB intervention; and (4) the immediate and future costs and health 
benefits associated with individual-level PA and SB interventions.  
Health economists new to carrying out economic evaluations in the field of public health can draw 
on the range of pre-existing peer-reviewed public health tools which are designed to support 
researchers in the conduct of trials which are fit for purpose (pragmatic). Similarly, health 
economists may benefit from methods used in anthropology. For example, by providing ‘thick’ 
descriptions of the context in which an intervention is delivered this may help improve the analyst’s 
understanding of the resource implications of implementing and delivering a PA and/or SB 
intervention. Furthermore, health economists could make use of the information they receive about 
the intervention and setting context from the informal conversations they have with stakeholders 
and multidisciplinary experts during the study period.  
The different terminology and methods used in economic evaluations compared to effectiveness 
evaluations demands trialists to have an understanding on what and how economic data is 
important to measure. Trialists and health economists should require a trial-based tool, such as a 
SOP, to ensure an economic perspective is incorporated into the trial design, to monitor data 
completeness and to support dissemination of evidence on resource use. Section 6 of this SOP 
outlines a procedure to improve the conduct and communication of an economic evaluation of a 
individual-level PA and/or SB trial. The procedure provides detailed advice on how some key steps 
in economic evaluation could be carried out in practice. The SOP draws on insight and existing 
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practical methods from the disciplines of public health, anthropology and health economics. 
Practical templates and examples to support implementation of the SOP are provided in 
Appendices E.1-E.3.    
4.  Definitions  
4.1. Definitions of key public health terms  
Stakeholders: individuals or organisations who are likely to be affected by the intervention of 
interest. Identifying stakeholders is similar to stating the study perspective.  
Logic model: a conceptual model which graphically depicts and hypothesises the relationships 
between inputs, activities, outputs, and short-, medium- and long-term outcomes of typically one 
intervention of interest. Typically, public health logic models report improved health and wellbeing 
as the final outcomes. Long-term cost implications, length of life and quality of life are not typically 
incorporated in public health logic models, but they could be.  
Equity: A key objective of public health interventions. Equity refers to the unfair distribution of 
health and income in society.  
4.2. Definitions of key anthropological terms 
Ethnographic data: sources of data typically collected in an informal and unstructured manner 
from everyday interactions including day to day observations and informal conversations. The aim 
of ethnographic data is to explicitly document how complex the ‘real world’ is rather than simplify it.  
Ethnographic reflections: descriptions of what happened (i.e. what actions were taken) and an 
interpretation on why this happened (i.e. why these actions were taken). Interpretative content is 
informed by the detailed descriptions and observations recorded from everyday interactions (the 
ethnographic data). This documentation is similar to the documentation that is increasingly 
requested by journal reporting guidelines. For instance, many reporting guidelines necessitate that 
analysts transparently report what exact methods they chose and why.  
4.3. Definitions of key health economic terms 
Economic evaluation: comparison of both costs and effects of at least two intervention (or policy) 
options 
Costing: a two-step process. The first-step involves identifying the type and amount of resources 
used. The second section involves assigning an appropriate unit cost. Published national unit cost 
data sources are recommended in the UK, although most published data is for healthcare which 
makes assigning costs to interventions delivered in non-healthcare settings particularly challenging.  
Opportunity cost: the benefits given up as a result of choosing one course of action (e.g. an 
intervention activity) over another. For example, when resources (e.g. time, materials, capital) are 
used up to support the operation of one intervention, then these resources are no longer available 
at that point in time for another intervention. The potential benefits of the intervention which is not 
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delivered represents the benefits that are foregone. In health economics the foregone benefits are 
called the ‘opportunity cost’.  
Time horizon: time period in which costs and outcomes are analysed over. In a trial-based 
economic evaluation, the time horizon is typically the study follow up time (e.g. 12 months follow 
up). 
Perspective: the individuals or organisations who are likely to be affected by the intervention of 
interest. Stating the study perspective is similar to the identification of relevant stakeholders. 
Incremental analyses: analysis of the between group difference in the outcome (costs) of interest. 
Some health economists may use the term ‘additional benefits (costs)’ to describe this. 
Incremental cost-effectiveness ratio (ICER): the most commonly reported summary statistic for 
economic evaluations. The ratio represents the additional difference in costs of two intervention 
options divided by the additional difference in effects of the options.  
Willingness-to-pay (WTP) threshold/ Cost-effectiveness threshold: The maximum amount a 
decision-maker is willing to pay per unit of benefit.  
Decision-analytic model: an analytical methodology that draws on primary and secondary data 
sources to estimate the costs and effects of at least two courses of action (e.g. intervention or 
policy strategy) for a pre-specified population group over a pre-specified time period. Model 
parameters are similar to the variables included in logic models but also include cost implications, 
length of life and quality of life.  
5. Responsibilities 
5.1. Health Economist 
It is the responsibility of health economist to implement the procedures outlined in the SOP. In 
particular, it is the responsibility of the health economist to draw on the data from this SOP and 
specify in the trial documents (e.g. protocol and health economic analysis plan) what resource use 
data is relevant and important to collect for each PA/ SB trial. The final decision on how resource 
use data will be collected and quantified will be decided by the health economist.  
5.2. Trial team 
It is the responsibility of the trial manager and trial team involved in the collection and monitoring of 
the trial data, to read through this SOP so as they understand the overarching approach that will be 
applied for the generation of resource use data. It is expected that the trial manager and trial team 
will provide advice about the practicability of the data collection methods proposed by the health 
economist. In addition, the trial team can support the health economist to document the complex 
contextual factors associated with the intervention and trial. This information can be recorded and 
discussed with the health economist through informal ongoing trial meetings.  
6. Procedure 
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The following 13 items listed in Table 1 in section 6.1 and the guidance provided in section 6.2 are 
intended to support a multidisciplinary and pragmatic approach to the identification and 
measurement of resource use associated with individual-level PA and/or SB trials.  
6.1. Overview of key steps to address 
Table 1. Overview of items included in the revised framework 
Items* 
1 How can complexity be incorporated into the studies generating evidence on resource use? 
2 How can studies generating evidence on resource use define their study question? 
3 How can important and relevant resource use be identified? 
4 How can intervention set up and operating costs be measured? 
5 How can health and social care resource use be measured? 
6 How can participant-related resource use be measured? 
7 How can employer-related resource use be measured? 
8 How can resources be valued? 
9 How can summary data can be presented? 
10 How can equity be incorporated into the analysis? 
11 How can the study results be interpreted? 
12 How can resource use evidence be disseminated?   
13 How can the resource use evidence be used to support public health practice and research?   
* Adapted from the methodological quality assessment checklist outlined in the Drummond et al. 
(2015) and informed by the empirical studies (Study 1-3) from the thesis by Cochrane, 2020.  
  
6.2. Explanatory guidance to support implementation of the SOP 
Item 1. How can complexity be incorporated into the studies generating evidence on resource use? 
As economic evaluations require data from studies which compare at least two comparator groups, 
clinical effectiveness trials represent a key opportunity to collect primary data on resource use. It is 
advisable that a researcher with expertise in health economics (e.g. health economist) is involved 
in the trial from its inception. This is to ensure a health economic perspective and economic data 
collection is incorporated into the study design. Key activities at the start of the trail, may include a 
health economist participating in both the formal trial management group meetings as well as the 
more informal conversations around the trial planning and set up. Together the health economist 
and trial team could commit to the collection and presentation of resource use data by stating it in 
the trial’s registered protocol. 
PA/ SB interventions are typically set in non-healthcare settings. It is advised that the health 
economist captures the context in which the trial is being implemented, this could be captured 
through ethnographic data and reflections (see definitions in section 4.2 of this SOP). In order, to 
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gather contextual data in a systematic way, it may be helpful to reflect on the nine domains from a 
tool called the Pragmatic Explanatory Indicator Summary 2 (PRECIS-2) tool. PRECIS-2 derives 
from the trial methodology literature. It encourages researchers to explain their trial design 
decisions and to reflect on whether their trial is fit for purpose. The nine domains could be used to 
structure any informal discussions with the trial team around context and the complexity of the 
intervention and trial setting. Domains from the PRECIS-2 tool which are particularly relevant from 
a health economic perspective include: (1) the setting- where is the trial being delivered?; (2) the 
organisation- what skills, expertise and other resources are needed to deliver the intervention?; (3) 
the outcomes- how relevant are the outcome measures to the individual participants and other 
stakeholders?; and (4) the analysis- for instance, for economic evaluations it is recommended that 
the intention-to-treat (ITT) principle is followed, whereby all participants are analysed according to 
the group they were assigned to, regardless of whether they have adhered to their group’s 
protocol.   
Item 2. How can studies generating evidence on resource use define their study question? 
Defining the study question is similar to an approach used in effectiveness evaluations where the 
population, intervention, outcome, comparator, study type (PICOS) framework is commonly used to 
define the components of a well-defined study aim. In health economics, the following five pieces of 
information are recommended when defining the study question: study type, study technique (how 
results are presented), study perspective, time horizon and population (Drummond et al. 2015). An 
applied approach for addressing these five factors in practice is outlined below: 
1. Study type: It is recommended that the team explicitly state in the trial protocol that both 
resource use and effects are being collected from at least two comparator groups. 
Comparator groups may include a new or refined PA/SB intervention, no intervention, or a 
group that represents usual care for the study setting.  
2. Technique (summary results presented): It is recommended that resource use categories 
and outcomes are analysed and presented separately in a disaggregated format. In 
addition, present resource use and outcomes according to the stakeholder (perspective) in 
which they related to. This is similar to the way a cost-consequence analysis is typically 
presented.  
3. Study perspectives: It is helpful to define the study perspective by making a list of all the 
individuals and organisations you think may be impacted by the implementation of a PA/SB 
intervention (see item 3 of the SOP for more detailed guidance on this step). 
4. Time horizon: It is helpful if the data collection and analysis of the trial-derived resource 
use data is done over the same time schedule as the effectiveness data. A six-month recall 
period is deemed acceptable for participants taking part in PA/SB trials.  
5. Target population and subgroups:. For practical and efficiency reasons related to the data 
collection schedule, it is recommended that the target population for the economic data is 
the participants recruited for the clinical effectiveness trial. One way to incorporate equity 
into the study could be to do subgroup analyses for the following subgroups: age, sex, 
socioeconomic status and pre-existing medical condition.  
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Item 3. How can important and relevant resource use be identified? 
It may be helpful for the trial team to do this step together in order to ensure all important and 
relevant resources are considered. This could involve two key steps. Firstly, it may be helpful to 
stimulate discussion by referring to Rutter et al.’s (2018) complex systems thinking framework for 
PA. In part, the framework has been designed to help researchers understand the multiple sectors 
and stakeholders who may be related to the challenge of physical inactivity. The complex systems 
framework for PA is freely available in the public health literature. Secondly, as a team it may be 
helpful to identify and list all the individuals and organisations who are involved in: paying, 
providing, hosting, participating and setting up the PA/SB intervention. Individuals and 
organisations may fall into more than one of these categories (e.g. if the intervention is set in the 
workplace, the employer represents the host organisation and employer’s perspective). The 
following types of perspectives and their associated resource use could be discussed: 
1. The payer’s perspective may include the planned intervention costs such as the resources 
required to set up and deliver the PA/SB intervention as specified in the protocol 
2. The provider’s perspective may include the resources used to set up and deliver the 
intervention which are not captured or differ to those specified in the protocol (e.g. 
additional preparatory time, ongoing support time) 
3. The host organisation’s perspective (the setting’s perspective) may include the resources 
used to set up and deliver the intervention which are not captured or differ to those 
specified in the protocol (e.g. the use of private rooms to deliver the intervention).   
4. Health and social care costs may include primary healthcare activity (e.g. consultations 
with the GP, practice nurse and allied health professionals). In addition, it may include 
secondary healthcare activity (e.g. A&E, inpatient, outpatient and day case visits to the 
hospital).  
5. The participant’s perspective may include the participant’s out of pocket expenses (e.g. 
expenses for clothing, travel, gym membership) and productivity losses (e.g. loss of leisure 
time, loss of earnings) which accrue due to taking part in the PA/SB intervention. 
6. The employer’s perspective may include the indirect losses and/or gains in absenteeism 
and presenteeism. If the intervention is set in the workplace, time given up (and potentially 
income loss) due to staff participating in the intervention during working hours may also be 
captured.   
 
Item 4. How can intervention set up and operating costs be measured? 
As individual-level PA and SB interventions may represent a new intervention model which has not 
been evaluated from a health economic perspective, it is recommended that a microcosting 
exercise is carried out. That said, this may depend on the time and purpose of the economic 
evaluation. At a minimum, it is advised that the health economist check their interpretation of the 
interventions of interest with the trial team. Microcosting is recommended as it is expected to be 
more accurate that aggregate costs or block contract costs. Microcosting has a role in identifying 
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inefficiencies in resource use as well as capturing additional resource use that may not have been 
previously captured. The latter is important, as this ‘hidden’ resource use may help explain the 
phenomenon known as the ‘implementation gap’.  
 
Microcosting involves describing in detail the interventions of interest. In addition to describing the 
interventions of interest, it is recommended that the same description is provided for the 
comparison groups, even if these represent usual care. This is because usual care may vary 
geographically and/or by organisation. It may be helpful to base the intervention and usual care 
descriptions on items from the Template for Intervention Description and Replication (TIDieR). 
TIDieR is a reporting tool from the public health and trial methodology literature which encourages 
researchers to describe: what activities and equipment are required for an intervention; who 
delivers the intervention and how; where is the intervention delivered; is the intervention tailored or 
modified; and is the intervention delivered as planned (Hoffmann et al. 2014). An adapted version 
of the TIDieR framework is provided in the supplementary material (Appendix E.1). The adapted 
version provides further questions in order to help the research to quantify the resource use data. 
Furthermore, the tool categorises resource use into three broad categories: people-related (e.g. 
expertise and time), materials (e.g. resources specific to the intervention), place-related (e.g. 
existing resources at the host organisation not specific to the intervention, travel to the location). 
 
Intervention resource use could be captured through a range of data sources including 
ethnographic data such as informal conversations and observations (see definitions in 4.2), diaries 
or logs, as well as more formal approaches such as face to face meeting at the intervention setting 
with the trial and intervention staff. If possible, collect this data prospectively. Prospective data 
collection is preferred as it is expected to be more accurate since it does not rely on human recall. 
Nevertheless, it may be necessary to be flexible on how and when this data is collected as 
individuals and organisations providing this data may have a preferred option especially if they 
perceive the collection of this type of data as being a burden. Resource use quantities gathered 
over the course of the study can be collated into a microcosting spreadsheet in a time stamped 
computer. An example on how this data could be presented is provided in Appendix E.2. 
 
Item 5. How can health and social care resource use be measured? 
It is advisable that this data is captured at the same baseline and follow up time points as the 
effectiveness evaluation. In the UK, methods for extracting resource use data from primary and 
secondary electronic medical records are expensive and underdeveloped. It is therefore advised 
that at a minimum, a self-report questionnaire is used to collect health and social care data. 
Questionnaires are inexpensive and can be easily incorporated into the questionnaire booklet for 
the effectiveness evaluation. The self-report questionnaire presented in Appendix B.1 is 
recommended as it has been successfully applied in practice to a PA and SB trial. The structure of 
the questionnaire is based a validated healthcare utilisation questionnaire called the Client Service 
Receipt Inventory (CSRI) (Beecham and Knapp, 1999). Adaptations to the original questionnaire 
include the addition of definitions for the secondary health care questions (e.g. defining inpatient 
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care) so as to support participants interpretation of the questions. A range of health and social care 
professionals are included in the primary care section of the questionnaire. Nonetheless, if there is 
a need to shorten the questionnaire (e.g. due to participant burden or limited resources), then the 
following types of primary care consultations can be prioritised as preliminary evidence (from 
Chapter 4 and 5) indicates these are the most commonly used primary care professionals amongst 
physically inactive and highly sedentary individuals: GP, Practice Nurse, Counsellor and 
Physiotherapist. 
 
It is beyond the scope of this SOP to advise on how a decision-analytical model could be 
developed for PA/ SB interventions. If time and resources are limited, an alternative could be for 
the health economist to add resource use variables to a logic model. Logic models are increasingly 
cited in the public health literature. In brief they are designed to encourage researchers to consider 
how inputs, activities, outputs and outcomes. Outcomes are typically broken down in to short-, 
medium- and long-term outcomes. This degree of detail on resource use is not typically 
incorporated in logic models presented in the effectiveness evaluation. It is possible that this may 
be related to the observation that health economists are not usually involved in the development of 
a logic model. 
 
Item 6. How can participant-related resource use be measured? 
It is recommended that participant resource use data is captured through self-report methods and 
at the same data collection time points as the effectiveness evaluation. The participant cost 
questionnaire presented in Appendix B.1. may be helpful for capturing this data. This questionnaire 
is based on a pre-existing self-report questionnaire (Wordsworth and Thompson, 2001) retrieved 
from the Database of Instruments for Resource Use Measurement (DIRUM) and has been adapted 
to include examples of resource items related to PA/ SB interventions. The DIRUM database is a 
relatively new initiative by a group of trial-based health economists in the UK who aim to share 
measurement tools they have designed and applied to trials from various disease areas. At 
present, there is a lack of tools on DIRUM which have been applied to the context of individual-
level PA and SB interventions. At minimum it is helpful to ask participants to estimate on average, 
the following:  
1. time they spent taking part in and travelling to the PA/SB intervention, and whether this 
time represented an opportunity cost (i.e. did they give up leisure activities or incur a loss 
of earnings in order to take part which is deemed more valuable that the intervention) 
2. whether their participation in the intervention led to a change in expenses (e.g. they 
purchased trainers, parking expenses, gym membership). As PA and SB are multi-
dimensional behaviours it is also helpful to request that the participants report the units 
alongside the expenses they report. More specifically, units can be requested by asking 
the participants to report the following information (examples can also be provided to 
support the participants understanding): type of purchase (e.g. swimming session), the 
duration of purchase (e.g. 30 minutes of swimming) and the frequency (e.g. 5 times per 
month for three months). These questions align with the FITT framework from the PA and 
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SB literature which request PA and SB is described in terms of frequency, intensity, time 
(duration) and type (Barisic et al. 2011) 
3. whether participation led to an increase or decrease in absenteeism and presenteeism 
which in turn led to an increase or decrease in income for the participant (i.e. this question 
may be most relevant for participants employed through casual and/or temporary 
contracts).   
 
Item 7.  How can employer-related resource use be measured? 
If the intervention is not delivered in a workplace setting, the most efficient way to collect data on 
productivity from the employer’s perspective is likely to be from the participant’s self-report 
questionnaire. More specifically, the question which asks the participant whether they missed time 
in work due to participating in the intervention and whether this work time lost was a loss in 
earnings for the participant or employer. 
 
If the intervention is set in the workplace, then gain or loss in productivity as a result of staff 
participating in the intervention can be captured through a range of methods. Firstly, productivity is 
a multi-dimensional activity including the two broad dimensions absenteeism and presenteeism. It 
is recommended that the health economist and trial team work together to decide on what 
productivity measures are most appropriate. There is a range of validated questionnaires available 
in the clinical effectiveness literature for capturing absenteeism and presenteeism. By contrast, 
there is a lack of consensus in the health economic literature on how to incorporate productivity into 
economic evaluations and a lack of guidance on how to collect objective absenteeism data. 
Therefore, in the absence of consensus and guidance, the most appropriate approach is likely to 
be one where a range of data sources are explored early on during the trial so as the best quality 
data source can be prioritised for the remainder of the study. Quality is likely to be determined by 
the completeness of the data. Early on during the trial it is advisable that the health economist and 
trialists see if it possible to access a sample extract of the company’s electronic absenteeism 
records. Similarly, it is recommended that the completeness of the self-reported absenteeism and 
presenteeism questionnaires are also monitored early on.  
 
Item 8. How can resources be valued? 
This SOP focusses on the first step in the costing process which is the measurement and 
quantification of resource use (see example in Appendix E.2). It is helpful to present means and 
standard deviations for resource use data reported as continuous data (see example in Appendix 
E.3). If sample sizes are large enough it is advisable that the summary results are presented for the 
following equity subgroups: socioeconomic status, age, sex, medical condition. 
Item 9. How can summary data can be presented? 
Incremental differences between groups can be presented for each resource and outcome 
variable. In addition, it is recommended that means and standard deviations are reported for all 
continuous variables and proportions are reported along with the numerator and denominator for all 
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categorical variables. It may be helpful to display the summary resource use data in tabular form in 
accordance to the perspective they relate to. This table could resemble the format used for cost-
consequence balance sheets (an example of the resource use table is provided in Appendix E.3).  
Item 10. How can equity be incorporated into the analysis? 
As equity is a key objective of public health trials, it is helpful to pre-specify which characteristics 
will be explored through subgroup analyses (also referred to as an equity subgroup analysis). It 
may be helpful to refer to the PROGRESS-Plus checklist from the public health literature (O’Neill et 
al. 2014). In particular, it may be helpful to focus on characteristics which have been most 
commonly assessed across other studies from the field of PA/SB, these include: age, sex, 
socioeconomic status and pre-existing medical condition. It is recommended that the health 
economist and trialist collect this data at baseline alongside the other demographic data (e.g. via 
the participant’s questionnaire booklet). A key method used in public health practice for capturing 
socioeconomic status in the UK is by collecting data on postcode or place name. Postcode or place 
name data can be input into the Index of Multiple Deprivation (IMD) database (Department for 
Communities and Local Government, 2015) in order to interpret whether a person lives or works in 
an area of high deprivation. If it is deemed inappropriate to collect postcode or place names, 
alternative definitions for socioeconomic status could be used such as level of education, 
employment type.  
Item 11. How can the study results be interpreted? 
Observational notes and informal conversations (ethnographic data) gathered throughout the trial 
period can be reflected on during the trail. It is recommended that the health economist and trialists 
informally meet as a team to reflect on why methodological choices were made. These reflections 
can add contextual information to the study’s discussion around the generalisability of the results. 
As discussed in item 1, the nine domains of the PRECIS-2 tool may help the trial team work 
through the trial’s characteristics and reflect on whether they believe the findings are 
generalisability to other settings in the UK and transferable to other countries outside of the UK. For 
discussions on transferability it may be helpful to consideration of the funding and organisational 
structure of the multiple sectors involved in the PA/SB intervention. For example, in the UK health 
and social care is free at the point of use and publicly funded through tax.   
Item 12. How can resource use evidence be disseminated?  
It is advisable that the resource use data is displayed alongside the outcome data from the 
effectiveness evaluation. This could be either in main either in the main manuscript, journal 
companion paper or supplementary material.  
Item 13. How can the resource use evidence be used to support public health practice and 
research?   
Firstly, the disaggregated resource use evidence can be used to support immediate local 
government’s public health decisions about the likely resource implications of implementing an PA/ 
SB intervention. This is appropriate in the UK, since trial-derived resource use evidence is scarce, 
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yet there is the demand for this data amongst public health decision makers who operate of short-
term budgets. Secondly, the resource use data can feed into a full trial- and/or model- based 
economic evaluation. This can be done by the health economist carrying out the second step in 
costing after resource use measurement, which involves the assignment of unit costs to resource 
use items. Lastly, researchers involved in the development and design of interventions can use the 
resource use data to explore trends in levels of resource use and outcomes. The APEASE 
framework is a key tool from the behaviour change and implementation science literature (Michie et 
al. 2014). APEASE recognises that intervention design is more than effectiveness and recognises 
that the social context in which an intervention operates is also important. More specifically, the 
APEASE framework is designed to encourage researches to collect evidence on other factors such 
as affordability, practicability, acceptability and equity. Resource use data collected in accordance 
to this SOP can provide evidence to inform these specific factors.  
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7.1. Wider implications 
7.1.1. Implications for policy  
The framework supports the generation of resource use (economic) data. This type of data is in 
high demand amongst public sector decision makers within many countries (Frew et al., 2018). 
There is widespread interest in economic data with the number of trials collecting economic data 
increasing (Ramsey et al., 2015). In the public sector, year on year the demand for cost data 
continues to grow (Curtis and Burns, 2018). Reasons for this include the fact that in a number of 
countries public sector budgets are tighter and healthcare demand is increasing (Weatherly et al., 
2014). In the UK, it is reported that Public Health Directors are ‘hungry’ for economic evidence on 
the short-term economic impact of the preventative interventions they commission (Willmott, 
Womack, Hollingworth, & Campbell, 2016). In the UK, there has been increased interest in 
improving costing methods, with the National Cost Collection (NCC) programme moving away from 
reference costs to patient-level costing (NHS improvement, 2019). Trueman and Anokye (2013) 
refer to CUA as a ‘powerful common currency tool’ for decision-makers, but point out that the level 
of detail provided in CCAs is more likely to be desirable to local level public health commissioners 
and non-health decision-makers. Overall, real-world decisions around behaviour change 
interventions are not just about effectiveness and cost-effectiveness, but about if the intervention is 
affordable, equitable, acceptable, practical and safe (Michie et al., 2014). Good economic 
evaluations depend on the collection and presentation of robust data. Outside the academic world, 
public and third sector agencies who have to make inevitable resource allocation decisions are 
drawing on other methodologies (e.g. SROI and break-even analysis) in order to understand value. 
The SROI methodology is growing rapidly, despite the approach’s academic validity being 
questioned (Fujiwara, 2015). Similarly, there is concern about the fact these novel economic 
methodologies have not undergone the same peer review process as happens with academic 
papers (Svistak and Pritchard, 2018). Overall, the framework enables the collection and 
presentation of resource use and quality of life evidence to become more commonplace. 
Policymakers can use the evidence generated through the framework, to inform their unavoidable 
resource allocation decisions, which they make on behalf of the population. In turn, the evidence 
has the potential to make the policymakers more accountable for their decisions, which encourages 
transparency.      
7.1.2. Recommendations for future research 
7.1.2.1. Piloting the framework with other researchers 
One way to refine the frameowkr further could be to conduct an RCT of the framework itself. One 
randomised group of trialists with no or limited experience of health economics, could be asked to 
apply the refined framework to a future upcoming trial, while a control group could be asked to 
conduct their trials as usual. A questionnaire could be disseminated to quantify how many and 
which items on the framework they adopted for the group using the framework. In addition, both the 
trialists using the framework and the control group could be asked about whether they used any 
other tools to support them in collecting and presenting resource use data. Focus groups and 
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interviews could also be done to see how practical the trialists found the framework and the 
presentation of the resource use data in the publications could be compared. The content of the 
publications could also be reviewed to see if the trialists applying the framework have reported 
resource use quantitatively alongside their effectiveness data. Further piloting can be done if only 
minor adjustments are required, or if more major adjustments are needed, a Delphi study could be 
done with a larger sample of trialists from around the UK, to help reconsider the design of the 
framework. 
7.1.2.2. Measurement tools for resource use 
More research is needed to develop the tools used to measure resource use since there are many 
limitations reported for the existing tools. Length of the questionnaire can influence uptake. This 
was suggested as a reason for the lack of update of the annotated patient cost questionnaire 
(Thorn et al., 2018, Thompson and Wordsworth, 2001). GP records have been found to provide 
more reliable estimates on visits to health professionals in GP surgeries (e.g. the GP and Practice 
Nurse) compared to patient-recall (Byford et al., 2007). However, in the same study it was found 
that GP records generated less reliable estimates on visits to primary and community care health 
professionals outside of GP surgeries, and secondary care services. Although there are concerns 
around patient recall bias, one review found that there was good agreement between patient self-
report data and medical records (Ridyard and Hughes, 2015). Self-report methods are still the 
preferred option for resource use data in economic evaluations in England (especially if secondary 
care is not a major cost) due to the time-consuming data extraction periods and the data sharing 
agreements associated with electronic datasets (Franklin and Thorn, 2019). An additional, problem 
with patient self-report measures is that they have been found to be prone to recall bias (Jessep et 
al., 2009) and patients do not reportedly know which specific type of health professionals they have 
seen (Thorn et al., 2018). One study found that patients did not know what the term ‘Practice 
Nurse’ means, the authors argue that definitions need to be provided alongside this (Byford et al., 
2007). A strength of the healthcare utilisation questionnaires used in the SLaMM and Co-PARS 
trial was that they were modified to include definitions for outpatient, inpatient and day case 
hospital visits. Future measurement tools should also include definitions to help participants 
understand the type of primary or secondary healthcare you are interested in. 
7.1.2.3. Microcosting 
Although microcosting is the preferred approach to costing, analysts have typically combined 
different levels of costing and thus different levels of accuracy within a single study. This is due to 
the lack of resource use data available (Mogyorosy and Smith, 2005). The authors argue that 
bottom-up approaches are likely to be more accurate for complex interventions since the input mix 
of resources is complex. Future studies should continue to collect more accurate resource data on 
the interventions they are delivering. Collecting just resource quantities may reduce the expensive, 
high researcher burden and practical challenges of microcosting (Mogyorosy and Smith, 2005). It 
has been reported in a key review that interventions are poorly described in the literature 
(Hoffmann et al., 2014). The review found the materials used in the delivery of an intervention are 
the most commonly omitted piece of information when researchers describe their interventions. 
This makes it challenging for others to replicate this intervention in their own setting. That is to say, 
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until valid and reliable standardised microcosting tools are available, data collection tools may need 
to be tailored to the intervention staff’s preferences in order achieve good completion rates 
(Hughes et al., 2016). In addition, a recommendation from this thesis is that completion of the 
objective absenteeism data should be assessed prior to the start of the trial, so additional self-
report measures can be included whereby participants are asked to report the number of sick days 
they have had over the desired time point. 
7.1.2.4. Quality of life measurement tools 
The EQ-5D tool was the most commonly used tool to measure QALYs in the studies reviewed in 
Chapter 2, and in the wider literature. Nonetheless, the EQ-5D only captures the functional health 
of an individual. Future studies could use other recently developed quality of life tools such as the 
ICECAP-A (Al-Janabi et al., 2012, Al-Janabi et al., 2013, Flynn et al., 2015), which has been 
designed to capture capability in a broader sense, beyond functional health. Another solution is for 
analysts to agree on a tool which crosswalks between PA outcomes and a summary tool like the 
EQ-5D. There is currently a mapping database of studies that map the EQ-5D tool to other 
outcomes measures (Dakin et al., 2018). No studies on the database have mapped a PA specific 
tool to the EQ-5D; future research should address this gap. 
7.2. Interdisciplinary researcher 
This PhD project provided me with the opportunity to train in a new discipline, health economics. It 
also provided me with the opportunity to build on my existing discipline-specific knowledge in public 
health and anthropology. In particular, I believe this PhD project has enabled me to develop the 
practical skills and knowledge on how to identify and measure resource use relevant to PA and SB 
trials. More specifically, I have improved my skills in working with different types of stakeholders 
(e.g. staff from the local authority, leisure centre, workplace and the participants) as well as 
researchers with different disciplinary backgrounds (public health researchers, exercise science 
experts, physiologists, psychologists, trialists and health economists). The meetings and informal 
conversations I had with these various stakeholders and researchers made me aware of how 
important these relationships are for understanding and mapping out what resource use is relevant 
and for gaining an insight on how resource use can be measured and quantified in PA and SB 
trials. Furthermore, over the last three years, I feel I have becoming increasingly more confident 
and skilled in articulating health economic, public health and anthropology concepts. This skill 
developed as a result of the range of multi-stakeholder and multidisciplinary meetings I arranged 
throughout this PhD. This is also evident through the definitions I provide in my SOP which are 
intended to support multidisciplinary learning. Throughout this PhD, I handled both self-report 
resource use data (e.g. intervention costs, healthcare utilisation, participant out-of-pocket and 
productivity loss) and electronic absenteeism data (e.g. company records). I believe this PhD has 
strengthened my awareness and knowledge on the strengths and limitations of using different data 
collection approaches in the measurement of resource use for PA and SB trials. My training in 
health economics also raised my awareness of the concept opportunity cost. This is a concept that 
is not commonly discussed in the public health literature which is surprising since it is relevant to 
the types of decisions and trade-offs national and local public health decisions-makers frequently 
made on behalf of the others. 
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7.3. Novel contributions of the thesis 
There are four novel contributions of this thesis, these include: 
• My development as a true interdisciplinary researcher. More specifically, I have trained in 
health economics so as I can make an important interdisciplinary contribution to the field of 
public health economics. I have demonstrated how my knowledge in public health and 
anthropology has contributed to the studying of complexity within PA and SB trials.      
• My systematic review provides an update on how analysts are addressing the four 
methodological challenges associated with economic evaluations of individual-level PA/ SB 
interventions. 
• I present a SOP to support early career health economists to identify, measure and present 
resource use in a systematic way alongside individual-level PA and SB trials. Presently, 
the trial unit I work at does not have a SOP for identifying and measuring resource use 
data for complex public health trials, including individual-level PA and SB trials. I intend to 
apply my SOP to future PA and SB trials and disseminate it amongst other early career 
health economists.  
• The SOP can be used as an interface to improve understanding and communication for 
multidisciplinary trial teams. In particular, the SOP can be an interface between the health 
economist and members of the trail team who do not have expertise in health economics. 
7.4. Conclusion 
Trials evaluating the impact of PA and SB interventions rarely collect and present economic data 
alongside their effectiveness results. The overarching aim of this PhD was to develop a 
multidisciplinary and pragmatic framework to support researchers carrying out trial-based economic 
evaluations for individual-level PA and SB interventions. Three studies, a systematic review and 
two PA and SB economic evaluations, were carried out to specifically address this aim. A unique 
feature of these studies was the reflective content embedded throughout. The reflective content 
describes in detail the interdisciplinary actions I took in order to develop and implement a 
multidisciplinary and pragmatic framework. Methods of narrative synthesis were used to organise 
the reflective content from this thesis in order to consider how the practicability of the framework 
could be improved. The narrative synthesis shed light on how the framework could be refined to 
support early career health economists to tackle on the ground some of the complexity involved in 
the identification and measurement of resource use in PA and SB trials. In order to promote 
multidisciplinary working in PA and SB trials, the final framework is presented in the form of a SOP 
which can be read by all key members of the trial team. In particular, the SOP can act as an 
interface between the health economist and other trial team members in order to improve 
communication across the multiple disciplines in which the fields of PA and SB cut across. 
Importantly, SOP is expected to improve the practicability, consistency, transparency and efficiency 
of the identification and measurement of resource use alongside individual-level PA and SB trials.   
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Appendix A.1. Search strategy 
Example of search strategy in Medline (Jan 2009- March Week 1 2017) 
MEDLINE Ovid Jan Week 1 2009-March Week 1 2017 
Search Terms Type Results Justification 
1 exp exercise/ Controlled 
vocabulary 
 
153597 • Used in Cochrane Review (likely to be informed by information specialist): 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008366.pub3/full  
• Exploded as specific terms look relevant 
2 exp physical fitness/ Controlled 
vocabulary 
 
25466 • Used in Cochrane Review(likely to be informed by information specialist): 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008366.pub3/full  
• Exploded as specific terms looked relevant 
3 *Exercise therapy Controlled 
vocabulary 
 
22422 • Used in BMJ SR on PA brief interventions: 
http://bjsm.bmj.com/content/early/2015/10/05/bjsports-2015-094655.full  
• Focused the search (*) as description of term was not wholly relevant 
4 “Physical Education and Training” Controlled 
vocabulary 
 
13386 • Used in Cochrane Review(likely to be informed by information specialist): 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008366.pub3/full  
• Did not explode as no specific terms available 
5 Recreation/ OR Dancing/ OR 
Gardening/ OR Hobbies/ OR exp “Play 
and Playthings”/ OR exp Sports/ OR 
exp Relaxation  
Controlled 
vocabulary 
 
192825 • Used in Cochrane Review(likely to be informed by information specialist): 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008366.pub3/full 
• Exploded where specific terms and definition/or were relevant 
6 Physical exertion Controlled 
vocabulary 
 
55942 • Used in BMJ SR on PA brief interventions: 
http://bjsm.bmj.com/content/early/2015/10/05/bjsports-2015-094655.full 
• Did not explode as no specific terms 
7 Life style/ OR healthy lifestyle/ OR 
sedentary lifestyle 
Controlled 
vocabulary 
 
55760 • Typed in sedentary and lifestyle came up 
• Did not explode life style as not all specific terms were relevant  
8 OR/ 1-7 OR 368620 • Combined controlled vocabulary related to PA and SB 
9 (start* or sustain* or maintain* or 
promot* or uptak* or increas* or 
Free text 
 
8669486 • Terms taken from Cochrane Review and BMJ article 
• Some terms from online thesaurus 
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improv* or adher* or encourag* 
prevent* or reduc* or decreas* or 
discourag* or chang*) ab,ti. 
10 8 AND 9 AND 206888 • Combined controlled vocabulary terms for PA with free text terms related to increase/ 
decrease 
11 ((start* or sustain* or maintain* or 
promot* or uptak* or increas* or 
improv* or adher* or encourag* 
prevent* or reduc* or decreas* or 
discourag* or chang*) adj3 (inactiv* or 
activ* or exercis* or fit* or gym* or 
desk* or station* or sit* or sedentary or 
stand* or sport* or walk* or lifestyle* or 
life-style*)).ab,ti. 
Free text 670297 • Terms taken from Cochrane Review and BMJ article 
• Some terms from online thesaurus 
12 10 OR 11 OR  811698  
13 Exp Economics/ Controlled 
vocabulary 
548321 • Used in BMJ SR on PA brief interventions: 
http://bjsm.bmj.com/content/early/2015/10/05/bjsports-2015-094655.full 
14 Exp “Costs and Cost Analysis”/ Controlled 
vocabulary 
208732 • Controlled vocabulary 
• Exploded as done in BMJ article and includes relevant specific terms e.g. Cost Allocation, 
Cost-Benefit Analysis 
15 Exp models, economic/  Controlled 
vocabulary 
12614 • Controlled vocabulary 
• Exploded as done in BMJ article 
16 (cost* or money* or pric* or economic* 
or budget*) adj2 (effect* or benefit* or 
utilis* or utilit* or valu* or consequence* 
or minim* or evaluat* or analys* or 
apprais* or assess* or model*) ab,ti. 
Free text 140074 • Controlled vocabulary 
• Terms used in BMJ article and Economic Evaluation SR PHI (2016) 
• Some terms from online thesaurus 
17 OR/13-16 OR 625912 • Combined controlled vocabulary and free text terms for economics 
18 12 AND 17 AND 10522 • Combined PA and SB terms with economics 
19 Add limits: English, 2009- March Week 
2 2017, Humans 
Limits 4,120  
 
 
 
Appendix A.2. Updated scoping search 
A description of the search conducted is described below. Results of the updated searches are 
presented in the Figure 1 (PRISMA flow diagram). Four studies met the inclusion criteria and are 
presented in Table 1. Notably, one study presented in Table 1 is an economic evaluation of a SB 
intervention. The remaining three studies compare PA interventions.  
Amendment to limits in Medline (Ovid) Database: 2017- Jan Week 2 2019.  
 
Figure 1. PRISMA flow diagram of study select for updated search (March Week 3 2017-January 
Week 2 2019) 
Database searching 
The nine studies retrieved in the original database searching are listed below, all nine came from 
the Medline Database. This provided the rationale to only rerun the updated search in Medline.  
iv. Elley et al. (2011): Medline 
v. Boehler et al. (2011): Medline 
vi. Pavey et al. (2011): Medline 
vii. Anokye et al. (2011): Medline 
viii. Edwards et al. (2013): Medline 
ix. Young et al. (2012): Medline 
x. Iliffe et al. (2014): Medline 
xi. Larsen et al. (2015): Medline 
xii. Maddison et al. (2015): Medline 
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Supplementary searching: Key websites 
The only websites successful at identifying relevant studies in the original search where the NIHR 
and NICE evidence websites. These two sites were examined for the updated search (2017-2019). 
The following study was identified on the NIHR website in the Health Technology Assessment 
Journal, using the search term “PA”: 
Harris T, Kerry S, Victor C, Iliffe S, Ussher M, Fox-Rushby J, et al. A pedometer-based walking 
intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-
arm cluster RCT. Health Technol Assess 2018;22(37) 
NICE evidence, searching “PA” (first 10 pages) 
Relevant, but already retrieved from NIHR website 
Harris T, Kerry S, Victor C, Iliffe S, Ussher M, Fox-Rushby J, et al. A pedometer-based walking 
intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-
arm cluster RCT. Health Technol Assess 2018;22(37) 
Excluded due to focus being on population level 
PA and the environment: guidance (NG90). Source:  National Institute for Health and Care 
Excellence - NICE - 22 March 2018. This guideline covers how to improve the physical 
environment to encourage and support PA. The aim is to increase the general population’s PA 
levels. 
Health economic assessment tool (HEAT) for walking and for cycling. Methods and user guide on 
PA, air pollution, injuries and carbon impact assessments (2017) [PDF]. Source:  WHO Regional 
Office for Europe - WHO Europe - 10 November 2017 
Supplementary searching: Key authors 
Economic evaluations of targeted SB interventions were searched for via the Google search 
engine. These included the economic evaluation for key SB interventions: the Stand More at Work 
intervention in the UK, the Stand More at Work intervention in the US, and the Stand Up Victoria 
intervention in Australia. Only one economic evaluation was found: 
Scandinavian Journal of Work Environment and Health 2018;44(5):503-511 
doi:10.5271/sjweh.3740. Economic evaluation of a randomized controlled trial of an intervention to 
reduce office workers’ sitting time: the "Stand Up Victoria" trial by Gao L, Flego A, Dunstan DW, 
Winkler EAH, Healy GN, Eakin EG, Willenberg L, Owen N, LaMontagne AD, Lal A, Wiesner GH, 
Hadgraft NT, Moodie ML 
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Appendix A.3. Data extraction form 
Data extraction form template 
1. Study & intervention characteristics 
Author & Year 
Reviewer 
Date Reviewed 
Record no. from Endnote 
Title  
Journal/ Source 
Perspective 
Vehicle 
Intervention 
Brief description of intervention 
Comparators 
Brief description of comparators 
Eligible population 
Subgoup population 
Geographical location 
Setting 
Sample size 
Follow up length of primary data 
Duration of effect 
Time horizon 
Technique  
Discount rate 
Currency 
Price year 
Additional info  
2. Short term effects in EE 
Short term effects identified for EE 
Definition of change in PA 
Measurement tool for PA  
Measurement tool for HRQoL 
Measurement tool for other effects in EE (PVO2) 
Follow up period of primary data 
How are short-term effects expressed? 
Additional info 
3. Long-term effects in EE 
Perspective  
Long-term outcomes identified for EE or CCA 
Data source for long-term effects 
Duration of effect 
Time-horizon 
How are long-term effects expressed 
Additional info 
4. Costs 
Perspective 
Cost categories 
Follow up period for primary data  
Data source  
Additional info 
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5. Results & Sensitivity 
Reporting of results 
Base case results 
Assessment of uncertainty 
Key results reported from uncertainty assessment 
Additional info 
6. Equity 
Equity considerations 
Additional info 
7. Strengths & Limitations reported by author  
 
 
 
 
 
Appendix A.4. Quality Assessment  
Table 1: Drummond’s Checklist Quality Assessment Items 1-5
Study Q1. Was a well-defined 
question posted in an 
answerable form? 
Q2 Was a comprehensive 
description of the competing 
alternative given? (i.e. can 
you tell who did what to 
whom, where, and how 
often?) 
Q3 Was the effectiveness of 
the programmes or services 
established? 
Q4 Were all the important and 
relevant costs and 
consequences for each 
alternative identified? 
Q5 Were costs and consequences 
measured accurately in appropriate 
physical units prior to valuation (e.g. 
hours of nursing time, number of 
physical visits, lost work-days, 
gained life-years)? 
de Vries et al. 2016 Yes Yes Yes No, societal perspective 
stated, health sector costs 
included only 
Yes 
Pavey et al. 2011 Yes Yes Yes Yes Can’t tell, but reference for 
secondary source provided  
Anokye et al. 2012; 
Anokye et al. 2014 
Yes Yes Yes Yes Can’t tell, but reference for 
secondary source provided  
Larsen et al. 2015 Yes Yes Yes Yes Yes 
Maddison et al. 2015 No, perspective not stated Yes Yes Can’t tell, perspective not 
stated 
Can’t tell, disaggregated costs not 
presented 
Iliffe et al. 2014 Yes Yes Yes Yes Yes 
Edwards et al. 2013; 
Murphy et al. 2012 
Yes Yes Yes Yes Yes 
Anokye et al. 2011 Yes Yes Yes Yes Can’t tell, but reference for 
secondary source provided  
Elley et al. 2011 Yes Yes Yes Yes Yes 
Shaw et al. 2011 No, perspective not stated Yes Yes Can’t tell, perspective not 
stated 
Yes 
Over et al. 2012 Yes Yes Yes Yes Yes 
Campbell et al. 2015 Yes Yes Yes Yes Can’t tell, but reference for 
secondary source provided  
Boehler et al. 2011 Yes Yes Yes No, health sector perspective 
stated, indirect change in 
healthcare utilisation not 
included 
Yes 
Leung et al. 2012 Yes Yes Yes Yes Yes 
Young et al. 2012 Yes Yes Yes No, societal perspective 
stated,  health sector costs 
included only 
Yes 
 
 
 
Table 2: Drummond’s Checklist Quality Assessment Items 6-10 
Study Q6 Were costs 
and 
consequences 
valued credibly? 
Q7 Were costs and 
consequences adjusted 
for differential timing? 
Q8 Was an incremental 
analysis of costs and 
consequences of 
alternatives performed? 
Q9 Was uncertainty in 
the estimates of costs 
and consequences 
adequately 
characterised? 
Q10 Did the presentation 
and discussion of study 
results include all issues of 
concern to the users? 
Number of items 
scored ‘No’ 
de Vries et al. 2016 Yes Yes Yes Yes Yes 1 
Pavey et al. 2011 Yes Yes Yes Yes Yes 0 
Anokye et al. 2012; 
Anokye et al. 2014 
Yes Yes Yes Yes Yes 0 
Larsen et al. 2015 Yes Yes Yes Yes Yes 0 
Maddison et al. 2015 No, price source 
not stated 
Yes Yes Yes Yes 2 
Iliffe et al. 2014 Yes Yes Yes Yes Yes 0 
Edwards et al. 2013; 
Murphy et al. 2012 
Yes Yes Yes Yes Yes 0 
Anokye et al. 2011 Yes Yes Yes Yes Yes 0 
Elley et al. 2011 Yes No, two year follow up Yes Yes Yes 1 
Shaw et al. 2011 Yes Yes Yes Yes Yes 1 
Over et al. 2012 Yes Yes Yes Yes Yes 0 
Campbell et al. 2015 Yes Yes Yes Yes Yes 0 
Boehler et al. 2011 Yes Yes Yes Yes Yes 1 
Leung et al. 2012 Yes Yes Yes Yes Yes 0 
Young et al. 2012 Yes Yes Yes Yes Yes 1 
 
 
 
Appendix A.5. Supplementary searches 
Table 1. Supplementary searches: grey literature  
Websites Date searched No. new 
studies 
NIHR Public Health  02.06.2017 1 
NICE (evidence search) 02.06.2017 1 
International Society for Pharmoeconomics and Outcomes Research (scientific 
presentations database) 
05.06.2017 0 
Centre for Diet and Activity Research (publications database) 05.06.2017 0 
National Obesity Observatory (National Archives Gov.UK) 05.06.2017 0 
Gov.UK 05.06.2017 0 
Fuse.ac.uk 05.06.2017 0 
DECIPHer (Development and Evaluation of Complex Interventions for Public 
Health Improvement) 
05.06.2017 0 
UK Economic and Social Research Council  05.06.2017 0 
Publications from School of Sport, Exercise and Health Sciences at 
Loughborough University 
05.06.2017 0 
Centre for Excellence (Northern Ireland) 05.06.2017 0 
Centre for Disease Control and Prevention (US gov) 05.06.2017 0 
http://www.greylit.org/home  07.06.2017 0 
http://www.opengrey.eu/ 07.06.2017 0 
Reference lists of systematic reviews Date searched No. new 
studies  
Vijay et al., 2016 07.06.2017 2  
Wu et al., 2011 07.06.2017 0 
Protocol search for completed study Date searched No. new 
studies  
de Vries et al., 2013 07.06.2017 1 
Kolt et al., 2009 07.06.2017 1 
 
 
 
Appendix B.1. Cost measurement tools 
Table 1. Cost items and measurement tools 
Study  Leung et al. (2012) Larsen et al. (2015) Illiffe et al. (2014) Edwards et al. (2013)  Elley et al. (2011) Over et al. (2012) Isaac et al. (2007) 
used by Campbell 
et al. (2015), 
Payey et al. 
(2011), Anokye et 
al. (2011) 
Perspective Public health system 
and participant  
Payer  NHS (also collect 
participant/private 
costs) 
Multi-agency public 
sector  
Societal  Health care Societal  
Intervention costs 
Data collection 
method 
Not reported Not reported Study trial records Budget breakdown of 
13 ERS from Welsh 
Government; 
Telephone interviews 
with NERS 
programme directors 
at WG and leisure 
centre managers to 
capture additional 
operating and set up 
costs 
Study trial records Bottom-up costing 
of theoretical 
intervention; Not 
primary data 
Microcosting 
exercise based on 
planned 
intervention 
sessions 
Room hire  Not reported Not reported Hall hire  LA annual operating 
costs= room hire  
Not reported Not reported Not reported 
Equipment  Not reported Pedometer  
Computer 
Printer 
Scanner 
Scanner software 
Software for updating 
the expert system  
Printed booklets  
Scanner paper 
Binders 
 
Refreshments 
Mats 
Resistance bands 
Instruction booklet 
 
National annual 
operating costs= 
printing and stationary 
LA authority annual 
operating costs= 
promotional material 
Not reported Pedometer with 
electronic diary 
Facilities (not 
described 
however) 
Staff time and salary Common costs for 
coordinating 
programme and 
telephone counselling 
excluded 
GP visits 
Trainer salary (with 
44% fringe benefits 
and 10% overheads) 
Research assistant 
salary (with 44% fringe 
benefits and 10% 
overheads) 
Community 
physiotherapist 
salary (including 
preparation, clear-
up and travel time) 
National annual 
operating costs= 
Salary of PA specialist 
(0.8 WTE) 
Salary Line 
Management Grade 7 
(0.02 WTE) 
Time spend 
delivering 
intervention 
Primary care 
nurse; 
Time spent on 
telephone support 
GP assistant 
approaching 
patients; GP 
checking PA level; 
GP counselling; 3x 
GP assistant follow 
up sessions  
Exercise trainers 
 
 
237 
 
Salary Executive 
officers (1.2 WTE) 
Meeting costs 
National resources 
Exercise professionals 
(36 WTE)  
Training 
Travel  
Joint national and local 
authority annual 
operating cost= 
coordinator salary and 
on-costs (13 WTE, 
50% funded by WG & 
LA) 
Local authority= Staff 
management, 
attending conferences   
 
by Regional sport 
trust staff 
Administrative 
support  
Not reported Postage of 
intervention material 
Postage of 
questionnaire with first 
class return stamp 
Not reported National annual 
operating costs: 
administration;  
Not reported Not reported Administrative 
support  
Set up costs 
Data collection 
method 
Not reported Not reported Not reported Budget breakdown of 
13 ERS from Welsh 
Government; 
Telephone interviews 
with NERS 
programme directors 
at WG and leisure 
centre managers to 
capture additional 
operating and set up 
costs 
 
Not reported Not reported Not reported 
Staff time and salary Not reported Not reported Not reported PA specialist 
(0.2 WTE in yr 1, 0.6 
WTE yr 2)  
 
Line Management 
(0.02 WTE yrs 1&2 
Grade 7) 
 
Not reported Not reported Not reported 
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Executive officer (0.2 
WTE yr 2) 
 
Local authority staff 
attending meetings 
 
Meetings Not reported Not reported Not reported Meetings Not reported Not reported Not reported 
Equipment Not reported Not reported Not reported Resources & printing; 
IT; Staff clothing; 
Promotion or 
advertising; Home 
working facilities 
Not reported Not reported Not reported 
Translation costs Not reported Not reported Not reported Translation costs Not reported Not reported Not reported 
Training 
for exercise 
professionals 
Not reported Not reported Not reported Exercise professionals 
training (Level 3) 
Not reported Not reported Not reported 
Pilot exercise 
referral project 
Not reported Not reported Not reported Costs incurred by WG 
for 
the 6 pilot areas in 
2006–07 are included 
as part of 
NERS development 
costs (£183,600). 
Not reported Not reported Not reported 
Healthcare utilisation 
Data collection 
method 
Quarterly diaries for 12 
months 
Not reported GP records 6 
months during 
intervention 12 
months follow up 
Knapp M, Beecham J. 
Costing mental health 
services: the client 
service receipt 
inventory. Psychol 
Med 1990;20:893-908; 
Baseline, 6 and 12 
months  
12 months before 
each assessment 
Not reported, as 
model using 
secondary data  
Case-note review 
of GP records 12 
and 6 months 
before and after 
the intervention 
start date 
Primary care 
contacts  
GP visits 
Physiotherapy visits 
Nurses 
Home help 
Other allied health 
professionals 
(acupuncturist, 
dietician, occupational 
therapist, podiatrist, 
social worker, and 
speech therapist) 
 Number of contacts 
with GP, Nurse, 
Out of hours 
service, other 
senior-level 
practitioners 
(community 
matron, specialist 
nurse, counsellor, 
pharmacist);, other 
middle-level 
practitioners 
(district nurse, 
GP consultation: in 
surgery; at home, 
telephone. 
Practice nurse 
consultation; 
Mental health 
professional  
GP visit non-
accident related; 
GP accident-
related; GP after 
hours. 
Visits to other 
health providers/ 
allied health 
therapy (e.g. 
physiotherapist, 
chiropractors, 
osteopaths, 
occupational 
GP checking PA 
level and 
counselling 
session; GP 
assistant 
approaching 
patient and 3 follow 
up sessions; 
GP visits 
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allied health 
professionals), 
lower-level 
practitioners 
(health-care 
assistant, support 
worker, 
phlebotomist, 
podiatrist): 
Contact at practice 
or Home visits or 
Telephone calls  
 
therapists, 
acupuncturists) 
including after 
hours.   
Pharmaceuticals 
prescribed 
Not reported Not reported Not reported Primary care 
prescribing 
Not reported Not reported Pharmaceuticals 
prescribed by GP 
Secondary care 
contacts  
Admitted to patient as 
inpatient  
Hospital specialist  
Hospital outpatient 
test/procedure  
Not reported Number of A&E 
visits for falls; 
Number of hospital 
admissions for 
falls; 
Number of inpatient 
nights for falls  
Outpatient consultant; 
Outpatient specialist; 
Outpatient 
Physiotherapist; 
Outpatient other 
hospital attendances; 
Day cases; 
Inpatient hospital days 
(all causes) 
A&E attendances  
Tests 
Inpatient hospital 
admissions; 
outpatient initial 
visit; outpatient 
follow up visit; 
emergency 
department visit 
Not reported Hospital 
admissions (day 
case and inpatient) 
Participant costs 
Data collection 
methods 
Recorded by 
participants in 
quarterly diaries for 12 
months 
Not reported Diary returns (six 
during the 
intervention, 4 in 
the subsequent 12 
month follow up 
period); Travel 
costs= At the end 
of the intervention 
(6months), 
participants asked 
usual method of 
getting to the class; 
At post intervention 
assessment asked 
what activity they 
had given up to 
attend the exercise 
classes.  
Self-completed 
questionnaire at 12 
months: 1 willingness-
to-pay (WTP) question 
for exercise classes;  
Self-reported face-
to-face 
questionnaire 
delivered by a 
research nurse at 
baseline, 12 
months and 24 
months (assessing 
12 months before 
each assessment) 
Not reported, as 
model using 
secondary data 
Self-completed 
questionnaire 10 
weeks follow up 
assessment 
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Out of pocket costs Sports equipment 
PA fees/ classes  
Not reported Clothes 
Equipment 
Gym membership 
Travel costs to 
exercise classes 
WTP per session Exercise costs: 
purchase of 
exercise or sports 
shoes, 
membership fees 
to exercise groups 
or gyms, costs of 
exercise groups or 
gyms, costs of 
exercise 
equipment. 
 
Transport/ travel 
costs to and from 
the location of 
exercise or PA 
 
Any other 
additional costs 
associated with 
exercise  
 
Not reported Equipment 
Childcare 
Travel cost 
Productivity cost Not reported Not reported Time given up to 
attend the classes  
Not reported Sick day leave 
Accident-related 
leave 
Not reported Time working or 
non-working 
Provider (leisure centre) 
Data collection 
methods 
Not reported Not reported Not reported Telephone interviews Not reported Not reported Not reported 
Provider productivity 
cost 
Not reported Not reported Not reported Loss in revenue Not reported Not reported Not reported 
 
 
 
Health care utilisation questionnaire 
It is very important that you try to answer every question. If you are unable to remember the 
exact answers, please try to estimate them as best you can. 
Primary Care Services 
Question 1: In the last X months, which of the following primary care services have you used for 
any reason (not including hospital appointments recorded in Question 5)? 
Please enter ‘0’ in the first row if you have not had any appointments in the last X months. 
Service Tick 
if 
YES 
Tick if 
paid for 
privately 
Number of 
appointments 
at the clinic/ 
office/ 
surgery in 
the last 6  
months? 
Number of 
appointments 
in your own 
home in the 
last 6 
months? 
Number of 
appointments 
over the 
telephone in 
the last 6 
months? 
On 
average 
how many 
minutes 
did you 
see/talk to 
them for 
each 
time? 
General 
Practitioner 
(GP) 
      
Practice Nurse       
Other allied health professionals 
Physiotherapist       
Chiropractor       
Osteopath       
Occupational 
therapist 
      
Acupuncturist       
Specialist 
Nurse 
      
District Nurse       
Counsellor       
Pharmacist       
Health-care 
assistant 
      
Support worker       
Phlebotomist       
Podiatrist       
Dietician       
Social worker       
Speech 
therapist 
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Mental health 
professional 
      
Other 
(describe) 
……………….. 
      
Other 
(describe) 
……………….. 
      
Other 
(describe) 
……………….. 
      
 
Question 2: Please list all medications you have taken in the last X months. Indicate what dose, 
how often it is taken, and how many weeks you took this medication/ has been taking it. Please list 
prescription medications only. 
Medication name Dose (mg) (if known) How many 
times per 
day 
For how 
many weeks? 
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Secondary care services 
Question 3: Hospital inpatient care: If you have stayed overnight in hospital in the last X 
months for any reason, please give details below about each stay. 
Please enter ‘0’ in the first row if you have not stayed in hospital in the last X months. 
Admissions Speciality of the ward you 
stayed in (e.g. general ward, 
surgical ward) 
Number of nights for each 
stay 
1st admission   
2nd admission   
3rd admission   
4th admission   
5th admission   
6th admission   
 
 
Question 4: Hospital outpatient care: If you have had any hospital outpatient appointments in 
the last X months for any reason, please give details below about each episode. 
Please enter ‘0’ in the first row if you haven’t had any appointments in the last X months. 
Outpatient department/ Consultant speciality 
(e.g. Rheumatology, Orthopaedic Surgeon, 
Pain clinic) 
Number of appointments in the last X months 
  
  
  
  
  
 
Question 5: Accident & Emergency visits: How many times have you visited a hospital accident 
and emergency department (A&E, casualty) in the last X months for any reason. 
Number of visits     …….. 
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Participant’s Cost questionnaire 
Background information 
In this questionnaire, we are trying to find out the costs to you for participating in the Exercise Referral 
Scheme. Unfortunately, we are unable to reimburse these costs. However, your answers are 
important because they will give people who make decisions about these services an idea of how 
much the scheme costs you.  
Please answer every question. If you are not sure or cannot remember the exact details, please give 
the best answer you can.  
 
Section A: Participant travel costs 
- Question 1:  
Over the last 12 weeks how many times have you attended an Exercise Referral Scheme 
consultation. Please write the number of times in the box below. Put zero if you have not attended 
an Exercise Referral Scheme consultation over the last 12 weeks for your consultations.  
Number of times ……….. (/max 4) 
If you answered 1 or more to the question above please continue to Question 2. Otherwise, skip to  
Section B. 
 
- Question 2:  
When you visited the leisure centre for your consultations, how did you normally travel? Please 
circle the number that best describes how you normally travelled from your home to the leisure 
centre for consultations. If you normally used more than one form of transport, please indicate the 
way you travelled for the main (longest in terms of distance) part of your journey.  
Walked .........................................................................1 
Cycled...........................................................................2 
Bus................................................................................3 
Train/metro..................................................................4 
Taxi...............................................................................5  
Private car.....................................................................6  
Motorbike ....................................................................7 
Other (please specify) ………………………..………8 
 
- Question 3:  
If you normally travelled by public transport (e.g. bus or train) for part or the entire journey, what 
was the cost of the one-way fare? Please write the cost in the box below. Put 0 if you did not 
normally travel by public transport at all or if you did not normally pay a fare.  
Cost of one-way fare (£)…....._ ……..pence  
If you normally travelled by taxi for part or the entire journey, what was the cost of the one-way 
fare? Please write the cost in the box below. Put 0 if you did not normally travel by taxi at all or if 
you did not normally pay a fare.  
Total cost of one-way fare (£)………_……..pence  
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If you normally travelled by private car or motorbike for part or the entire journey how many miles 
did you travel one-way? Please write the number of miles in the box below. Put 0 if you did not 
normally travel by private car or motorbike at all. 
Number of miles one-way………… 
If you normally travelled by private car or motorbike for part or the entire journey and had to pay 
tolls or parking fees how much did these amount to? Please write the cost in the box below. Put 0 if 
you did not normally travel by private car or motorbike at all or did not normally pay tolls or parking 
fees.  
Expenditure on tolls or parking fees (£)…………._………….pence  
 
- Question 4:  
When you visited the leisure centre, how long did it normally take to travel there from your home? 
Please write the number of hours and minutes in the box below.  
Number of hours……….._.............minutes 
 
Section B: Participant Time Costs 
Question 5:  
When you visited the leisure centre for your consultations, how long did you normally spend there? 
Please write the number of hours and minutes in the box below. Include in your answer the time you 
normally spent waiting and the time you normally spent with the Exercise Referral Practitioner.  
 
Number of hours………_........minutes 
 
 
- Question 6:  
What would you normally have been doing as your main activity if you had not gone to the 
Exercise Referral consultations? Please circle the number that best describes what you normally 
would have been doing as your main activity if you had not gone to the consultations. 
Housework................................................................. 1 
Childcare.................................................................... 2  
Caring for a relative or friend.................................... 3  
Voluntary work.......................................................... 4  
Leisure activities........................................................ 5  
Attending school or university.................................. 6  
On sick leave.............................................................. 7  
Seeking work ............................................................. 8  
Paid work................................................................... 9  
Other (please specify)…………………………...... 10 
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If you normally took time off from paid work (or business activity if self-employed) please continue 
with Question 7. Otherwise, go to Section C. 
 
- Question 7:  
If you took time off from paid work (or business activity if self-employed) to go to the consultations at 
the leisure centre approximately how much time did you normally take off work (or business activity 
if self-employed)? Please write the number of hours and minutes in the box below.  
Number of hours………_..........minutes 
Did you normally lose earnings as a result? Please circle the appropriate answer? 
Yes………………………….1 
No……………………………………….2 
 
What is your main occupation? 
…………………………………………………………………. 
 
Section C: Other costs 
- Question 8:  
In the last 3 months have you incurred any other costs because of taking part in the Exercise 
Referral Scheme (e.g. induction cost, purchasing gym membership, equipment and/ or clothing 
purchased because of participating in the intervention, paying for sessions)? 
Yes ...........................................................................................1  
No ............................................................................................2 
 
If yes, what were they for and how much did you spend? In the table below please write the 
purpose of other costs and the amount of money spent.  
Purpose Amount spent 
 £……-….p 
 £……-….p 
 £……-….p 
 £……-….p 
 £……-….p 
 
Do you have any further comments or any information you would like to add about the cost to you 
of coming to the leisure centre for the Exercise Referral Scheme? 
………………………………………………………………………………………………… 
………………………………………………………………………………………………… 
…………………………………………………………………………………………………
 
 
Interview Schedule_Additional operating and set up costs  
 
Cost effectiveness evaluation 
 
Interview/ Focus group Guide - Additional operating and setting up costs for Intervention Personnel (e.g. centre contact/ organisational gatekeeper, team leaders, 
movement champions) 
Section 1: Additional operating costs 
1: Have you incurred any additional operating costs because of running the workplace intervention (e.g. IT, equipment, attending meetings, promotion or advertising)? 
 
If yes, in the table below please write the purpose of the additional setting up costs and the amount of time or money spent.  
Purpose (Please detail the staff required and/or equipment)  Time spent/ Amount 
 …….mins/  £……-….p   
 …….mins/  £……-….p   
 …….mins/  £……-….p   
 …….mins/  £……-….p   
 …….mins/  £……-….p   
 
Do you have any further comments or any information you would like to add about the additional cost of operating the workplace intervention?  
 
2: Is there anything else that you would like to tell us about operating the workplace intervention or this interview?  
 
Section 2: Additional setting up costs 
Question 3: Have you incurred any additional setting up costs because of running the workplace intervention (e.g. training, meetings, resources & printing, room hire, 
administration, travel)? 
 
If yes, in the table below please write the purpose of the additional setting up costs and the amount of time or money spent.  
Purpose (Please detail the staff required and/or equipment)  Time spent/ Amount 
 …….mins/  £……-….p   
 …….mins/  £……-….p   
 …….mins/  £……-….p   
 …….mins/  £……-….p   
 …….mins/  £……-….p   
 
Do you have any further comments or any information you would like to add about the additional setting up costs of the workplace intervention?  
 
Question 4: Is there anything else that you would like to tell us about setting up the workplace intervention or this interview? 
 
 
 
 
Appendix C.1. Microcosting exercise  
 
 
 
 
Figure 1. CONSORT Flow Diagram of Usual Care and New Intervention (Co-PARS) from trial 
protocol 
  
Full	sample
Baseline	physiological	data	collection:
• Height,	weight,	waist	circumference
• Blood	pressure
• Lifestyle	questionnaire
• +	IPAQ	&	WEMWEBS
• Arterial	health		(ultrasound)
- FMD	&	CAR
• Cycle	submaximal	VO2	test
Week	4	Consultation
• Week	4 consultation	form	and	review	patient	logbook
Week	12	Consultation
• Week	12	consultation	form	and	review	patient	logbook
• +	repeat	baseline	measures	(Subsample	and	full	sample)
Week	18	Consultation
• Week	18	consultation	form	and	review	patient	logbook
Intervention	Arm	(Wavertree)Control	Arm	(Garston)
Induction	with	ERP	+
• Usual	care	induction
6	&	12	Month	Data	Collection
• +	repeat	baseline	measures	(Subsample	and	full	sample)
Subsample
Induction	with	ERP	+
• Adapted	induction	form	and	patient	logbook
Subsample
Full	sample
6	&	12	Month	Data	Collection
• +	repeat	baseline	measures	(Subsample	and	full	sample)
Week	12	Consultation
• Week	12	usual	care	consultation
• +	repeat	baseline	measures	(Subsample	and	full	sample)
Baseline	data	collectiom
• Physical	activity	questionnaire	(IPAQ)
• Mental	wellbeing	questionnaire	(WEMWBS)
• 7	day	accelerometry
Baseline	data	collectiom
• Physical	activity	questionnaire	(IPAQ)
• Mental	wellbeing	questionnaire	(WEMWBS)
• 7	day	accelerometry
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Microcosting tool 
The structure of the microcosting exercise tool is based on four types of resources: people, place, 
programme specific and payments. Definitions for these four concepts have been informed by the 
ACE-Prevention approach (Vos et al., 2007) and TIDieR framework (Hoffmann et al., 2014).  
1. People: Who does what, when and how, and who else is involved 
2. Place: Where does it happen and consequently what fixed (capital) equipment (resources) 
are needed 
3. Programme specific: What variable equipment (resources) are needed  
4. Payments: What out-of-pocket costs are paid 
The tables below, provide examples of the microcosting tables populated in an Excel spreadsheet 
for the microcosting of the Co-PARS intervention from the public sector perspective. The same 
struture was used to populate a spreadsheet with data on the usual care intervention.   
Table 1.1. People: Who does what, when and how  
Activity name When 
(week) 
1.1. Who (& how) 1.1. 
Frequency 
(number 
of times) 
1.1. 
Duration 
(mins) 
1.1. Unit 
cost (£ 
per 
minute) 
1.1. 
Total 
cost 
(£) 
Booking induction  After 
referral  
Receptionist face-
to-face, one-to-one 
1 5 0.18 0.90 
Induction preparation  1-2 days 
before 
induction 
date 
ERP face to face,  
one-to-one 
1 6.43 0.43 2.76 
Induction/ Call & rebook 
for no shows 
4 weeks 
after 
induction 
booked 
ERP face to face,  
one-to-one 
1 60 0.43 25.8 
Consultations/ Call 
backs 
Every 4 
weeks 
(week 4, 8, 
12, 18) 
ERP face to face,  
one-to-one 
4 30 0.43 51.6 
 
 
 
 
 
 
 
 
 
 
250 
 
Table 1.2. Who else is involved 
Activity name 1.2. Who 
else: 
Participant 
1.2. Frequency 1.2. 
Duration 
(mins) 
1.2. Unit cost 
(£ £ minute) 
1.2. Total 
cost 
Booking induction  Participant 1 5 0 0 
Induction preparation  0 0 0 0 0 
Induction/ Call & rebook 
for no shows 
Participant 1 60 0 0 
Consultations/ Call 
backs 
Participant 4 30 0 0 
 
Table 2.1. Where does it happen  
 
Activity name 2.1. Where: 
Capital 
equipment/ fixed 
costs 
2.1. Frequency 2.1. 
Duration 
(minutes) 
2.1. Unit 
cost (£ per 
minute) 
2.1. 
Total 
cost (£) 
Booking induction  Leisure Centre 
reception 
1 5 0 0 
Induction preparation  Private room in 
Leisure Centre  
1 6.43 0 0 
Induction/ Call & rebook 
for no shows 
Private room in 
Leisure Centre  
1 60 0 0 
Consultations/ Call 
backs 
Private room in 
Leisure Centre  
4 30 0 0 
 
Table 2.2. What fixed (capital) resources (equipment) are needed 
Activity name 2.2. Where: Capital 
equipment/ fixed costs 
2.2. Frequency  2.2. Unit 
cost (£) 
2.2.Total 
cost (£) 
Booking induction  IT system at leisure centre  1 0 0 
Induction preparation  IT system and telephone at 
leisure centre  
1 0 0 
Induction/ Call & rebook 
for no shows 
IT system and telephone at 
leisure centre 
1 0 0 
Consultations/ Call 
backs 
IT system and telephone at 
leisure centre 
1 0 0 
 
 
 
 
 
251 
 
Table 3.1. What variable equipment (resources) are needed  
Activity name 3.1.Equipment (variable 
costs) 
3.1. Frequency 
(pages) 
3.1. Unit cost 
(£ page of 
printing) 
3.1. Total cost 
(£) 
Booking induction  Booking form 1 0.02 0.02 
Induction preparation  0 0 0 0 
Induction/ Call & rebook 
for no shows 
Participant log book 56 0.07 3.92 
Consultations/ Call 
backs 
0 0 0 0 
 
Table 3.2. What other variable equipment (resources) are needed 
Activity name 3.2. Equipment (variable 
costs) 
3.2. 
Frequency 
(months) 
3.2. Unit cost (£) 3.2. Total 
cost (£) 
Booking induction  0 0 0 0 
Induction preparation  0 0 0 0 
Induction/ Call & rebook 
for no shows 
Subsidised membership  3 15 45 
Consultations/ Call 
backs 
0 0 0 0 
 
Table 3.3. What other variable equipment (resources) are needed 
Activity name 3.3. Equipment (variable 
costs) 
3.3. Frequency  3.3. Unit 
cost (£) 
3.3. Total 
cost (£) 
Booking induction  0 0 0 0 
Induction preparation  0 0 0 0 
Induction/ Call & rebook 
for no shows 
ERP consultation log book 7 0.07 0.49 
Consultations/ Call backs 0 0 0 0 
 
Table 3.3. What other variable equipment (resources) are needed 
Activity name 3.4. Equipment 
(variable costs) 
3.4. 
Frequency  
3.4. Unit cost (£) 3.4. Total cost 
(£) 
Booking induction  0 0 0 0 
Induction preparation  0 0 0 0 
Induction/ Call & rebook for 
no shows 
Medical 
questionnaire   
2 0.02 0.04 
Consultations/ Call backs 0 0 0 0 
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Table 4.1. What other variable equipment (resources) are needed 
Activity name 4.1. Out of pocket costs 
(Participants) 
4.1. Frequency 4.1. Unit 
cost (£) 
4.1. 
Total 
cost (£) 
Booking induction  Induction booking fee 1 7.5 0 
Induction preparation  0 0 0 0 
Induction/ Call & rebook for 
no shows 
0 0 0 0 
Consultations/ Call backs 0 0 0 0 
 
 
 
Appendix C.2. Unit Cost calculations 
 
Table 1. Unit cost healthcare utilisation 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
GP clinic Cost per 9.22 
minutes  
Curtis and 
Burns (2018) 
Unit cost used was GP with qualifications but 
excluding direct care staff. This approach was 
used by Anokye et al. (2018) 
 
Self-reported consultation time by all 3 groups. 
Mean= 11.9 minutes; Median= 10 minutes; 
Range= 5-30mins  
£34 per 9.22 
minute 
consultation 
(2018) 
No £34 
GP Home visit Cost per 1 
minute= £3.66 
 
Curtis and 
Burns (2018) 
Average travel time of 12 minutes was taken from 
Curtis (2015) and added to the average clinic 
consultation time of 9.22 minutes from Curtis and 
Burns (2018). It was therefore assumed the 
average time was 21.22 minutes.  
£77.66 per 
21.22 minute 
consultation 
(2018)  
No £77.66 
GP telephone call Cost per 1 
minute= £3.60 
Curtis and 
Burns (2018) 
Average telephone call of 7.1 minutes was taken 
from Curtis (2015). 
£25.99 per 7.1 
minute 
consultation 
(2018) 
No £25.99 
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Practice Nurse 
clinic1 
£42 per hour 
with 
qualifications  
Curtis and 
Burns (2018)  
Unit cost used was Practice Nurse with 
qualifications. This approach was used by Anokye 
et al. (2018) 
 
£42 per hour equates to £0.70 per minute. Time 
spent with the practice nurse varied from 5-
30minutes, therefore a standard published time 
was applied, assuming the average consultation 
time is 15.5 minutes, taken from Curtis (2015). 
£10.85 per 
15.5 minute 
consultation 
(2018) 
No £10.85 
Physiotherapist1,2 £49.38 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
At Band 6, the average salary Band for 
Physiotherapist (Curtis and Burns, 2018) the cost 
per working hour is £46 excluding qualifications 
(Curtis and Burns, 2018). With qualifications it is 
£5,410 extra per year for Physiotherapists. 
£5,410/ working hours per year (1,599)= £3.38 per 
hour.  
 
£46+3.38= £49.38 per hour/ £0.82 per minute 
(£2018). 
£0.82 per 
minute, 
consultation 
length as 
reported by 
participant 
No £0.82 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
Chiropractor1,2 £49.38 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
Band 6 was assumed which was similar to the 
Physiotherapist Band. No qualification costs were 
provided, and so that reported for physiotherapists 
were assumed.  
£0.82 No £0.82  
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Osteopath n/a n/a Osteopathy not typically provided on NHS in 
England. It is typically sought privately. No 
participants in this study reported using this 
service at baseline or 12 weeks, and so a cost 
was not sought 
n/a n/a n/a 
Occupational 
Therapist1  
£47 per hour 
with 
qualifications 
Curtis and 
Burns (2018) 
Unit cost came from Curtis and Burns (2018) for 
Community Occupational Therapist including 
qualifications (£47 per hour/ £0.78 per minute). 
This approach was used by Anokye et al. (2018) 
£0.78 No £0.78 
Acupuncturist £49.38 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
No national unit cost available. Assume it is a 
Physiotherapist delivering the Acupuncture as 
described as is typical in NHS in England 
£0.82 No £0.82  
Specialist Nurse 
clinic2 
£87 per hour  Curtis (2017) Band 7 Specialist Nurse Cost per hour was £87/ 
cost per minute was £1,45 (Curtis, 2017)  
£1.45 (2017) Yes. UK’s GDP Deflator was 
applied to inflate the price 
from 2016/17 to 2018/19 
(Multiplier 1.0392). £1.51 per 
minute 
£1.51  
District Nurse2 £41.73 PSSRU (2012) 
as cited in 
Curtis and 
Burns (2018) 
as the unit 
cost for the 
year 2016/ 
2017  
District Nurse cost per hour was £41.73 in 2016/ 
2017/ cost per minute is £0.70 
£0.70 (2017) Yes. UK’s GDP Deflator was 
applied to inflate the price 
from 2016/17 to 2018/19 
(Multiplier 1.0392). £0.73 per 
minute 
£0.73 
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Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
Counsellor1,2  £49.38 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
In line with the other similar allied Health 
Professionals Band 6 was used (Curtis and Burns, 
2018). The cost per working hour is £46 excluding 
qualifications (Curtis and Burns, 2018). With 
qualifications it is £5,410 extra per year (there is 
no unit cost for Counsellor or Psychologist 
qualifications, therefore Physiotherapists unit cost 
was used: £5,410/ working hours per year 
(1,599)= £3.38 per hour.  
 
£46+3.38= £49.38 per hour/ £0.82 per minute 
(£2018). 
£0.82 per 
minute, 
consultation 
length as 
reported by 
participant 
No £0.82 
Pharmacist 1,2 £51.17 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
It was assumed the Pharmacist would be a Band 
6 (Curtis and Burns, 2018). The cost per working 
hour is £46 excluding qualifications (Curtis and 
Burns, 2018). With qualifications it is £8,263 extra 
per year (1,599 hours per year for Band 6): £5.17 
per hour 
 
£46+5.17= £51.17 per hour/ £0.85per minute 
(£2018) 
£0.85 per 
minute, 
consultation 
length as 
reported by 
participant 
No £0.85 
Healthcare 
assistant clinic2 
£10.79 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Healthcare Assistants are Band 2 with an annual 
£0.18 per 
minute 
No £0.18 
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pay rate from April 2018 of £17,260 for those 
experienced between <1 year to 5 years. 
According to Curtis and Burn (2018) most 
community health care staff work 42.6 weeks 
(1599 hours) per year. Unit cost= £10.79 per hour 
or £0.18 per minute. Efforts to estimate the 
overhead costs were not done due to the small 
magnitude of this cost in terms of the quantity and 
unit cost (just two participant reported this 
resource) and the small magnitude of the unit cost 
for this health professional (Drummond et al. 
2015: 220). 
 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
Support Worker2 £10.79 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Support Workers are Band 2 with an annual pay 
rate from April 2018 of £17,260 for those 
experienced between <1 year to 5 years. 
According to Curtis and Burn (2018) most 
community health care staff work 42.6 weeks 
(1599 hours) per year. Unit cost= £10.79 per hour 
or £0.18 per minute. Efforts to estimate the 
overhead costs were not done due to the small 
magnitude of this cost in terms of the quantity and 
£0.18 per 
minute 
No £0.18 
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unit cost (just one participant reported this 
resource) and the small magnitude of the unit cost 
for this health professional (Drummond et al. 
2015: 220). 
Phlebotomist2 £10.79 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Phlebotomist’s are Band 2 with an annual pay rate 
from April 2018 of £17,260 for those experienced 
between <1 year to 5 years. According to Curtis 
and Burn (2018) most community health care staff 
work 42.6 weeks (1599 hours) per year. Unit cost= 
£10.79 per hour or £0.18 per minute. Efforts to 
estimate the overhead costs were not done due to 
the small magnitude of this cost in terms of the 
quantity and unit cost (just one participant 
reported this resource) and the small magnitude of 
the unit cost for this health professional 
(Drummond et al. 2015: 220). 
£0.18 per 
minute 
No £0.18 
Podiatrist 1,2 £49.38 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
Band 6 was assumed which was similar to the 
Chiropractor/ Physiotherapists. No qualification 
costs were provided, and so that reported for 
chiropractor/ physiotherapists were assumed.  
 
 
 
 
 
£0.82 No £0.82  
 
 
259 
 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
Dietician2 £48.52 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
Unit cost is not broken down by type of visit, 
therefore the same unit cost was applied for clinic 
visits, home visits and telephone consultations. At 
Band 6, the average salary Band for Dietician 
(Curtis and Burns, 2018) the cost per working hour 
is £45 excluding qualifications (Curtis and Burns, 
2018). With qualifications it is £5,622 extra per 
year for Dietician. £5,622/ working hours per year 
(1,599)= £3.52 per hour.  
 
£45+£3.52= £48.52 per hour/ £0.81 per minute 
(£2018). 
£0.81 per 
minute, 
consultation 
length as 
reported by 
participant 
No £0.81 
Social Worker1 £84 per hour 
with 
qualifications, 
client-related 
work  
Curtis and 
Burns (2018)  
Unit cost used was Social Worker with 
qualifications. This approach was used by Anokye 
et al. (2018).  
 
£84 per hour equates to £1.40 per minute. Time 
spent with the practice nurse varied from 5-
30minutes, therefore a standard published time 
was applied, assuming the average consultation 
time is 15.5 minutes, taken from Curtis (2015). 
£1.40 per 
minute, 
consultation 
length as 
reported by 
participant 
No £1.40 
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Speech Therapist 
1,2 
£48.47 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
At Band 6, the average salary Band for Speech 
Therapist (Curtis and Burns, 2018) the cost per 
working hour is £45 excluding qualifications 
(Curtis and Burns, 2018). With qualifications it is 
£5,556 extra per year for Speech Therapist. 
£5,556/ working hours per year (1,599)= £3.47 per 
hour.  
 
£45+£3.47= £48.47 per hour/ £0.81 per minute 
(£2018). 
 
£0.81 per 
minute, 
consultation 
length as 
reported by 
participant 
No £0.81 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
Mental Health 
Professional2 
£24.24 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Mental Health Nurses. The participants were not 
asked to specify what type of Mental Health 
Professional, therefore it was assumed the same 
Mental Health Professionals delivering the 
Behavioural Activation interventions would apply 
(Curtis and Burns, 2018). Wages of Mental Health 
Nurses are Band 7 (according to Curtis and Burn, 
2018) with an annual pay rate from April 2018 of 
£38,765 for those experienced between 4-5 years. 
According to Curtis and Burn (2018) most 
community health care staff work 42.6 weeks 
£0.40 per 
minute 
No £0.40 
 
 
261 
 
(1599 hours) per year. Unit cost= £24.24 per hour 
or £0.40 per minute. Efforts to estimate the 
overhead costs were not done due to the small 
magnitude of this cost in terms of the quantity and 
unit cost (just one participant reported this 
resource) and the small magnitude of the unit cost 
for this health professional (Drummond et al. 
2015: 220). 
Health Trainer2 £13.65 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Healthcare Assistants are Band 4 with an annual 
pay rate from April 2018 of £21,819 for those 
experienced between 3-4 years. According to 
Curtis and Burn (2018) most community health 
care staff work 42.6 weeks (1599 hours) per year. 
Unit cost= £13.65 per hour or £0.28 per minute. 
Efforts to estimate the overhead costs were not 
done due to the small magnitude of this cost in 
terms of the quantity and unit cost (just two 
participant reported this resource) and the small 
magnitude of the unit cost for this health 
professional (Drummond et al. 2015: 220). 
 
 
 
 
 
£0.28 per 
minute 
No £0.28 
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Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
Number of hospital 
admissions for 
inpatient care 
(stayed overnight) 
£3,894 NHS reference 
costs (2018) 
Hospital admissions for inpatient care, assuming 
this care is elective (planned), if it was non-
elective inpatient care then this would be a lower 
cost at £1,603 per case. Cost data in the UK is 
coded by Healthcare Resource Groups (HRGs) for 
which there are over 2,812 groups (NHS 2018). 
Selecting a cost requires accurate description by 
the participant if using a self-reported 
questionnaire as well as expertise on the 
descriptions of the HRGs and then judgement to 
decide which description matches the participants 
best out of the 2,812 HRG groups.  
 
Type of procedure in secondary care was only 
recommended as a bolt on module item to collect 
for studies specifically concerned with extended 
hospital care because for instance, admissions 
and re-admissions are prevalent (Thorn et al. 
2018) ISRUM 
 
Each HRG had an expected bed day, it was 
assumed participants did not exceed the expected 
£3,894 No £3,894 
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bed day and so the exceeded bed day unit cost 
(£346) was not added on. 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
Number of hospital 
admissions for day 
patient care 
£742 NHS reference 
costs (2018) 
Cost data in the UK is coded by Healthcare 
Resource Groups (HRGs) for which there are over 
2,812 groups (NHS 2018). Selecting a cost 
requires accurate description by the participant if 
using a self-reported questionnaire as well as 
expertise on the descriptions of the HRGs and 
then judgement to decide which description 
matches the participants best out of the 2,812 
HRG groups. 
£742 No £742 
Number of hospital 
outpatient 
appointments  
£125 NHS reference 
costs (2018) 
Cost data in the UK is coded by Healthcare 
Resource Groups (HRGs) for which there are over 
2,812 groups (NHS 2018). Selecting a cost 
requires accurate description by the participant if 
using a self-reported questionnaire as well as 
expertise on the descriptions of the HRGs and 
then judgement to decide which description 
matches the participants best out of the 2,812 
HRG groups. 
£125 No £125 
Number of visits to 
A&E  
£160 NHS reference 
costs (2018) 
A&E attendance £160 No £160 
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Number of 
admissions to 
hospital, after A&E 
£1,603 NHS reference 
costs (2018) 
Non-elective inpatient (excluding excess bed 
days): £1,603 per case. Non-elective means 
emergency, but can be via GP not just A&E 
 
 
 
£1,603 No £1,603 
Footnotes:  
1 Unit cost is not broken down by type of visit, therefore the same unit cost was applied for clinic visits, home visits and telephone consultations. 
2 Data on the average length of consultation was not provided and so the estimates reported by the participants were used. This was deemed appropriate since only a very small proportion 
reported this resource. 
 
Table 2. Intervention unit costs 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
Receptionist £10.79 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Secretary staff are Band 2 with an annual pay rate 
from April 2018 of £17,260 for those experienced 
between <1 year to 5 years. According to Curtis 
and Burn (2018) most community health care staff 
work 42.6 weeks (1599 hours) per year. Unit cost= 
£10.79 per hour or £0.18 per minute. Efforts to 
estimate the overhead costs were not done due to 
£0.18 per 
minute 
No £0.18 
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the small magnitude of this cost in terms of the 
quantity and unit cost (just one participant 
reported this resource) and the small magnitude of 
the unit cost for this health professional 
(Drummond et al. 2015: 220). 
Exercise referral 
practitioner 
£13.65 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Fitness Instructors are Band 4 with an annual pay 
rate from April 2018 of £21,819 for those 
experienced between 3-4 years. According to 
Curtis and Burn (2018) most community health 
care staff work 42.6 weeks (1599 hours) per year. 
Unit cost= £13.65 per hour or £0.28 per minute.  
 
Published PA Referral Instructor salary for local 
council, published in 2019 with Level 3 was 
£13.86-£15 per hour. 
 
Efforts to estimate the overhead costs were not 
done due to the small magnitude of this cost in 
terms of the quantity and unit cost (just two 
participant reported this resource) and the small 
magnitude of the unit cost for this health 
professional (Drummond et al. 2015: 220). 
£0.28 per 
minute 
No £0.28 
Grade 6 
Researcher  
£23.54 Research 
Institute’s pay 
(2018) 
Grade 6 Researcher (mean annual income of 
£35,929) including salary on-costs (national 
insurance and superannuation of 14%). University 
contract of 6 weeks annual leave, 8 bank holidays, 
£23.54 No £23.54 
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4 days Christmas closure; 35 hours per week. 
1526 hours per year. Hourly unit cost= £23.54 
Printing £0.07 per A4 
page in colour 
Research 
Institute’s 
Printing costs 
(2018) 
Calculation per page: £0.07 £0.07 No £0.07 
Subsidised leisure 
centre membership  
£15 per month Leisure centre 
webpage 
(2019) 
Off peak-membership at the leisure centres costed 
£15 per month: 3 months= £45 
£45 No £45 
 
Table 3. Productivity loss: average weekly earnings and hours worked 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit 
cost 
for 
£2018 
Average UK wage £14.52 per 
hour 
ONS (2018) According to the latest data from ONS on average 
earnings and hours worked in the UK, for 2018 
average weekly earnings were £569 (median). 
Average hours worked per week were 39.2 hours 
(mean). ONS 2018: 
https://www.ons.gov.uk/employmentandlabourmar
ket/peopleinwork/earningsandworkinghours/bulleti
ns/annualsurveyofhoursandearnings/2018. This 
provides an estimate of £14.52 per hour. Efforts to 
estimate the overhead costs were not done due to 
the small magnitude of this cost in terms of the 
£14.52 per 
hour (2018) 
No £14.52 
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quantity and unit cost (just one participant 
reported this resource) and the small magnitude of 
the unit cost for this health professional 
(Drummond et al. 2015: 220).  
 
 
Appendix C.3. Participant costs data collection tools 
 
Participant Travel, Time and Out-of-pocket Costs 
Background information 
In this questionnaire, we are trying to find out the costs to you for participating in the Exercise 
Referral Scheme. Unfortunately, we are unable to reimburse these costs. However, your 
answers are important because they will give people who make decisions about these 
services an idea of how much the scheme costs you.  
Please answer every question. If you are not sure or cannot remember the exact details, 
please give the best answer you can.  
 
Section A: Participant travel costs 
- Question 1:  
Over the last 12 weeks how many times have you attended an Exercise Referral Scheme 
consultation. Please write the number of times in the box below. Put zero if you have not 
attended an Exercise Referral Scheme consultation over the last 12 weeks for your 
consultations.  
Number of times ……….. (/max 4) 
If you answered 1 or more to the question above please continue to Question 2. Otherwise, 
skip to  Section B. 
 
- Question 2:  
When you visited the leisure centre for your consultations, how did you normally travel? 
Please circle the number that best describes how you normally travelled from your home to 
the leisure centre for consultations. If you normally used more than one form of transport, 
please indicate the way you travelled for the main (longest in terms of distance) part of your 
journey.  
Walked .........................................................................1 
Cycled...........................................................................2 
Bus................................................................................3 
Train/metro..................................................................4 
Taxi...............................................................................5  
Private car.....................................................................6  
Motorbike ....................................................................7 
Other (please specify) ………………………..………8 
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- Question 3:  
If you normally travelled by public transport (e.g. bus or train) for part or the entire journey, 
what was the cost of the one-way fare? Please write the cost in the box below. Put 0 if you 
did not normally travel by public transport at all or if you did not normally pay a fare.  
Cost of one-way fare (£)…....._ ……..pence  
If you normally travelled by taxi for part or the entire journey, what was the cost of the one-
way fare? Please write the cost in the box below. Put 0 if you did not normally travel by taxi 
at all or if you did not normally pay a fare.  
Total cost of one-way fare (£)………_……..pence  
If you normally travelled by private car or motorbike for part or the entire journey how many 
miles did you travel one-way? Please write the number of miles in the box below. Put 0 if 
you did not normally travel by private car or motorbike at all. 
Number of miles one-way………… 
If you normally travelled by private car or motorbike for part or the entire journey and had to 
pay tolls or parking fees how much did these amount to? Please write the cost in the box 
below. Put 0 if you did not normally travel by private car or motorbike at all or did not 
normally pay tolls or parking fees.  
Expenditure on tolls or parking fees (£)…………._………….pence  
 
- Question 4:  
When you visited the leisure centre, how long did it normally take to travel there from your 
home? Please write the number of hours and minutes in the box below.  
Number of hours……….._.............minutes 
 
Section B: Participant Time Costs 
Question 5:  
When you visited the leisure centre for your consultations, how long did you normally spend 
there? Please write the number of hours and minutes in the box below. Include in your answer 
the time you normally spent waiting and the time you normally spent with the Exercise 
Referral Practitioner.  
 
Number of hours………_........minutes 
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- Question 6:  
What would you normally have been doing as your main activity if you had not gone to the 
Exercise Referral consultations? Please circle the number that best describes what you 
normally would have been doing as your main activity if you had not gone to the 
consultations. 
Housework................................................................. 1 
Childcare.................................................................... 2  
Caring for a relative or friend.................................... 3  
Voluntary work.......................................................... 4  
Leisure activities........................................................ 5  
Attending school or university.................................. 6  
On sick leave.............................................................. 7  
Seeking work ............................................................. 8  
Paid work................................................................... 9  
Other (please specify)…………………………...... 10 
 
If you normally took time off from paid work (or business activity if self-employed) please 
continue with Question 7. Otherwise, go to Section C. 
 
- Question 7:  
If you took time off from paid work (or business activity if self-employed) to go to the 
consultations at the leisure centre approximately how much time did you normally take off 
work (or business activity if self-employed)? Please write the number of hours and minutes in 
the box below.  
Number of hours………_..........minutes 
Did you normally lose earnings as a result? Please circle the appropriate answer? 
Yes………………………….1 
No……………………………………….2 
 
What is your main occupation? 
…………………………………………………………………. 
 
 
Section C: Other costs 
- Question 8:  
In the last 3 months have you incurred any other costs because of taking part in the 
Exercise Referral Scheme (e.g. induction cost, purchasing gym membership, equipment 
and/ or clothing purchased because of participating in the intervention, paying for sessions)? 
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Yes ...........................................................................................1  
No ............................................................................................2 
 
If yes, what were they for and how much did you spend? In the table below please write the 
purpose of other costs and the amount of money spent.  
Purpose Amount spent 
 £……-….p 
 £……-….p 
 £……-….p 
 £……-….p 
 £……-….p 
 
Do you have any further comments or any information you would like to add about the cost 
to you of coming to the leisure centre for the Exercise Referral Scheme? 
………………………………………………………………………………………………… 
………………………………………………………………………………………………… 
………………………………………………………………………………………………… 
 
Willingness to pay Questions 
In the three questions below, you will be asked to imagine you were going to take part in a PA 
programme, and what you would be willing to pay for this.     
This information will not impact on any current services you are receiving, but will be used to 
make recommendations to help inform delivery of PA programmes in future.   
Please note there are no minimum or maximum amounts.  If you would not be willing 
to pay anything, please write £0.00.    
1. Suppose a one-to-one induction at your local leisure centre involves developing a 
personalised plan of PA which is tailored to your needs and preferences. The 
induction is done face-to-face with an Exercise Practitioner and takes 1 hour. 
Suppose that an induction improves your motivation, confidence and ability to be 
more physically active.  What is the most that you would be willing to pay for this 
induction?  
 
 (£)…..... : ……..pence    
 
Additional comments (e.g. reasons for the amount suggested) 
…………………………………………………………………………………………………………
……………………………………….. 
…………………………………………………………………………………………………………
……………………………………….. 
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2. Suppose that a swimming session, gym session or exercise class at your local 
leisure centre improves your motivation, confidence and ability to be more physically 
active. What is the most that you would be willing to pay per swimming session, 
gym session or exercise class? 
Please provide an answer for each type of activity.  
 
Swimming:  (£)…..... : ……..pence 
 
Gym session:  (£)…..... : ……..pence 
 
Exercise class:  (£)…..... : ……..pence 
 
Additional comments (e.g. reasons for the amounts suggested) 
…………………………………………………………………………………………………………
……………………………………….. 
…………………………………………………………………………………………………………
………………………………………… 
 
3. Suppose you were to take part in 4 one-to-one progress consultations over an 18-
week period at your local leisure centre, which involve reviewing your personalised 
plan of PA (tailored to your needs and preferences). Each consultation is done 
either face-to-face or over the telephone with an Exercise Practitioner and takes 
approximately 20 minutes. Suppose that each consultation improves your 
motivation, confidence and ability to be more physically active.  What is the most 
that you would be willing to pay per consultation?  
Please provide an answer for both face-to-face and telephone consultations.  
Face-to-face:  (£)…..... : ……..pence   
 
Over the telephone: (£)…..... : ……..pence 
 
Additional comments (e.g. reasons for the amounts suggested) 
…………………………………………………………………………………………………………
…………………………………………. 
…………………………………………………………………………………………………………
…………………………………………. 
 
 
 
Appendix C.4. Disaggregated costs and consequences 
Table 1. Incremental QALYs: unadjusted for baseline imbalances 
Variable Co-PARS Usual Care ERS Control 
Mean (SD) per participant Mean (SD) per participant Mean (SD) per participant 
QALYs 
Unadjusted QALYs  0.355 (0.081) 0.364 (0.087) 0.436 (0.064) 
Incremental QALYs unadjusted 
Co-PARS vs Usual Care -0.009 (SE:0.027; 95% CI: -0.062-0.044); this means the Co-PARS group has 0.009 less QALYs compared to 
usual care 
Co-PARS vs Control -0.081 (SE: 0.023; 95% CI: -0.127- -0.034); this means the Co-PARS group has 0.081 less QALYs compared 
to the control group 
Breakdown of Unadjusted QALYs 
Life years 0.5 years 0.5 years 0.5 years 
Unadjusted EQ-5D score for 
all three time points  
0.709 (0.160) 0.728 (0.175) 0.871 (0.129) 
EQ-5D score at Baseline 0.640 (0.238) 0.724 (0.156) 0.872 (0.135) 
EQ-5D score at 12 weeks 0.759 (0.161) 0.751 (0.180) 0.877 (0.121) 
EQ-5D score at 6 months 0.729 (0.159) 0.708 (0.242) 0.863 (0.163) 
* Adjusted for differences in baseline EQ-5D score using multiple regression 
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Table 2. Incremental costs: unadjusted for baseline imbalances 
Variables Co-PARS Usual Care  Control  
Mean (SD) per participant Mean (SD) per participant Mean (SD) per participant 
Costs 
Unadjusted total 
costs at 6 Months 
£861.80 (£1,073.89) £538.24 (£1,122.99) £356.68 (£738.50) 
Incremental costs unadjusted 
Co-PARS vs Usual 
Care 
£323.56 (SE:£369.25; 95% CI: £-369.25- £1,016.37); this means the Co-PARS group costs £323.56 more compared to 
usual care 
Co-PARS vs Control £505.12 (SE:£291.69; 95% CI: £-66.59-£1,076.83); this means the Co-PARS group costs £505.12 more compared to the 
control group 
 
Table 3. Unadjusted ICER result 
ICER unadjusted analysis 
Variables coPARS vs Usual Care coPARS vs Control 
ICER unadjusted for baseline 
differences 
Usual Care ERS dominates Co-PARS. Costing 
saving result: £35,798 saved per QALY gained 
 
Control group dominates Co-PARS. Cost saving result: 
£6,255 saved per QALY gained 
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Table 4. Key activities and intervention operating costs for the Co-PARS and usual care interventions 
Key intervention 
activities 
Co-PARS Usual Care ERS 
Description of resources consumed Mean cost Description of resources consumed Mean cost 
Booking induction Booking form; Receptionists time (5 
mins) 
£0.92 Booking form; Receptionist’s time (5 mins) £0.92 
1-2 days before 
induction date 
ERP time  
(45 mins per week for 7 inductions) 
£2.76 n/a £0 
Induction delivery/ 
Call and rebook no 
shows 
ERP time (60 minutes per participant); 
ERP consultation log book; Participant 
log book; Medical questionnaire; Free 3 
months subsidised membership) 
£75.25 ERP time (60 minutes per participant); 
Personalised Plan; Medical questionnaire; 
Free 3 months subsidised membership) 
£71.33 
Consultations/ Call 
back 
ERP time (30 minutes per participant per 
consultation; 4 consultations in total) 
£51.60 n/a £0 
Information about 
post-scheme options 
n/a £0 Receptionists time (10 minutes) to arrange 
post-scheme options with participant 
£4.30 
Total mean cost per 
participant 
 £130.53  £76.55 
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Table 5. Intervention set up costs 
 Co-PARS Total cost Usual Care  No treatment control  
Design of 
consultation 
and participant 
log books 
1 day (7 hours) Grade 6 
Researcher  
£164.78 n/a £0 n/a £0 
Roll out 
meeting  
Six meetings to plan the roll 
out of the intervention at the 
selected site, average 
meeting time (2hours). Time 
of ERP and Grade 6 
researcher. Overhead costs 
included in salaries.  
£446.28 
Preparing for 
training 
workshop   
1 day (7 hours) of 
preparation by Grade 6 
Researcher 
£164.78 
Training 
workshop 
2 two day training workshops 
delivered by the Grade 6 
Researcher to ERP 
£520.66 
Training one-to-
one support 
6 hours of one to one 
support delivered by Grade 6 
Researcher to ERP 
£223.14 
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Reflection on 
workshop 
delivery  
6 hour reflection on training  £141.24 
Ongoing email 
and telephone 
support 
Delivered by Grade 6 
Researcher to ERP 
(approximately 2 hours in 
total) 
£74.38 
Total cost - £1,735.26 
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Table 6. Most frequently visited healthcare professionals in primary care  
Resource type  Unit Cost Co-PARS Usual care Control group 
Mean number 
of visits (SD);  
Number of 
people 
reporting any 
use 
Total Mean 
Cost (SD) 
Mean number 
of visits (SD); 
Number of 
people 
reporting any 
use 
Total Mean 
Cost (SD) 
Mean number 
of visits (SD); 
Number of 
people 
reporting any 
use 
Total Mean 
Cost (SD) 
GP consultations at 
Baseline 
£34 per 9.11 
minute 
consultation 
5.60 (5.16);  
n=24/ 25 
£184.78 
(£164.60) 
2.88 (3.34);  
n=10/ 16 
£93.34 
(£107.44) 
2.35 (3.41); 
n=10/14 
£72.71 
(£98.49) 
GP consultations at 6 
months 
3.00 (2.52);  
n=20/ 25 
£100.08 
(£84.36) 
2.50 (3.08);  
n=11/ 16 
£60.62 
(£71.32) 
1.50 (1.51); 
n=9/14 
£49.29 
(£49.03) 
Practice Nurse 
consultations at Baseline  
£10.85 per 15.5 
minute 
consultation  
 
1.24 (1.69); 
n=16/ 25 
£10.85 
(£11.72) 
0.94 (1.24); 
n=8/ 16 
£10.17 
(£13.41) 
2.29 (5.20); 
n=10/14 
£24.80 
(£56.37) 
Practice Nurse 
consultations at 6 
months 
0.75 (0.94); 
n=14/ 25 
£8.14 
(£10.24) 
0.38 (0.62); 
n=6/ 16 
£4.07 (£6.72) 
 
0.71 (0.99); 
n=7/14 
£7.75 
(£10.79) 
Physiotherapist visits at 
Baseline 
£0.82 per 
minute visit, 
range of 
average visit 
was 20-40 
minutes 
0.64 (1.93);  
n=7/ 25 
£16.40 
(£50.27) 
2.19 (3.70); 
n=6/ 16 
£107.83 
(£270.51) 
0.07 (0.27); 
n=1/14 
£1.17 (£4.38) 
Physiotherapist visits at 
6 months 
0.24 (0.60); 
n=4/ 25 
£1.97 
(£7.21) 
 
0.31 (1.01); 
n=2/ 16 
£6.15 
(324.60) 
2.00 (6.42); 
n=2/14 
£4.69 
(£17.53) 
Counsellor visits at 
Baseline 
£0.82 per 
minute visit,  
0.72 (2.07); 
n=3/ 25 
£24.93 
(£86.40) 
0.25 (1.00); 
n=1/ 16 
£12.30 
(£49.20) 
0.86 (3.21); 
n=1/14 
£21.09 
(£78.90) 
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range of 
average visit 
was 50-60 
minutes 
 
Counsellor visits at 6 
months 
1.88 (4.16); 
n=6/ 25 
£76.75 
(£191.12) 
0 (0); 
n=0/ 16 
£0 (£0) 0 (0); 
n=0/14 
£0 (£0) 
 
 
Table 7. Secondary care healthcare utilisation  
Resource type 
Unit Cost  Co-PARS Usual care Control group 
Mean resource 
use (SD); 
Number of people 
reporting any use 
Total Mean Cost 
(SD) 
Mean resource 
use (SD); 
Number of people 
reporting any use 
Total Mean Cost 
(SD) 
Mean resource 
use (SD); 
Number of people 
reporting any use 
Total Mean Cost 
(SD) 
Outpatient and 
Day Case visit 
at Baseline 
£433.50 per 
visit* 
 
1.96 (2.30); 
n= 16/ 25 
£849.66 
(£997.05) 
0.81 (0.83); 
n=10/ 16 
£352.22 
(£361.62) 
1.21 (2.97); 
n=4/ 14 
£526.38 
(£1,285.73) 
Outpatient and 
Day Case visit 
at 6 months 
 
0.84 (1.37); 
n=9/ 25 
 
£364.14 
(£595.96) 
0.25 (0.58); 
n=3/16 
£108.38 
(£250.28) 
0.64 (1.64); 
n= 3/14 
£278.68  
(£713.47) 
Inpatient 
admission at 
Baseline 
£3,894 per 
admission 
 
0.12 (0.33); 
n=3/ 25 
£467.28 
(£1,291.49) 
0.25 (0.45); 
n=4/ 16 
£973.50 
(£1,741.45) 
0.15 (0.38); 
n=2/ 14 
£556.29 
(£1,414.05) 
Inpatient 
admission at 6 
months 
0.04 (0.20); 
n=1/ 25 
£155.76 
(£778.80) 
0.06 (0.25); 
n=1/ 16 
£243.38 
(£973.50) 
0 (0); 
n=0/14 
£0 (£0) 
A&E visits at 
Baseline 
£160 per visit 
 
0.24 (0.44); 
n=6/ 25 
£38.40 (£69.74) 0.19 (0.40); 
n=3/ 16 
£30 (£64.50) 0.07 (0.27); 
n=1/ 14 
£11.43 (£42.76) 
A&E visits at 6 
months 
0.08 (0.28); 
n=2/ 25 
£12.80 (£44.30) 0.06 (0.25); 
n=1/ 16 
£10 (£40) 0 (0); 
n=0/14 
£0 (£0) 
*Average cost for outpatient unit cost (£125) and Day case patient unit cost (£742), to be tested in the sensitivity analysis; ** Adjusted for differences in baseline 
utility using ANCOVA 
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Table 8. Change in healthcare use for most frequently used services  
Primary care 
Resource item  Co-PARS Usual Care No treatment control  
GP consultations at Baseline  n=24/ 25 n=10/ 16 n=10/14 
GP consultations at 6 months n=20/ 25  n=11/ 16  n=9/14  
Practice Nurse at Baseline n=16/ 25 n=8/ 16 n=10/14 
Practice Nurse at 6 months n=14/ 25 n=6/ 16 n=7/14 
Physiotherapist at Baseline n=7/ 25 n=6/ 16 n=1/14 
Physiotherapist at 6 months n=4/ 25 n=2/ 16 n=2/14 
Counsellor at Baseline n=3/ 25 n=1/ 16 n=1/14 
Counsellor at 6 months n=6/ 25 n=0/ 16 n=0/14 
Secondary care 
Resource item  Co-PARS Usual Care No treatment control  
Outpatient/ Day cases at 
Baseline; Visiting orthopaedic 
department (most common 
department visited)  
n= 16/ 25; Orthopaedics: n=2 n=10/ 16; Orthopaedics: n=3 n=4/ 14; Orthopaedics: n=2 
Outpatient/ Day cases at 6 
months 
n=9/ 25; Orthopaedics: n=2 n=3/ 16; Orthopaedics: n=1 n= 3/14; Orthopaedics: n=1 
Inpatient admissions Baseline n=3/ 25  n=4/ 16 n=2/ 14 
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Inpatient admissions 6 months n=1/ 25 n=1/ 16 n=0/14 
A&E visits Baseline n=6/ 25  n=3/ 16 n=1/ 14 
A&E visits 6 months n=2/ 25 n=1/ 16 n=0/14 
Green: reduction in resource use; Red: increase in resource use 
One-way scenario analysis 
The aim of the one-way scenario analysis was to assess how sensitive the cost-effectiveness results were to the choice in unit cost for outpatient appointments/ day 
cases. This was because the healthcare utilisation questionnaire did not ask patients to distinguish between these two activities. In the base case, £433.50 was used 
as the unit cost, which was an average of the unit costs for outpatients (£125) and day cases (£742). Nevertheless, outpatient appointments were more common 
than day cases, therefore the one-way scenario analysis assess the impact of using just the outpatient unit cost. As shown in Table 9, the results were consistent 
with the base case results, whereby Co-PARS group generated was cost-effective (under NICE’s threshold) compared to usual care, but not compared to the control 
group. 
Table 9. One-way scenario analysis for outpatient appointment unit costs 
Variables coPARS vs Usual Care coPARS vs Control 
One-way sensitivity analysis 
Outpatient/Day patient unit cost: ICER 
unadjusted for baseline differences 
Usual Care ERS dominates Co-PARS: 
£15,661 saved per QALY gained for 
usual care 
 
No treatment control group dominates Co-PARS: $5,502 saved 
per QALY gained for usual care 
 
One-way sensitivity analysis 
Outpatient/Day patient unit cost: ICER 
adjusted* for baseline utility and costs 
£8,439 per QALY £143,500 per QALY 
 
 
 
 
283 
 
 
 
Table 10. Cost-effectiveness analysis by subgroups within the Co-PARS group 
Characteristic Adjusted ICER* 
Most deprived quintile group vs four least deprived quintiles group Most deprived group dominates (£24 saved per QALY gained for most 
deprived group)# 
Cardiometabolic as main referral reason vs other referral reasons Cardiometabolic referral reasons dominates (£48,358 saved per QALY 
gained for cardiometabolic group)# 
Males vs Females £48,286 per QALY (For males Co-PARS is more effective but more 
expensive) 
Aged 55 years and over vs under 55 years £2,033 per QALY (For those aged 55 and over Co-PARS is more 
effective but more expensive)# 
*Adjusted for baseline healthcare costs and HRQoL score using multiple regression; #Cost-effective/ cost-saving based on NICE’s willingness to pay threshold of 
£30,000 per QALY 
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Table 11. Prescribed medications in the last 6 months 
 Variable coPARS Usual Care No treatment control 
Baseline 6 months 
follow up 
Change over 
time 
Baseline 6 months 
follow up 
Change over 
time 
Baseline 6 months 
follow up 
Change 
over time 
Answered question  n=16/25 (64%) n=13/16 (81.25%) n=10/14 (71.43%) 
At least one 
medication 
prescribed 
n=14/16 
(87.5%) 
n=12/16 
(75%) 
Improved n=12/13 
(92.31%) 
n=12/13 
(92.31%) 
No change n=9/10 
(90%) 
n=9/10 
(90%) 
No change 
Any prescribed 
medications: mean 
3.06 2.56 Improved 3.62 2.92 Improved 2.7 2.5 Improved 
Any prescribed 
medications: median 
2.5 2 Improved 3 3 No change 2 2.5 Worse 
Type: High Blood 
Pressure 
n=5/16 
(31.25%) 
n=5/16 
(31.25%) 
No change n=6/13 
(46.15%) 
n=6/13 
(46.15%) 
No change n=5/10 
(50%) 
n=5/10 
(50%) 
No change 
Type: High 
cholesterol 
n=4/16  
(25%) 
n=3/16 
(18.75%) 
Improved n=4/13 
(30.77%) 
n=4/13 
(30.77%) 
No change n=2/10 
(20%) 
n=2/10 
(20%) 
No change 
Type: 
Antidepressants  
n= 3/16 
(18.75%) 
n=2/16 
(12.5%) 
Improved n=3/13 
(23.08%) 
n=3/13 
(23.08%) 
No change n=1/10 
(10%) 
n=2/10 
(20%) 
Worse 
Type: T2D  n=1/16 
(6.25%) 
n=1/16 
(6.25%) 
No change n=2/13 
(15.38%) 
n=1/13 
(7.69%) 
No change 0 0 No change 
Type: Moderate to 
strong painkillers  
n=1/16 
(6.25%) 
0 Improved n=2/13 
(15.38%) 
n=2/13 
(15.38%) 
No change n=1/10 
(10%) 
n=2/10 
(20%) 
Worse 
Type: Angina or high 
blood pressure 
n=2/16 
(12.5%) 
n=2/16 
(11.77%) 
No change n=1/13 
(7.69%) 
n=1/13 
(7.69%) 
No change 0 0 No change 
 
 
 
Participant costs 
Table 12. Participant costs 
Time (12 weeks) 
Variable Co-PARS Usual Care No intervention control  
Number of one-to-one 
consultations with ERP 
Mean: 2.21  
Median: 2  
Range: 1-4 
Answered question correctly: n=19/25 
Mean: 1.4 
Median: 1 
Range: 1-3 
Answered question correctly: 10/16 
n/a 
 
Travel time one-way from 
home to leisure centre (two-
way/ return) 
Mean:19mins (38mins) 
Median:15mins (30mins)  
Range:5-60mins (10-120mins) 
Answered question correctly: 19/25 
Mean: 13mins (26mins) 
Median: 10mins (20mins) 
Range: 3-60mins (5-120mins) 
Answered question correctly: 13/16 
Consultation time per visit Mean: 53mins  
Median: 40mins  
Range: 30-120mins 
Answered question correctly: 19/25 
Mean: 62mins  
Median: 60mins  
Range: 15-150mins 
Answered question correctly: 14/16 
Activity displaced due to 
taking part  
Answered question correctly (selected 
one activity): 15/25 
More than one activity named: 7/25 
Most common: Leisure Time only n=5/15  
 
Answered question correctly (selected 
one activity): 9/16 
More than one activity named: 5/16 
Most common: Housework only 
n=5/16 
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Lost time in work due to 
attending in consultations  
Yes: n=3/15  
Loss of earnings due to attending 
consultations: n=1/3 
Number of hours of paid work missed: 1 
hour x1 time (n=1/1) 
Yes: n=2/9 
Loss of earnings due to attending 
consultations: n=0/2 
Number of hours of paid work missed: 
n/a 
Travel distance (12 weeks) 
Variable Co-PARS Usual Care No intervention control  
Most common mode of travel 
to the leisure centre 
Private car  n=11/20 Private car n=9/11 n/a 
Private car  miles travelled Mean: 2.6 miles  
Median: 2 miles 
Range: 1-8 miles 
Answered question correctly: n=10/11 
Mean: 2.4 miles  
Median: 2.5 miles 
Range: 1-3 miles 
Answered question correctly: n=8/9 
Out of pocket costs (12 weeks) 
Variable Co-PARS Usual Care No intervention control  
Incurred a cost (excluding 
induction fee) 
Answered question correctly: n=23/25 
Incurred a cost: n=13/23 
 
Answered question correctly: n=14/16 
Incurred a cost: n=6/14 
Answered the question correctly: 
n=12/14 
Incurred a cost: n=7/12 
Gym membership cost* Range: £7-£30 
n=7/13 
Range: £20-£163 
n=2/6 
Range: £42-£63 
n=5/7 
Clothing/ footwear item Range: £14-£54 
n=4/13 
Range: £55-90 
n=2/6 
Range: £50-160 
n=2/7 
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Equipment  Range: £6-£199 (fitbit watch) 
n=3/13 
n=0/6 n=0/7 
Class/ Swimming sessions* Range: £4-£30 
n=6/13 
Range: £1-£12 
n=3/6 
Range: £5.50-£72 
n=6/7 
Outdoor activities n=0/13 n=0/6 Range: £30-£240 (2xIronman+open 
water swimming) 
n=2/7 
Personal trainer £30 per hour x2 
n=1/13 
n=0/6 0/7 
Out-of-pocket costs (6 Months) 
Variable Co-PARS Usual Care No intervention control  
Incurred a cost (excluding 
induction fee) 
n=17/25 n=12/15 n=8/14 
Gym membership cost* Range: £15-£150 
n=9/17 
Range: £15-£150 
n=6/12 
Range: £20-£56 
n=5/8 
Clothing/ footwear item Range: £6-£65 
n=6/17 
Range: £35-£100 
n=2/12 
Range: £50-150 
n=4/8 
Equipment  Price: £22 (bike tyres) 
n=1/17 
n=0/12 n=0/8 
Class/ Swimming sessions* Range: £1-£82 
n=8/17 
Range: £1-£30 
n=5/12 
Range: £16.50-£240 
n=3/8 
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Outdoor activities (excluding 
travel/ accommodation) 
n=0/17 n=0/12 Range: £50-£150 (1/2 Ironman) 
n=2/8 
Personal trainer n=0/17 n=0/12 n=0/8 
HCU (Baseline and 6 Months) 
Variable Co-PARS Usual Care No intervention control  
Private HCU at Baseline • 60mins with Acupuncturist (2 at 
clinic)= £98.40 (n=1) 
• 30mins with Chiropractor (3 at 
clinic)= £73.80 (n=1) 
• 10mins with Podiatrist (4 at 
clinic)= £65.60 (n=1) 
• 30mins with Acupuncturist (1 at 
clinic)= £24.60 (n=1) 
 • 60mins Sports Massage (6 at 
clinic)= £270 (n=1) 
  
Private HCU at 6 months • 60mins with Counsellor (6 at 
clinic)= £295.20 (n=1) 
• 45mins with Acupuncturist (6 at 
clinic)= £221.40 (n=1) 
• 15mins with Podiatrist (2 at 
clinic)= £24.60 (n=1) 
• GP consultations (10 at 
surgery; 1 telephone)= 
£365.99  (n=1) 
• 60mins Physiotherapy (24 at 
clinic)= £393.60 (n=1) 
• 60mins Sports Massage (1 at 
clinic; 4 at home)= £225 (n=1) 
• 45mins with Chiropractor (1 at 
clinic)= £36.90 (n=1) 
*unclear whether referring to per item or aggregate total; **unclear if per same leisure centre as intervention and also if represents per month or past 3 month 
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Willingness to pay analysis 
By large, participants in the control group were willing-to-pay twice as much (£19.64) than the coPARS (£8.23) and usual care (£9.25) group for a hypothetical induction. 
Similarly, the control group were willing-to-pay twice as much (£13.23) than the Co-PARS (£4.64) and usual care (£6.07) group  for a face-to-face consultation. Co-PARS 
participants appeared to value the swimming sessions slightly more than the gym sessions and exercises classes. 
Table 13. Participants’ willingness to pay 
Willingness to pay (reported at 6 months) 
Variable coPARS Usual Care No intervention control  
Willingness to pay per 
induction 
Mean: £8.23  
Median: £8.50 
Range: £0- £20 
Answered question correctly: n=22/25 
Most deprived quintile: n=11/22 (50%) 
Mean: £9.25  
Median: £8.75 
Range: £0- £20 
Answered question correctly: 
n=14/16 
Most deprived quintile: n=3/14 
(21.42%) 
Mean: £19.64  
Median: £20 
Range: £0- £40 
Answered question correctly: 
n=14/14 
Most deprived quintile: n=4/14 
(21.42%) 
Willingness to pay per 
face-to-face progress 
consultation  
Mean: £4.64 
Median: £3 
Range: £0- £20 
Answered question correctly: n=22/25 
Most deprived quintile: n=11/22 (50%) 
Mean: £6.07  
Median: £5 
Range: £0- £20 
Answered question correctly: 
n=15/16 
Most deprived quintile: n=3/15 
(20%) 
Mean: £13.23  
Median: £10 
Range: £0- £50 
Answered question correctly: 
n=13/14 
Most deprived quintile: n=4/13 
(30.77%) 
Willingness to pay per 
telephone progress 
consultation 
Mean: £0.64 
Median: £0 
Range: £0- £5 
Answered question correctly: n=19/25 
Mean: £1.60  
Median: £1 
Range: £0- £8 
Mean: £6.50  
Median: £3.50 
Range: £0- £30 
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Most deprived quintile: n=10/19 
(52.63%) 
Answered question correctly: 
n=15/16 
Most deprived quintile: n=3/15 
(20%) 
Answered question correctly: 
n=12/14 
Most deprived quintile: n=4/12 
(33.33%) 
Willingness to pay per 
swimming session 
Mean: £3.24 
Median: £2.50 
Range: £0- £20 
Answered question correctly: n=22/25 
Most deprived quintile: n=11/22 (50%) 
Mean: £2.70  
Median: £3 
Range: £0- £5 
Answered question correctly: 
n=15/16 
Most deprived quintile: n=3/15 
(20%) 
Mean: £3.93  
Median: £5 
Range: £0- £10 
Answered question correctly: 
n=14/14 
Most deprived quintile: n=4/14 
(21.42%) 
Willingness to pay per 
gym session 
Mean: £2.70 
Median: £2 
Range: £0- £10 
Answered question correctly: n=22/25 
Most deprived quintile: n=11/22 (50%) 
Mean: £3.63  
Median: £3 
Range: £1- £10 
Answered question correctly: 
n=15/16 
Most deprived quintile: n=3/15 
(20%) 
Mean: £6.79  
Median: £5 
Range: £0- £20 
Answered question correctly: 
n=14/14 
Most deprived quintile: n=4/14 
(21.42%) 
Willingness to pay per 
exercise class 
Mean: £2.50 
Median: £2 
Range: £0- £5 
Answered question correctly: n=21/25 
Most deprived quintile: n=10/21 
(48.57%) 
Mean: £3.10  
Median: £3 
Range: £0- £5 
Answered question correctly: 
n=15/16 
Most deprived quintile: n=3/15 
(20%) 
Mean: £6.61  
Median: £5 
Range: £0- £20 
Answered question correctly: 
n=14/14 
Most deprived quintile: n=4/14 
(21.42%) 
 
 
Appendix D.1. Intervention materials  
 
 
 
 
LIVERPOOL JOHN MOORES UNIVERSITY   
CALL AGENT SCREENING FORM 
  
Agent Name: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Email: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Hours worked per week: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Contract type: Agency/ Permanent  
Team leader: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
Criteria Met 
(Y/N) 
Comments 
Full time member of staff ≥0.6 full time or part time equivalent 
worker (22.5h min) 
 
  
Call agent job role    
Based onsite (Kirkby)  throughout the trial period (July 
2018-March 2019)  
 
  
Access to a work telephone and desktop computer with 
internet  
 
  
Aged ≥18 years    
 
Ambulatory- Able to walk without aid 
 
  
No health problems that would impact ability to stand for 
10 minutes at a time  
 
  
No planned absence >3 weeks during first 3 months of 
the trial [July-October 2018] 
 
  
No planned relocation to another workplace/site during 
the first 3 months of the intervention [July-October 2018] 
 
  
Not pregnant    
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2. Example of weekly infographic email 
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3. Example of daily log book 
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Appendix D.2. Microcosting exercise 
Figure 1. CONSORT Flow Diagram of SLaMM+ intervention and SLaMM (active control) 
 
 
 
Weekly electronic log 
In Table 1 we are trying to find out about the additional costs to Serco, for setting up the Sit Less and Move More (SLaMM) Project. Please complete the basic information 
section followed by Table 1. For the table please write the purpose of the additional setting up costs and the amount of time or money you spent. Please refer to the examples 
in grey for guidance. If you are not sure or cannot remember the exact details, please give the best answer you can. If you have a problem in completing the table, please 
contact the Researcher Maddy Cochrane from Liverpool John Moores University: m.a.cochrane@2016.ljmu.ac.uk 
 
Question 1: Staff Member Job Title=  
Question 2: Staff Salary Band (Optional)=  
 
Table 1. Additional setting up costs 
Purpose (Please detail the task type and/or equipment)  Time spent (mins/ hours) 
/ Amount if equipment 
( £……-….p)   
Additional information (if possible 
to add detail) 
Example of time: scheduling Call Agent Briefs  7 hours 5 hours one day and 2 hours on one 
day the week after 
Example of equipment: printing off posters from Serco Printer to advertise the Sit Less and Move More 
Project 
 
50p 
 
5 sheets, 10p per sheet 
Example of time: Email contact with other Serco staff about organising Team Leader Briefs  
 
5 mins  
Example of time: Meetings about organising Team Leader Briefs  
 
None  
Team Leader Briefs 
 
Time spent (mins/ hours) 
/ Amount if equipment 
( £……-….p)   
Additional information (if possible 
to add detail) 
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Scheduling Team Leader Briefs into Excel Spreadsheets 
 
  
Face-to-face meetings about organising Team Leader Briefs 
  
  
Email contact about organising Team Leader Briefs 
 
  
Telephone contact about organising Team Leader Briefs  
 
 
  
Call Agent Briefs 
 
Time spent (mins/ hours) 
/ Amount if equipment 
( £……-….p)   
Additional information (if possible 
to add detail) 
Scheduling Call Agent Briefs into Excel Spreadsheets 
 
  
Face-to-face meetings about organising Call Agent Briefs 
 
  
Email contact organising Call Agent Briefs  
 
  
Telephone contact about organising Call Agent Briefs 
 
  
Call Agent Health Checks 
 
Time spent (mins/ hours) 
/ Amount if equipment 
( £……-….p)   
Additional information (if possible 
to add detail) 
Scheduling Call Agent Health Checks into Excel Spreadsheets 
 
  
Face-to-face meetings about organising Call Agent Health Checks  
 
  
Email contact about organising Call Agent Health Checks  
 
  
Telephone contact about organising Call Agent Health Checks  
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The 1st Call Agent Education and Training Session 
 
Time spent (mins/ hours) 
/ Amount if equipment 
( £……-….p)   
Additional information (if possible 
to add detail) 
Scheduling the 1st Call Agent Education and Training Session into Excel Spreadsheets 
 
  
Face-to-face meetings about organising the 1st Call Agent Education and Training Session  
 
  
Email contact about organising the 1st Call Agent Education and Training Session  
 
  
Telephone about organising the 1st Call Agent Education and Training Session  
 
  
Other tasks/ materials not detailed above 
 
Time spent (mins/ hours) 
/ Amount if equipment 
( £……-….p)   
Additional information (if possible 
to add detail) 
 
 
  
 
 
  
 
 
 
Microcosting spreadsheet tool 
The structure of the microcosting exercise tool is based on four types of resources: people, place, 
programme specific and payments. Definitions for these four concepts have been informed by the 
ACE-Prevention approach (Vos et al., 2007) and TIDieR framework (Hoffmann et al., 2014). 
1. People: Who does what, when and how, and who else is involved 
2. Place: Where does it happen and consequently what fixed (capital) equipment (resources) 
are needed 
3. Programme specific: What variable equipment (resources) are needed  
4. Payments: What out-of-pocket costs are paid 
The tables below, provide examples of the microcosting tables populated in an Excel spreadsheet for 
the microcosting of the SLaMM+ intervention from the public sector and private sector employer’s 
perspective. The same spreadsheet was used to estimate the SLaMM (active control) costs with the 
deduction of the heigh-adjustable desk costs.   
Table 1.1. People: Who does what, when and how  
Activity name When 
(week) 
1.1. Who (& how) 1.1. 
Frequency 
(number of 
times) 
1.1. 
Duration 
(hours in 
decimals 
format) 
1.1. Unit 
cost 
(£hour) 
1.1. 
Total 
cost 
(£) 
Height-adjustable desk 
July- 
October 
2017 Agent 20 0 0 0 
Weekly emails 
July- 
October 
2018 
Grade 6 researcher 
via email 12 0.0833 23.54 23.53 
Organisation of 
Education & Training 
sessions 
At least 1 
week 
before 
Week 1, 3, 
10 
Grade 6 researcher 
via email/ telephone 3 0.25 23.54 17.66 
Education & training 
sessions 
Week 1, 3, 
10 
Grade 6 researcher 
face to face 12 0.75 23.54 
211.8
6 
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Table 1.2. Who else is involved 
Activity name 1.2. Who 
else: 
Participant 
1.2. Frequency 1.2. 
Duration 
(hours in 
decimals 
format)  
1.2. Unit cost 
(£per hour) 
1.2. Total 
cost 
Height-adjustable desk 0 0 0 0 0 
Weekly emails 
Team Manager- 
centre contact 12 0.0833 26.31 26.30 
Organisation of 
Education & Training 
sessions 
Resource 
planner 3 1.65 19.6 97.02 
Education & training 
sessions Call agent 
120 (40 agents x 3 
sessions)  0.5 7.87 472.2 
 
Table 2.1. Where does it happen  
Activity name 2.1. Where: 
Capital 
equipment/ fixed 
costs 
2.1. Frequency 2.1. Duration 
(hours in 
decimals 
format)  
2.1. Unit cost 
(£ per hour) 
2.1. 
Total 
cost (£) 
Height-adjustable desk Office floor 0 0 0 0 
Weekly emails Via email 12 0 0 0 
Organisation of 
Education & Training 
sessions Email/ Telephone 6 0 0 0 
Education & training 
sessions 
Private room in 
contact centre 1 1 0 0 
 
Table 2.2. What fixed (capital) resources (equipment) are needed 
Activity name 2.2. Where: Capital 
equipment/ fixed costs 
2.2. 
Frequenc
y  
2.2. 
Dura
tion 
2.2. Unit 
cost (£) 
2.2.Total cost 
(£) 
Height-adjustable desk 0 0 0 0 0 
Weekly emails Email 12 0 0 0 
Organisation of Education 
& Training sessions Email/ telephone 2 0 0 0 
Education & training 
sessions 
Contact centre- Travel for 
Researchers (1 car) 1 14.8 0.15 2.22 
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Table 3.1. What variable equipment (resources) are needed  
Activity name 3.1.Equipment (variable 
costs) 
3.1. Frequency 
(pages) 
3.1. Unit cost 
(£ page of 
printing) 
3.1. Total cost 
(£) 
Height-adjustable desk 
Posturite height 
adjustable desk 19 14.73 279.87 
Weekly emails IT system 1 0 0 
Organisation of Education 
& Training sessions IT system 3 0 0 
Education & training 
sessions IT system 3 0.75 0 
 
Table 3.2. What other variable equipment (resources) are needed 
Activity name 3.2. Equipment (variable 
costs) 
3.2. 
Frequency 
(months) 
3.2. Unit cost (£) 3.2. Total 
cost (£) 
Height-adjustable desk Printing of instructions A4 19 0.07 1.33 
Weekly emails 
   
0 
Organisation of 
Education & Training 
sessions 
   
0 
Education & training 
sessions Timer  40 2.38 95.2 
 
Table 3.3. What other variable equipment (resources) are needed 
Activity name 3.3. Equipment (variable 
costs) 
3.3. Frequency  3.3. Unit 
cost (£) 
3.3. Total 
cost (£) 
Height-adjustable desk Lamination cost A4 19 0.18 3.42 
Weekly emails 
   
0 
Organisation of Education 
& Training sessions 
   
0 
Education & training 
sessions 
Printing log book A7 (8 weeks 
per page; 2 pages for 12 weeks) 38 0.07 2.66 
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Table 4.1. What other out of pocket costs are paid  
Activity name 4.1. Out of pocket costs 
(Participants) 
4.1. Frequency 4.1. Unit 
cost (£) 
4.1. 
Total 
cost (£) 
Height-adjustable desk 0 0 0 0 
Weekly emails 0 0 0 0 
Organisation of Education & 
Training sessions 0 0 0 0 
Education & training 
sessions 0 0 0 0 
 
 
 
Appendix D.3. Unit cost calculations 
Table 1. Unit cost healthcare utilisation 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit cost 
for 
£2018 
GP clinic Cost per 9.22 
minutes  
Curtis and 
Burns (2018) 
Unit cost used was GP with qualifications but 
excluding direct care staff. This approach was 
used by Anokye et al. (2018) 
 
Self-reported consultation time by all 3 groups. 
Mean= 11.9 minutes; Median= 10 minutes; 
Range= 5-30mins  
£34 per 9.22 
minute 
consultation 
(2018) 
No £34 
GP Home visit Cost per 1 
minute= £3.66 
 
Curtis and 
Burns (2018) 
Average travel time of 12 minutes was taken from 
Curtis (2015) and added to the average clinic 
consultation time of 9.22 minutes from Curtis and 
Burns (2018). It was therefore assumed the 
average time was 21.22 minutes.  
£77.66 per 
21.22 minute 
consultation 
(2018)  
No £77.66 
GP telephone call Cost per 1 
minute= £3.60 
Curtis and 
Burns (2018) 
Average telephone call of 7.1 minutes was taken 
from Curtis (2015). 
£25.99 per 7.1 
minute 
consultation 
(2018) 
No £25.99 
Practice Nurse 
clinic1 
£42 per hour 
with 
qualifications  
Curtis and 
Burns (2018)  
Unit cost used was Practice Nurse with 
qualifications. This approach was used by Anokye 
et al. (2018) 
 
£42 per hour equates to £0.70 per minute. Time 
spent with the practice nurse varied from 5-
20minutes, therefore a standard published time 
£10.85 per 
15.5 minute 
consultation 
(2018) 
No £10.85 
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was applied, assuming the average consultation 
time is 15.5 minutes, taken from Curtis (2015). 
Physiotherapist Zero visits baseline nor 12 weeks 
 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit cost 
for 
£2018 
Chiropractor Zero visits baseline nor 12 weeks 
Osteopath Zero visits baseline nor 12 weeks 
Occupational 
Therapist 
Zero visits baseline nor 12 weeks 
Acupuncturist Zero visits baseline nor 12 weeks 
Specialist Nurse 
clinic2 
£87 per hour  Curtis (2017) Band 7 Specialist Nurse Cost per hour was £87/ 
cost per minute was £1,45 (Curtis, 2017)  
£1.45 (2017) Yes. UK’s GDP Deflator 
was applied to inflate the 
price from 2016/17 to 
2018/19 (Multiplier 1.0392). 
£1.51 per minute 
£1.51  
District Nurse Zero visits baseline nor 12 weeks 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit cost 
for 
£2018 
Counsellor1,2  £49.38 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
In line with the other similar allied Health 
Professionals Band 6 was used (Curtis and Burns, 
2018). The cost per working hour is £46 excluding 
qualifications (Curtis and Burns, 2018). With 
qualifications it is £5,410 extra per year (there is 
no unit cost for Counsellor or Psychologist 
qualifications, therefore Physiotherapists unit cost 
£0.82 per 
minute, 
consultation 
length as 
reported by 
participant 
No £0.82 
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was used: £5,410/ working hours per year 
(1,599)= £3.38 per hour.  
 
£46+3.38= £49.38 per hour/ £0.82 per minute 
(£2018). 
Pharmacist 1,2 £51.17 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
It was assumed the Pharmacist would be a Band 
6 (Curtis and Burns, 2018). The cost per working 
hour is £46 excluding qualifications (Curtis and 
Burns, 2018). With qualifications it is £8,263 extra 
per year (1,599 hours per year for Band 6): £5.17 
per hour 
 
£46+5.17= £51.17 per hour/ £0.85per minute 
(£2018) 
£0.85 per 
minute, 
consultation 
length as 
reported by 
participant 
No £0.85 
Healthcare 
assistant clinic2 
£10.79 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Healthcare Assistants are Band 2 with an annual 
pay rate from April 2018 of £17,260 for those 
experienced between <1 year to 5 years. 
According to Curtis and Burn (2018) most 
community health care staff work 42.6 weeks 
(1599 hours) per year. Unit cost= £10.79 per hour 
or £0.18 per minute. Efforts to estimate the 
overhead costs were not done due to the small 
magnitude of this cost in terms of the quantity and 
unit cost (just two participant reported this 
resource) and the small magnitude of the unit cost 
for this health professional (Drummond et al. 
2015: 220). 
£0.18 per 
minute 
No £0.18 
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Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit cost 
for 
£2018 
Support Worker Zero visits baseline nor 12 weeks 
Phlebotomist2 £10.79 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Phlebotomist’s are Band 2 with an annual pay rate 
from April 2018 of £17,260 for those experienced 
between <1 year to 5 years. According to Curtis 
and Burn (2018) most community health care staff 
work 42.6 weeks (1599 hours) per year. Unit cost= 
£10.79 per hour or £0.18 per minute. Efforts to 
estimate the overhead costs were not done due to 
the small magnitude of this cost in terms of the 
quantity and unit cost (just one participant 
reported this resource) and the small magnitude of 
the unit cost for this health professional 
(Drummond et al. 2015: 220). 
£0.18 per 
minute 
No £0.18 
Podiatrist Zero visits baseline nor 12 weeks 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit cost 
for 
£2018 
Dietician2 £48.52 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
Unit cost is not broken down by type of visit, 
therefore the same unit cost was applied for clinic 
visits, home visits and telephone consultations. At 
Band 6, the average salary Band for Dietician 
(Curtis and Burns, 2018) the cost per working hour 
is £45 excluding qualifications (Curtis and Burns, 
£0.81 per 
minute, 
consultation 
length as 
reported by 
participant 
No £0.81 
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2018). With qualifications it is £5,622 extra per 
year for Dietician. £5,622/ working hours per year 
(1,599)= £3.52 per hour.  
 
£45+£3.52= £48.52 per hour/ £0.81 per minute 
(£2018). 
Social Worker Zero visits baseline nor 12 weeks 
Speech Therapist 
1,2 
£48.47 per 
hour with 
qualifications 
Curtis and 
Burns (2018) 
At Band 6, the average salary Band for Speech 
Therapist (Curtis and Burns, 2018) the cost per 
working hour is £45 excluding qualifications 
(Curtis and Burns, 2018). With qualifications it is 
£5,556 extra per year for Speech Therapist. 
£5,556/ working hours per year (1,599)= £3.47 per 
hour.  
 
£45+£3.47= £48.47 per hour/ £0.81 per minute 
(£2018). 
 
£0.81 per 
minute, 
consultation 
length as 
reported by 
participant 
No £0.81 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit cost 
for 
£2018 
Mental Health 
Professional2 
£24.24 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Mental Health Nurses. The participants were not 
asked to specify what type of Mental Health 
Professional, therefore it was assumed the same 
Mental Health Professionals delivering the 
Behavioural Activation interventions would apply 
(Curtis and Burns, 2018). Wages of Mental Health 
£0.40 per 
minute 
No £0.40 
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Nurses are Band 7 (according to Curtis and Burn, 
2018) with an annual pay rate from April 2018 of 
£38,765 for those experienced between 4-5 years. 
According to Curtis and Burn (2018) most 
community health care staff work 42.6 weeks 
(1599 hours) per year. Unit cost= £24.24 per hour 
or £0.40 per minute. Efforts to estimate the 
overhead costs were not done due to the small 
magnitude of this cost in terms of the quantity and 
unit cost (just one participant reported this 
resource) and the small magnitude of the unit cost 
for this health professional (Drummond et al. 
2015: 220). 
Health Trainer2 £13.65 per 
hour 
Agenda for 
Change (2018) 
According to the Agenda for Change Band’s 
Healthcare Assistants are Band 4 with an annual 
pay rate from April 2018 of £21,819 for those 
experienced between 3-4 years. According to 
Curtis and Burn (2018) most community health 
care staff work 42.6 weeks (1599 hours) per year. 
Unit cost= £13.65 per hour or £0.28 per minute. 
Efforts to estimate the overhead costs were not 
done due to the small magnitude of this cost in 
terms of the quantity and unit cost (just two 
participant reported this resource) and the small 
magnitude of the unit cost for this health 
professional (Drummond et al. 2015: 220). 
£0.28 per 
minute 
No £0.28 
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Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit cost 
for 
£2018 
Number of hospital 
admissions for 
inpatient care 
(stayed overnight) 
£3,894 NHS reference 
costs (2018) 
Hospital admissions for inpatient care, assuming 
this care is elective (planned), if it was non-
elective inpatient care then this would be a lower 
cost at £1,603 per case. Cost data in the UK is 
coded by Healthcare Resource Groups (HRGs) for 
which there are over 2,812 groups (NHS 2018). 
Selecting a cost requires accurate description by 
the participant if using a self-reported 
questionnaire as well as expertise on the 
descriptions of the HRGs and then judgement to 
decide which description matches the participants 
best out of the 2,812 HRG groups.  
 
Type of procedure in secondary care was only 
recommended as a bolt on module item to collect 
for studies specifically concerned with extended 
hospital care because for instance, admissions 
and re-admissions are prevalent (Thorn et al. 
2018) ISRUM 
 
Each HRG had an expected bed day, it was 
assumed participants did not exceed the expected 
bed day and so the exceeded bed day unit cost 
(£346) was not added on. 
£3,894 No £3,894 
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Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit cost 
for 
£2018 
Number of hospital 
admissions for day 
patient care 
£742 NHS reference 
costs (2018) 
Cost data in the UK is coded by Healthcare 
Resource Groups (HRGs) for which there are over 
2,812 groups (NHS 2018). Selecting a cost 
requires accurate description by the participant if 
using a self-reported questionnaire as well as 
expertise on the descriptions of the HRGs and 
then judgement to decide which description 
matches the participants best out of the 2,812 
HRG groups. 
£742 No £742 
Number of hospital 
outpatient 
appointments  
£125 NHS reference 
costs (2018) 
Cost data in the UK is coded by Healthcare 
Resource Groups (HRGs) for which there are over 
2,812 groups (NHS 2018). Selecting a cost 
requires accurate description by the participant if 
using a self-reported questionnaire as well as 
expertise on the descriptions of the HRGs and 
then judgement to decide which description 
matches the participants best out of the 2,812 
HRG groups. 
£125 No £125 
Number of visits to 
A&E  
£160 NHS reference 
costs (2018) 
A&E attendance £160 No £160 
Number of 
admissions to 
hospital, after A&E 
£1,603 NHS reference 
costs (2018) 
Non-elective inpatient (excluding excess bed 
days): £1,603 per case. Non-elective means 
emergency, but can be via GP not just A&E 
 
 
£1,603 No £1,603 
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Intervention costs 
Cost item Published 
unit cost 
Published 
source for 
unit cost  
Assumptions and calculations of unit cost Calculated 
unit cost 
(price year) 
Adjustment to price year Unit cost 
for 
£2018 
Grade 6 
Researcher*  
£23.54 LJMU pay 
(2018) 
Grade 6 Researcher (mean annual income of 
£35,929) including salary on-costs (national 
insurance and superannuation of 14%). University 
contract of 6 weeks annual leave, 8 bank holidays, 
4 days Christmas closure; 35 hours per week. 
1526 hours per year. Hourly unit cost= £23.54 
£23.54 No £23.54 
Senior Manager* £35,000-
£50,000 
UK average by 
Search 
Recruitment 
study (2010)  
Call Centre Manager (mean annual income of 
£42,500 which excludes salary on costs). If 
including salary on-costs (national insurance UK 
2018 rate of 13.8% and superannuation of 14% 
was applied in line with the research professionals 
in this study) the annual total cost=£42,550 x 
1.278= £54,315 per year. Assuming senior 
permanent staff have longer holidays: Assuming a 
control of 6 weeks annual leave, 8 bank holidays, 
4 days Christmas closure; 35 hours per week. 
1526 hours per year. Hourly unit cost= £35.59 
£35.59 Yes. UK’s GDP Deflator 
was applied to inflate the 
price from 2010/11 to 
2018/19 (Multiplier 1.1424). 
£40.66 
Team Manager* £25,000-
£30,000 
UK average by 
Search 
Recruitment 
study (2010)  
Team Manager (mean annual income of £27,500 
which excludes salary on costs). If including salary 
on-costs (national insurance UK 2018 rate of 
13.8% and superannuation of 14% was applied in 
line with the research professionals in this study) 
the annual total cost=£27,500 x 1.278= £35,145 
£23.03 Yes. UK’s GDP Deflator 
was applied to inflate the 
price from 2010 to 2018/19 
(Multiplier 1.1424). 
£26.31 
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per year. Assuming 28 days (5.6 weeks) leave; 
37.5 hours per week. 1740 hours per year. Hourly 
unit cost= £20.19 
Resource planner* £18,000-
£23,000 
UK average by 
Search 
Recruitment 
study (2010)  
Call Centre Manager (mean annual income of 
£20,500 which excludes salary on costs). If 
including salary on-costs (national insurance UK 
2018 rate of 13.8% and superannuation of 14% 
was applied in line with the research professionals 
in this study) the annual total cost=£20,500 x 
1.278= £26,199 per year. Assuming 28 days (5.6 
weeks) leave; 37.5 hours per week. 1740 hours 
per year. Hourly unit cost= £15.05 
£15.05 Yes. UK’s GDP Deflator 
was applied to inflate the 
price from 2010 to 2018/19 
(Multiplier 1.1424). 
£17.19 
Call agent* £12,000-
£16,000 
UK average by 
Search 
Recruitment 
study (2010)  
Call Centre Manager (mean annual income of 
£12,000 which excludes salary on costs, over 80% 
agents are not permanent staff; majority of staff 
had worked there less than 1 year). Assuming 28 
days (5.6 weeks) leave; 37.5 hours per week. 
1740 hours per year. Hourly unit cost= £6.89 
£6.89 Yes. UK’s GDP Deflator 
was applied to inflate the 
price from 2010 to 2018/19 
(Multiplier 1.1424). 
£7.87 
Travel to contact 
centre 
0.15 pence per 
mile 
AA mileage 
calculator 
(2018) 
7.4 miles one way (14.8 miles return) based on 
postcode of research institute and contact centre 
postcode. One car for all researchers. 
£2.22 No £2.22 
Posturite height 
adjustable desk 
£319.14 Posturite 
deskrite 100 
sit-stand 
platform 
(2018) 
Inclusive of VAT. 
https://www.posturite.co.uk/deskrite-100-sit-stand-
platform.html  
The desk life was not reported. It was assumed to 
have an expected lifetime of 5 years (as 
recommended in Drummond et al. (2015) on the 
expected lifetime of equipment). Calculation: 52 
£14.73 No £14.73 
 
 
312 
 
weeks x 5= 260 weeks. Cost for 12 weeks= 
12/260= 0.046 x £319.14= £14.73 per 12 week 
period 
Laminated 
instructions card 
£0.07 per A4 
page in colour; 
Lamination 
£1.04 per A4 
page 
Research 
Insitute’s 
Printing costs 
(2018) 
Calculation per participant: £0.07+£1.04= £1.11 £1.11 No £1.11 
Timer £2.38 Receipt (2018) Unit cost per timer: £2.38 inclusive of VAT 
https://www.nisbets.co.uk/canteen-magnetic-
countdown-timer/df672  
£2.38  No £2.38 
Log book £0.07 per 
page in colour 
Research 
Insitute’s 
Printing costs 
(2018) 
Calculation per participant: A7 booklets requires 2 
pages, £0.07 x 2= £0.14 
£0.14 No £0.14 
* Efforts to estimate the overhead costs were not done due to the small magnitude of this cost in terms of the quantity and unit cost (just two participant reported this resource) 
and the small magnitude of the unit cost for this health professional (Drummond et al. 2015: 220). 
 
 
Appendix D.4. Disaggregated costs and consequences 
Table 1. Cost-utility analysis results unadjusted results 
Variable SLaMM+ SLaMM 
Mean (SD) per participant Mean (SD) per participant 
QALYs 0.188 (SD: 0.045) 0.201 (SD: 0.031) 
Total costs  £497.51 (SD: £1,356.59) £309.22 (SD: £89.16) 
Incremental QALYs & Costs  
Incremental QALYs: 
SLaMM+ vs SLaMM 
-0.0137 (SE: 0.0124; 95% CI: -0.0381 to 0.0106); this means the SLaMM+ group has 0.0137 
less QALYs compared to SLaMM  
Incremental Costs: 
SLaMM+ vs SLaMM 
£188.29 (SE:£318.81; 95% CI: £-436.57 to £813.15); this means the SLaMM+ group costs 
£188.29 more than the SLaMM group 
ICER statistic 
ICER  £-13,731 per QALY 
 
Table 2. Research Institute (Payer) Perspective: Intervention operating costs 
Key intervention 
activities 
SLaMM+ SLaMM 
Description of resources 
consumed 
Mean cost 
per 
participant 
Description of resources 
consumed 
Mean cost 
per 
participant 
Height-adjustable 
desk 
Cost of height-adjustable desk 
for 12-weeks assuming a desk 
life of 5 years; Printing; 
Laminated instruction sheet  
£14.23 n/a £0 
Weekly emails Time of Grade 6 researcher to 
disseminate infographic via email 
(5mins x12 weeks) 
£0.59 Time of Grade 6 researcher to 
disseminate infographic via email 
(5mins x12 weeks) 
£0.59 
Organisation of 
Education & 
Training Sessions 
Time of Grade 6 researcher to 
organise sessions (15 mins x3 
sessions)  
£0.44 Time of Grade 6 researcher to 
organise sessions (15 mins x3 
sessions) 
£0.44 
Delivery of 
Education & 
Training sessions 
Time of Grade 6 researcher 
(30mins x 3+15mins preparation 
time); Travel costs to workplace 
(14.8 miles return journey); 
Timer; Printing 
£7.80 Time of Grade 6 researcher 
(30mins x 3+15mins preparation 
time); Travel costs to workplace 
(14.8 miles return journey); Timer; 
Printing 
£7.80 
Total costs  £23.06  £8.83 
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Table 3. Employer (host) Perspective: Intervention operating costs 
Key intervention 
activities 
SLaMM+ SLaMM 
Description of resources 
consumed 
Mean cost 
per 
participant 
Description of resources consumed Mean cost 
per 
participant 
Height-adjustable 
desk 
No costs incurred by employer £0 n/a £0 
Weekly emails Time of Centre Contact to 
disseminate via email (5mins 
x12 weeks); Time of call agent 
to review infographic via work 
email (1minx12 weeks) 
£2.23 Time of Centre Contact to 
disseminate via email (5mins x12 
weeks); Time of call agent to review 
infographic via work email (1minx12 
weeks) 
£2.23 
Organisation of 
Education & 
Training Sessions 
Time of Centre Contact to 
organise sessions (15 mins x3 
sessions); Time of Resource 
Planner to organise sessions 
(3x45minutes to scheduling 
offline time+15minutes 
email/phone communication) 
£2.92 Time of Centre Contact to organise 
sessions (15 mins x3 sessions); 
Time of Resource Planner to 
organise sessions (3x45minutes to 
scheduling offline time+15minutes 
email/phone communication) 
£2.92 
Delivery of 
Education & 
Training sessions 
Time of agents to attend 
sessions during worktime 
(30minutesx3 sessions); Time of 
Centre Contact to coordinate 
session (3x15minutes).   
£12.30 Time of agents to attend sessions 
during worktime (30minutesx3 
sessions); Time of Centre Contact to 
coordinate session (3x15minutes).   
£12.30 
Total costs  £17.45  £17.45 
 
Table 4. Research Institute Perspective: Intervention set up costs 
Key intervention 
activities 
SLaMM+ SLaMM 
Description of resources 
consumed 
Mean cost 
per 
participant 
Description of resources 
consumed 
Mean cost 
per 
participant 
1 hour consultation 
with senior 
management 
(approximately 3 
months before 
intervention starts) 
Time of two Grade 6 researchers 
(1 hour); Printing; Travel costs to 
workplace (14.8 miles return 
journey). 
£1.27 Time of two Grade 6 researchers 
(1 hour); Printing; Travel costs to 
workplace (14.8 miles return 
journey). 
£1.27 
30 minute 
consultation with 
Resource Planner 
(approximately 3 
Time of two Grade 6 researchers 
(30 minutes); Printing; Travel 
costs to workplace (14.8 miles 
return journey). 
£0.66 Time of two Grade 6 researchers 
(30 minutes); Printing; Travel 
costs to workplace (14.8 miles 
return journey). 
£0.66 
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months before 
intervention starts) 
Organisation of 
Team Manager 
briefs 
(approximately 3 
months before 
intervention starts)  
Time of Grade 6 researchers via 
phone/ email (15 minutes). 
£0.15 Time of Grade 6 researchers via 
phone/ email (15 minutes). 
£0.15 
Delivery of Team 
Manager briefs 
(approximately 2 
months before 
intervention starts) 
Time of Grade 6 Researcher (45 
minutes including preparation 
time); Travel costs to workplace 
(14.8 miles return journey). 
£0.50 Time of Grade 6 Researcher (45 
minutes including preparation 
time); Travel costs to workplace 
(14.8 miles return journey). 
£0.50 
Organisation of 
Agents briefs 
(approximately 2 
months before 
intervention starts) 
Time of Grade 6 researchers via 
phone/ email (15 minutes) 
£0.15 Time of Grade 6 researchers via 
phone/ email (15 minutes) 
£0.15 
Delivery of Agent 
briefs 
(approximately 1 
month before 
intervention starts) 
Time of Grade 6 researchers to 
deliver briefs (15 minutes per 
session) 
£0.64 Time of Grade 6 researchers to 
deliver briefs (15 minutes per 
session) 
£0.64 
Installation of 
height-adjustable 
desk (1 working day 
before intervention 
start date) 
Time of two Grade 6 researcher 
to install height-adjustable desks 
(2 hours); Travel costs to 
workplace (14.8 miles return 
journey). 
£2.41 n/a £0 
Total cost per 
participant 
 £5.77  £3.36 
 
Table 5. Employer’s Perspective: Intervention set up costs 
Key intervention 
activities 
SLaMM+ SLaMM 
Description of resources 
consumed 
Mean cost 
per 
participant 
Description of resources 
consumed 
Mean cost 
per 
participant 
1 hour consultation 
with senior 
management 
(approximately 3 
months before 
intervention starts) 
Time of Senior Manager at 
company (1 hour); Time of Centre 
Contact (1 hour) 
£1.67 Time of Senior Manager at 
company (1 hour); Time of Centre 
Contact (1 hour) 
£1.67 
30 minute 
consultation with 
Resource Planner 
(approximately 3 
Time of Senior Manager at 
company (30 minutes); Time of 
Resource Planner (30 minutes) 
£1.26 Time of Senior Manager at 
company (30 minutes); Time of 
Resource Planner (30 minutes) 
£1.26 
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months before 
intervention starts) 
Organisation of 
Team Manager 
briefs 
(approximately 3 
months before 
intervention starts)  
Time of Resource Planner to 
organise sessions (45 minutes); 
Time of Centre Contact to 
organise sessions via phone/ 
email (15 minutes) 
£0.53 Time of Resource Planner to 
organise sessions (45 minutes); 
Time of Centre Contact to 
organise sessions via phone/ 
email (15 minutes) 
£0.53 
Delivery of Team 
Manager briefs 
(approximately 2 
months before 
intervention starts) 
Time of two Centre Contacts to 
coordinate sessions (15 minutes); 
Time of 13 Team Managers to 
attend (15 minutes) 
£2.47 Time of two Centre Contacts to 
coordinate sessions (15 minutes); 
Time of 13 Team Managers to 
attend (15 minutes) 
£2.47 
Organisation of 
Agents briefs 
(approximately 2 
months before 
intervention starts) 
Time of Resource Planner to 
organise sessions (45 minutes); 
Time of Centre Contact to 
organise sessions via phone/ 
email (15 minutes) 
£1.07 Time of Resource Planner to 
organise sessions (45 minutes); 
Time of Centre Contact to 
organise sessions via phone/ 
email (15 minutes) 
£1.07 
Delivery of Agent 
briefs 
(approximately 1 
month before 
intervention starts) 
Time of agents to attend brief (15 
minutes); 
Time of two Centre Contacts to 
coordinate sessions (15 minutes). 
£2.26 Time of agents to attend brief (15 
minutes); 
Time of two Centre Contacts to 
coordinate sessions (15 minutes). 
£2.26 
Installation of 
height-adjustable 
desk (1 working day 
before intervention 
start date) 
Time of two Centre Contacts to 
coordinate the installation of the 
height-adjustable desks (5 hours) 
£6.51  £0 
Total costs  £15.77  £9.26 
 
Table 6. Most commonly used primary care activity   
Resource type  Unit Cost SLaMM+ SLaMM 
Mean 
number of 
visits (SD);  
Number of 
people 
reporting any 
use 
Total Mean 
Cost (SD) 
Mean number 
of visits (SD); 
Number of 
people 
reporting any 
use 
Total Mean Cost 
(SD) 
GP consultations at 
Baseline 
£34 per 9.11 
minute 
consultation 
1.17 (2.20);  
n=9/19 
£38.78 
(£73.07) 
1.95 (2.42);  
n=13/21 
£71.09 (£93.26) 
GP consultations at 
6 months 
1.67 (2.74);  
n=8/19 
£54.44 
(£88.08) 
1.76 (3.87);  
n=12/21 
£59.10 (£113.72) 
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Practice Nurse 
consultations at 
Baseline  
£10.85 per 
15.5 minute 
consultation  
 
0.15 (0.50); 
n=2/19 
£1.71 (£5.44) 0.28 (0.78); 
n=3/21 
£3.10 (£8.50) 
Practice Nurse 
consultations at 6 
months 
0.21 (0.71); 
n=2/19 
£2.28 (£7.74) 0.19 (0.51); 
n=3/21 
£2.07 (£5.55) 
 
Counsellor at 
Baseline 
£0.82 per 
minute visit,  
range of 
average visit 
was 45 
minutes 
1.05 (3.34); 
n=0/19 
£0 (£0) 
 
1.05 (3.34); 
n=0/21 
£0 (£0) 
Counsellor at 6 
months 
1.05 (3.34); 
n=3/19 
£38.84 
(£123.29) 
0 (0); 
n=0/21 
£0 (£0) 
 
Table 7. Breakdown of all secondary care activity  
Resource type 
Unit Cost  SLaMM+ SLaMM 
Number of 
people reporting 
any use 
Total Mean 
Cost (SD) 
Number of 
people reporting 
any use 
Total Mean 
Cost (SD) 
Outpatient 
visit at 
Baseline 
£125 per 
visit 
 
n=2/19 
 
£19.74 
(£62.68) 
n=4/21 £41.67 
(£99.48) 
Outpatient and 
Day Case visit 
at 6 months 
 
n=3/19 £39.47 
(£102.51) 
n=3/21 £35.71 
(£89.64) 
Day case visit 
at Baseline 
£742 per 
visit 
n=0/19 £0 n=1/21 £35.33 
(£161.92) 
Day case visit 
at 6 months 
n=1/19 £78.11 
(£340.45) 
n=0/21 £0 
Inpatient 
admission at 
Baseline 
£3,894 per 
admission 
 
n=0/19 £0 n=1/21 £185.43 
(£849.74) 
Inpatient 
admission at 6 
months 
n=1/19 £204.95 
(£893.34) 
n=1/21 £185.43 
(£849.74) 
A&E visits at 
Baseline 
£160 per 
visit 
 
n=2/19 £16.84 
(£50.45) 
n=1/21 £7.62 (£34.91) 
A&E visits at 6 
months 
n=1/19 £33.68 
(£146.83) 
n=1/21 £7.62 (£34.91) 
 
 
Table 8. Prescribed medications in the last 12 weeks 
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 SLaMM+ SLaMM  
Prescribed any medication Baseline 40% (n=6/15); 
12-weeks 60% (n=9/15) 
Baseline 38.89% 
(n=7/18); 
12-weeks 44.44% 
(n=8/18) 
+14.45% 
Prescribed moderate-to-
strong painkillers  
Baseline 13.33% 
(n=2/15); 
12-weeks 13.33% 
(n=2/15) 
Baseline 22.22% 
(n=4/18); 16.66% 
12-weeks (n=3/18); 
-5.56% 
Prescribed antibiotics  Baseline 6.67% (n=1/15); 
12-weeks 0% (n=0/15) 
Baseline 11.11% 
(n=2/18); 
12-weeks 11.11% 
(n=2/18) 
+6.67% 
High blood pressure  Baseline n=1/15;  
12 weeks n=1/15 
Baseline n=0/18; 12 
weeks n=0/18 
No change 
High cholesterol  Baseline n=1/15;  
12 weeks n=1/15 
Baseline n=0/18; 12 
weeks n=0/18 
No change 
T2D Baseline n=1/15;  
12 weeks n=1/15 
Baseline n=0/18; 12 
weeks n=0/18 
No change 
Stomach Baseline n=1/15;  
12 weeks n=1/15 
Baseline n=0/18; 12 
weeks n=0/18 
No change 
Weight loss for obesity Baseline n=1/15;  
12 weeks n=1/15 
Baseline n=0/18; 12 
weeks n=0/18 
No change 
Antidepressants Baseline n=1/15;  
12 weeks n=1/15 
Baseline 5.56% n=1/18; 
12 weeks 0% n=0/18 
-5.56% 
Anti-inflammatory/ allergy Baseline 13.33%  n=2/15; 
6.67% 
12 weeks n=1/15 
Baseline 0% n=0/18; 12 
weeks 5.56% n=1/18 
+12.23% 
 
Table 9. Productivity loss 
Employer’s costs 
Variable SLaMM+ (n=16/19) SLaMM (n=14/21) Difference 
Days of certified 
sickness (Baseline) 
21  
(n=1/16) 
0  
(n=0/14) 
+21 
Days of certified 
sickness (12 weeks) 
6  
(n=1/16) 
11  
(n=1/14) 
-5 
Employee’s costs 
Variable SLaMM+ (n=16/19) SLaMM (n=14/21) Mean difference 
Hours of uncertified 
sickness (Baseline) 
Mean: 
15hr32min34secs 
Median: 
15hrs20mins00secs 
(n=14/16) 
Mean: 
16hr47min13secs  
Median: 
5hrs31mins30secs 
(n=9/14) 
Mean: -1hr14mins39secs (less for 
SLaMM+) 
Median: +9hr48mins30secs (more for 
SLaMM+) 
Hours of uncertified 
sickness (12 weeks) 
Mean: 
11hr37min19secs 
Mean: 
7hr42min43secs 
Mean: +3hr54mins36secs (more for 
SLaMM+) 
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Median: 
6hrs30mins00secs 
(n=11/16) 
Median: 
7hrs03mins00secs 
(n=10/14) 
Median: +33mins30secs (less for 
SLaMM+) 
Employer or employee cost* 
Agents with 4 or more 
days of uncertified 
sickness who may have 
claimed Statutory Sick 
Pay (Baseline) 
n=1/16 n=0/14 +1 
Agents with 4 or more 
days of uncertified 
sickness who may have 
claimed Statutory Sick 
Pay working days (12 
weeks) 
n=3/16 n=0/14 +3 
Agents with 2-3 days 
uncertified sickness 
who may have claimed 
Statutory Sick Pay for 
working and non-
working days 
(Baseline)** 
n=2/16 n=3/14 -1 
Agents with 2-3 days 
uncertified sickness 
who may have claimed 
Statutory Sick Pay for 
working and non-
working days (12 
weeks)** 
n=1/16 n=2/14 -1 
*This depended upon whether the agent had been working at the company for a minimum of 3 months. If they 
had worked there for less than 3 months they had to claim from the state; **this depended on whether the 
employee claimed sickness during the weekend days (non-working days)  
Table 7. QALY breakdown by group (unadjusted) 
 SLaMM+  SLaMM 
 Mean (SD) Mean (SD) 
Life years 0.23 years/ 12 weeks 0.23 years/ 12 weeks 
Unadjusted HRQoL for 
all three time points  
0.814 (0.194) 0.873 (0.135) 
HRQoL at Baseline 0.780 (0.212) 0.884 (0.154) 
HRQoL at 12 weeks 0.847 (0.220) 0.862 (0.137) 
 
 
 
Appendix E.1. Microcosting tool 
1. People (Human 
resources) 
Type of resource and context: 
1. What is your job title and if possible skill level/ grade?  
2. Name the tasks (activities) which you do which are related to the intervention? (if they perform more than one task, perform 
this questioning exercise for each task starting in chronological order) 
3. When do you perform this task? (before the intervention starts, first week, after the intervention) 
4. Who else is involved in this task?* 
Quantification of resource: 
5. On average how long does this task take to perform each time? (duration) 
6. How many times is this take performed? (frequency) 
Additional context to consider opportunity costt:  
7. Where any specific tasks (activities) given up or done differently because of this additional task? 
8. Was the impact minor, moderate or major? 
*This can include the participant. Arrange a consultation with the people identified in question 4 and repeat questions 1-8 with those 
people. If it is anticipated that it will not be feasible to arrange a consultation with any of the other people identified, ask the present 
stakeholder to estimate their resource use by answering question 1-7 on their behalf.  
2. Place/ Setting (Capital 
resources) 
Quantification of capital resources described in natural units: 
1. How is this task performed? (e.g. face-to-face, email, telephone) 
2. Where does the task take place? (private room at leisure centre) 
3. How many times is this task performed in this place? (frequency) 
4. On average how much time is required to perform the task in this place? (duration) 
5. If you have to travel to this place, how much of your time does it take to travel one way? 
6. On average what mode of transport do you use? 
7. Which other places, if any, does this task take place at?* 
Additional context to consider opportunity cost:  
8. Where any specific activities not related to the intervention given up or done differently because of the place being used for 
this task? 
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9. Was the impact minor, moderate or major? 
*Repeat questions 1-7 for each place identified for the task 
3. Materials (Equipment) Quantification of equipment described in natural units: 
1. What materials are required for this task?  
2. On average how much of this specific material is required for this task? (frequency) 
3. Which other equipment, if any, does this task take place at?* 
Additional context to consider opportunity costt:  
4. Where any specific activities not related to the intervention given up or done differently because of the equipment being 
used for this task? 
9. Was the impact minor, moderate or major? 
*Repeat questions 1-5 for each equipment identified for the task 
4. Out-of-pocket 
payments 
Quantification of out-of-pocket expenses: 
1. What out-of-pocket payments are paid for this task (exclude payments for any capital resources or equipment)? 
2. How many times is this paid? 
3. What other out-of-pocket payments, if any are paid?* 
Additional context to consider opportunity cost:  
4. Is anything, not related to the intervention, given up or done differently because of this out-of-pocket payment?    
5. Was the impact minor, moderate or major? 
*Repeat questions 1-5 for each out-of-pocket payment identified for the task 
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Appendix E.2. Example of resource use quantification 
Task (activity): Scheduling of Education & Training sessions 
Context Calculations to quantify resource use Total 
resource use  
(per 
intervention 
participant) 
1. Human Resource: Resource Planner (junior level) schedules three Education and Training 
sessions on weeks 1, 3 and 7 of the SLaMM intervention for 60 participants. They also liase with the 
researchers via telephone and email. Minor impact, no specific activities given up or done 
differently. 
• 3 x 45 minutes of 
scheduling per 60 
participants 
• 3 x 15 minutes of liaising 
with researchers per 60 
participants  
3 minutes  
2. Place: In usual office, on usual computer and via telephone to speak to researchers. The 
schedule for education and training session was via email to the researcher. No other place 
involved. Minor impact, no specific activities given up or done differently (negligible resource use). 
• 3 x IT system 
• 3 x Telephone system 
0 
3. Materials: None Not applicable 0 
4. Out of pocket payments: None Not applicable 0 
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Appendix E.3. Example of presentation of results 
Stakeholder (perspective): Leisure Centre 
Activity Resource type Resource item Intervention A Intervention B Key Result: 
Incremental Analysis 
(per participant) 
Total resource use 
(per participant)* 
Total resource use 
(per participant)* 
Education session  Human Resource Time of Gym Instructor 
(one to one) 
30 minutes 15 minutes +15 minutes 
Capital  Consultation room 30 minutes 15 minutes + 15 minutes 
Material Information leaflet in 
colour 
6 pages 2 pages + 4 pages 
Gym class Human Resource Time of Gym Instructor 3 minutes Not applicable +3 minutes 
Capital  Gym class room  
(15 people: 45 min class) 
3 minutes Not applicable +3 minutes 
Stakeholder (perspective): Healthcare Sector 
Activity Resource type Resource item Intervention A Intervention B Key Result: 
Incremental Analysis 
(per participant) 
Total resource use 
(per participant)* 
Total resource use 
(per participant)* 
Primary care  Human Resource GP visits 5 visits 2 visits +3 visits  
Practice Nurse visits 2 visits 2 visits No difference 
Secondary care  Services A&E visits 1 visits 0 visits +1 visits  
Outpatient appointments 1 visits 4 visits -3 visits 
*Report means 
 
